lineage,string contains lineage,ID
Alpha,"In addition, we examined the competition of two SARS-CoV-2 isolates, representatives of the ancestral lineage A and the alpha variant of concern (VOC) B.1.1.7 through co-infection of WTD.",PMC8725908
B.1.1.7,"In addition, we examined the competition of two SARS-CoV-2 isolates, representatives of the ancestral lineage A and the alpha variant of concern (VOC) B.1.1.7 through co-infection of WTD.",PMC8725908
B.1.351,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
P.1,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
B.1.427,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
B.1.526,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccines.",PMC8725896
B.1.1.7,"The SARS-CoV-2 viruses USA-WA1/2020 (WA1), hC0V-19/USA/CACDC_5574/2020 (B.1.1.7), hCoV-19/South Africa/KRISP-K005325/2020 (B.1.351), hCoV-19/Japan/TY7-503/2021 (P.1), and hCoV-19/USA/NY-NP-DOH1/2021 (B.1.526) were obtained from BEI Resources (NIAID, NIH).",PMC8725896
B.1.1.1,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
R.1,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.617.2,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.617.1,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
B.1.525,"Here we assessed 2–36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484 K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PMC8725896
Alpha,"Strains were classified into seven GISAID clades, the major one being GRY, and 36 Pango lineages, with three variants of concern identified: alpha, delta and omicron.",PMC9121641
B.1.1.7,"The first VOC is alpha (B.1.1.7 Pango Lineage; GRY GISAID clade), originating from the United Kingdom in December 2020 (Davies et al., 2021; Younes et al., 2021).",PMC9121641
B.1.351,"Second is beta (B.1.351 Pango Lineage; GH GISAID clade), first detected in South Africa in October 2020 (Tegally et al., 2021).",PMC9121641
Beta,"Second is beta (B.1.351 Pango Lineage; GH GISAID clade), first detected in South Africa in October 2020 (Tegally et al., 2021).",PMC9121641
P.1.2,"Third, gamma, (P.1, P.1., and P.1.2 Pango Lineages; GR GISAID clade) originated in Brazil in December 2020 (Wang et al., 2021).",PMC9121641
P.1,"Third, gamma, (P.1, P.1., and P.1.2 Pango Lineages; GR GISAID clade) originated in Brazil in December 2020 (Wang et al., 2021).",PMC9121641
Gamma,"Third, gamma, (P.1, P.1., and P.1.2 Pango Lineages; GR GISAID clade) originated in Brazil in December 2020 (Wang et al., 2021).",PMC9121641
B.1.617.2,"It is designated the GK GISAID clade, with the main Pango Lineage B.1.617.2, accompanied by a number of AY sub-lineages, the latter being an alias of the former, with various geographical distributions (Callaway, 2021).",PMC9121641
B.1.1.529,"Finally, the most recent variant omicron, first detected in November 2021 and also known as the B.1.1.529 lineage, belongs to the newly formed GRA GISAID clade (Global Initiative on Sharing All Influenza Data (GISAID), 2022)..",PMC9121641
B.1.398,"As for the other clades, first, the aforementioned B.1.398 lineage formed ca.",PMC9121641
B.1,"Second, B.1 and B.1.36.1 constituted 37.25 and 23.53% of the GH clade, respectively.",PMC9121641
B.1.36.1,"Second, B.1 and B.1.36.1 constituted 37.25 and 23.53% of the GH clade, respectively.",PMC9121641
B.1.1,"Finally, B.1.1 constituted 30.56% of the GR clade, alongside 27.78% of this clade's strains being labeled as “none” by the Pango lineage classification.",PMC9121641
B.1.177,"As for the GRA, GV and O clades, the most prevalent lineages were BA.1, B.1.177 and B.4 lineages.",PMC9121641
B.4,"As for the GRA, GV and O clades, the most prevalent lineages were BA.1, B.1.177 and B.4 lineages.",PMC9121641
Gamma,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
B.1.617.2,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
B.1.1.7,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
B.1.1.529,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
Alpha,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
B.1.351,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
P.1,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
Beta,"Among them, the B.1.1.7 Alpha,12 B.1.351 Beta,13 P.1 Gamma,14 B.1.617.2 Delta,15 and recently emerged B.1.1.529 Omicron variants16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility17 and ability to escape convalescent and vaccine-induced antibody responses.18, 19, 20, 21, 22 Recent studies showing a decrease in the effectiveness of mRNA vaccines against the new VOCs23 report of breakthrough infections,24 and concerns of reduced efficacy of vaccination in older patients25 or immune-compromised individuals26 highlight the need to develop a new and complementary generation of vaccines as prophylaxis or boosters that include T- and B-cell selected antigens that are potentially less affected by the mutations of VOCs..",PMC9113741
Iota,"SARS-CoV-2 Panel 11 plates are MULTI-SPOT 96-well, 10 Spot, coated with RBD proteins from various SARS-CoV-2 lineages: Wuhan; Alpha; Beta and Botswana; Gamma; Delta sub-lineages and Vietnam; Epsilon, California, and New York; Eta, Iota, India, Zeta, and Kentucky; New York; U.K. and Philippines; Kappa and India.",PMC9113741
Zeta,"SARS-CoV-2 Panel 11 plates are MULTI-SPOT 96-well, 10 Spot, coated with RBD proteins from various SARS-CoV-2 lineages: Wuhan; Alpha; Beta and Botswana; Gamma; Delta sub-lineages and Vietnam; Epsilon, California, and New York; Eta, Iota, India, Zeta, and Kentucky; New York; U.K. and Philippines; Kappa and India.",PMC9113741
Kappa,"SARS-CoV-2 Panel 11 plates are MULTI-SPOT 96-well, 10 Spot, coated with RBD proteins from various SARS-CoV-2 lineages: Wuhan; Alpha; Beta and Botswana; Gamma; Delta sub-lineages and Vietnam; Epsilon, California, and New York; Eta, Iota, India, Zeta, and Kentucky; New York; U.K. and Philippines; Kappa and India.",PMC9113741
Epsilon,"SARS-CoV-2 Panel 11 plates are MULTI-SPOT 96-well, 10 Spot, coated with RBD proteins from various SARS-CoV-2 lineages: Wuhan; Alpha; Beta and Botswana; Gamma; Delta sub-lineages and Vietnam; Epsilon, California, and New York; Eta, Iota, India, Zeta, and Kentucky; New York; U.K. and Philippines; Kappa and India.",PMC9113741
Eta,"SARS-CoV-2 Panel 11 plates are MULTI-SPOT 96-well, 10 Spot, coated with RBD proteins from various SARS-CoV-2 lineages: Wuhan; Alpha; Beta and Botswana; Gamma; Delta sub-lineages and Vietnam; Epsilon, California, and New York; Eta, Iota, India, Zeta, and Kentucky; New York; U.K. and Philippines; Kappa and India.",PMC9113741
B.3,Phylogenetic analyses of these sequences revealed mainly two circulating strains with 74 samples assigned to lineage B.3 and 6 samples assigned to lineage B.1.,PMC9088089
A.3,identified six lineages derived from lineage A (denoted A.1-A.6) and two descendant sub-lineages of A.1 (A.1.1 and A.3).,PMC9088089
A.1,identified six lineages derived from lineage A (denoted A.1-A.6) and two descendant sub-lineages of A.1 (A.1.1 and A.3).,PMC9088089
B.1,"They also described 16 lineages, which were directly derived from lineage B. Lineage B.1 is the predominant lineage globally and it has been divided into more than 70 sub-lineages.",PMC9088089
Alpha,"The spread of the first described variant of concern (Alpha variant, B.1.1.7, VOC) was confirmed early in Austria and increased from 0.7% in January to > 99% in April 2021 in the study area of East Tyrol (https://www.ages.at/themen/krankheitserreger/coronavirus/sars-cov-2-varianten-in-oesterreich/).",PMC9090742
B.1.1.7,"The spread of the first described variant of concern (Alpha variant, B.1.1.7, VOC) was confirmed early in Austria and increased from 0.7% in January to > 99% in April 2021 in the study area of East Tyrol (https://www.ages.at/themen/krankheitserreger/coronavirus/sars-cov-2-varianten-in-oesterreich/).",PMC9090742
B.1.617.2,"As of December 2020, the European Center for Disease Prevention and Control (ECDC) noticed a sharp decline of the Alpha variant in the European Union (EU; 14.5%) followed by a fast spread of the Delta variant (B.1.617.2) in spring, 2021, plus a very small percentage of the Gamma variant (P1 or B.1.1.28.1, 0.3%) as well as other variants (0.3%).",PMC9090742
Gamma,"As of December 2020, the European Center for Disease Prevention and Control (ECDC) noticed a sharp decline of the Alpha variant in the European Union (EU; 14.5%) followed by a fast spread of the Delta variant (B.1.617.2) in spring, 2021, plus a very small percentage of the Gamma variant (P1 or B.1.1.28.1, 0.3%) as well as other variants (0.3%).",PMC9090742
Beta,"For example, N501Y in the Alpha, Beta and Omicron variant, a nucleotide exchange at position E484 to K in the Alpha- (in a subvariant), Beta and Gamma variants, to Q in a Delta subvariant or to A in both Omicron subvariants BA.1 and BA.2.",PMC9090742
B.1.1,"3Chronology and frequency of the appearance of convergent intra-host mutations.Evolution of mutations in the region coding for spike in a strain of the clade B.1.1, as they have been proven in identical form in the VOC.",PMC9090742
B.1.1.529,"The mutations marked in orange are also found in the Omicron variant (B.1.1.529) in similar or identical expression (10 out of 17), mutations marked in red are found in other VOC (3 of 17; 17.6%).",PMC9090742
B.1.617.1,"E484K is a well-established distinction of the VOC B.1.1.7 with E484K, P.1, P.2, B.1.315, B.1.525, B.1.526 as well as B.1.617.1 (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC9090742
B.1.525,"E484K is a well-established distinction of the VOC B.1.1.7 with E484K, P.1, P.2, B.1.315, B.1.525, B.1.526 as well as B.1.617.1 (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC9090742
P.2,"E484K is a well-established distinction of the VOC B.1.1.7 with E484K, P.1, P.2, B.1.315, B.1.525, B.1.526 as well as B.1.617.1 (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC9090742
P.1,"E484K is a well-established distinction of the VOC B.1.1.7 with E484K, P.1, P.2, B.1.315, B.1.525, B.1.526 as well as B.1.617.1 (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC9090742
B.1.315,"E484K is a well-established distinction of the VOC B.1.1.7 with E484K, P.1, P.2, B.1.315, B.1.525, B.1.526 as well as B.1.617.1 (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC9090742
B.1.526,"E484K is a well-established distinction of the VOC B.1.1.7 with E484K, P.1, P.2, B.1.315, B.1.525, B.1.526 as well as B.1.617.1 (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html).",PMC9090742
Mu,"This mutation was previously described as a reaction of SARS-CoV-2 after monoclonal antibody treatment, seeming to maintain ACE2 binding activity35 and has also developed in the VOI Mu, 21H, B.1.621 (https://covariants.org/shared-mutations; Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)..

S:D950N arose around day 171 and is as adaptive mutation assigned to the Gamma and Delta variant (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)..",PMC9090742
B.1.621,"This mutation was previously described as a reaction of SARS-CoV-2 after monoclonal antibody treatment, seeming to maintain ACE2 binding activity35 and has also developed in the VOI Mu, 21H, B.1.621 (https://covariants.org/shared-mutations; Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)..

S:D950N arose around day 171 and is as adaptive mutation assigned to the Gamma and Delta variant (Center for Disease Control and Prevention; https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)..",PMC9090742
B.1.1,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
B.4,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
B.1.540,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
B.1.428.2,"Multiple lineage introductions were noted during the initial phase of the pandemic, including B.4, B.1.1, B.1.428.2, B.1.540 and B.1.1.189.",PMC9085353
Alpha,The Alpha variant (B.1.1.7 lineage) was identified in February 2021 and firstly observed in the center of our country.,PMC9085353
B.1.1.7,The Alpha variant (B.1.1.7 lineage) was identified in February 2021 and firstly observed in the center of our country.,PMC9085353
B.1.351,"Epidemiological and phylogenetic studies revealed that the significant increase in the rate of infection and/or death was correlated with the emergence of fourVariant of Concern (VOC) belonging to B.1.1.7, B.1.351, B.1.617.2 and B.1.1.28 lineages.",PMC9085353
B.1.617.2,"Epidemiological and phylogenetic studies revealed that the significant increase in the rate of infection and/or death was correlated with the emergence of fourVariant of Concern (VOC) belonging to B.1.1.7, B.1.351, B.1.617.2 and B.1.1.28 lineages.",PMC9085353
B.1.1.28,"Epidemiological and phylogenetic studies revealed that the significant increase in the rate of infection and/or death was correlated with the emergence of fourVariant of Concern (VOC) belonging to B.1.1.7, B.1.351, B.1.617.2 and B.1.1.28 lineages.",PMC9085353
Gamma,"On May 31, 2021, WHO published a new nomenclature proposal applying to VOC based on the Greek alphabet: Alpha, Beta, Delta and Gamma, respectively (Parums, 2021)..

During the initial stage of the pandemic, due to the lack of specific treatments that prevent or block viral replication, massive prevention strategies were applied by most countries.",PMC9085353
Beta,"On May 31, 2021, WHO published a new nomenclature proposal applying to VOC based on the Greek alphabet: Alpha, Beta, Delta and Gamma, respectively (Parums, 2021)..

During the initial stage of the pandemic, due to the lack of specific treatments that prevent or block viral replication, massive prevention strategies were applied by most countries.",PMC9085353
A.2,"A.1, A.2, A.3, …) and sub sub-lineages (e.g.",PMC9085353
A.3,"A.1, A.2, A.3, …) and sub sub-lineages (e.g.",PMC9085353
B.1.1.189,"B.4, B.1.1.189 and B.1.540 were identified in tow patient each one (n = 2; 3.4%).",PMC9085353
B.1.333,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.177.6,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.597,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.356,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
B.1.9,"B.55, B.1.9, B.1.177.6, B.1.333, B.1.356 and B.1.597 lineages were identified in one patient each (Fig.",PMC9085353
A.27,A local cluster of the A.27 lineage was detected in Zaghouan and Sousse (Supplementary data Fig.,PMC9085353
B.1,"Indeed, among the 14 different lineages generated in this study six were identified during the early phase including B.1, B.1.1, B.1.1.189, B.1.428.2, B.1.597 and B4.",PMC9085353
B.1.177,"As the majority of European countries B.1.160, B.1.177 and B.1.1.7 were the predominant lineages during the second and the third waives (Hodcroft et al., 2021)..

Our data revealed a clear difference between the North of the country (Tunis, Nabeul, Ben Arous and Ariana) where diverse lineages circulated and the South (Gafsa, Djerba, Sidi Bouzid) where only one lineage was exclusively present.",PMC9085353
B.1.160,"As the majority of European countries B.1.160, B.1.177 and B.1.1.7 were the predominant lineages during the second and the third waives (Hodcroft et al., 2021)..

Our data revealed a clear difference between the North of the country (Tunis, Nabeul, Ben Arous and Ariana) where diverse lineages circulated and the South (Gafsa, Djerba, Sidi Bouzid) where only one lineage was exclusively present.",PMC9085353
Beta,"The causative agent of the pandemic, a novel beta coronavirus (i.e., severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was initially found to be less pathogenic with pneumonia-like illness in infected individuals at first emergence in Wuhan, China in December 2019 [2].",PMC9083482
B.1.1.529,"Since the emergence of the COVID-19 pandemic in 2019, the WHO has declared six SARS-CoV-2 variants as VOCs, including omicron (SARS-CoV-2 lineage; B.1.1.529), which is the most recent one and was first identified in South Africa with potentially increased transmissibility, a significant reduction in neutralization by some EUL monoclonal antibody treatments, and potential reduction in neutralization by postvaccination sera (Table 1).",PMC9083482
Kappa,"Similarly, increased hospitalization with more severe clinical disease and significantly reduced susceptibility to approved therapeutics or EUL are also attributed to a VOHC [3].Table 1SARS-CoV-2 variants with key mutations and their particular functions [3]VariantKey mutationsLineageMutations functionFirst detectedAlpha (VOC 29–12–2020)D614GB.1.1.7B.1.1.177B.1.258Makes the virus more infectiousUKdelH69V70Alters the shape of the spike (S) protein and enables the virus to evade some antibodiesdelY144Alters the shape of the S protein and enables the virus to evade some antibodiesN439KImpacts the ability of the virus to evade antibody-mediated immunityN501YHelps to latch the virus more tightly on human cellsP681HEnhances systemic infection and increases virus transmissibilityBeta (VOC 29–12–2020)D512GB.1.351B.1.1.33Helps to latch the virus more tightlySouth AfricaD614GMakes the virus more infectiousE484KReduces antibody recognition by the virus and confers vaccine resistanceK417NBinds the virus more tightly to human cellsL18FHelps to latch the virus more tightlyN501YHelps to latch the virus more tightly on human cellsGamma (VOC 29–12–2020)D614GP.1Makes the virus more infectiousBrazil and in Japan (detected in travelers from Brazil)E484KReduces antibody recognition by the virus and confers vaccine resistanceK417THelps to latch the virus more tightlyL18FHelps to latch the virus more tightlyN501YHelps to latch the virus more tightly on human cellsT20NHelps to latch the virus more tightlyDelta (VOC 11–05–2021)Kappa (VOI 07–05–2021)E484Q*B.1.617.2B.1.617.1B.1.617.3Similar to E484K in function while associated with immune escape and increased virus transmissibilityIndiaL452RAn advantage to spread over other variantsP681RHelps to latch the virus more tightly and increases virus transmissibilityEpsilon (VOC 19–03–2021)(VOI 26–02–2021) (VOI 29–06–2021)L452RB.1.427B.1.429Reduces virus recognition to antibodiesCalifornia, USAS13IAssociated with variants of increased transmissibilityZeta (VOI 26–02–2021)V1176FP.2Reduces antibody neutralization by some antibody treatmentsBrazilEta (VOI 26–02–2021)D614GB.1.525B.1.1.207Makes the virus more infectiousUK/NigeriadelH69V70Alters the shape of the S protein and enables the virus to evade some antibodiesE484KReduces antibody recognition by the virus and confers vaccine resistanceF888LReduces the antibody neutralization by some antibody treatmentsP681HEnhances virus systemic infection and increases virus transmissibilityIota (VOI 26–02–2021)S477NB.1.526Reduces the susceptibility of the virus to the immune systemNew York, USAMink variantD614GB.1.1.298Makes the virus more infectious-Lambda (VOI 15–06–2021)RSYLTPGD246-253 NC.37Resistance to viral-induced immune responsesPeruL452QResistance to viral-induced immune responsesF490SResistance to viral-induced immune responsesT76IEnhances the rate of virus transmissibilityL452QEnhances the rate of virus transmissibilityMuT95IB.1.621Confers vaccine resistanceColombiaY144SConfers vaccine resistanceY145NConfers vaccine resistanceR346KConfers vaccine resistanceE484KReduces antibody recognition by the virus and confers vaccine resistanceN501YHelps to latch the virus more tightly on human cellsD614GMakes the virus more infectiousP681HEnhances virus systemic infection and increases virus transmissibilityD109NConfers vaccine resistanceOmicron (VOC 26–11–2021)A67VB.1.1.529Potential increased transmissibilitySouth AfricaK417NPotential reduction in neutralization by some EUA monoclonal antibody treatmentsD614GMakes the virus more infectiousE484APotential reduction in neutralization by postvaccination sera.",PMC9083482
B.1.351,"The SARS-CoV-2 variant B.1.1.7 contains a mutation near the protease cleavage site (i.e., E484K) and ultimately threatens S protein stability (Table 1) [31]..

Several variant lineages including B.1.351, B.1.1.28.1, B.1.525, and B.1.526 contain a coincidence mutation (i.e., E484K) that is located at a very critical position in the receptor-binding motif (RBM) of the RBD [5, 32].",PMC9083482
B.1.526,"The SARS-CoV-2 variant B.1.1.7 contains a mutation near the protease cleavage site (i.e., E484K) and ultimately threatens S protein stability (Table 1) [31]..

Several variant lineages including B.1.351, B.1.1.28.1, B.1.525, and B.1.526 contain a coincidence mutation (i.e., E484K) that is located at a very critical position in the receptor-binding motif (RBM) of the RBD [5, 32].",PMC9083482
B.1.1.7,"The SARS-CoV-2 variant B.1.1.7 contains a mutation near the protease cleavage site (i.e., E484K) and ultimately threatens S protein stability (Table 1) [31]..

Several variant lineages including B.1.351, B.1.1.28.1, B.1.525, and B.1.526 contain a coincidence mutation (i.e., E484K) that is located at a very critical position in the receptor-binding motif (RBM) of the RBD [5, 32].",PMC9083482
B.1.525,"The SARS-CoV-2 variant B.1.1.7 contains a mutation near the protease cleavage site (i.e., E484K) and ultimately threatens S protein stability (Table 1) [31]..

Several variant lineages including B.1.351, B.1.1.28.1, B.1.525, and B.1.526 contain a coincidence mutation (i.e., E484K) that is located at a very critical position in the receptor-binding motif (RBM) of the RBD [5, 32].",PMC9083482
B.1.427,"Table 4 lists all vaccines approved or EUL of the FDA, CDC, or EMA that have been administered worldwide to curb the COVID-19 pandemic.Table 4Vaccines developed against COVID-19 with their efficacy data, doses, and eligibility criteria from phase III clinical trialsClinical trial regimeVaccine manufacturer and nameVaccine platformSARS-CoV-2 lineage at the time of trialEndpoint measures to determine the vaccine efficacyOverall vaccine efficacy, results by severity, and eligibilityTwo doses (21 days apart)Pfizer–BioNTech (BnT162b2)mRNAB.1.351, P.1, B.1.427/B.1.419, P.2, B.1.526Symptomatic COVID-19 and positive RT-PCR test result95%, 100% effective in preventing CDC-defined severe disease; 95.3% effective in preventing FDA-defined severe disease > 16 years oldTwo doses (28 days apart)Moderna (mRNA-1273)mRNAB.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result94%, 100% efficacy against severe disease, ≥ 18 years old (12 years old to younger than 18 years (NCT04649151) and 6 months old to younger than 12 years (NCT04796896))Two doses (< 6 weeks apart), two doses (> 12 weeks apart)AstraZeneca– University of Oxford (AZD1222 (Vaxzevria, also called Covishield when manufactured by SII under license))Viral vectorB.1.1.7, B.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive NAAT result55–81%, 100% efficacy against hospitalization, ≥ 18 years old (WHO); ≥ 40 years old and not pregnant in the UKOne doseJohnson & Johnson (Ad26.CoV2-S)Viral vectorB.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive RT-PCR test result66%, 85.4% efficacy against severe–critical disease occurring ≥ 28 days after vaccination,  ≥ 18 years oldTwo doses (21 days apart)Gamaleyab (Sputnik V)Viral vectorNo variants have been identified originating from the trial locations from the trial start date to the present (June 2021)Symptomatic COVID-19 and positive RT-PCR test result92%, No data available (June 2021), ≥ 18 years oldTwo doses (28 days apart)Bharat Biotech (Covaxin)Viral vectorPhase III trial began on 16 November 2020 and is ongoing in India; variants identified include B.1.617.2 and B.1.617.1Symptomatic COVID-19 and positive RT-PCR test result at least 14 days after the second dose78%, 100% efficacy against hospitalization, ≥ 18 years old (2–18 years old: study ongoing)Two doses (14 days apart; 14 or 28 days apart in Chile)Sinovac Biotech (CoronaVac)Inactivated virusP.1 and P.2Symptomatic, virologically confirmed COVID-19 occurring from 2 weeks after the second dose up to 1 year after the first doseMultiple studies in different countries: 50.7% (Brazil), 56.5% (Chile), 65% (Indonesia), 78% (Brazil) and 91% (Turkey), 51% efficacy against symptomatic SARS-CoV-2 infection; 100% efficacy against severe disease; 100% efficacy against hospitalization from 14 days after second dose, ≥ 18 years oldTwo doses (21 days apart)Sinopharm (BBIBP-CorV)Inactivated virusNo variants have been identified originating from the trial locations during this time (June 2021)Occurrence of COVID-1978%, 79% efficacy against hospitalization, ≥ 18 years oldTwo doses (21 days apart)Novavax (NVX-CoV2373)Protein subunitB.1.1.7, B.1.351, B.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result at least 7 days after the second dose89%, 100% efficacy against severe disease and hospitalization, ≥ 18 years old (12–17 years old: study ongoing, NCT04611802)Two doses (21–28 days apart)VECTOR (EpiVacCorona) (NCT04780035)Protein subunitNo variants have been identified originating in the trial locations during this time (June 2021)Symptomatic COVID-19, laboratory-confirmed COVID-19 within 6 months after the first doseNo data available (June 2021), No data available (June 2021), ≥ 18 years oldCDC Centers for Disease Control and Prevention; FDA US Food and Drug Administration; NAAT nucleic acid amplification test; RT-PCR reverse transcription-polymerase chain reaction; SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.",PMC9083482
B.1.617.2,"Table 4 lists all vaccines approved or EUL of the FDA, CDC, or EMA that have been administered worldwide to curb the COVID-19 pandemic.Table 4Vaccines developed against COVID-19 with their efficacy data, doses, and eligibility criteria from phase III clinical trialsClinical trial regimeVaccine manufacturer and nameVaccine platformSARS-CoV-2 lineage at the time of trialEndpoint measures to determine the vaccine efficacyOverall vaccine efficacy, results by severity, and eligibilityTwo doses (21 days apart)Pfizer–BioNTech (BnT162b2)mRNAB.1.351, P.1, B.1.427/B.1.419, P.2, B.1.526Symptomatic COVID-19 and positive RT-PCR test result95%, 100% effective in preventing CDC-defined severe disease; 95.3% effective in preventing FDA-defined severe disease > 16 years oldTwo doses (28 days apart)Moderna (mRNA-1273)mRNAB.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result94%, 100% efficacy against severe disease, ≥ 18 years old (12 years old to younger than 18 years (NCT04649151) and 6 months old to younger than 12 years (NCT04796896))Two doses (< 6 weeks apart), two doses (> 12 weeks apart)AstraZeneca– University of Oxford (AZD1222 (Vaxzevria, also called Covishield when manufactured by SII under license))Viral vectorB.1.1.7, B.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive NAAT result55–81%, 100% efficacy against hospitalization, ≥ 18 years old (WHO); ≥ 40 years old and not pregnant in the UKOne doseJohnson & Johnson (Ad26.CoV2-S)Viral vectorB.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive RT-PCR test result66%, 85.4% efficacy against severe–critical disease occurring ≥ 28 days after vaccination,  ≥ 18 years oldTwo doses (21 days apart)Gamaleyab (Sputnik V)Viral vectorNo variants have been identified originating from the trial locations from the trial start date to the present (June 2021)Symptomatic COVID-19 and positive RT-PCR test result92%, No data available (June 2021), ≥ 18 years oldTwo doses (28 days apart)Bharat Biotech (Covaxin)Viral vectorPhase III trial began on 16 November 2020 and is ongoing in India; variants identified include B.1.617.2 and B.1.617.1Symptomatic COVID-19 and positive RT-PCR test result at least 14 days after the second dose78%, 100% efficacy against hospitalization, ≥ 18 years old (2–18 years old: study ongoing)Two doses (14 days apart; 14 or 28 days apart in Chile)Sinovac Biotech (CoronaVac)Inactivated virusP.1 and P.2Symptomatic, virologically confirmed COVID-19 occurring from 2 weeks after the second dose up to 1 year after the first doseMultiple studies in different countries: 50.7% (Brazil), 56.5% (Chile), 65% (Indonesia), 78% (Brazil) and 91% (Turkey), 51% efficacy against symptomatic SARS-CoV-2 infection; 100% efficacy against severe disease; 100% efficacy against hospitalization from 14 days after second dose, ≥ 18 years oldTwo doses (21 days apart)Sinopharm (BBIBP-CorV)Inactivated virusNo variants have been identified originating from the trial locations during this time (June 2021)Occurrence of COVID-1978%, 79% efficacy against hospitalization, ≥ 18 years oldTwo doses (21 days apart)Novavax (NVX-CoV2373)Protein subunitB.1.1.7, B.1.351, B.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result at least 7 days after the second dose89%, 100% efficacy against severe disease and hospitalization, ≥ 18 years old (12–17 years old: study ongoing, NCT04611802)Two doses (21–28 days apart)VECTOR (EpiVacCorona) (NCT04780035)Protein subunitNo variants have been identified originating in the trial locations during this time (June 2021)Symptomatic COVID-19, laboratory-confirmed COVID-19 within 6 months after the first doseNo data available (June 2021), No data available (June 2021), ≥ 18 years oldCDC Centers for Disease Control and Prevention; FDA US Food and Drug Administration; NAAT nucleic acid amplification test; RT-PCR reverse transcription-polymerase chain reaction; SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.",PMC9083482
P.2,"Table 4 lists all vaccines approved or EUL of the FDA, CDC, or EMA that have been administered worldwide to curb the COVID-19 pandemic.Table 4Vaccines developed against COVID-19 with their efficacy data, doses, and eligibility criteria from phase III clinical trialsClinical trial regimeVaccine manufacturer and nameVaccine platformSARS-CoV-2 lineage at the time of trialEndpoint measures to determine the vaccine efficacyOverall vaccine efficacy, results by severity, and eligibilityTwo doses (21 days apart)Pfizer–BioNTech (BnT162b2)mRNAB.1.351, P.1, B.1.427/B.1.419, P.2, B.1.526Symptomatic COVID-19 and positive RT-PCR test result95%, 100% effective in preventing CDC-defined severe disease; 95.3% effective in preventing FDA-defined severe disease > 16 years oldTwo doses (28 days apart)Moderna (mRNA-1273)mRNAB.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result94%, 100% efficacy against severe disease, ≥ 18 years old (12 years old to younger than 18 years (NCT04649151) and 6 months old to younger than 12 years (NCT04796896))Two doses (< 6 weeks apart), two doses (> 12 weeks apart)AstraZeneca– University of Oxford (AZD1222 (Vaxzevria, also called Covishield when manufactured by SII under license))Viral vectorB.1.1.7, B.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive NAAT result55–81%, 100% efficacy against hospitalization, ≥ 18 years old (WHO); ≥ 40 years old and not pregnant in the UKOne doseJohnson & Johnson (Ad26.CoV2-S)Viral vectorB.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive RT-PCR test result66%, 85.4% efficacy against severe–critical disease occurring ≥ 28 days after vaccination,  ≥ 18 years oldTwo doses (21 days apart)Gamaleyab (Sputnik V)Viral vectorNo variants have been identified originating from the trial locations from the trial start date to the present (June 2021)Symptomatic COVID-19 and positive RT-PCR test result92%, No data available (June 2021), ≥ 18 years oldTwo doses (28 days apart)Bharat Biotech (Covaxin)Viral vectorPhase III trial began on 16 November 2020 and is ongoing in India; variants identified include B.1.617.2 and B.1.617.1Symptomatic COVID-19 and positive RT-PCR test result at least 14 days after the second dose78%, 100% efficacy against hospitalization, ≥ 18 years old (2–18 years old: study ongoing)Two doses (14 days apart; 14 or 28 days apart in Chile)Sinovac Biotech (CoronaVac)Inactivated virusP.1 and P.2Symptomatic, virologically confirmed COVID-19 occurring from 2 weeks after the second dose up to 1 year after the first doseMultiple studies in different countries: 50.7% (Brazil), 56.5% (Chile), 65% (Indonesia), 78% (Brazil) and 91% (Turkey), 51% efficacy against symptomatic SARS-CoV-2 infection; 100% efficacy against severe disease; 100% efficacy against hospitalization from 14 days after second dose, ≥ 18 years oldTwo doses (21 days apart)Sinopharm (BBIBP-CorV)Inactivated virusNo variants have been identified originating from the trial locations during this time (June 2021)Occurrence of COVID-1978%, 79% efficacy against hospitalization, ≥ 18 years oldTwo doses (21 days apart)Novavax (NVX-CoV2373)Protein subunitB.1.1.7, B.1.351, B.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result at least 7 days after the second dose89%, 100% efficacy against severe disease and hospitalization, ≥ 18 years old (12–17 years old: study ongoing, NCT04611802)Two doses (21–28 days apart)VECTOR (EpiVacCorona) (NCT04780035)Protein subunitNo variants have been identified originating in the trial locations during this time (June 2021)Symptomatic COVID-19, laboratory-confirmed COVID-19 within 6 months after the first doseNo data available (June 2021), No data available (June 2021), ≥ 18 years oldCDC Centers for Disease Control and Prevention; FDA US Food and Drug Administration; NAAT nucleic acid amplification test; RT-PCR reverse transcription-polymerase chain reaction; SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.",PMC9083482
P.1,"Table 4 lists all vaccines approved or EUL of the FDA, CDC, or EMA that have been administered worldwide to curb the COVID-19 pandemic.Table 4Vaccines developed against COVID-19 with their efficacy data, doses, and eligibility criteria from phase III clinical trialsClinical trial regimeVaccine manufacturer and nameVaccine platformSARS-CoV-2 lineage at the time of trialEndpoint measures to determine the vaccine efficacyOverall vaccine efficacy, results by severity, and eligibilityTwo doses (21 days apart)Pfizer–BioNTech (BnT162b2)mRNAB.1.351, P.1, B.1.427/B.1.419, P.2, B.1.526Symptomatic COVID-19 and positive RT-PCR test result95%, 100% effective in preventing CDC-defined severe disease; 95.3% effective in preventing FDA-defined severe disease > 16 years oldTwo doses (28 days apart)Moderna (mRNA-1273)mRNAB.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result94%, 100% efficacy against severe disease, ≥ 18 years old (12 years old to younger than 18 years (NCT04649151) and 6 months old to younger than 12 years (NCT04796896))Two doses (< 6 weeks apart), two doses (> 12 weeks apart)AstraZeneca– University of Oxford (AZD1222 (Vaxzevria, also called Covishield when manufactured by SII under license))Viral vectorB.1.1.7, B.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive NAAT result55–81%, 100% efficacy against hospitalization, ≥ 18 years old (WHO); ≥ 40 years old and not pregnant in the UKOne doseJohnson & Johnson (Ad26.CoV2-S)Viral vectorB.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive RT-PCR test result66%, 85.4% efficacy against severe–critical disease occurring ≥ 28 days after vaccination,  ≥ 18 years oldTwo doses (21 days apart)Gamaleyab (Sputnik V)Viral vectorNo variants have been identified originating from the trial locations from the trial start date to the present (June 2021)Symptomatic COVID-19 and positive RT-PCR test result92%, No data available (June 2021), ≥ 18 years oldTwo doses (28 days apart)Bharat Biotech (Covaxin)Viral vectorPhase III trial began on 16 November 2020 and is ongoing in India; variants identified include B.1.617.2 and B.1.617.1Symptomatic COVID-19 and positive RT-PCR test result at least 14 days after the second dose78%, 100% efficacy against hospitalization, ≥ 18 years old (2–18 years old: study ongoing)Two doses (14 days apart; 14 or 28 days apart in Chile)Sinovac Biotech (CoronaVac)Inactivated virusP.1 and P.2Symptomatic, virologically confirmed COVID-19 occurring from 2 weeks after the second dose up to 1 year after the first doseMultiple studies in different countries: 50.7% (Brazil), 56.5% (Chile), 65% (Indonesia), 78% (Brazil) and 91% (Turkey), 51% efficacy against symptomatic SARS-CoV-2 infection; 100% efficacy against severe disease; 100% efficacy against hospitalization from 14 days after second dose, ≥ 18 years oldTwo doses (21 days apart)Sinopharm (BBIBP-CorV)Inactivated virusNo variants have been identified originating from the trial locations during this time (June 2021)Occurrence of COVID-1978%, 79% efficacy against hospitalization, ≥ 18 years oldTwo doses (21 days apart)Novavax (NVX-CoV2373)Protein subunitB.1.1.7, B.1.351, B.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result at least 7 days after the second dose89%, 100% efficacy against severe disease and hospitalization, ≥ 18 years old (12–17 years old: study ongoing, NCT04611802)Two doses (21–28 days apart)VECTOR (EpiVacCorona) (NCT04780035)Protein subunitNo variants have been identified originating in the trial locations during this time (June 2021)Symptomatic COVID-19, laboratory-confirmed COVID-19 within 6 months after the first doseNo data available (June 2021), No data available (June 2021), ≥ 18 years oldCDC Centers for Disease Control and Prevention; FDA US Food and Drug Administration; NAAT nucleic acid amplification test; RT-PCR reverse transcription-polymerase chain reaction; SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.",PMC9083482
B.1.429,"Table 4 lists all vaccines approved or EUL of the FDA, CDC, or EMA that have been administered worldwide to curb the COVID-19 pandemic.Table 4Vaccines developed against COVID-19 with their efficacy data, doses, and eligibility criteria from phase III clinical trialsClinical trial regimeVaccine manufacturer and nameVaccine platformSARS-CoV-2 lineage at the time of trialEndpoint measures to determine the vaccine efficacyOverall vaccine efficacy, results by severity, and eligibilityTwo doses (21 days apart)Pfizer–BioNTech (BnT162b2)mRNAB.1.351, P.1, B.1.427/B.1.419, P.2, B.1.526Symptomatic COVID-19 and positive RT-PCR test result95%, 100% effective in preventing CDC-defined severe disease; 95.3% effective in preventing FDA-defined severe disease > 16 years oldTwo doses (28 days apart)Moderna (mRNA-1273)mRNAB.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result94%, 100% efficacy against severe disease, ≥ 18 years old (12 years old to younger than 18 years (NCT04649151) and 6 months old to younger than 12 years (NCT04796896))Two doses (< 6 weeks apart), two doses (> 12 weeks apart)AstraZeneca– University of Oxford (AZD1222 (Vaxzevria, also called Covishield when manufactured by SII under license))Viral vectorB.1.1.7, B.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive NAAT result55–81%, 100% efficacy against hospitalization, ≥ 18 years old (WHO); ≥ 40 years old and not pregnant in the UKOne doseJohnson & Johnson (Ad26.CoV2-S)Viral vectorB.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526, C.37Symptomatic COVID-19 and positive RT-PCR test result66%, 85.4% efficacy against severe–critical disease occurring ≥ 28 days after vaccination,  ≥ 18 years oldTwo doses (21 days apart)Gamaleyab (Sputnik V)Viral vectorNo variants have been identified originating from the trial locations from the trial start date to the present (June 2021)Symptomatic COVID-19 and positive RT-PCR test result92%, No data available (June 2021), ≥ 18 years oldTwo doses (28 days apart)Bharat Biotech (Covaxin)Viral vectorPhase III trial began on 16 November 2020 and is ongoing in India; variants identified include B.1.617.2 and B.1.617.1Symptomatic COVID-19 and positive RT-PCR test result at least 14 days after the second dose78%, 100% efficacy against hospitalization, ≥ 18 years old (2–18 years old: study ongoing)Two doses (14 days apart; 14 or 28 days apart in Chile)Sinovac Biotech (CoronaVac)Inactivated virusP.1 and P.2Symptomatic, virologically confirmed COVID-19 occurring from 2 weeks after the second dose up to 1 year after the first doseMultiple studies in different countries: 50.7% (Brazil), 56.5% (Chile), 65% (Indonesia), 78% (Brazil) and 91% (Turkey), 51% efficacy against symptomatic SARS-CoV-2 infection; 100% efficacy against severe disease; 100% efficacy against hospitalization from 14 days after second dose, ≥ 18 years oldTwo doses (21 days apart)Sinopharm (BBIBP-CorV)Inactivated virusNo variants have been identified originating from the trial locations during this time (June 2021)Occurrence of COVID-1978%, 79% efficacy against hospitalization, ≥ 18 years oldTwo doses (21 days apart)Novavax (NVX-CoV2373)Protein subunitB.1.1.7, B.1.351, B.1.427/B.1.429, B.1.526Symptomatic COVID-19 and positive RT-PCR test result at least 7 days after the second dose89%, 100% efficacy against severe disease and hospitalization, ≥ 18 years old (12–17 years old: study ongoing, NCT04611802)Two doses (21–28 days apart)VECTOR (EpiVacCorona) (NCT04780035)Protein subunitNo variants have been identified originating in the trial locations during this time (June 2021)Symptomatic COVID-19, laboratory-confirmed COVID-19 within 6 months after the first doseNo data available (June 2021), No data available (June 2021), ≥ 18 years oldCDC Centers for Disease Control and Prevention; FDA US Food and Drug Administration; NAAT nucleic acid amplification test; RT-PCR reverse transcription-polymerase chain reaction; SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.",PMC9083482
Alpha,"Vaccine safety was similar to that of other viral vaccines over a median of 2 months [45].Table 5Comparative analyses of vaccine effectiveness against different outcomes of dominant SARS-CoV-2 alpha VOCs [15, 16]OutcomesVaccine effectivenessPfizer-BioNTechOxford-AstraZenecaOne doseTwo dosesOne doseTwo dosesSymptomatic COVID-19 infections/disease55–70%a85–95%a55–70%a70–85%bHospitalization of COVID-19 patients75–85%a90–99%b75–85%a80–99%cMortality70–85%95–99%b75–85%b75–99%cCOVID-19 infection55–70%b70–90%c55–70%b65–90%cCOVID-19 transmission (secondary cases)45–50%cNo data35–50%cNo dataaHigh confidence.",PMC9083482
Epsilon,"Therefore, the conclusions of this study should be used carefully in the context of intestinal immune response in severe COVID-19..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD20 Monoclonal AntibodyThermoFisher ScientificCat#MA1-10135; RRID: AB_11152399CD3-εPolyclonal AntibodyImmunoWayCat#YT0761CD3 epsilon antibodyGenetexCat#GTX42110; RRID: AB_11178619Recombinant Anti-CD16 AntibodyAbcamCat#ab246222;Purified anti-human CD1c AntibodyBiolegendCat#331502; RRID: AB_1088995Recombinant Anti-CD163 AntibodyAbcamCat#ab182422; RRID: AB_2753196CD74 (D5N3I) XP® Rabbit mAbCell SignalingCat#77274S; RRID: AB_2799893Granzyme B mouse mAb(PT0564)ImmunoWayCat#YM4028CD38 Monoclonal AntibodyProteintechCat#60006-1-Ig; RRID: AB_716994CD69 Polyclonal AntibodyProteintechCat#10803-1-AP; RRID: AB_2074965ZO-1 Monoclonal AntibodyThermoFisher ScientificCat#33–9100; RRID: AB_2533147Recombinant Anti- Claudin 1 AntibodyAbcamCat#ab211737IFN gamma Monoclonal AntibodyR&D systemsCa#AF-285-NA; RRID: AB_354445IFN gamma Monoclonal AntibodyThermoFisher ScientificCat#MA5-23718; RRID: AB_2609805Alexa Fluor 488 Donkey Anti-Goat IgG (H + L)ThermoFisher ScientificCat#A11055; RRID: AB_2534102Alexa Fluor® 488 Goat Anti-rat IgG H&LAbcamCat#ab150157; RRID: AB_2722511Alexa Fluor® 555 Goat Anti-Mouse IgG-H&LAbcamCat#ab150114; RRID: AB_2687594Alexa Fluor 647 donkey Anti-Rabbit IgG (H + L)AbcamCat#ab150075; RRID: AB_2752244NHP T/B/NK Cell CocktailBD BiosciencesCat#558639; RRID: AB_1645290PerCP-Cy™5.5 Mouse Anti-Human CD3BD BiosciencesCat#552852; RRID: AB_394493Brilliant Violet 421™ Anti-human CD19 AntibodyBioLegendCat#302234; RRID: AB_11142678FITC Anti-human CD14 AntibodyBioLegendCat#301804; RRID: AB_314186PE Mouse Anti-Human CD56BD BiosciencesCat#556647; RRID: AB_396511PE/Cyanine7 Anti-human HLA-DR AntibodyBioLegendCat#307616; RRID: AB_493588PE/Cyanine7 Anti-human CD163 AntibodyBioLegendCat#333614; RRID: AB_2562641SARS-CoV-2 Nucleocapsid Antibody, Rabbit MabSino BiologicalCat#40143-R001; RRID: AB_2827974Bacterial and virus strainsSARS-CoV-2-KMS1/2020(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Chemicals, peptides, and recombinant proteinsLymphocyte Separation Medium (Human)SolarbioCat#P8610Trypsin-EDTA SolutionSIGMACat#T4049RNase-free WaterTAKARACat#9012Dulbecco’s Modified Eagle’s Medium (DMEM)SigmaCat#d8371DAPIAbcamCat#ab104139Phosphate Buffered Saline (PBS)CorningCat#21-040-CVCFetal bovine serum (FBS)GibcoCat#10099–141TRNzol Universal ReagentTianGenCat#DP424Albumin bovine serumSigma-AldrichCat#A1933Sodium Citrate bufferSolarbio®Cat#C1010Triton®X-100BioFroxCat#1139ML500Tween 20BioFroxCat#1247ML500Critical commercial assaysGEXSCOPE® Single Cell RNA Amplification & Library Reagents KitSingleronCat1110011LA1GEXSCOPE® Single Cell Barcoding Beads KitSingleronCat#1110011SB2GEXSCOPE® Single Cell Microchip & Wash Buffer Set KitSingleronCat#1110011MC3Hematoxylin-Eosin/HE Staining KitSolarbioCat#G1120Metal Enhanced DAB Substrate KitSolarbioCat#DA1015Universal Two-Step Detection Kit (Mouse/Rabbit Enhanced Polymer Detection System)ZSGB-BIOCat#PV-9000One Step PrimScript RT-PCR KitTaKaRaCat#RR064ANon-human Primate Cytokine Magnetic Bead PanelMilliporePRCYTOMAG-40K, PCYTMG-40K-PX23, PRCYMAG40PMX23BKGEXSCOPE® Single Cell RNA Amplification & Library Reagents TissueSingleronCat#1110011LA1GEXSCOPE® Tissue Preservation SolutionSingleronCat#SN154211GEXSCOPE® Tissue Dissociation MixSingleronCat#SN421201OligonucleotidesProbe: ORF1ab-P: 5′-CCGTCTGCGGTATGTGGAAAGGTTATGG-3′(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Primer: ORF1ab-F: 5′-CCCTGTGGGTTTTACACTTA-3′(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Primer: ORF1ab-R: 5′-ACGATTGTGCATCAGCTG-3′(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Software and algorithmsPrism 8.0Graphpadhttps://www.graphpad.com/scientific-software/prism/Adobe IllustratorAdobe Illustratorhttps://www.adobe.com/Adobe PhotoshopAdobe Photoshophttps://www.adobe.com/BioRenderBioRenderhttps://biorender.com/Python version 3.7Python (2020)https://www.python.org/downloads/release/python-370/R version 3.5R Foundation for Statistical Computing (2017)https://www.R-project.orgSeurat (v3.1.2, R package)(Stuart et al., 2019)https://github.com/satijalab/seuratClusterProfiler (v3.16.1, R package)(Yu et al., 2012)http://www.bioconductor.org/packages/release/bioc/html/clusterProfiler.htmlCellPhoneDB(v2.1.7)(Efremova et al., 2020)https://github.com/Teichlab/cellphonedbUCell (v1.1.0, R package)(Andreatta and Carmona, 2021)https://github.com/carmonalab/UCellMfuzz (2.46.0, R package)(Kumar and Futschik, 2007)http://www.bioconductor.org/packages/releaseDeposited dataRaw and analyzed dataThis paperCNSA:CNP0002884OtherIron beadsSolarbioCat#YA3031
.",PMC9080054
Gamma,"Therefore, the conclusions of this study should be used carefully in the context of intestinal immune response in severe COVID-19..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD20 Monoclonal AntibodyThermoFisher ScientificCat#MA1-10135; RRID: AB_11152399CD3-εPolyclonal AntibodyImmunoWayCat#YT0761CD3 epsilon antibodyGenetexCat#GTX42110; RRID: AB_11178619Recombinant Anti-CD16 AntibodyAbcamCat#ab246222;Purified anti-human CD1c AntibodyBiolegendCat#331502; RRID: AB_1088995Recombinant Anti-CD163 AntibodyAbcamCat#ab182422; RRID: AB_2753196CD74 (D5N3I) XP® Rabbit mAbCell SignalingCat#77274S; RRID: AB_2799893Granzyme B mouse mAb(PT0564)ImmunoWayCat#YM4028CD38 Monoclonal AntibodyProteintechCat#60006-1-Ig; RRID: AB_716994CD69 Polyclonal AntibodyProteintechCat#10803-1-AP; RRID: AB_2074965ZO-1 Monoclonal AntibodyThermoFisher ScientificCat#33–9100; RRID: AB_2533147Recombinant Anti- Claudin 1 AntibodyAbcamCat#ab211737IFN gamma Monoclonal AntibodyR&D systemsCa#AF-285-NA; RRID: AB_354445IFN gamma Monoclonal AntibodyThermoFisher ScientificCat#MA5-23718; RRID: AB_2609805Alexa Fluor 488 Donkey Anti-Goat IgG (H + L)ThermoFisher ScientificCat#A11055; RRID: AB_2534102Alexa Fluor® 488 Goat Anti-rat IgG H&LAbcamCat#ab150157; RRID: AB_2722511Alexa Fluor® 555 Goat Anti-Mouse IgG-H&LAbcamCat#ab150114; RRID: AB_2687594Alexa Fluor 647 donkey Anti-Rabbit IgG (H + L)AbcamCat#ab150075; RRID: AB_2752244NHP T/B/NK Cell CocktailBD BiosciencesCat#558639; RRID: AB_1645290PerCP-Cy™5.5 Mouse Anti-Human CD3BD BiosciencesCat#552852; RRID: AB_394493Brilliant Violet 421™ Anti-human CD19 AntibodyBioLegendCat#302234; RRID: AB_11142678FITC Anti-human CD14 AntibodyBioLegendCat#301804; RRID: AB_314186PE Mouse Anti-Human CD56BD BiosciencesCat#556647; RRID: AB_396511PE/Cyanine7 Anti-human HLA-DR AntibodyBioLegendCat#307616; RRID: AB_493588PE/Cyanine7 Anti-human CD163 AntibodyBioLegendCat#333614; RRID: AB_2562641SARS-CoV-2 Nucleocapsid Antibody, Rabbit MabSino BiologicalCat#40143-R001; RRID: AB_2827974Bacterial and virus strainsSARS-CoV-2-KMS1/2020(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Chemicals, peptides, and recombinant proteinsLymphocyte Separation Medium (Human)SolarbioCat#P8610Trypsin-EDTA SolutionSIGMACat#T4049RNase-free WaterTAKARACat#9012Dulbecco’s Modified Eagle’s Medium (DMEM)SigmaCat#d8371DAPIAbcamCat#ab104139Phosphate Buffered Saline (PBS)CorningCat#21-040-CVCFetal bovine serum (FBS)GibcoCat#10099–141TRNzol Universal ReagentTianGenCat#DP424Albumin bovine serumSigma-AldrichCat#A1933Sodium Citrate bufferSolarbio®Cat#C1010Triton®X-100BioFroxCat#1139ML500Tween 20BioFroxCat#1247ML500Critical commercial assaysGEXSCOPE® Single Cell RNA Amplification & Library Reagents KitSingleronCat1110011LA1GEXSCOPE® Single Cell Barcoding Beads KitSingleronCat#1110011SB2GEXSCOPE® Single Cell Microchip & Wash Buffer Set KitSingleronCat#1110011MC3Hematoxylin-Eosin/HE Staining KitSolarbioCat#G1120Metal Enhanced DAB Substrate KitSolarbioCat#DA1015Universal Two-Step Detection Kit (Mouse/Rabbit Enhanced Polymer Detection System)ZSGB-BIOCat#PV-9000One Step PrimScript RT-PCR KitTaKaRaCat#RR064ANon-human Primate Cytokine Magnetic Bead PanelMilliporePRCYTOMAG-40K, PCYTMG-40K-PX23, PRCYMAG40PMX23BKGEXSCOPE® Single Cell RNA Amplification & Library Reagents TissueSingleronCat#1110011LA1GEXSCOPE® Tissue Preservation SolutionSingleronCat#SN154211GEXSCOPE® Tissue Dissociation MixSingleronCat#SN421201OligonucleotidesProbe: ORF1ab-P: 5′-CCGTCTGCGGTATGTGGAAAGGTTATGG-3′(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Primer: ORF1ab-F: 5′-CCCTGTGGGTTTTACACTTA-3′(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Primer: ORF1ab-R: 5′-ACGATTGTGCATCAGCTG-3′(Zheng et al., 2020a)https://pubmed.ncbi.nlm.nih.gov/33180882/Software and algorithmsPrism 8.0Graphpadhttps://www.graphpad.com/scientific-software/prism/Adobe IllustratorAdobe Illustratorhttps://www.adobe.com/Adobe PhotoshopAdobe Photoshophttps://www.adobe.com/BioRenderBioRenderhttps://biorender.com/Python version 3.7Python (2020)https://www.python.org/downloads/release/python-370/R version 3.5R Foundation for Statistical Computing (2017)https://www.R-project.orgSeurat (v3.1.2, R package)(Stuart et al., 2019)https://github.com/satijalab/seuratClusterProfiler (v3.16.1, R package)(Yu et al., 2012)http://www.bioconductor.org/packages/release/bioc/html/clusterProfiler.htmlCellPhoneDB(v2.1.7)(Efremova et al., 2020)https://github.com/Teichlab/cellphonedbUCell (v1.1.0, R package)(Andreatta and Carmona, 2021)https://github.com/carmonalab/UCellMfuzz (2.46.0, R package)(Kumar and Futschik, 2007)http://www.bioconductor.org/packages/releaseDeposited dataRaw and analyzed dataThis paperCNSA:CNP0002884OtherIron beadsSolarbioCat#YA3031
.",PMC9080054
Alpha,"In September 2020, the Alpha variant (Pango lineage B1.1.7) was first detected in England and designated as a VOC [16].",PMC9069976
Beta,"Almost simultaneously, the Beta VOC (Pango lineage B1.351) with the same amino acid substitution (N501Y) was reported from South Africa.",PMC9069976
P.1,"In January 2021, the Gamma VOC (Pango linage P.1) with ten substitutions (L18F, T20N, P26S, D138Y, R190S, H655Y, T1027I V1176, K417T, E484K, and N501Y) in the S protein was detected from four Brazilians travelling to Japan [21].",PMC9069976
Gamma,"In January 2021, the Gamma VOC (Pango linage P.1) with ten substitutions (L18F, T20N, P26S, D138Y, R190S, H655Y, T1027I V1176, K417T, E484K, and N501Y) in the S protein was detected from four Brazilians travelling to Japan [21].",PMC9069976
B.1.1,"The virulence of Delta VOC was also compared with B.1.1, the parent variant of Omicron VOC.",PMC9069976
B.1,"The neutralizing antibodies produced by infection with the Delta VOC can effectively neutralize Beta VOC, B.1 and B1.617.3 with an observed decrease of 2.5/1.8/1.8-fold, respectively [57]..",PMC9069976
B.1.1.529,"The latest variant of SARS-CoV-2, called B.1.1.529 variant or Omicron, was first discovered in the specimens collected in Botswana, a country in South Africa, on November 11, 2021 (Prevention, 2021).",PMC9065598
Alpha,"As a result, the PCR tests cannot detect an Omicron, or Alpha, variant (Control, 2022)..",PMC9065598
B.1.1,"Compared to the previous B.1, B.1.1, and Delta SARS-CoV-2 variants, the Omicron SARS-CoV-2 virus has several sequence modifications.",PMC9065598
B.1,"Compared to the previous B.1, B.1.1, and Delta SARS-CoV-2 variants, the Omicron SARS-CoV-2 virus has several sequence modifications.",PMC9065598
Mu,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
Gamma,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
B.1.621,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
C.37,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
B.1.617.2,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
B.1.1.7,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
B.1.351,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
P.1,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
Beta,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
Lambda,"This table represents a detailed comparative overview of the most studied variants of Covid-19, first detection, changes in amino acids including amino acid mutation in S protein, number of mutations, transmissibility, and GISAID clade.Covid-19 VariantsAlpha (α) (B.1.1.7)Beta (β) (B.1.351)Gamma (γ) (P.1)Delta (δ) (B.1.617.2)Lambda (λ) (C.37)Mu (μ) (B.1.621)Omicron (ο) (B.1.1.529)GISAID cladeGRYGH/501Y.V2GR/501Y.V3G/478 K.V1GR/452Q.V1GHGRANext strain clade20I (V1)20H (V2)20 J (V3)21A, 21I, 21 J21G21H21 K, 21L, 21 MMonitored Amino acid changes+S:484 K+S:452R+S: L18F+S:681H+S:417 N+S:484 K––+S: R346KFirst detectionUnited Kingdom (UK)South Africa (SA)BrazilIndia (IN)PeruColombiaSeveral CountriesInitially recorded samplesSept 2020May 2020Nov 2020Oct 2020Dec 2020Jan 2021Nov 2021Date of DesignationDec 18, 2020Dec 18, 2020Jan 11, 2021May 11, 2021Jun 14, 2021Aug 13, 2021Nov 26, 2021No.",PMC9065598
Mu,"The neutralizing capacity was measured at one, three, and six-months post-vaccination by plaque reduction neutralization assay using SARS-CoV-2 B.1 (D614G) and the Gamma, Alpha, Delta, and Mu variants.",PMC9108166
B.1,"The neutralizing capacity was measured at one, three, and six-months post-vaccination by plaque reduction neutralization assay using SARS-CoV-2 B.1 (D614G) and the Gamma, Alpha, Delta, and Mu variants.",PMC9108166
Alpha,"The neutralizing capacity was measured at one, three, and six-months post-vaccination by plaque reduction neutralization assay using SARS-CoV-2 B.1 (D614G) and the Gamma, Alpha, Delta, and Mu variants.",PMC9108166
Gamma,"The neutralizing capacity was measured at one, three, and six-months post-vaccination by plaque reduction neutralization assay using SARS-CoV-2 B.1 (D614G) and the Gamma, Alpha, Delta, and Mu variants.",PMC9108166
Beta,"The World Health Organization (WHO) has currently designated five VOCs -Alpha, Beta, Gamma, Delta, and Omicron- and two VOIs -Lambda and Mu-, many of which contain important mutations for immune evasion such as E484K and N501Y (5, 7).",PMC9108166
B.1.117,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
B.1.621,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
B.1.617.2,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
P.1,"The lineages assessed were B.1 (D614G) (hCoV-19/Colombia/ANTUdeA-200325-01/2020 ID accession: EPI_ISL_536399), variants of concern (VOC) Gamma (P.1) (hCoV-19/Colombia/ANT-UdeA-21002835v/2021 ID accession: EPI_ISL_4926393), Alpha (B.1.117) (hCoV-19/Colombia/ANT-UdeA-21001965v/2021 ID accession: and Delta (B.1.617.2) (hCoV-19/Colombia/ANT-UdeA-36211/2021 ID accession: EPI_ISL_5103929), and the variant of interest (VOI) Mu (B.1.621) (hCoV-19/Colombia/ANT-UdeA-21002149/2021 ID accession: EPI_ISL_4005445).",PMC9108166
B.1.111,"found that serum neutralizing activity from individuals vaccinated with BNT162b2 decreased by 75.7- and 17.7-fold against Mu, with respect to B.1.111 lineage and Gamma variant, respectively (26).",PMC9108166
C.1.2,"reported that Mu and C.1.2 variants were more resistant to neutralization by BNT162b2 vaccination (6.8- and 7.3-fold decrease in titer, respectively, compared with D614G strain) (27).",PMC9108166
B.1.1.529,"In March 2022, the Omicron variant (B.1.1.529 and BA lineages) is the most recently recognized variant of concern, and it has spread worldwide (WHO, 2022).",PMC9057982
B.1.1,"Additionally, the S protein of BA.1 is less efficiently cleaved by furin and less fusogenic than those of the Delta variant and an ancestral SARS-CoV-2 variant belonging to the B.1.1 lineage (Meng et al., 2022; Suzuki et al., 2022), and the pathogenicity of BA.1 is attenuated relative to that of Delta and the ancestral B.1.1 virus (Halfmann et al., 2022; Shuai et al., 2022; Suzuki et al., 2022).",PMC9057982
Gamma,"For example, BA.1 differs from BA.2 by 50 amino acids, which is approximately twice the number found among four other variants of concern (Alpha, Beta, Gamma, and Delta) and Wuhan-Hu-1, a prototypical SARS-CoV-2 isolate (Figure 1B).",PMC9057982
Alpha,"For example, BA.1 differs from BA.2 by 50 amino acids, which is approximately twice the number found among four other variants of concern (Alpha, Beta, Gamma, and Delta) and Wuhan-Hu-1, a prototypical SARS-CoV-2 isolate (Figure 1B).",PMC9057982
Beta,"For example, BA.1 differs from BA.2 by 50 amino acids, which is approximately twice the number found among four other variants of concern (Alpha, Beta, Gamma, and Delta) and Wuhan-Hu-1, a prototypical SARS-CoV-2 isolate (Figure 1B).",PMC9057982
B.1.617.2,"The dynamics of BA.1, BA.1.1, BA.2, and Delta (B.1.617.2 and AY lineages) in each country from October 1, 2021, to January 25, 2022, were analyzed.",PMC9057982
B.1.1.7,"We confirmed that the relative effective reproduction number of BA.2 in Denmark estimated by our model (1.28) is comparative with that by the previous study (1.26) (Table S1)..

Plasmids expressing the SARS-CoV-2 S proteins of B.1.1 (the parental D614G-bearing variant), Alpha (B.1.1.7), Delta (B.1.617.2) and BA.1 variants were prepared in our previous studies (Kimura et al., 2022; Meng et al., 2022; Motozono et al., 2021; Ozono et al., 2021; Saito et al., 2022; Suzuki et al., 2022).",PMC9057982
Kappa,"The obtained coding sequences of the variable regions of the heavy and light chains were cloned into the pCAGGS vector containing the sequences of the human immunoglobulin 1 and kappa constant region [kindly provided by Dr. Hisashi Arase (Osaka University, Japan)].",PMC9057982
Gamma,"For the ML analysis, we used GTR nucleotide substitution model and GAMMA among-site rate heterogeneity (four discrete rate categories) in RAxML (https://raxml-ng.vital-it.ch).",PMC9113349
Beta,"In the Syrian hamster studies, when S-Trimer was adjuvanted with SWE, higher levels of neutralizing antibodies were induced against live SARS-CoV-2 from the original lineage and against the emergence of variants (Beta or Delta) with a slightly decreased potency.",PMC9101745
B.1.351,"Here, we evaluated the neutralization ability of the serum samples collected from the hamsters vaccinated with various doses of S-Trimer with SWE adjuvant against the SARS-CoV-2 Beta (B.1.351) or Delta (B.1.617.2) variants compared to the neutralization of wild-type SARS-CoV-2 (Figure 8).",PMC9101745
B.1.617.2,"Here, we evaluated the neutralization ability of the serum samples collected from the hamsters vaccinated with various doses of S-Trimer with SWE adjuvant against the SARS-CoV-2 Beta (B.1.351) or Delta (B.1.617.2) variants compared to the neutralization of wild-type SARS-CoV-2 (Figure 8).",PMC9101745
B.1,"For example, a Beta strain (B.1.351) that encodes the K417N/E484K/N501Y mutations in RBD abolished the neutralizing activity in the plasma from individuals vaccinated with BNT162b2 (Pzifer/BioNTech) or mRNA-1273 (Moderna), who exhibited reductions of 10.3- to 14-fold or 3.8- to 8.4-fold, respectively, when compared to that of the B.1 (D614G) strain [39,40,41,42,43].",PMC9101745
B.1.617.2,"Here we report the isolation of five neutralizing mAbs from an Indian convalescent donor, out of which two (THSC20.HVTR04 and THSC20.HVTR26) showed potent neutralization of SARS-CoV-2 VOCs at picomolar concentrations, including the Delta variant (B.1.617.2).",PMC9089897
Alpha,"These mAbs have variable activity against different VOCs, including loss of neutralization activity of Bamlanivimab against Delta and Beta variants, loss of activity of Etesivimab against Beta and reduced activity against Alpha variant, and reduced activity of Casirivimab against the Beta variant.",PMC9089897
Beta,"These mAbs have variable activity against different VOCs, including loss of neutralization activity of Bamlanivimab against Delta and Beta variants, loss of activity of Etesivimab against Beta and reduced activity against Alpha variant, and reduced activity of Casirivimab against the Beta variant.",PMC9089897
Gamma,"We report the discovery of two monoclonal antibodies (THSC20.HVTR04 and THSC20.HVTR26) that have non-competing epitope specificities on the RBD and show potent neutralization of Alpha, Beta, Gamma, and Delta VOCs.",PMC9089897
Kappa,"While all the five mAbs as purified IgGs neutralized pseudovirus expressing spikes of SARS-CoV-2 wild type, Alpha, Beta and Kappa (with IC50 ranging from 0.003–7.2 μg/mL), one of the mAbs (THSC20.HVTR39) showed evidence of neutralizing both SARS-CoV and SARS-CoV2.",PMC9089897
Lambda,"Except for THSC20.HVTR88, which has a kappa light chain, all the other four mAbs (THSC20.HVTR04, THSC20.HVTR06, THSC20.HVTR26 and THSC20.HVTR39) have lambda light chains.",PMC9089897
B.1.36,"For the corresponding light chains, the level of IGLV gene somatic mutation ranges from 93.01 to 97.92, while the mAb with a kappa chain is 100% identical to its IGKV germline (S2 Table)..

Next, we examined the ability of the newly isolated mAbs to neutralize the SARS-CoV-2 VOCs (Alpha, Beta, Gamma, and Delta) and variants of interest (VOIs) that have circulated in India (Kappa, B.1.36 and Delta plus).",PMC9089897
B.1.617.1,"For this purpose, we expressed the SARS-CoV-2 spikes representing Wuhan wild-type or Kappa (B.1.617.1) variant sequences on the surface of 293T cells and measured binding of mAbs to cell surface spike by fluorescence-activated cell sorting (FACS).",PMC9089897
B.1.351,"Here, we generate LNP-mRNAs specifically encoding wild-type (WT), B.1.351, and B.1.617 SARS-CoV-2 spikes, and systematically study their immune responses.",PMC9040489
B.1.617,"Here, we generate LNP-mRNAs specifically encoding wild-type (WT), B.1.351, and B.1.617 SARS-CoV-2 spikes, and systematically study their immune responses.",PMC9040489
Beta,"All three vaccines offer potent protection against in vivo challenges of authentic viruses of WA-1, Beta, and Delta variants.",PMC9040489
B.1.617.3,"Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the pathogen of coronavirus disease 2019 (COVID-19), has caused the ongoing global pandemic.1 Although lipid nanoparticle (LNP)-mRNA-based vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have demonstrated high efficacy against COVID-19, breakthrough infections have been widely reported in fully vaccinated individuals.2, 3, 4, 5, 6, 7, 8 Moreover, the virus continues to , and multiple dangerous variant lineages have evolved, such as B.1.1.7, B.1.351, and, more recently, B.1.617.9
,
10 The B.1.1.7 lineage (Alpha variant, or “UK variant”) has an increased rate of transmission and higher mortality.11 The B.1.351 lineage (Beta variant, or “South Africa variant”) has an increased rate of transmission, resistance to antibody therapeutics, and reduced vaccine efficacy.12, 13, 14 The lineage B.1.617 (“Indian variant” lineage, including B.1.617.1 “Kappa variant,” B.1.617.2 “Delta variant,” and B.1.617.3) has recently emerged, spread rapidly, and become dominant in multiple regions in the world.15
,
16 The on-going surge of infections in the US is predominantly caused by the Delta variant, originating from the B.1.617 lineage that has >1,000-fold higher viral load in infected individuals.17
,
18 The B.1.617 lineage has an increased rate of transmission, showing reduced serum antibody reactivity in vaccinated individuals, and exhibits resistance to antibody therapeutics.19, 20, 21, 22, 23 These variants often spread faster than the ancestral “wild-type” (WT) virus (also noted as Wuhan-1 or WA-1, with identical spike sequences), cause more severe disease, are more likely to escape certain host immune response, cause disproportionally higher numbers of breakthrough infections despite the status of full vaccination,12
,
14
,
24, 25, 26 and have been designated by WHO and CDC as “variants of concern” (VoCs).27 Regarding their effects on vaccine efficacy, B.1.351, for example, has been known to reduce the efficacy of the Pfizer-BioNTech vaccine from >90% to near 70%.26 The Delta variant has also resulted in significant reduction of vaccine efficacy, especially for individuals who received only a single dose,25 and has caused widespread breakthrough infections despite the status of full vaccination.28
.",PMC9040489
B.1.617.2,"Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the pathogen of coronavirus disease 2019 (COVID-19), has caused the ongoing global pandemic.1 Although lipid nanoparticle (LNP)-mRNA-based vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have demonstrated high efficacy against COVID-19, breakthrough infections have been widely reported in fully vaccinated individuals.2, 3, 4, 5, 6, 7, 8 Moreover, the virus continues to , and multiple dangerous variant lineages have evolved, such as B.1.1.7, B.1.351, and, more recently, B.1.617.9
,
10 The B.1.1.7 lineage (Alpha variant, or “UK variant”) has an increased rate of transmission and higher mortality.11 The B.1.351 lineage (Beta variant, or “South Africa variant”) has an increased rate of transmission, resistance to antibody therapeutics, and reduced vaccine efficacy.12, 13, 14 The lineage B.1.617 (“Indian variant” lineage, including B.1.617.1 “Kappa variant,” B.1.617.2 “Delta variant,” and B.1.617.3) has recently emerged, spread rapidly, and become dominant in multiple regions in the world.15
,
16 The on-going surge of infections in the US is predominantly caused by the Delta variant, originating from the B.1.617 lineage that has >1,000-fold higher viral load in infected individuals.17
,
18 The B.1.617 lineage has an increased rate of transmission, showing reduced serum antibody reactivity in vaccinated individuals, and exhibits resistance to antibody therapeutics.19, 20, 21, 22, 23 These variants often spread faster than the ancestral “wild-type” (WT) virus (also noted as Wuhan-1 or WA-1, with identical spike sequences), cause more severe disease, are more likely to escape certain host immune response, cause disproportionally higher numbers of breakthrough infections despite the status of full vaccination,12
,
14
,
24, 25, 26 and have been designated by WHO and CDC as “variants of concern” (VoCs).27 Regarding their effects on vaccine efficacy, B.1.351, for example, has been known to reduce the efficacy of the Pfizer-BioNTech vaccine from >90% to near 70%.26 The Delta variant has also resulted in significant reduction of vaccine efficacy, especially for individuals who received only a single dose,25 and has caused widespread breakthrough infections despite the status of full vaccination.28
.",PMC9040489
B.1.617.1,"Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the pathogen of coronavirus disease 2019 (COVID-19), has caused the ongoing global pandemic.1 Although lipid nanoparticle (LNP)-mRNA-based vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have demonstrated high efficacy against COVID-19, breakthrough infections have been widely reported in fully vaccinated individuals.2, 3, 4, 5, 6, 7, 8 Moreover, the virus continues to , and multiple dangerous variant lineages have evolved, such as B.1.1.7, B.1.351, and, more recently, B.1.617.9
,
10 The B.1.1.7 lineage (Alpha variant, or “UK variant”) has an increased rate of transmission and higher mortality.11 The B.1.351 lineage (Beta variant, or “South Africa variant”) has an increased rate of transmission, resistance to antibody therapeutics, and reduced vaccine efficacy.12, 13, 14 The lineage B.1.617 (“Indian variant” lineage, including B.1.617.1 “Kappa variant,” B.1.617.2 “Delta variant,” and B.1.617.3) has recently emerged, spread rapidly, and become dominant in multiple regions in the world.15
,
16 The on-going surge of infections in the US is predominantly caused by the Delta variant, originating from the B.1.617 lineage that has >1,000-fold higher viral load in infected individuals.17
,
18 The B.1.617 lineage has an increased rate of transmission, showing reduced serum antibody reactivity in vaccinated individuals, and exhibits resistance to antibody therapeutics.19, 20, 21, 22, 23 These variants often spread faster than the ancestral “wild-type” (WT) virus (also noted as Wuhan-1 or WA-1, with identical spike sequences), cause more severe disease, are more likely to escape certain host immune response, cause disproportionally higher numbers of breakthrough infections despite the status of full vaccination,12
,
14
,
24, 25, 26 and have been designated by WHO and CDC as “variants of concern” (VoCs).27 Regarding their effects on vaccine efficacy, B.1.351, for example, has been known to reduce the efficacy of the Pfizer-BioNTech vaccine from >90% to near 70%.26 The Delta variant has also resulted in significant reduction of vaccine efficacy, especially for individuals who received only a single dose,25 and has caused widespread breakthrough infections despite the status of full vaccination.28
.",PMC9040489
B.1.1.7,"Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the pathogen of coronavirus disease 2019 (COVID-19), has caused the ongoing global pandemic.1 Although lipid nanoparticle (LNP)-mRNA-based vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have demonstrated high efficacy against COVID-19, breakthrough infections have been widely reported in fully vaccinated individuals.2, 3, 4, 5, 6, 7, 8 Moreover, the virus continues to , and multiple dangerous variant lineages have evolved, such as B.1.1.7, B.1.351, and, more recently, B.1.617.9
,
10 The B.1.1.7 lineage (Alpha variant, or “UK variant”) has an increased rate of transmission and higher mortality.11 The B.1.351 lineage (Beta variant, or “South Africa variant”) has an increased rate of transmission, resistance to antibody therapeutics, and reduced vaccine efficacy.12, 13, 14 The lineage B.1.617 (“Indian variant” lineage, including B.1.617.1 “Kappa variant,” B.1.617.2 “Delta variant,” and B.1.617.3) has recently emerged, spread rapidly, and become dominant in multiple regions in the world.15
,
16 The on-going surge of infections in the US is predominantly caused by the Delta variant, originating from the B.1.617 lineage that has >1,000-fold higher viral load in infected individuals.17
,
18 The B.1.617 lineage has an increased rate of transmission, showing reduced serum antibody reactivity in vaccinated individuals, and exhibits resistance to antibody therapeutics.19, 20, 21, 22, 23 These variants often spread faster than the ancestral “wild-type” (WT) virus (also noted as Wuhan-1 or WA-1, with identical spike sequences), cause more severe disease, are more likely to escape certain host immune response, cause disproportionally higher numbers of breakthrough infections despite the status of full vaccination,12
,
14
,
24, 25, 26 and have been designated by WHO and CDC as “variants of concern” (VoCs).27 Regarding their effects on vaccine efficacy, B.1.351, for example, has been known to reduce the efficacy of the Pfizer-BioNTech vaccine from >90% to near 70%.26 The Delta variant has also resulted in significant reduction of vaccine efficacy, especially for individuals who received only a single dose,25 and has caused widespread breakthrough infections despite the status of full vaccination.28
.",PMC9040489
Alpha,"Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the pathogen of coronavirus disease 2019 (COVID-19), has caused the ongoing global pandemic.1 Although lipid nanoparticle (LNP)-mRNA-based vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have demonstrated high efficacy against COVID-19, breakthrough infections have been widely reported in fully vaccinated individuals.2, 3, 4, 5, 6, 7, 8 Moreover, the virus continues to , and multiple dangerous variant lineages have evolved, such as B.1.1.7, B.1.351, and, more recently, B.1.617.9
,
10 The B.1.1.7 lineage (Alpha variant, or “UK variant”) has an increased rate of transmission and higher mortality.11 The B.1.351 lineage (Beta variant, or “South Africa variant”) has an increased rate of transmission, resistance to antibody therapeutics, and reduced vaccine efficacy.12, 13, 14 The lineage B.1.617 (“Indian variant” lineage, including B.1.617.1 “Kappa variant,” B.1.617.2 “Delta variant,” and B.1.617.3) has recently emerged, spread rapidly, and become dominant in multiple regions in the world.15
,
16 The on-going surge of infections in the US is predominantly caused by the Delta variant, originating from the B.1.617 lineage that has >1,000-fold higher viral load in infected individuals.17
,
18 The B.1.617 lineage has an increased rate of transmission, showing reduced serum antibody reactivity in vaccinated individuals, and exhibits resistance to antibody therapeutics.19, 20, 21, 22, 23 These variants often spread faster than the ancestral “wild-type” (WT) virus (also noted as Wuhan-1 or WA-1, with identical spike sequences), cause more severe disease, are more likely to escape certain host immune response, cause disproportionally higher numbers of breakthrough infections despite the status of full vaccination,12
,
14
,
24, 25, 26 and have been designated by WHO and CDC as “variants of concern” (VoCs).27 Regarding their effects on vaccine efficacy, B.1.351, for example, has been known to reduce the efficacy of the Pfizer-BioNTech vaccine from >90% to near 70%.26 The Delta variant has also resulted in significant reduction of vaccine efficacy, especially for individuals who received only a single dose,25 and has caused widespread breakthrough infections despite the status of full vaccination.28
.",PMC9040489
B.1.351,"LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2.",PMC9035363
B.1.1.7,"LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2.",PMC9035363
B.1.427,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.617.2,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.1.529,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
P.1,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.526,"In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant.",PMC9035363
B.1.429,"Variants such as B.1.1.529, BA.2, B.1.1.7, B.1.351, P.1, B.1.526, B.1.427, and B.1.429 affect the in vitro binding of antibodies being tested clinically or of those already authorized for emergency use to varying degrees (Kuzmina et al., 2021; Liu et al., 2021; Rees-Spear et al., 2021; Iketani et al., 2022).",PMC9035363
B.1.617.3,"LY-CoV1404 binds to or neutralizes variants, including B.1.1.529 (Omicron) and those first identified in India (B.1.617.1, B.1.617.2, and B.1.617.3), the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526).",PMC9035363
B.1.617.1,"LY-CoV1404 binds to or neutralizes variants, including B.1.1.529 (Omicron) and those first identified in India (B.1.617.1, B.1.617.2, and B.1.617.3), the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526).",PMC9035363
B.1.426,"LY-CoV1404 binds to or neutralizes variants, including B.1.1.529 (Omicron) and those first identified in India (B.1.617.1, B.1.617.2, and B.1.617.3), the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526).",PMC9035363
Gamma,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.617.2,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.1.7,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
Alpha,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.351,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
P.1,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
Beta,"As of November 25th 2021, four SARS-CoV − 2 variants of concern (VOC: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)) have been detected.",PMC9034743
B.1.351,"Indeed, the recently emerged lineages of viral variants in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) with mutations in the RBD exhibit resistance to neutralizing mAbs and have reduced the efficacy of vaccines and immunity from natural infection (17–19).",PMC9089791
P.1,"Indeed, the recently emerged lineages of viral variants in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) with mutations in the RBD exhibit resistance to neutralizing mAbs and have reduced the efficacy of vaccines and immunity from natural infection (17–19).",PMC9089791
B.1.1.7,"Indeed, the recently emerged lineages of viral variants in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) with mutations in the RBD exhibit resistance to neutralizing mAbs and have reduced the efficacy of vaccines and immunity from natural infection (17–19).",PMC9089791
Gamma,"Surprisingly, hMab5.17 displayed very uniform neutralizing titers against the UK-dominant Alpha variant (B.1.1.7), Brazil-dominant Gamma variant (P.1), South Africa–dominant Beta variant (B.1.351), and the Delta variant (B.1.617.2) that spread throughout India, similar to its activity against WT SARS-CoV-2, and the IC50 value was approximately 12 μg/mL (Figure 5A and Supplemental Figure 5C).",PMC9089791
B.1.617.2,"Surprisingly, hMab5.17 displayed very uniform neutralizing titers against the UK-dominant Alpha variant (B.1.1.7), Brazil-dominant Gamma variant (P.1), South Africa–dominant Beta variant (B.1.351), and the Delta variant (B.1.617.2) that spread throughout India, similar to its activity against WT SARS-CoV-2, and the IC50 value was approximately 12 μg/mL (Figure 5A and Supplemental Figure 5C).",PMC9089791
Alpha,"Surprisingly, hMab5.17 displayed very uniform neutralizing titers against the UK-dominant Alpha variant (B.1.1.7), Brazil-dominant Gamma variant (P.1), South Africa–dominant Beta variant (B.1.351), and the Delta variant (B.1.617.2) that spread throughout India, similar to its activity against WT SARS-CoV-2, and the IC50 value was approximately 12 μg/mL (Figure 5A and Supplemental Figure 5C).",PMC9089791
Beta,"Surprisingly, hMab5.17 displayed very uniform neutralizing titers against the UK-dominant Alpha variant (B.1.1.7), Brazil-dominant Gamma variant (P.1), South Africa–dominant Beta variant (B.1.351), and the Delta variant (B.1.617.2) that spread throughout India, similar to its activity against WT SARS-CoV-2, and the IC50 value was approximately 12 μg/mL (Figure 5A and Supplemental Figure 5C).",PMC9089791
B.1.617.1,"On the basis of knowledge from the aforementioned studies, it is apparent that the S2 subunit may be a better antiviral target for the development of broad-spectrum prophylactic or therapeutic agents..

Because S2 is markedly more conserved and less prone to retain mutations than is S1, we analyzed and demonstrated the ability of hMab5.17 to neutralize emerging natural variants, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.1), and Kappa (B.1.617.1) (Figure 5 and Supplemental Figure 5C).",PMC9089791
Kappa,"On the basis of knowledge from the aforementioned studies, it is apparent that the S2 subunit may be a better antiviral target for the development of broad-spectrum prophylactic or therapeutic agents..

Because S2 is markedly more conserved and less prone to retain mutations than is S1, we analyzed and demonstrated the ability of hMab5.17 to neutralize emerging natural variants, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.1), and Kappa (B.1.617.1) (Figure 5 and Supplemental Figure 5C).",PMC9089791
B.1.1.529,"As demonstrated in vivo through animal protection experiments, hMab5.17 exhibited potent therapeutic effectiveness in hamsters infected with the Delta (B.1.617.1) variant of SARS-CoV-2 (Figure 5C), which was in line with the finding that CV3-25 exhibits in vivo protection against both Alpha (B.1.1.7) and Beta (B.1.351) variants in the K18-hACE2 prophylactic mouse model (25, 26)..

At the beginning of November 2021, the newly emerged omicron variant belonging to Pango lineage B.1.1.529 was found to display an unusually large number of mutations in the S protein, which is of grave concern (52).",PMC9089791
Beta,"Genomes with lineages assigned by Pangolin were included (coverage > 70%, Tables S1 and S2 detail the quality of the genomes, sequences with coverage >90% and mean depth >100: Delta 840/ 908 and Omicron 987/ 1,119).Query mutations were manually confirmed with Integrated Genomics viewer (IGV) (Version 2.8.10), clades were determined using Nextclade beta v 1.13.2 (clades.nextstrain.org, Last accessed March 30, 2022), and lineages were determined with Pangolin COVID-19 lineage Assigner.17.",PMC9020587
Alpha,"In contrast, the Delta displacement of Alpha variant occurred in a time of markedly low circulation of the latter (Figure S1 and14).",PMC9020587
B.1.621,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
C.37,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
B.1.623,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
B.1.1.7,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
Alpha,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
Lambda,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
Mu,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
Beta,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
P.1,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
Gamma,"Protective efficacy against variants were 100% for alpha (B.1.1.7) and lambda (C.37) variants, 88·6% (14·9–99·7) for B.1.623, 93·6% (80·1–98·7) for gamma (P.1), and 92·4% (81·2–97·6) for mu (B.1.621) variants, and lowest against beta (B.1.351; 72·2% [33·1–89·9]) and delta (B.1.617.2; 77·2% [61·3–87·2]) variants.",PMC9015644
B.1.1.529,"The most notable variant of concern throughout most of 2021, the delta (B.1.617.2) variant, has itself been displaced by the omicron (B.1.1.529) variant.3 Most of the authorised vaccines in use, or experimental formulations in development, have focused on the spike protein (S protein) of the SARS-CoV-2 virus,4 which is an essential component for viral cell entry.5 The Clover Biopharmaceuticals vaccine candidate consists of a recombinant SARS-CoV-2 S protein that has been stabilised in the native pre-fusion trimeric conformation using proprietary Trimer-Tag technology.",PMC9015644
B.1.617.2,"The most notable variant of concern throughout most of 2021, the delta (B.1.617.2) variant, has itself been displaced by the omicron (B.1.1.529) variant.3 Most of the authorised vaccines in use, or experimental formulations in development, have focused on the spike protein (S protein) of the SARS-CoV-2 virus,4 which is an essential component for viral cell entry.5 The Clover Biopharmaceuticals vaccine candidate consists of a recombinant SARS-CoV-2 S protein that has been stabilised in the native pre-fusion trimeric conformation using proprietary Trimer-Tag technology.",PMC9015644
B.1.351.3,"Protective efficacy due to previous exposure after the first dose of placebo in participants with and without evidence of previous exposure to SARS-CoV-2 (A); the additional efficacy of one dose of vaccine in participants who had evidence of previous exposure to SARS-CoV-2 (B); the additional efficacy of two doses of vaccine in participants who had evidence of previous exposure to SARS-CoV-2 (C).Table 2Protective efficacy due to natural exposure to SARS-CoV-2SARS-CoV-2-naive individuals (n=7331)SARS-CoV-2-exposed individuals (n=7339)Protective efficacy (95% CI)*Cumulative follow-up in person-years†Number of patients with an eventCumulative follow-up in person-years†Number of patients with an eventAny severity rtPCR-confirmed COVID-19‡1088·93531192·56583·2% (78·0 to 87·3)Moderate-to-severe rtPCR-confirmed COVID-191088·9731192·5692·5% (82·9 to 97·3)Severe rtPCR-confirmed COVID-19‡1088·9101192·50100% (59·3 to 100)Protective efficacy endpoints against rtPCR-confirmed COVID-19 due to specific identified variantsAlpha variant (B.1.1.7)1088·9191192·50100% (80·4 to 100)Beta variant (B.1.351, B.135.2, B.1.351.3)1088·9231192·5772·2% (33·1 to 89·9)Delta variant (B.1.617.2)1088·9721192·51877·2% (61·3 to 87·2)Gamma variant (P.1; P.1.1; P.1.2)1088·9431192·5393·6% (80·1 to 98·7)Mu variant (B.1.621)1088·9601192·5592·4% (81·2 to 97·6)Lambda variant (C.37)1088·971192·50100% (36·7 to 100)B.1.623 variant1088·981192·5188·6% (14·9 to 99·7)Other1088·91211192·53176·6% (65·1 to 84·8)*95% CI for protective efficacy was calculated using the Clopper-Pearson method, which was based on conditional binomial distribution.†Cumulative follow-up was calculated for all participants at risk within each group using the time period from 1 day after the first dose to analysis cutoff on Aug 10, 2021.‡Protective efficacy due to natural immunity in placebo recipients with evidence of previous exposure to SARS-CoV-2..

Kaplan-Meier plots of any severity of rtPCR-confirmed COVID-19.",PMC9015644
P.1.2,"Protective efficacy due to previous exposure after the first dose of placebo in participants with and without evidence of previous exposure to SARS-CoV-2 (A); the additional efficacy of one dose of vaccine in participants who had evidence of previous exposure to SARS-CoV-2 (B); the additional efficacy of two doses of vaccine in participants who had evidence of previous exposure to SARS-CoV-2 (C).Table 2Protective efficacy due to natural exposure to SARS-CoV-2SARS-CoV-2-naive individuals (n=7331)SARS-CoV-2-exposed individuals (n=7339)Protective efficacy (95% CI)*Cumulative follow-up in person-years†Number of patients with an eventCumulative follow-up in person-years†Number of patients with an eventAny severity rtPCR-confirmed COVID-19‡1088·93531192·56583·2% (78·0 to 87·3)Moderate-to-severe rtPCR-confirmed COVID-191088·9731192·5692·5% (82·9 to 97·3)Severe rtPCR-confirmed COVID-19‡1088·9101192·50100% (59·3 to 100)Protective efficacy endpoints against rtPCR-confirmed COVID-19 due to specific identified variantsAlpha variant (B.1.1.7)1088·9191192·50100% (80·4 to 100)Beta variant (B.1.351, B.135.2, B.1.351.3)1088·9231192·5772·2% (33·1 to 89·9)Delta variant (B.1.617.2)1088·9721192·51877·2% (61·3 to 87·2)Gamma variant (P.1; P.1.1; P.1.2)1088·9431192·5393·6% (80·1 to 98·7)Mu variant (B.1.621)1088·9601192·5592·4% (81·2 to 97·6)Lambda variant (C.37)1088·971192·50100% (36·7 to 100)B.1.623 variant1088·981192·5188·6% (14·9 to 99·7)Other1088·91211192·53176·6% (65·1 to 84·8)*95% CI for protective efficacy was calculated using the Clopper-Pearson method, which was based on conditional binomial distribution.†Cumulative follow-up was calculated for all participants at risk within each group using the time period from 1 day after the first dose to analysis cutoff on Aug 10, 2021.‡Protective efficacy due to natural immunity in placebo recipients with evidence of previous exposure to SARS-CoV-2..

Kaplan-Meier plots of any severity of rtPCR-confirmed COVID-19.",PMC9015644
B.1.351,"Protective efficacy due to previous exposure after the first dose of placebo in participants with and without evidence of previous exposure to SARS-CoV-2 (A); the additional efficacy of one dose of vaccine in participants who had evidence of previous exposure to SARS-CoV-2 (B); the additional efficacy of two doses of vaccine in participants who had evidence of previous exposure to SARS-CoV-2 (C).Table 2Protective efficacy due to natural exposure to SARS-CoV-2SARS-CoV-2-naive individuals (n=7331)SARS-CoV-2-exposed individuals (n=7339)Protective efficacy (95% CI)*Cumulative follow-up in person-years†Number of patients with an eventCumulative follow-up in person-years†Number of patients with an eventAny severity rtPCR-confirmed COVID-19‡1088·93531192·56583·2% (78·0 to 87·3)Moderate-to-severe rtPCR-confirmed COVID-191088·9731192·5692·5% (82·9 to 97·3)Severe rtPCR-confirmed COVID-19‡1088·9101192·50100% (59·3 to 100)Protective efficacy endpoints against rtPCR-confirmed COVID-19 due to specific identified variantsAlpha variant (B.1.1.7)1088·9191192·50100% (80·4 to 100)Beta variant (B.1.351, B.135.2, B.1.351.3)1088·9231192·5772·2% (33·1 to 89·9)Delta variant (B.1.617.2)1088·9721192·51877·2% (61·3 to 87·2)Gamma variant (P.1; P.1.1; P.1.2)1088·9431192·5393·6% (80·1 to 98·7)Mu variant (B.1.621)1088·9601192·5592·4% (81·2 to 97·6)Lambda variant (C.37)1088·971192·50100% (36·7 to 100)B.1.623 variant1088·981192·5188·6% (14·9 to 99·7)Other1088·91211192·53176·6% (65·1 to 84·8)*95% CI for protective efficacy was calculated using the Clopper-Pearson method, which was based on conditional binomial distribution.†Cumulative follow-up was calculated for all participants at risk within each group using the time period from 1 day after the first dose to analysis cutoff on Aug 10, 2021.‡Protective efficacy due to natural immunity in placebo recipients with evidence of previous exposure to SARS-CoV-2..

Kaplan-Meier plots of any severity of rtPCR-confirmed COVID-19.",PMC9015644
Theta,"In the Philippines, the alpha lineage, which predominated before the study, was rapidly replaced by the beta, theta, and delta variants, but previous infection still provided 83·5% (76·1 to 88·8) protection against a subsequent episode (table 3
).Table 3Protective efficacy against any severity of COVID-19 due to previous SARS-CoV-2 exposure in placebo recipients, by countryPredominant variantsSARS-CoV-2-naive patientsSARS-CoV-2-exposed patientsProtective efficacy (95% CI)*Before the study†During the studyCumulative follow-up in person-years‡Number of individuals with an eventCumulative follow-up in person-years‡Number of individuals with an eventBelgiumAlphaAlpha65·048·70100% (−1032 to 100)BrazilGammaGamma (57%); delta (13%)290·753128·1387·2% (60·4 to 97·4)ColombiaAlpha, gamma, mu, lambdaMu (49%); gamma (10%); B.1.623 (7%); lambda (6%)199·5123168·42278·8% (66·5 to 87·2)PhilippinesAlphaDelta 29%); beta (15%); alpha (14%); theta (3%)486·8132847·33883·5% (76·1 to 88·8)South AfricaBetaDelta (61%); beta (7%)46·94140·0294·3% (78·0 to 99·3)Overall....1088·93531192·56583·2% (78·0 to 87·3)*95% CI for protective efficacy was calculated using Clopper-Pearson method, which was based on conditional binomial distribution.†Sourced from Nextstrain and the Philippines Genome center .‡Cumulative follow-up was calculated in all participants at risk within each group using the time period from 14 days after the first dose to analysis cutoff on Aug 10, 2021..",PMC9015644
A.2.2,"Our simulations showed that one infected agent with the ancestral (A.2.2) variant has a 14% chance of crossing a threshold of sustained community transmission (SCT) (i.e., > 5 infections per day, more than 3 days in a row), assuming no change in the prevailing preventative and counteracting policies.",PMC9012253
Alpha,"However, one agent carrying the alpha (B.1.1.7) variant has a 43% chance of crossing the same threshold; a threefold increase with respect to the ancestral strain; while, one agent carrying the delta (B.1.617.2) variant has a 60% chance of the same threshold, a fourfold increase with respect to the ancestral strain.",PMC9012253
B.1.617.2,"However, one agent carrying the alpha (B.1.1.7) variant has a 43% chance of crossing the same threshold; a threefold increase with respect to the ancestral strain; while, one agent carrying the delta (B.1.617.2) variant has a 60% chance of the same threshold, a fourfold increase with respect to the ancestral strain.",PMC9012253
B.1.1.7,"However, one agent carrying the alpha (B.1.1.7) variant has a 43% chance of crossing the same threshold; a threefold increase with respect to the ancestral strain; while, one agent carrying the delta (B.1.617.2) variant has a 60% chance of the same threshold, a fourfold increase with respect to the ancestral strain.",PMC9012253
B.1.617.1,"Variants such as the B.1.617.1 (or kappa) and B.1.617.2 (or delta) lineages that emerged in India have been shown to be up to 2.5 times more transmissible than the ancestral strain9,11–13.",PMC9012253
Kappa,"Variants such as the B.1.617.1 (or kappa) and B.1.617.2 (or delta) lineages that emerged in India have been shown to be up to 2.5 times more transmissible than the ancestral strain9,11–13.",PMC9012253
B.1.617.2,The Delta variant (B.1.617.2) was a significant factor during the second wave.,PMC9005225
Alpha,"The study tried to comprehend the pandemic response in the UK and India to the spread of the B.1.1.7 (Alpha, UK) variant and B.1.617.2 (Delta, India) variant..",PMC9005225
B.1.1.7,"The study tried to comprehend the pandemic response in the UK and India to the spread of the B.1.1.7 (Alpha, UK) variant and B.1.617.2 (Delta, India) variant..",PMC9005225
B.1.617.1,"The first sub-lineage is B.1.617.1, the second sub-lineage is B.1.617.2, and the third sub-lineage is B.1.617.3.",PMC9005225
B.1.351,"Several scientists have used the GISAID to analyze the millions of sequences in different variants such as B.1.1.7 (Alpha; originated from the UK), B.1.617.2 (Delta; originated from India), P1 (Gamma; originated from Brazil), B.1.351 (Beta; originated from South Africa) (Kalia et al., 2021; Zelenova et al., 2021; Khare et al., 2021).",PMC9005225
B.1.617,(F) Bottom zoom view of the interaction between RBD and hACE2 residues of B.1.617 variant.Fig.,PMC9005225
B.1.429,"This mutation was detected in other variants, B.1.429/ B.1.427 (VOI), which is also related to augmented transmissibility.",PMC9005225
B.1.427,"This mutation was detected in other variants, B.1.429/ B.1.427 (VOI), which is also related to augmented transmissibility.",PMC9005225
B.1,Live virus microneutralization against the B.1 and Delta SARS-CoV-2 variants was performed in VERO E6 cell cultures.,PMC9025891
Alpha,"The Alpha variant quickly replaced the wild-type SARS-CoV-2 lineages and dominated from December 2020 to June 2021; then, the Delta variant quickly superseded the Alpha variant, remaining the largely prevailing lineage until December 2021.",PMC9025891
Beta,"Notably, all the administered vaccines are based on the wild-type Wuhan-like B.1 isolate; thus, cross-protection through vaccination remains a key point to monitor..

Extensive work demonstrated that vaccination-elicited antibodies can neutralize the subsequently emerging VoCs, including alpha, beta and gamma, in vitro, although with reduced titers compared to the immunizing B.1 lineage [1,2,3].",PMC9025891
Gamma,"Notably, all the administered vaccines are based on the wild-type Wuhan-like B.1 isolate; thus, cross-protection through vaccination remains a key point to monitor..

Extensive work demonstrated that vaccination-elicited antibodies can neutralize the subsequently emerging VoCs, including alpha, beta and gamma, in vitro, although with reduced titers compared to the immunizing B.1 lineage [1,2,3].",PMC9025891
Beta,"The colors refer to the secondary structures: alpha-helix in cyan, beta sheets in purple and turns in magenta.",PMC8994061
Alpha,"It has a potential role in protein folding, dynamics, stability, and accessibility to the receptor and is composed mainly of random structures (35.6%) and β-sheets (33%), followed by turns (19.1%) and alpha helices (12.4%) [59]..",PMC8994061
B.1.1.318,"By March 1, 2022, only the lineages B.1.640, C.1.2, and B.1.1.318 are on the VBM list..

Variants of interest (VOIs) have specific genetic markers associated with changes in receptor binding, mainly mediated by S protein, considerable potential for avoidance of neutralizing antibodies generated by previous infection or vaccination and a reduction in the efficacy of available treatments, a potential impact on diagnosis, or the possibility of increased transmissibility or severity of the disease [89].",PMC8994061
C.1.2,"By March 1, 2022, only the lineages B.1.640, C.1.2, and B.1.1.318 are on the VBM list..

Variants of interest (VOIs) have specific genetic markers associated with changes in receptor binding, mainly mediated by S protein, considerable potential for avoidance of neutralizing antibodies generated by previous infection or vaccination and a reduction in the efficacy of available treatments, a potential impact on diagnosis, or the possibility of increased transmissibility or severity of the disease [89].",PMC8994061
B.1.640,"By March 1, 2022, only the lineages B.1.640, C.1.2, and B.1.1.318 are on the VBM list..

Variants of interest (VOIs) have specific genetic markers associated with changes in receptor binding, mainly mediated by S protein, considerable potential for avoidance of neutralizing antibodies generated by previous infection or vaccination and a reduction in the efficacy of available treatments, a potential impact on diagnosis, or the possibility of increased transmissibility or severity of the disease [89].",PMC8994061
Mu,"Only the strains Lambda (C.37) and Mu (B.1.621) are currently (March 1, 2022) classified as VOI by the WHO [90]..",PMC8994061
B.1.621,"Only the strains Lambda (C.37) and Mu (B.1.621) are currently (March 1, 2022) classified as VOI by the WHO [90]..",PMC8994061
C.37,"Only the strains Lambda (C.37) and Mu (B.1.621) are currently (March 1, 2022) classified as VOI by the WHO [90]..",PMC8994061
Lambda,"Only the strains Lambda (C.37) and Mu (B.1.621) are currently (March 1, 2022) classified as VOI by the WHO [90]..",PMC8994061
Gamma,"This substitution does not seem to be present in any of the strains under monitoring [89]; however, Omicron bears an N440K mutation, close enough to have similar effects, as shown in Table 3..

Other mutations in RBD are present in most strains considered VOC, such as K417T (K417N in Omicron), E484K (in omicron E484A, [89]), and N501Y, the latter two directly in RBM, shared by Gamma and Beta.",PMC8994061
Iota,"The S477N mutation in Iota (former VBM) and Omicron showed a decrease in protein stability in computer-based analysis, which is still under peer review, compared with N501Y, which stabilizes the protein structure [133].",PMC8994061
B.1.1.519,"The T478K mutation, also seen in Delta strains and Mexican B.1.1.222 and B.1.1.519, located in the RBD part of the spike protein, forms three additional hydrogen bonds with F486, leading to a stabilization effect in the protein.",PMC8994061
B.1.1.222,"The T478K mutation, also seen in Delta strains and Mexican B.1.1.222 and B.1.1.519, located in the RBD part of the spike protein, forms three additional hydrogen bonds with F486, leading to a stabilization effect in the protein.",PMC8994061
P.2,"While Alpha, B.1.1.298, and B.1.429 continued to be neutralized, variants P.2 and Gamma significantly reduced the neutralization capacity of vaccine-induced antibodies.",PMC8994061
B.1.1.298,"While Alpha, B.1.1.298, and B.1.429 continued to be neutralized, variants P.2 and Gamma significantly reduced the neutralization capacity of vaccine-induced antibodies.",PMC8994061
B.1.429,"While Alpha, B.1.1.298, and B.1.429 continued to be neutralized, variants P.2 and Gamma significantly reduced the neutralization capacity of vaccine-induced antibodies.",PMC8994061
B.1.351,"The neutralizing power against gamma and alpha was similar, and few samples failed to demonstrate 100% neutralization in serum dilutions of 1:20, while the neutralization of variant beta (B.1.351) was reduced 7.6-fold in patients immunized with the Pfizer vaccine and ninefold with the AstraZeneca vaccine.",PMC8994061
Eta,"3.Table 2Mutations A67V to K417N in spike protein of the Omicron variant: locations, previous association to other SARS-CoV-2 variants and current knowledge about them (December 2021)S protein substitutionsLocation in spikePrevious variantsWhat is already known about this substitutionA67Vβ3-β4 loop of NTD [153]Eta [153]Decreased protein stability by − 0.01 [119]Might promote new hydrophobic interconnections in the β3-β4 loop [153]del69-70β3-β4 loop of NTD [153]Alpha, Beta, Eta, and B.1.375 [153, 154]- Clinical: in a study (n = 25), this single mutation showed prolonged inflammation, viral excretion, and late exacerbation 18 days after [155].",PMC8994061
B.1.375,"3.Table 2Mutations A67V to K417N in spike protein of the Omicron variant: locations, previous association to other SARS-CoV-2 variants and current knowledge about them (December 2021)S protein substitutionsLocation in spikePrevious variantsWhat is already known about this substitutionA67Vβ3-β4 loop of NTD [153]Eta [153]Decreased protein stability by − 0.01 [119]Might promote new hydrophobic interconnections in the β3-β4 loop [153]del69-70β3-β4 loop of NTD [153]Alpha, Beta, Eta, and B.1.375 [153, 154]- Clinical: in a study (n = 25), this single mutation showed prolonged inflammation, viral excretion, and late exacerbation 18 days after [155].",PMC8994061
B.1.1.7,"It seems to increase ACE2 binding interaction by 1.2-fold [227]- Diagnostic: used before to discriminate between Beta and Gamma [228]N679KFurin site between S1/S2B.1.1.433, AT.1 B.1.258, B.1.1.7, P.1 and C.1.2- Clinical: the cluster H655Y+N679K+P681H is associated with a higher in cell invasion and improved metastasis [223]- Structural: decreased protein stability − 0.32 [120].",PMC8994061
B.1.258,"It seems to increase ACE2 binding interaction by 1.2-fold [227]- Diagnostic: used before to discriminate between Beta and Gamma [228]N679KFurin site between S1/S2B.1.1.433, AT.1 B.1.258, B.1.1.7, P.1 and C.1.2- Clinical: the cluster H655Y+N679K+P681H is associated with a higher in cell invasion and improved metastasis [223]- Structural: decreased protein stability − 0.32 [120].",PMC8994061
P.1,"It seems to increase ACE2 binding interaction by 1.2-fold [227]- Diagnostic: used before to discriminate between Beta and Gamma [228]N679KFurin site between S1/S2B.1.1.433, AT.1 B.1.258, B.1.1.7, P.1 and C.1.2- Clinical: the cluster H655Y+N679K+P681H is associated with a higher in cell invasion and improved metastasis [223]- Structural: decreased protein stability − 0.32 [120].",PMC8994061
A.27,"Likely to improve furin cleavage [230]aN764KN-terminal of S2P.1- Structural: decreased protein stability − 0.21, and in SIFT tool protein stability analysis, this mutation affected protein function[120]D796YHMN.19B [231] and A.27 [232]- Structural: decreased protein stability − 0.09 [120].",PMC8994061
Alpha,"Abbreviation: SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2..

WHO has reported that instances of alpha variants have been diagnosed in around 170 countries and various territories across the globe.",PMC9088647
B.1.1.7,"This strain clade 201/501Y.V1, Pango lineage B.1.1.7, and GISAID clade are all recognized alpha variants by various scientific names.",PMC9088647
Beta,"Numerous official designations are assigned to the beta variant, including strain clade 20H/501.V2 and Pango lineage B.1.351.",PMC9088647
B.1.351,"26
 There are three mutations of significant importance in the spike area of the lineage, B.1.351 genome, K417N, E484K, N501Y, and a further five spike mutations, L18F, D80A, D215G, R246I, A701V, that have so far raised little concern.",PMC9088647
P.1,"56
 Safety and immunogenicity study of a SARS‐CoV‐2 variant vaccine (mRNA‐1273.351) is currently ongoing sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) (NCT04785144)..

Lineage P.1, frequently referred to as the gamma variant, is a cause of COVID‐19.",PMC9088647
Gamma,"56
 Safety and immunogenicity study of a SARS‐CoV‐2 variant vaccine (mRNA‐1273.351) is currently ongoing sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) (NCT04785144)..

Lineage P.1, frequently referred to as the gamma variant, is a cause of COVID‐19.",PMC9088647
P.2,Gamma variant is particularly found from the other Brazilian zeta variant (Lineage P.2).,PMC9088647
Zeta,Gamma variant is particularly found from the other Brazilian zeta variant (Lineage P.2).,PMC9088647
Epsilon,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.429,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.427,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.617,"B.1.617.2 (Delta variant) is a variant of lineage B.1.617 of SARS‐CoV‐2, which is the reason for India's second wave in this pandemic of COVID‐19.",PMC9088647
B.1.617.1,"83
 The B.1.617.1 strain is 6.8‐fold more resistant to neutralization by sera from COVID‐19 convalescent and Moderna and Pfizer vaccinated patients, according to a live virus experiment.",PMC9088647
C.1.2,"92
 Researchers discovered that this new C.1.2 variation is evolving and mutating at a faster pace inside its genome than other VOC or VOI along with the Delta variant.",PMC9088647
Lambda,"“The variant is related to the lambda and beta variants, which are linked to innate immunity.",PMC9088647
B.1.1.529,"K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, and P681H are the most common spike protein mutations found in omicron variant.”
94
 According to preliminary laboratory findings, three doses of the Pfizer‐BioNTech COVID‐19 vaccine neutralize the Omicron variation (B.1.1.529 lineage), but two doses had much lower neutralization titers.",PMC9088647
Mu,"Second, despite the P681H mutation, the fusogenicity of Mu and Omicron is much lower than that of other variations.",PMC9088647
A.1,"Next, the derived A.1 lineage was introduced.",PMC8978495
B.1,"For example, B.1 was introduced into LA County during its outbreak in Italy and New York, while B.1.2 was introduced into LA County during its outbreak in Louisiana.",PMC8978495
B.1.2,"For example, B.1 was introduced into LA County during its outbreak in Italy and New York, while B.1.2 was introduced into LA County during its outbreak in Louisiana.",PMC8978495
Gamma,(g–i) SARS-CoV-2 variants of concern on Vero CCL81 cells (g: Alpha; h: Beta; i: Gamma).,PMC8967087
B.1.128,Genome sequencing showed that these belonged to the B.1.279 and B.1.128 lineages widely circulating in Alberta at the time.,PMC8967087
B.1.279,Genome sequencing showed that these belonged to the B.1.279 and B.1.128 lineages widely circulating in Alberta at the time.,PMC8967087
Alpha,"Several reports also showed a lack of similarity and cross-reactivity between alpha coronaviruses and SARS-CoVs (18, 32, 38, 56).",PMC9044950
Alpha,"Here, we characterize increasing circulation of the Alpha variant in early 2021, subsequently replaced by the Delta variant around May 2021.",PMC9005350
Gamma,"As of 10 January 2022, the World Health Organization (WHO) has designated five VOCs associated with increased transmissibility and various extents of immune escape2–4, namely the Alpha, Beta, Gamma, Delta and Omicron variants, first detected in the United Kingdom, South Africa, Brazil, India and multiple countries, respectively5.",PMC9005350
Beta,"As of 10 January 2022, the World Health Organization (WHO) has designated five VOCs associated with increased transmissibility and various extents of immune escape2–4, namely the Alpha, Beta, Gamma, Delta and Omicron variants, first detected in the United Kingdom, South Africa, Brazil, India and multiple countries, respectively5.",PMC9005350
A.1,"The nonvariant strains include lineages A, A.1, B and B.1; the sublineages of four VOCs are aggregated with the parent lineages.",PMC9005350
B.1.621,"The sublineages of four VOCs were aggregated with the parent lineages; the designated variants of interest include lineages C.37, B.1.621 and their sublineages; other lineages include nonvariant strains and other variants.",PMC9005350
C.37,"The sublineages of four VOCs were aggregated with the parent lineages; the designated variants of interest include lineages C.37, B.1.621 and their sublineages; other lineages include nonvariant strains and other variants.",PMC9005350
B.1.1.529,"Considering that a new VOC (Omicron, B.1.1.529) was designated on 26 November 2021, we additionally downloaded all the genomic data of Omicron variants from GISAID on 31 December 2021..

To gain additional insights regarding the extent of public availability of genomic data of SARS-CoV-2 variants, we extracted country-specific, variant-specific and time-specific aggregated data on the number of SARS-CoV-2 variant cases from official websites, using the same sources as above, except for the literature source.",PMC9005350
Mu,"All recorded data were cross-checked by coauthors..

We used the variant naming system proposed by WHO, where five VOCs and two VOIs (Lambda and Mu) had been designated as of 27 November 2021 (ref.",PMC9005350
Lambda,"All recorded data were cross-checked by coauthors..

We used the variant naming system proposed by WHO, where five VOCs and two VOIs (Lambda and Mu) had been designated as of 27 November 2021 (ref.",PMC9005350
P.1.7,"The performed analysis demonstrated that the majority of the strains sequenced during the period belong to the Gamma P.1.7 (32.4%) lineage, followed by Delta AY.99.2 (27.8%), with the first detection of VOC Omicron.",PMC9031820
Gamma,"The performed analysis demonstrated that the majority of the strains sequenced during the period belong to the Gamma P.1.7 (32.4%) lineage, followed by Delta AY.99.2 (27.8%), with the first detection of VOC Omicron.",PMC9031820
B.1.617.2,"The global emergence of several VOCs, recently renamed by the World Health Organization (WHO), including the UK variant (Alpha or B.1.1.7), the South Africa variant (Beta or B.1.351), the Brazil variant (Gamma or P.1), and the India variant (Delta or B.1.617.2), highlights the utmost importance of genomic surveillance for monitoring viral mutations [7,8].",PMC9031820
B.1.1.7,"The global emergence of several VOCs, recently renamed by the World Health Organization (WHO), including the UK variant (Alpha or B.1.1.7), the South Africa variant (Beta or B.1.351), the Brazil variant (Gamma or P.1), and the India variant (Delta or B.1.617.2), highlights the utmost importance of genomic surveillance for monitoring viral mutations [7,8].",PMC9031820
Alpha,"The global emergence of several VOCs, recently renamed by the World Health Organization (WHO), including the UK variant (Alpha or B.1.1.7), the South Africa variant (Beta or B.1.351), the Brazil variant (Gamma or P.1), and the India variant (Delta or B.1.617.2), highlights the utmost importance of genomic surveillance for monitoring viral mutations [7,8].",PMC9031820
B.1.351,"The global emergence of several VOCs, recently renamed by the World Health Organization (WHO), including the UK variant (Alpha or B.1.1.7), the South Africa variant (Beta or B.1.351), the Brazil variant (Gamma or P.1), and the India variant (Delta or B.1.617.2), highlights the utmost importance of genomic surveillance for monitoring viral mutations [7,8].",PMC9031820
P.1,"The global emergence of several VOCs, recently renamed by the World Health Organization (WHO), including the UK variant (Alpha or B.1.1.7), the South Africa variant (Beta or B.1.351), the Brazil variant (Gamma or P.1), and the India variant (Delta or B.1.617.2), highlights the utmost importance of genomic surveillance for monitoring viral mutations [7,8].",PMC9031820
Beta,"The global emergence of several VOCs, recently renamed by the World Health Organization (WHO), including the UK variant (Alpha or B.1.1.7), the South Africa variant (Beta or B.1.351), the Brazil variant (Gamma or P.1), and the India variant (Delta or B.1.617.2), highlights the utmost importance of genomic surveillance for monitoring viral mutations [7,8].",PMC9031820
P.2,"The second most common lineage was P.1.7 (27.0% or 122 genomes), followed by AY.99.2 (17.9% or 81 genomes), AY.43 (9.5% or 43 genomes), P.2 (3.5% or 16 genomes), and B.1.1.28 (3.1% or 14 genomes).",PMC9031820
B.1.1.28,"The second most common lineage was P.1.7 (27.0% or 122 genomes), followed by AY.99.2 (17.9% or 81 genomes), AY.43 (9.5% or 43 genomes), P.2 (3.5% or 16 genomes), and B.1.1.28 (3.1% or 14 genomes).",PMC9031820
B.1.1.33,"We also point out that during the initial period, the predominant lineages circulating in Brazil were B.1.1.28 and B.1.1.33, followed by the rise of P.2, a descendant of the B.1.1.28 lineage, which formed a clear, evolving differentiation.",PMC9031820
Zeta,"Nevertheless, these lineages were rapidly replaced by the variant of interest (VOI) Zeta (P.2) and, especially, by the Gamma VOC (P.1 and P.1.7), which rapidly spread and dominated the epidemiological scenarios across different regions of Brazil [8].",PMC9031820
Gamma,"Conversely, recognition of some epitopes is eliminated for SARS-CoV-2 variants, including spike (S) epitopes in the Alpha, Beta, Gamma, and Delta variant lineages..",PMC8986086
Beta,"Conversely, recognition of some epitopes is eliminated for SARS-CoV-2 variants, including spike (S) epitopes in the Alpha, Beta, Gamma, and Delta variant lineages..",PMC8986086
Alpha,"Conversely, recognition of some epitopes is eliminated for SARS-CoV-2 variants, including spike (S) epitopes in the Alpha, Beta, Gamma, and Delta variant lineages..",PMC8986086
B.1.351,"Cross-recognition of an HLA-DP–restricted peptide that is nearly identical in SARS-CoV-2, OC43, and HKU1 N proteins was also observed (Supplemental Figure 12)..

To choose variants for study, we correlated SARS-CoV-2 T cell epitopes detected using Wuhan-Hu-1 (Wu-1)/WA1 reagents with variants both in early 2020 data and in early 2021 variants being monitored (VBM), concentrating on the B.1.1.7, B.1.351, and P1 lineages.",PMC8986086
B.1.1.7,"Cross-recognition of an HLA-DP–restricted peptide that is nearly identical in SARS-CoV-2, OC43, and HKU1 N proteins was also observed (Supplemental Figure 12)..

To choose variants for study, we correlated SARS-CoV-2 T cell epitopes detected using Wuhan-Hu-1 (Wu-1)/WA1 reagents with variants both in early 2020 data and in early 2021 variants being monitored (VBM), concentrating on the B.1.1.7, B.1.351, and P1 lineages.",PMC8986086
P.1,"There was no recognition of variants with substitutions K417N and K417T, which are present in the B.1.351 and P.1 lineages, respectively.",PMC8986086
B.1.617.2,"95), and lineage B.1.617.2 (Delta) (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Interest).",PMC8986086
Gamma,"Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively.",PMC8954379
B.1.617.2,"Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively.",PMC8954379
B.1.1.7,"Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively.",PMC8954379
Alpha,"Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively.",PMC8954379
B.1.351,"Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively.",PMC8954379
P.1,"Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively.",PMC8954379
Beta,"Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively.",PMC8954379
B.1.1.529,"On 26 November 2021, the WHO proposed SARS-CoV-2 variant B.1.1.529, named Omicron, as a fifth VOC.",PMC8954379
B.1.177,"Results of SARS-CoV-2 variants after RT-PCR analysis were compared with NGS sequenced data of all 132 SARS-CoV-2-positive samples and, after Pangolin classification (github.com/cov-lineages/pangolin), showed a concordance of 100% (95% CI, 97.2–100%) between NGS sequenced data and RT-PCR data for the Alpha, Beta, Gamma, Delta, and other variants not investigated (B.1.177, B.1.258, B.1.545) (Table 3).",PMC8954379
B.1.545,"Results of SARS-CoV-2 variants after RT-PCR analysis were compared with NGS sequenced data of all 132 SARS-CoV-2-positive samples and, after Pangolin classification (github.com/cov-lineages/pangolin), showed a concordance of 100% (95% CI, 97.2–100%) between NGS sequenced data and RT-PCR data for the Alpha, Beta, Gamma, Delta, and other variants not investigated (B.1.177, B.1.258, B.1.545) (Table 3).",PMC8954379
B.1.258,"Results of SARS-CoV-2 variants after RT-PCR analysis were compared with NGS sequenced data of all 132 SARS-CoV-2-positive samples and, after Pangolin classification (github.com/cov-lineages/pangolin), showed a concordance of 100% (95% CI, 97.2–100%) between NGS sequenced data and RT-PCR data for the Alpha, Beta, Gamma, Delta, and other variants not investigated (B.1.177, B.1.258, B.1.545) (Table 3).",PMC8954379
B.1,"Pangolin submission identified 34 Alpha variants, 9 Gamma variants, 6 Beta variants, 40 Delta variants, 13 A variants, 2 B variants, and 58 B.1 variants with other sub-lineages (different from examined VOCs).",PMC8954379
A.1,"The developed custom genotyping panel probes differentiate between the Alpha, Beta, Gamma, and Delta, as well as all B.1-derived variants (all carrying the D614G mutation), from the A.1 (Wuhan) lineage.",PMC8954379
B.1.525,"Among the 132 sequenced clinical samples was an already-reported B.1.525 variant; at the time that this variant was reported on PANGO lineage, its frequency in Italy was less than 0.9% (Table S2).",PMC8954379
B.1.1.529,"The Omicron (B.1.1.529) variant has been shown to be highly transmissible with decreased susceptibility to therapeutic monoclonal antibodies and neutralizing antibodies conferred by vaccination or prior infection (Flemming, 2022; VanBlargan et al., 2022; CDC COVID-19 Response Team, 2021).",PMC8930394
B.1.617.2,"Omicron has spread to become the predominant circulating lineage worldwide as of February 2022 amidst lower background levels of Delta (B.1.617.2) variant infection (Mullen et al., 2020).",PMC8930394
Alpha,"The VoC harbouring mutations in the RBD may lead to a decreased neutralising ability of the vaccine-derived antibodies as has been shown against VoC such as the alpha, beta, gamma and delta variants.2,3 Omicron has 30 amino acid substitutions, 3 deletions, and 1 insertion in its S protein (15 substitutions in RBD alone) and thus may escape vaccine induced immunity.4.",PMC8923830
Beta,"The VoC harbouring mutations in the RBD may lead to a decreased neutralising ability of the vaccine-derived antibodies as has been shown against VoC such as the alpha, beta, gamma and delta variants.2,3 Omicron has 30 amino acid substitutions, 3 deletions, and 1 insertion in its S protein (15 substitutions in RBD alone) and thus may escape vaccine induced immunity.4.",PMC8923830
Gamma,"The VoC harbouring mutations in the RBD may lead to a decreased neutralising ability of the vaccine-derived antibodies as has been shown against VoC such as the alpha, beta, gamma and delta variants.2,3 Omicron has 30 amino acid substitutions, 3 deletions, and 1 insertion in its S protein (15 substitutions in RBD alone) and thus may escape vaccine induced immunity.4.",PMC8923830
B.1.617,"Here, we sequence-characterized the spike gene from breakthrough infections that corresponded to B.1.617 sublineage.",PMC8927725
B.1.617.3,"The extent of spread was attributed to fitness-conferring mutations in the parental lineage B.1.617, leading to the emergence of sublineages such as B.1.617.1, B.1.617.2, and B.1.617.3 of SARS-CoV-2 (Rambaut et al, 2020).",PMC8927725
B.1.617.2,"The extent of spread was attributed to fitness-conferring mutations in the parental lineage B.1.617, leading to the emergence of sublineages such as B.1.617.1, B.1.617.2, and B.1.617.3 of SARS-CoV-2 (Rambaut et al, 2020).",PMC8927725
B.1.617.1,"The extent of spread was attributed to fitness-conferring mutations in the parental lineage B.1.617, leading to the emergence of sublineages such as B.1.617.1, B.1.617.2, and B.1.617.3 of SARS-CoV-2 (Rambaut et al, 2020).",PMC8927725
B.1,"While the E156G/∆157-158 mutation was underrepresented in parental B.1 lineage, it was detected with high frequency in at least 157 countries in B.1.617.2 and B.1.617.3 lineage and was found in multiple PANGO lineages, including the AY lineage (Elbe & Buckland-Merrett, 2017; https://outbreak.info/) (Fig 1E).",PMC8927725
Mu,"The lentiviral spike PVs carried a luciferase gene, and the values were represented after normalizing to the milli units of reverse transcriptase (RT mU).",PMC8927725
Lambda,"One of Delta variant’s siblings, a variant called Lambda, also carries changes in the spike NTD, in addition to L452Q, and these alterations have been associated with the virus’ higher infectivity and immune evasion ability (Acevedo et al, 2021
Preprint; Kimura et al, 2021
Preprint).",PMC8927725
B.1.1.159,"Most recently, a new SARS-CoV-2 variant Omicron (B.1.1.159) is identified.",PMC8927725
Alpha,"Despite the rapid development and approval of vaccines, there are several challenges that might have limited the success stories of the vaccines: (a) failure to adhere to COVID-19 appropriate behavior, (b) lack of quick production of vaccines in large numbers, (c) variants of concerns emerging from the parent strain, (d) comorbidities associated with a large number of COVID-19-positive patients, (e) fatalities despite taking the necessary doses of approved vaccines, and (f) concerns about the duration of the memory responses mediated by the vaccines and whether there is any requirement of booster doses..

On May 31, 2021, the WHO designated different variants of COVID-19 using Greek alphabets like alpha, beta, gamma, and delta among others.",PMC8923340
Beta,"Despite the rapid development and approval of vaccines, there are several challenges that might have limited the success stories of the vaccines: (a) failure to adhere to COVID-19 appropriate behavior, (b) lack of quick production of vaccines in large numbers, (c) variants of concerns emerging from the parent strain, (d) comorbidities associated with a large number of COVID-19-positive patients, (e) fatalities despite taking the necessary doses of approved vaccines, and (f) concerns about the duration of the memory responses mediated by the vaccines and whether there is any requirement of booster doses..

On May 31, 2021, the WHO designated different variants of COVID-19 using Greek alphabets like alpha, beta, gamma, and delta among others.",PMC8923340
Gamma,"Despite the rapid development and approval of vaccines, there are several challenges that might have limited the success stories of the vaccines: (a) failure to adhere to COVID-19 appropriate behavior, (b) lack of quick production of vaccines in large numbers, (c) variants of concerns emerging from the parent strain, (d) comorbidities associated with a large number of COVID-19-positive patients, (e) fatalities despite taking the necessary doses of approved vaccines, and (f) concerns about the duration of the memory responses mediated by the vaccines and whether there is any requirement of booster doses..

On May 31, 2021, the WHO designated different variants of COVID-19 using Greek alphabets like alpha, beta, gamma, and delta among others.",PMC8923340
B.1.617.2,"The B.1.617.2 variant, otherwise known as the delta variant, was first detected in October 2020 in the country, which became the most obvious variant in April 2021, leading to a huge uptick in the number of positive cases [2].",PMC8923340
C.37,"The former is exclusive to C.37 and is responsible for enhancing the affinity for the ACE2 receptor, while the latter is responsible for decreased neutralization by antibodies [121, 122]).",PMC8923340
B.1.1.523,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
C.36.3,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
B.1.1.318,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
B.1.1.319,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
B.1.620,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
B.1.466.2,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
B.1.214.2,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
C.1.2,"T76I is also involved in increasing viral infectivity [123]11B.1.62121HMuVOICOLT95I, Y144S, Y145N, R346K, E484K, N501Y, P681HMutations that are also found in the previously mentioned Alpha, Beta, Gamma and Delta variants show similar effects as described previously12B.1.427 and B.1.42921CEpsilonVOI (currently De-escalated)USAS13I, W152C, L452RL452R mutation decreases the activity of multiple RBD specific monoclonal antibodies, while W152C and L452R abrogate the action of the NTD supersite directed antibodies [124]13B.1.1.51920B/S:732A--MULT478K, P681H, T732AT478K and P681H mutations present in the Delta, Alpha and Gamma variants show similar effects as mentioned before [125]14B.1.61920A/S:126A--MULI210T, N440K, E484K, D936N, S939F, T1027IFurther studies are needed15P.320B/S:265CThetaCurrently De-escalatedPHLE484K, N501Y, P681H, E1092K, H1101Y, V1176FOne study reported this variant had a high potential to spread among the population owing to its increased immune evasion abilities [126]R.1, B.1.466.2, B.1.1.318, B.1.1.319, C.36.3, B.1.214.2, B.1.1.523, B.1.620, C.1.2, B.1.618- are some of the important variants that have also been detected.",PMC8923340
B.1.617,The first traces of the B.1.617 family were detected in India in October of 2020.,PMC8923340
Kappa,"The B.1.617 lineage consists of three sub-lineages, B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.617.3.",PMC8923340
B.1.617.1,"The B.1.617 lineage consists of three sub-lineages, B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.617.3.",PMC8923340
B.1,This parental B.1.617 family has originated from the B.1 lineage with the original D614G mutation in the S protein [2].,PMC8923340
Mu,"B The 1273 amino acid long S protein of the SARS-CoV-2 showing different domains with mutations belonging to the delta, delta plus, and mu variants.",PMC8923340
B.1.621,"The black arrows point to the major mutations across the S protein for the B.1.617.2 (Delta) variant, while the red and cyan arrows indicate the exclusive mutations present in the AY.1 (delta plus) and B.1.621 (Mu) variants, respectively.",PMC8923340
A.1,"The same study observed that the development of neutralizing antibody is associated with the activation of T cells..

One study noted that across 4 variants of SARS-CoV-2 (A.1, B.1.1.7, B.1, N501Y), infection and vaccine-mediated immunity could be retained against the B.1.1.7 variant [49].",PMC8923340
B.1.1.7,"The same study observed that the development of neutralizing antibody is associated with the activation of T cells..

One study noted that across 4 variants of SARS-CoV-2 (A.1, B.1.1.7, B.1, N501Y), infection and vaccine-mediated immunity could be retained against the B.1.1.7 variant [49].",PMC8923340
B.1.351,"The BioNTech/Pfizer’s BNT162b2 vaccine demonstrated relatively high titers of neutralizing antibodies against the B.1.351, B.1.1.7 and P.1 variants [51].",PMC8923340
P.1,"The BioNTech/Pfizer’s BNT162b2 vaccine demonstrated relatively high titers of neutralizing antibodies against the B.1.351, B.1.1.7 and P.1 variants [51].",PMC8923340
C.1,C.1.2 got evolved from C.1 lineage; one of the lineages that dominated the first wave of COVID-19.,PMC8923340
B.1.1.529,"Two years after onset of the SARS-CoV-2 pandemic, its global course is currently being taken over by the fifth variant of concern (VOC) B.1.1.529, which has been denominated Omicron (WHO, 2021).",PMC8920075
B.1.427,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
B.1.617.2,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
Kappa,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
B.1.1.7,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
B.1.1.28,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
Lambda,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
B.1.351,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
P.1,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
B.1.526,"Such data would be available from comparative pseudotype or real-virus neutralization assays..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesPolyclonal rabbit anti-human-IgG, HRP-conjugatedAgilentCat# P021402-2; RRID: AB_2893418CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession numbers: DQ168569, DQ168570REGN10933 (Casirivimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGREGN-10987 (Imdevimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6XDGS309 (Sotrovimab)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyPDB code 6WPTBiological samplesHuman serum samplesKliniken Südostbayern Hospital Network, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AChemicals, peptides, and recombinant proteinsSARS CoV-1 RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyNCBI accession number: AY274119SARS CoV-2 (Wuhan) RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyGISAID accession number: EPI_ISL_ 402119Alpha (Great Britain, B.1.1.7) RBD [N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ABeta (South Africa, B.1.351) RBD [K417N, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AGamma (Brazil, B.1.1.28 P.1) RBD [K417T, E484K, N501Y]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ADelta (India, B.1.617.2) RBD [L452R, T478K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AEpsilon (Los Angeles, B.1.427) RBD [L452R]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AIota (New York, B.1.526) RBD [S477N, E484K]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AOmikron (Botswana, B.1.1.529) RBD [G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/AMink (Cluster 5) RBD [Y453F]David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/Asoluble biotinylated ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc-ACE2David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyACE2: Uniprot ID Q9BYF1NanoLuc: Uniprot ID Q9GV45ExpiFectamine™ 293 Transfection KitThermo Fisher ScientificCat# A14524Expi293™ Expression MediumThermo Fisher ScientificCat# A1435101Opti-MEM™ I Reduced Serum MediumThermo Fisher ScientificCat# 31985062HisTrap Excel 5 mLCytivaCat# 17371206PD-10 Desalting Columns (Sephadex G-25)CytivaCat# 17085101Amicon Ultra-15, 10 kDaMerck MilliporeCat# UFC901024HiTrap MabSelect SuRe 1 mLCytivaCat# 11003493HiTrap DEAE FFCytivaCat# 17515401Mikrogen TMB Substrate SolutionMikrogenCat# 12003Dulbecco’s Phosphate Buffered SalineGibcoCat# 14190-094Tween 20CaeloCat# 3472Fat free milk powderHeirlerwww.heirler.deImidazoleSigmaCat# 56749GlycineSigmaCat# 50046HEPESSigmaCat# 54457Sulfuric acidSupelcoCat# 1.09072Critical commercial assaysStreptavidin-POD ConjugateMerck MilliporeCat# 11089153001BirA biotin-protein ligase standard reaction kitAvidityCat# BirA500Nano-Glo Luciferase Assay ReagentPromegaCat# N1120OligonucleotidesMutagenesis primer N439K_fw: GCCTGGAACAGCAAgAACCTGGACTCCAAAGEurofins GenomicsN/AMutagenesis primer N439K_rev: CTTTGGAGTCCAGGTTcTTGCTGTTCCAGGCEurofins GenomicsN/AMutagenesis primer Y453F_fw: ACTACAATTACCTGTtCCGGCTGTTCCGGAAGEurofins GenomicsN/AMutagenesis primer Y453F_rev: CTTCCGGAACAGCCGGaACAGGTAATTGTAGTEurofins GenomicsN/AMutagenesis primer S477N_fw: TCTATCAGGCCGGCAatACCCCTTGCAACGGCEurofins GenomicsN/AMutagenesis primer S477N_rev: GCCGTTGCAAGGGGTatTGCCGGCCTGATAGAEurofins GenomicsN/AMutagenesis primer E484K_fw: CCTTGCAACGGCGTGaagGGCTTCAACTGCTACEurofins GenomicsN/AMutagenesis primer E484K_rev: GTAGCAGTTGAAGCCcttCACGCCGTTGCAAGGEurofins GenomicsN/AMutagenesis primer N501Y_fw: GGCTTTCAGCCCACAtATGGCGTGGGCTACCEurofins GenomicsN/AMutagenesis primer N501Y_rev: GGTAGCCCACGCCATaTGTGGGCTGAAAGCCEurofins GenomicsN/AMutagenesis primer L452R_fw: GGCAACTACAATTACAGATACCGGCTGTTCCGGEurofins GenomicsN/AMutagenesis primer L452R_rev: CCGGAACAGCCGGTATCTGTAATTGTAGTTGCCEurofins GenomicsN/AMutagenesis primer K417T_fw: CCTGGACAGACAGGCACAATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417T_rev: GTTGTAGTCGGCGATTGTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer K417N_fw: CCTGGACAGACAGGCAACATCGCCGACTACAACEurofins GenomicsN/AMutagenesis primer K417N_rev: GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGEurofins GenomicsN/AMutagenesis primer P337L_fw: ATCACCAATCTGTGCctgTTCGGCGAGGTGTTCEurofins GenomicsN/AMutagenesis primer P337L_rev: GAACACCTCGCCGAAcagGCACAGATTGGTGATEurofins GenomicsN/AMutagenesis primer R346S_fw: GTGTTCAATGCCACCtctTTCGCCTCTGTGTACEurofins GenomicsN/AMutagenesis primer R346S_rev: GTACACAGAGGCGAAagaGGTGGCATTGAACACEurofins GenomicsN/AMutagenesis primer T478K_fw: TCAGGCCGGCAGCAAGCCTTGCAACGGCGEurofins GenomicsN/AMutagenesis primer T478K_rev: CGCCGTTGCAAGGCTTGCTGCCGGCCTGAEurofins GenomicsN/ARecombinant DNApcDNA5/FRT/TO_SARS-CoV-1_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBDDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_WuhanDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_AlphaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_BetaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_GammaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_DeltaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_EpsilonDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_IotaDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_OmicronDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApcDNA5/FRT/TO_SARS-CoV-2_RBD_MinkDavid Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of lambda light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of kappa light chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_empty (pcDNA5/FRT/TO derivate providing a murine IgG1 signal peptide and the constant regions of IgG1 heavy chain)David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_CR3022David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_REGN-10933David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_lambda_REGN-10987David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_HC_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ApAb_LC_kappa_S309David Peterhoff, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, GermanyN/ASoftware and algorithmsGraphPad Prism 9.2.0GraphPad Softwarewww.graphpad.comSPSS Statistics 26IBMwww.ibm.comCorelDRAW 2018Corel Corporationwww.coreldraw.comHydroControlTecan Groupwww.tecan.comMicroplate Manager Ver.",PMC8920075
B.1.617.2,"The AY.4.2 spike displays three additional mutations (T95I, Y145H and A222V) in the N-terminal domain when compared to the original Delta variant (B.1.617.2) and remains poorly characterized..

We compared the Delta and the AY.4.2 spikes, by assessing their binding to antibodies and ACE2 and their fusogenicity.",PMC8917961
B.1.177,"Noticeably, the efficacy of the therapeutic anti-RBD antibody Imdevimab was reduced.Implications of all the available evidenceMutations and deletions of amino-acids 95, 141-145 and/or 222 of the spike appeared independently in several variants of concern and of interest (Omicron, Kappa, Alpha, Iota, B.1.177 or AY.4.2).",PMC8917961
Iota,"Noticeably, the efficacy of the therapeutic anti-RBD antibody Imdevimab was reduced.Implications of all the available evidenceMutations and deletions of amino-acids 95, 141-145 and/or 222 of the spike appeared independently in several variants of concern and of interest (Omicron, Kappa, Alpha, Iota, B.1.177 or AY.4.2).",PMC8917961
Alpha,"Noticeably, the efficacy of the therapeutic anti-RBD antibody Imdevimab was reduced.Implications of all the available evidenceMutations and deletions of amino-acids 95, 141-145 and/or 222 of the spike appeared independently in several variants of concern and of interest (Omicron, Kappa, Alpha, Iota, B.1.177 or AY.4.2).",PMC8917961
Kappa,"Noticeably, the efficacy of the therapeutic anti-RBD antibody Imdevimab was reduced.Implications of all the available evidenceMutations and deletions of amino-acids 95, 141-145 and/or 222 of the spike appeared independently in several variants of concern and of interest (Omicron, Kappa, Alpha, Iota, B.1.177 or AY.4.2).",PMC8917961
B.1,"The Delta Variant of Concern (VOC), originally identified in India in 2020, has supplanted pre-existing strains worldwide in less than 6 months.12 The spike protein of Delta contains 9 mutations, when compared to the B.1 ancestral strain (D614G), including five changes in the NTD (T19R, G142D, Δ156, Δ157, R158G), two in the receptor binding domain (RBD) (L452R, T478K), one mutation close to the furin cleavage site (P681R) and one in the S2 region (D950N).3 This set of mutations reduces sensitivity to antibody neutralization, enhances the fusogenicity of the spike and improves viral fitness.345678 The increased transmissibility of VOCs may also be due to mutations in other viral proteins, such as R203N in the nucleocapsid (N).9.",PMC8917961
B.1.617.1,The T95I substitution was previously detected in the close B.1.617.1 lineage (also termed Kappa)26.,PMC8917961
B.1.526,It was also present in the B.1.526 lineage (also termed Iota) that accounted for up to 30% of sequenced cases in New York City in early 2021.27 It is also present in the Omicron variant.21 This substitution was found in two vaccinated individuals with breakthrough infections and selected in immunocompromised individuals with chronic COVID-19 treated with convalescent plasma and monoclonal antibodies.2829 The T95 residue is located outside the NTD antigenic supersite and its contribution to immune evasion is poorly characterized.26.,PMC8917961
Beta,"Casirivimab is a Class 1 antibody whereas Imdevimab binds to a lateral domain and belongs to the Class 3.39 The anti-NTD antibodies bind uncharacterized epitopes within this domain, as assessed by Elisa (not shown)..

We previously assessed the ability of most of these antibodies to recognize the spikes of Alpha, Beta and Delta variants.3,37 To study their activity against AY.4.2, we first transfected the plasmids expressing the Delta and AY.4.2 spike proteins into 293T cells and analyzed antibody binding by flow cytometry (Figure 1a).",PMC8917961
Gamma,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
B.1.617.2,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
B.1.1.7,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
B.1.1.529,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
Alpha,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
B.1.351,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
P.1,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
Beta,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples.",PMC8917962
B.1.617.2,"We further determined the affinities of NB1A7 to the RBD mutants (P.1 strain [K417T, E484K and N501Y], B.1.526 strain [E484K, S477N], B.1.617.1 strain [L452R, E484Q], and B.1.617.2 strain [L452R, T478K]) with K
D values of 5.12 ± 0.03 nM, 5.70 ± 0.03 nM, 3.09 ± 0.03 nM, and 6.20 ± 0.065 nM (Figures 3B–3E and Table S1).",PMC8908544
P.1,"We further determined the affinities of NB1A7 to the RBD mutants (P.1 strain [K417T, E484K and N501Y], B.1.526 strain [E484K, S477N], B.1.617.1 strain [L452R, E484Q], and B.1.617.2 strain [L452R, T478K]) with K
D values of 5.12 ± 0.03 nM, 5.70 ± 0.03 nM, 3.09 ± 0.03 nM, and 6.20 ± 0.065 nM (Figures 3B–3E and Table S1).",PMC8908544
B.1.617.1,"We further determined the affinities of NB1A7 to the RBD mutants (P.1 strain [K417T, E484K and N501Y], B.1.526 strain [E484K, S477N], B.1.617.1 strain [L452R, E484Q], and B.1.617.2 strain [L452R, T478K]) with K
D values of 5.12 ± 0.03 nM, 5.70 ± 0.03 nM, 3.09 ± 0.03 nM, and 6.20 ± 0.065 nM (Figures 3B–3E and Table S1).",PMC8908544
B.1.526,"We further determined the affinities of NB1A7 to the RBD mutants (P.1 strain [K417T, E484K and N501Y], B.1.526 strain [E484K, S477N], B.1.617.1 strain [L452R, E484Q], and B.1.617.2 strain [L452R, T478K]) with K
D values of 5.12 ± 0.03 nM, 5.70 ± 0.03 nM, 3.09 ± 0.03 nM, and 6.20 ± 0.065 nM (Figures 3B–3E and Table S1).",PMC8908544
Gamma,"For instance, some variants were found to be more virulent and transmissible such as Alpha, Delta, Gamma, Kappa, and Omicron (Christie, 2021; Otto et al., 2021)..

Identifying mutations and correlating between them help to identify key features of different strains.",PMC8958014
Kappa,"For instance, some variants were found to be more virulent and transmissible such as Alpha, Delta, Gamma, Kappa, and Omicron (Christie, 2021; Otto et al., 2021)..

Identifying mutations and correlating between them help to identify key features of different strains.",PMC8958014
Alpha,"For instance, some variants were found to be more virulent and transmissible such as Alpha, Delta, Gamma, Kappa, and Omicron (Christie, 2021; Otto et al., 2021)..

Identifying mutations and correlating between them help to identify key features of different strains.",PMC8958014
C.36.3,"confirmed the presence of the C36 lineage early in the pandemic and its evolution into several sub-lineages, including C.36.1, C.36.3, and C.36.3.1, circulating across the Egyptian patients’ genome.",PMC8958014
C.36.1,"confirmed the presence of the C36 lineage early in the pandemic and its evolution into several sub-lineages, including C.36.1, C.36.3, and C.36.3.1, circulating across the Egyptian patients’ genome.",PMC8958014
C.36.3.1,"confirmed the presence of the C36 lineage early in the pandemic and its evolution into several sub-lineages, including C.36.1, C.36.3, and C.36.3.1, circulating across the Egyptian patients’ genome.",PMC8958014
Beta,"They also discovered that mutations in this lineage show potential fitness and pathogenicity in the same manner that mutations in Alpha, Beta, Gamma, Delta, and Omicron (variants of concern) do (Roshdy et al., 2022).",PMC8958014
P.1,"These mutations are found commonly in lineages B.1.1.7 (Alpha) (Caserta et al., 2021; Wu et al., 2021) and P.1 (Gamma) (Faria et al., 2021; Wu et al., 2021).",PMC8958014
B.1.1.7,"These mutations are found commonly in lineages B.1.1.7 (Alpha) (Caserta et al., 2021; Wu et al., 2021) and P.1 (Gamma) (Faria et al., 2021; Wu et al., 2021).",PMC8958014
Alpha,"During the period of the study, most symptomatic breakthrough infections were caused by the SARS-CoV-2 Alpha variant.",PMC8983140
Iota,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
Gamma,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
B.1.1.7,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
P.1,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
B.1.311,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
B.1,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
B.1.526,"In the FV-I, the B.1.1.7 clade (Alpha variant) represented 7 out of 11 sequenced SARS-CoV-2 infections; P.1 (Gamma variant), B.1.526 (Iota variant), B.1.311, and early B.1 lineage (19A Nextstrain) accounted for the remaining 4.",PMC8983140
C.37,"Our results indicate that from January to March 2021 there was a dominance of non-identifiable variants by the RT-qPCR-based screening; however, throughout WGS we were able to identify the Lambda (C.37) variant of interest (VOI).",PMC8914012
Lambda,"Our results indicate that from January to March 2021 there was a dominance of non-identifiable variants by the RT-qPCR-based screening; however, throughout WGS we were able to identify the Lambda (C.37) variant of interest (VOI).",PMC8914012
P.1,"From March to July, we observed the rapid emergence of mutations associated with the Gamma variant (P.1), which was quickly replaced by the appearance of a combination of samples harboring mutations associated with the Delta variant (B.1.617.2), which predominated until the end of the study.",PMC8914012
B.1.617.2,"From March to July, we observed the rapid emergence of mutations associated with the Gamma variant (P.1), which was quickly replaced by the appearance of a combination of samples harboring mutations associated with the Delta variant (B.1.617.2), which predominated until the end of the study.",PMC8914012
Gamma,"From March to July, we observed the rapid emergence of mutations associated with the Gamma variant (P.1), which was quickly replaced by the appearance of a combination of samples harboring mutations associated with the Delta variant (B.1.617.2), which predominated until the end of the study.",PMC8914012
B.1.1.7,"For example, the Alpha variant (B.1.1.7) had increased transmissibility compared to the ancestral strain, but the mutations in spike protein did not significantly alter the neutralization capability of antibodies like the Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants, which have been proven to be less susceptible to antibody neutralization (12–15).",PMC8914012
Alpha,"For example, the Alpha variant (B.1.1.7) had increased transmissibility compared to the ancestral strain, but the mutations in spike protein did not significantly alter the neutralization capability of antibodies like the Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants, which have been proven to be less susceptible to antibody neutralization (12–15).",PMC8914012
B.1.351,"For example, the Alpha variant (B.1.1.7) had increased transmissibility compared to the ancestral strain, but the mutations in spike protein did not significantly alter the neutralization capability of antibodies like the Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants, which have been proven to be less susceptible to antibody neutralization (12–15).",PMC8914012
Beta,"For example, the Alpha variant (B.1.1.7) had increased transmissibility compared to the ancestral strain, but the mutations in spike protein did not significantly alter the neutralization capability of antibodies like the Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants, which have been proven to be less susceptible to antibody neutralization (12–15).",PMC8914012
Mu,"In Chile, genomic surveillance of SARS-COV-2 variants allowed reporting the introduction of the B.1.1.7 lineage (Alpha, α) in December 2020, and subsequently the introduction of the P.1 (Gamma, γ) and P.2 lineages (Zeta, ζ) from Brazil and the detection of cases of the B.1.351 lineage (Beta, ß), B.1.427/9 (Epsilon, ε) lineages, B.1.621 (Mu, μ), B.1.617.2 (Delta, δ) and very recently the introduction of B.1.1.529 (Omicron, o) (23).",PMC8914012
B.1.427,"In Chile, genomic surveillance of SARS-COV-2 variants allowed reporting the introduction of the B.1.1.7 lineage (Alpha, α) in December 2020, and subsequently the introduction of the P.1 (Gamma, γ) and P.2 lineages (Zeta, ζ) from Brazil and the detection of cases of the B.1.351 lineage (Beta, ß), B.1.427/9 (Epsilon, ε) lineages, B.1.621 (Mu, μ), B.1.617.2 (Delta, δ) and very recently the introduction of B.1.1.529 (Omicron, o) (23).",PMC8914012
Zeta,"In Chile, genomic surveillance of SARS-COV-2 variants allowed reporting the introduction of the B.1.1.7 lineage (Alpha, α) in December 2020, and subsequently the introduction of the P.1 (Gamma, γ) and P.2 lineages (Zeta, ζ) from Brazil and the detection of cases of the B.1.351 lineage (Beta, ß), B.1.427/9 (Epsilon, ε) lineages, B.1.621 (Mu, μ), B.1.617.2 (Delta, δ) and very recently the introduction of B.1.1.529 (Omicron, o) (23).",PMC8914012
B.1.621,"In Chile, genomic surveillance of SARS-COV-2 variants allowed reporting the introduction of the B.1.1.7 lineage (Alpha, α) in December 2020, and subsequently the introduction of the P.1 (Gamma, γ) and P.2 lineages (Zeta, ζ) from Brazil and the detection of cases of the B.1.351 lineage (Beta, ß), B.1.427/9 (Epsilon, ε) lineages, B.1.621 (Mu, μ), B.1.617.2 (Delta, δ) and very recently the introduction of B.1.1.529 (Omicron, o) (23).",PMC8914012
B.1.1.529,"In Chile, genomic surveillance of SARS-COV-2 variants allowed reporting the introduction of the B.1.1.7 lineage (Alpha, α) in December 2020, and subsequently the introduction of the P.1 (Gamma, γ) and P.2 lineages (Zeta, ζ) from Brazil and the detection of cases of the B.1.351 lineage (Beta, ß), B.1.427/9 (Epsilon, ε) lineages, B.1.621 (Mu, μ), B.1.617.2 (Delta, δ) and very recently the introduction of B.1.1.529 (Omicron, o) (23).",PMC8914012
P.2,"In Chile, genomic surveillance of SARS-COV-2 variants allowed reporting the introduction of the B.1.1.7 lineage (Alpha, α) in December 2020, and subsequently the introduction of the P.1 (Gamma, γ) and P.2 lineages (Zeta, ζ) from Brazil and the detection of cases of the B.1.351 lineage (Beta, ß), B.1.427/9 (Epsilon, ε) lineages, B.1.621 (Mu, μ), B.1.617.2 (Delta, δ) and very recently the introduction of B.1.1.529 (Omicron, o) (23).",PMC8914012
Epsilon,"In Chile, genomic surveillance of SARS-COV-2 variants allowed reporting the introduction of the B.1.1.7 lineage (Alpha, α) in December 2020, and subsequently the introduction of the P.1 (Gamma, γ) and P.2 lineages (Zeta, ζ) from Brazil and the detection of cases of the B.1.351 lineage (Beta, ß), B.1.427/9 (Epsilon, ε) lineages, B.1.621 (Mu, μ), B.1.617.2 (Delta, δ) and very recently the introduction of B.1.1.529 (Omicron, o) (23).",PMC8914012
B.1.525,"This workflow allowed us to discriminate in real time, between the mutations found at spike gene of SARS-CoV-2 associated with the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Zeta (P.2), Eta (B.1.525), and Mu (B.1.621) variants.",PMC8914012
Eta,"This workflow allowed us to discriminate in real time, between the mutations found at spike gene of SARS-CoV-2 associated with the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Zeta (P.2), Eta (B.1.525), and Mu (B.1.621) variants.",PMC8914012
B.1.429,"From June 2021 onwards, we extended to a newly available assays, where we additionally searched for mutations W152C, L452R, K417T, and K417N in a single tube (AllplexTM SARS-CoV-2 Variants II assay, Seegene Technologies) to detect mutations associated with the Epsilon (B.1.427 and B.1.429) and Delta (B.1.617.2) variants.",PMC8914012
Kappa,"The proposed workflow was validated by whole genome sequencing and lead us to quickly identify the Zeta, Alpha, Gamma, Epsilon (B.1.429), Lambda, Mu, Eta and Delta variants and to suspect the presence of Kappa or Epsilon (B.1.427).",PMC8914012
Alpha,"In this report, we evaluated an alphavirus-based replicating RNA vaccine expressing Spike proteins from the original SARS-CoV-2 Alpha strain and recent VoCs delivered in vivo via a lipid inorganic nanoparticle.",PMC8983041
Beta,"However, new variants – such as Alpha, Beta and Omicron – have emerged that the vaccines do not work as well against, contributing to the ongoing spread of the virus..

One way to overcome this is to create a vaccine that can be quickly and easily updated to target new variants, like the vaccine against influenza.",PMC8983041
A.1,"Previously, we reported the development of an Venezuelan equine encephalitis virus (VEEV)-based replicating RNA (repRNA) vaccine encoding the spike protein of the original A.1 lineage of SARS-CoV2 delivered by a lipid inorganic nanoparticle (LION) (Erasmus et al., 2020a).",PMC8983041
B.1.351,"In this report we evaluated repRNA vaccine expressing the SARS-CoV2 spike protein of the SARS-CoV2 variants, B.1.1.7 and B.1.351 in mice and hamsters, using LION to mediate delivery via intramuscular (IM) injection.",PMC8983041
B.1.1.7,"In this report we evaluated repRNA vaccine expressing the SARS-CoV2 spike protein of the SARS-CoV2 variants, B.1.1.7 and B.1.351 in mice and hamsters, using LION to mediate delivery via intramuscular (IM) injection.",PMC8983041
B.1,"To determine whether this apparent enhancement of cell surface-expressed spike, conferred by the KV995PP mutation, can contribute to enhanced immunogenicity, either in terms of magnitude and/or breadth, we included the non-2P-stabilized as well as the 2P-stablized spike of the B.1 spike in the subsequent mouse immunogenicity study, as well as the 2P-stabilized B.1.1.7 and B.1.351 spikes..

(A) Using the full-length, pre-fusion-stabilized (KV995PP) spike (S) of the original A.1 lineage of SARS-CoV2 as a reference, including the signal peptide (sp) and regions corresponding to S1, S2, transmembrane (TM), and cytoplasmic (CD) domains, the various deletions and/or substitutions corresponding to the B.1, B.1.1.7, and B.1.351 lineages were introduced.",PMC8983041
B.1.617.2,"To evaluate immunogenicity of LION/repRNA in hamsters, at day 14 post-boost, serum samples were assayed by PRNT80 against A.1, B.1.351, or B.1.1.7 viruses as well as the more recently described B.1.617.2 virus (Delta) variant.",PMC8983041
B.1.1.529,"The emergence of the Delta VoC, more recently Omicron (B.1.1.529), and emerging evidence that existing vaccines have diminished efficacy against these VoCs compared to previous VoC (Ai et al., 2022; Carreño et al., 2022; Lopez Bernal et al., 2021; Sheikh et al., 2021; Brown et al., 2021) together indicate that continued development of vaccines for COVID-19 is warranted..

Several COVID-19 alphavirus-based replicon vaccines have been evaluated in animal models.",PMC8983041
B.1.529,"Our data also support a vaccine approach in which the vaccine is matched to a VoC to provide optimal immunity which may decrease the frequency of vaccine breakthrough-mediated transmission events, an important consideration for the rapid emergence of the B.1.529 (Omicron) VoC (Ai et al., 2022; Carreño et al., 2022; Kuhlmann et al., 2022).",PMC8983041
B.1,"Phylogenetic analysis and haplotype reconstruction were carried out with IQ-TREE software and RegressHaplo tool, respectively..

All viral strains isolated from patients infected in the nursing home were classified as B.1 lineage, clade G. Overall, 14 major single nucleotide variations (SNVs) (frequency > 80%) and 12 minor SNVs (frequency comprised between 20% and 80%) were identified with reference to the Wuhan-H-1 sequence (NC_045512.2)..

All patients presented the same 6 major SNVs: D614G in the S gene; P4715L, ntC3037T (F924F) and S5398P in Orf1ab gene; ntC26681T (F53F) in the M gene; and ntC241T in the non-coding UTR region.",PMC8855624
A.2,"In Europe, the dominant viral lineages from February to April 2020 were A.2 and A.5, while from January to May 2020 were B.1 and B.2 (Rambaut et al., 2020)..",PMC8855624
A.5,"In Europe, the dominant viral lineages from February to April 2020 were A.2 and A.5, while from January to May 2020 were B.1 and B.2 (Rambaut et al., 2020)..",PMC8855624
C.1,"The numbers on the right represent the percentage of the viral population characterized by the indicated haplotype..

As regard patient #6, a single haplotype (Hap C) was present at baseline while 2 haplotypes (Hap C and Hap C.1, with frequencies of 67% and 33%, respectively) were present on day 7 (Fig.",PMC8855624
Beta,"The newly emerged SARS-CoV-2 variant of concern (VOC) Omicron is spreading quickly worldwide, which manifests an urgent need of simple and rapid assay to detect and diagnose Omicron infection and track its spread..

To design allele-specific CRISPR RNAs (crRNAs) targeting the signature mutations in the spike protein of Omicron variant, and to develop a CRISPR-Cas12a-based assay to specifically detect Omicron variant..

Our system showed a low limit of detection of 2 copies per reaction for the plasmid DNA of Omicron variant, and could readily detect Omicron variant in 5 laboratory-confirmed clinical samples and distinguish them from 57 SARS-CoV-2 positive clinical samples (4 virus isolates and 53 oropharyngeal swab specimens) infected with wild-type (N = 8) and the variants of Alpha (N = 17), Beta (N = 17) and Delta (N = 15).",PMC8849905
Alpha,"The newly emerged SARS-CoV-2 variant of concern (VOC) Omicron is spreading quickly worldwide, which manifests an urgent need of simple and rapid assay to detect and diagnose Omicron infection and track its spread..

To design allele-specific CRISPR RNAs (crRNAs) targeting the signature mutations in the spike protein of Omicron variant, and to develop a CRISPR-Cas12a-based assay to specifically detect Omicron variant..

Our system showed a low limit of detection of 2 copies per reaction for the plasmid DNA of Omicron variant, and could readily detect Omicron variant in 5 laboratory-confirmed clinical samples and distinguish them from 57 SARS-CoV-2 positive clinical samples (4 virus isolates and 53 oropharyngeal swab specimens) infected with wild-type (N = 8) and the variants of Alpha (N = 17), Beta (N = 17) and Delta (N = 15).",PMC8849905
B.1.1.529,"Furthermore, Omicron lineage (B.1.1.529) has now evolved and divided into three sub-lineages BA.1, BA.2, and BA.3.",PMC8849905
B.1.351,"Plasmid copy number was calculated using the following formula: Plasmid copy number (copies/μL) = {[6.02 × 1023 × plasmid concentration (ng/μL) × 10−9]}/[Plasmid length × 660]..

Four SARS-CoV-2 virus isolates, including wild-type strain (19A) isolated from COVID-19 patient in Wuhan, China, and variant Alpha (B1.1.7), Beta (B.1.351) and Delta (B1.617.2) isolated from imported COVID-19 patients, were grown in Vero cells.",PMC8849905
Beta,1.351 (beta variant) containing the E484K and N501Y mutations is well known.,PMC8841208
R.1,"Vaccine efficacy against the R.1 lineage, which contains the E484K mutation but not the N501Y mutation, is uncertain.",PMC8841208
Alpha,The alpha variant (lineage B.,PMC8841208
B.1.617.2,"These lineages include B.1.1.7 (also referred to as alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).",PMC8839799
B.1.1.7,"These lineages include B.1.1.7 (also referred to as alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).",PMC8839799
Alpha,"These lineages include B.1.1.7 (also referred to as alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).",PMC8839799
Beta,"These lineages include B.1.1.7 (also referred to as alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).",PMC8839799
B.1.351,"These lineages include B.1.1.7 (also referred to as alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).",PMC8839799
P.1,"These lineages include B.1.1.7 (also referred to as alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).",PMC8839799
Gamma,"These lineages include B.1.1.7 (also referred to as alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).",PMC8839799
C.36,"To account that SARS-CoV-2 evolves and substances effective against the Wuhan-1 strain may not be useful in infections caused by novel variants of concern, drugs were tested against the spike proteins of five lineages: B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), and C.36 lineage.",PMC8839799
Alpha,"The early ancestral A lineage isolates detected in Wuhan, China and Seattle, WA (WA1 strain) were rapidly replaced worldwide by the B lineage VOC Alpha in 2020 (3).",PPR452891
Iota,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
Mu,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
Gamma,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
Zeta,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
Epsilon,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
Kappa,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
Beta,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
Lambda,"In agreement with the findings for RDV, GS-441524 was also found to be significantly (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 compared to 6240 ± 1300 nM for WA1..

To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian Influenza Data) database were evaluated.",PPR452891
B.1,The primary SARS-CoV-2 screening focused on the B.1 (Wuhan) lineage.,PMC8840742
B.1.617.2,"Interestingly, compound 1 showed a similar activity against the B.1 lineage and the B.1.1.7 (UK or Alpha variant) and B.1.617.2 (Indian or Delta variant) lineages in Vero E6 cells (Table 5).",PMC8840742
Alpha,"Interestingly, compound 1 showed a similar activity against the B.1 lineage and the B.1.1.7 (UK or Alpha variant) and B.1.617.2 (Indian or Delta variant) lineages in Vero E6 cells (Table 5).",PMC8840742
B.1.1.7,"Interestingly, compound 1 showed a similar activity against the B.1 lineage and the B.1.1.7 (UK or Alpha variant) and B.1.617.2 (Indian or Delta variant) lineages in Vero E6 cells (Table 5).",PMC8840742
B.1.1.529,"In late 2021, the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC) was reported with many mutations in the viral spike protein that were predicted to enhance transmissibility and allow viral escape of neutralizing antibodies.",PPR450180
B.1.351,"Previously, we reported on the development of a cationic nanocarrier, Lipid InOrganic Nanoparticle (LION), for delivery of a replicating RNA (repRNA) encoding the ancestral Spike of SARS-CoV-2 (16) as well as those of the B.1.1.7 and B.1.351 lineage viruses (17).",PPR450180
B.1.1.7,"Previously, we reported on the development of a cationic nanocarrier, Lipid InOrganic Nanoparticle (LION), for delivery of a replicating RNA (repRNA) encoding the ancestral Spike of SARS-CoV-2 (16) as well as those of the B.1.1.7 and B.1.351 lineage viruses (17).",PPR450180
A.1,"These animals had previously received 1μg doses, spaced 28 days apart, of either a prime/boost A.1-repRNA-CoV2S vaccine (A.1 Spike 2X), or a prime-only A.1-repRNA-CoV2S followed by a control boost of an influenza HA-repRNA (A.1 Spike 1X), or a control prime/boost of an influenza HA-repRNA vaccine (Influenza HA 2X) (Fig.",PPR450180
B.1.617.2,"These data are consistent with reports that A.1 vaccine-induced immunity remained protective against the B.1.1.7, B.1.351 and B.1.617.2 VoCs with diminished protection against B.1.1.529 (25, 26)..

An important consideration for global public health strategies against current and future emergent VoC is pre-existing immunity from vaccination and/or previous infection.",PPR450180
B.1.1.7,"Mutagenesis data explain the inefficient mouse infectivity of the SARS-CoV-2 B.1.1.7 isolate71 which incorporates the N501Y RBD mutation, relative to the efficient replication of the mouse-adapted SARS-CoV-2 isolate containing Q498Y42 or the pathogenic WBP-1 strain containing Q493K and Q498H70.",PMC8967715
Beta,"Those four are the Alpha (B.1.1.7), the Beta (B.1.135.1.",PMC8800542
Alpha,"Those four are the Alpha (B.1.1.7), the Beta (B.1.135.1.",PMC8800542
B.1.1.7,"Those four are the Alpha (B.1.1.7), the Beta (B.1.135.1.",PMC8800542
B.1.1.529,"), the Gamma variant (P1) and the Omicron variant (B.1.1.529).",PMC8800542
Gamma,"), the Gamma variant (P1) and the Omicron variant (B.1.1.529).",PMC8800542
Gamma,"The Delta variant, since its appearance, replaced the VOC Gamma, which was responsible for the major COVID-19 wave in Brazil.",PMC8800493
B.1.617.2,"Therefore, quick spread, genetic viral evolution, and incomplete vaccination schedules in many countries have been driving the emergence of SARS-CoV-2 variants that may interfere in the vaccine-derived immune response protective effectiveness (Kuzmina et al., 2021)..

SARS-CoV-2 variant B.1.617.2, also known as the Delta variant, has been quickly spread and detected in many countries (Bolze et al., 2021; Li et al., 2021; Public Health England, 2021).",PMC8800493
P.1,"Hatched squares correspond to at least one sequence with the given mutation although it has never been found with 100% frequency..

COVID-19 epidemic in Brazil, during 2021, was driven by the spread and predominance of the VOC Gamma (lineage P.1) which caused the highest wave of SARS-CoV-2, considering the number of cases, deaths, and hospitalization per day (Demoliner et al., 2021).",PMC8800493
B.1.1.28,"Despite this, in contrast to the huge COVID-19 epidemic wave associated with the substitution of B.1.1.28 by the VOC Gamma (Demoliner et al., 2021; Faria et al., 2021), Delta viral lineage replacement occurred without the SARS-CoV-2 cases increase, probably due to the high immunity levels (natural and/or vaccinated) in the RS State population (Secretaria da Saúde do Rio Grande do Sul, 2021b).",PMC8800493
B.1,"In contrast, lineage B.1 (clade G) and its descendant B.1.X (clades GR and GH) replaced lineages A and B and became the dominant lineages worldwide in March 2020.",PMC8786408
B.1.1,"Seventy-two virus genomes from this outbreak were assigned to lineage B.1.1 and shared the same molecular signature, which comprised seven SNPs and was mainly carried by European strains (Pang et al., 2020).",PMC8786408
Alpha,The second outbreak involved two childcare facilities experiencing infection activity with the variant of concern (VOC) B.1.1.7 (Alpha).,PMC8784653
B.1.1.7,The second outbreak involved two childcare facilities experiencing infection activity with the variant of concern (VOC) B.1.1.7 (Alpha).,PMC8784653
B.1.617.2,"Especially in light of the rapidly spreading VOC B.1.617.2 (Delta), our data underline the notion that rigorous SARS-CoV-2 testing in combination with screening of contacts regardless of symptoms is an important measure to prevent SARS-CoV-2 infection of unvaccinated individuals in daycare centers and associated households..

During the first wave of the SARS-CoV-2 pandemic in Germany, ranging from March until May 2020 , childcare facilities were closed in most federal states.",PMC8784653
B.1.1,The generated phylogenetic tree recapitulates the association of samples from F1 with B.1.1 and F2 and F3 with the variant B.1.1.7 (Fig.,PMC8784653
B.1.617.2,The delta variant (B.1.617.2) was initially reported in India and was found to spread throughout the world with substantial transmissibility (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html).,PMC8786941
B.1.1,"Finally, with respect to the assigned lineage, 80% of “caac” carriers were assigned to lineage B.1.1.291, 7% to B.1.1.290, 6% to B.1.1, in addition to several sporadic assignments, mostly to B.1.1 (Table 6).",PMC8786941
B.1.1.290,"Finally, with respect to the assigned lineage, 80% of “caac” carriers were assigned to lineage B.1.1.291, 7% to B.1.1.290, 6% to B.1.1, in addition to several sporadic assignments, mostly to B.1.1 (Table 6).",PMC8786941
B.1.1.291,"Finally, with respect to the assigned lineage, 80% of “caac” carriers were assigned to lineage B.1.1.291, 7% to B.1.1.290, 6% to B.1.1, in addition to several sporadic assignments, mostly to B.1.1 (Table 6).",PMC8786941
B.1.371,"In contrast, only 11% of the carriers of the reference haplotype “tggg” were assigned to the B.1.371 lineage.Table 5Relationships of identified SNV haplotype (t19839-g28881-g28882-g28883) with classifications of Nextstrain and clades by GISAID.HapcaactaaccgggtgggRaresNextstrainn = 120143429546211Unspecified7 (0.13)19A42 (0.77)19B1 (0.23)8 (27.59)1422 (26.03)1 (9.09)20A5 (17.24)1032 (18.89)4 (36.36)20A.EU220B1201 (100)423 (97.47)13 (44.83)2 (0.04)3 (27.27)20C3 (10.34)2005 (36.71)3 (27.27)20D2 (0.46)20E (EU1)1 (0.02)20F20G951 (17.41)20H/501Y.V220I/501Y.V18 (1.84)20 J/501Y.V3GISAID-CladeG1 (0.23)18 (62.07)858 (15.71)4 (36.36)GH3 (10.34)3131 (57.32)3 (27.27)GR1196 (99.58)429 (98.85)2 (18.18)GV1 (0.02)LO5 (0.42)2 (0.46)35 (0.64)1 (9.09)S2 (0.46)8 (27.59)1413 (25.87)1 (9.09)V24 (0.44)Table 6Relationships of identified SNV haplotype (t19839-g28881-g28882-g28883) with lineages assigned by Pangolin.HapcaactaaccgggtgggLineagen = 1201434*295462*A.12 (0.46)8 (27.59)1412 (25.85)B.11 (0.23)5 (17.24)937 (17.15)B.1.175 (6.24)B.1.1.1101 (0.08)B.1.1.15837 (3.08)1 (3.45)B.1.1.22223 (1.92)B.1.1.26136 (31.34)2 (0.04)B.1.1.29084 (6.99)1 (0.23)1 (3.45)B.1.1.291956 (79.6)7 (1.61)11 (37.93)B.1.1.6518 (4.15)1 (0.02)B.1.1.7620 (1.67)1 (0.02)B.1.1698 (1.84)52 (0.95)B.1.333.15 (0.42)5 (1.15)7 (0.13)B.1.3711 (3.45)617 (11.30)B.1.4262 (6.90)12 (0.22)*Corresponding lineages associated with ""taac"" only or ""tggg"" only are excluded.",PMC8786941
B.11,"In contrast, only 11% of the carriers of the reference haplotype “tggg” were assigned to the B.1.371 lineage.Table 5Relationships of identified SNV haplotype (t19839-g28881-g28882-g28883) with classifications of Nextstrain and clades by GISAID.HapcaactaaccgggtgggRaresNextstrainn = 120143429546211Unspecified7 (0.13)19A42 (0.77)19B1 (0.23)8 (27.59)1422 (26.03)1 (9.09)20A5 (17.24)1032 (18.89)4 (36.36)20A.EU220B1201 (100)423 (97.47)13 (44.83)2 (0.04)3 (27.27)20C3 (10.34)2005 (36.71)3 (27.27)20D2 (0.46)20E (EU1)1 (0.02)20F20G951 (17.41)20H/501Y.V220I/501Y.V18 (1.84)20 J/501Y.V3GISAID-CladeG1 (0.23)18 (62.07)858 (15.71)4 (36.36)GH3 (10.34)3131 (57.32)3 (27.27)GR1196 (99.58)429 (98.85)2 (18.18)GV1 (0.02)LO5 (0.42)2 (0.46)35 (0.64)1 (9.09)S2 (0.46)8 (27.59)1413 (25.87)1 (9.09)V24 (0.44)Table 6Relationships of identified SNV haplotype (t19839-g28881-g28882-g28883) with lineages assigned by Pangolin.HapcaactaaccgggtgggLineagen = 1201434*295462*A.12 (0.46)8 (27.59)1412 (25.85)B.11 (0.23)5 (17.24)937 (17.15)B.1.175 (6.24)B.1.1.1101 (0.08)B.1.1.15837 (3.08)1 (3.45)B.1.1.22223 (1.92)B.1.1.26136 (31.34)2 (0.04)B.1.1.29084 (6.99)1 (0.23)1 (3.45)B.1.1.291956 (79.6)7 (1.61)11 (37.93)B.1.1.6518 (4.15)1 (0.02)B.1.1.7620 (1.67)1 (0.02)B.1.1698 (1.84)52 (0.95)B.1.333.15 (0.42)5 (1.15)7 (0.13)B.1.3711 (3.45)617 (11.30)B.1.4262 (6.90)12 (0.22)*Corresponding lineages associated with ""taac"" only or ""tggg"" only are excluded.",PMC8786941
Gamma,"The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies.",PMC8782626
B.1.617.2,"The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies.",PMC8782626
B.1.1.7,"The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies.",PMC8782626
Alpha,"The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies.",PMC8782626
B.1.351,"The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies.",PMC8782626
P.1,"The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies.",PMC8782626
Beta,"The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies.",PMC8782626
B.1.1.529,"The SARS-CoV-2 Spike trimer protein of variant B.1.1.529 (Omicron) was purchased from ACROBiosystems Inc. (Newark, DE, USA, #SPN-C52Hz).",PMC8782626
B.1,The strain Slovakia/SK-BMC5/2020 (available at https://www.european-virus-archive.com/virus/sars-cov-2-strain-slovakiask-bmc52020) represents strains circulating in Europe in spring 2020 and carries the Spike D614G mutation (lineage B.1).,PMC8782626
Kappa,"In order to prepare AX290 and AX677 for clinical testing, their variable regions were fused to human kappa and IgG1 constant regions.",PMC8782626
B.1.617.2,"One of the variants that has emerged recently is the Delta variant (B.1.617.2), which was firstly detected in India.",PMC8782737
B.1.1.529,"In November 2021, a more ferocious mutant appeared in South Africa, also called omicron (B.1.1.529).",PMC8782737
B.1.1.7,"The most notable feature in this wave was the discovery of a new strain (B.1.1.7) that has higher potential transmissibility; hence, re-infections became more common.",PMC8782737
B.1.351,"The additional new strain discovered in South Africa (lineage B.1.351, variant 20H/501Y.V2) involved eight mutations through S protein; D80A, L18F, R246I, D215G, E484K, K417N, A701V, and N501Y.",PMC8782737
P.1,"The variant 20 J/501Y.V3 and lineage P.1 has also spread in Brazil through three S protein mutations, N501Y, E484K, and K417N, in common with 20J/501Y.V2 [13].",PMC8782737
Alpha,"These mutations that happened in omicron are also identified in the previous strains of COVID-19, including alpha and delta variants [47].",PMC8782737
Mu,"Variants of concern (VOCs) Alpha, Beta, Gamma and Delta co-circulate in the region, together with variants of interest (VOIs) Lambda, Mu and Zeta.",PMC8779862
Gamma,"Variants of concern (VOCs) Alpha, Beta, Gamma and Delta co-circulate in the region, together with variants of interest (VOIs) Lambda, Mu and Zeta.",PMC8779862
Alpha,"Variants of concern (VOCs) Alpha, Beta, Gamma and Delta co-circulate in the region, together with variants of interest (VOIs) Lambda, Mu and Zeta.",PMC8779862
Beta,"Variants of concern (VOCs) Alpha, Beta, Gamma and Delta co-circulate in the region, together with variants of interest (VOIs) Lambda, Mu and Zeta.",PMC8779862
Lambda,"Variants of concern (VOCs) Alpha, Beta, Gamma and Delta co-circulate in the region, together with variants of interest (VOIs) Lambda, Mu and Zeta.",PMC8779862
B.1,Most of SARS-CoV-2 variants circulating in the South American region belongs to B.1 genotypes and have substitutions in the spike and/or nucleocapsid and polymerase proteins that confer high transmissibility and/or immune resistance.,PMC8779862
B.1.617.2,": VOC Alpha (B.1.1.7, first identified in the United Kingdom); VOC Beta (B.1.351, first identified in South Africa); VOC Gamma (P.1, first identified in Brazil) and VOC Delta (B.1.617.2, first isolated in India).",PMC8779862
B.1.1.7,": VOC Alpha (B.1.1.7, first identified in the United Kingdom); VOC Beta (B.1.351, first identified in South Africa); VOC Gamma (P.1, first identified in Brazil) and VOC Delta (B.1.617.2, first isolated in India).",PMC8779862
B.1.351,": VOC Alpha (B.1.1.7, first identified in the United Kingdom); VOC Beta (B.1.351, first identified in South Africa); VOC Gamma (P.1, first identified in Brazil) and VOC Delta (B.1.617.2, first isolated in India).",PMC8779862
P.1,": VOC Alpha (B.1.1.7, first identified in the United Kingdom); VOC Beta (B.1.351, first identified in South Africa); VOC Gamma (P.1, first identified in Brazil) and VOC Delta (B.1.617.2, first isolated in India).",PMC8779862
B.1.1.529,"Very recently, by November 24th, 2021, a new VOC named Omicron (B.1.1.529) identified in South Africa (Wang and Cheng, 2021; Wang and Chen, 2021).",PMC8779862
Iota,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
Zeta,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
B.1.621,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
C.37,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
B.1.617.1,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
P.2,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
Kappa,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
Eta,"These variants are known as variants of interest (VOI): VOI Eta (B.1.52, first identified in Nigeria); VOI Iota (B.1.53, first identified in the United States); VOI Kappa (B.1.617.1, first identified in India); VOI Lambda (C.37, first identified in Peru), VOI Mu (B.1.621, first identified in Colombia) and VOI Zeta (P.2, first identified in Brazil).",PMC8779862
A.1,"Each descending lineage from either A or B is assigned by a numerical value (for example, lineage A.1 or lineage B.2).",PMC8779862
C.2,A.1.1.1.1 would become C.1; A.1.1.1.2 would become C.2)..,PMC8779862
B.1.429,"Here, we identify an instance of SARS-CoV-2 superinfection, whereby an individual was simultaneously infected with two distinct viral variants: Alpha (B.1.1.7) and Epsilon (B.1.429).",PPR445763
Epsilon,"Here, we identify an instance of SARS-CoV-2 superinfection, whereby an individual was simultaneously infected with two distinct viral variants: Alpha (B.1.1.7) and Epsilon (B.1.429).",PPR445763
Alpha,"Here, we identify an instance of SARS-CoV-2 superinfection, whereby an individual was simultaneously infected with two distinct viral variants: Alpha (B.1.1.7) and Epsilon (B.1.429).",PPR445763
B.1.1.7,"Here, we identify an instance of SARS-CoV-2 superinfection, whereby an individual was simultaneously infected with two distinct viral variants: Alpha (B.1.1.7) and Epsilon (B.1.429).",PPR445763
B.1.526,"All of these mutations are characteristic of the B.1.526 Iota-variant, prevalent in NYC in early 2021.",PPR445763
Iota,Instead it appears to be a recombinant descendant of Alpha and Iota viruses..,PPR445763
B.1.617.2,"Here, we report an expanded version of our previously described sloppy molecular beacon (SMB) Alpha/Beta/Gamma RT-PCR melting temperature (Tm) signature-based assay, which now includes modifications that allow specific detection of Delta (B.1.617.2) and Omicron (B.1.529) VOCs..

We developed a dual SMB assay (SMB-452), which targeted the T22917G (L452R) mutation in the SARS-CoV-2 spike protein to specifically detect the Delta VOC.",PPR445360
B.1.529,"Here, we report an expanded version of our previously described sloppy molecular beacon (SMB) Alpha/Beta/Gamma RT-PCR melting temperature (Tm) signature-based assay, which now includes modifications that allow specific detection of Delta (B.1.617.2) and Omicron (B.1.529) VOCs..

We developed a dual SMB assay (SMB-452), which targeted the T22917G (L452R) mutation in the SARS-CoV-2 spike protein to specifically detect the Delta VOC.",PPR445360
Alpha,"Here, we report an expanded version of our previously described sloppy molecular beacon (SMB) Alpha/Beta/Gamma RT-PCR melting temperature (Tm) signature-based assay, which now includes modifications that allow specific detection of Delta (B.1.617.2) and Omicron (B.1.529) VOCs..

We developed a dual SMB assay (SMB-452), which targeted the T22917G (L452R) mutation in the SARS-CoV-2 spike protein to specifically detect the Delta VOC.",PPR445360
Gamma,"Here, we report an expanded version of our previously described sloppy molecular beacon (SMB) Alpha/Beta/Gamma RT-PCR melting temperature (Tm) signature-based assay, which now includes modifications that allow specific detection of Delta (B.1.617.2) and Omicron (B.1.529) VOCs..

We developed a dual SMB assay (SMB-452), which targeted the T22917G (L452R) mutation in the SARS-CoV-2 spike protein to specifically detect the Delta VOC.",PPR445360
B.1.1.7,"The global emergence of SARS-CoV-2 variants of concern (VOC), B.1.1.7 (20I, Alpha), B.1.351 (20H, Beta), P.1 (20J, Gamma), B.1.617.2 (21A, Delta), and B.1.1.529 (21K/ Omicron) have been responsible for a series surges in reported COVID-19 cases (1).",PPR445360
B.1.1.529,"The global emergence of SARS-CoV-2 variants of concern (VOC), B.1.1.7 (20I, Alpha), B.1.351 (20H, Beta), P.1 (20J, Gamma), B.1.617.2 (21A, Delta), and B.1.1.529 (21K/ Omicron) have been responsible for a series surges in reported COVID-19 cases (1).",PPR445360
B.1.351,"The global emergence of SARS-CoV-2 variants of concern (VOC), B.1.1.7 (20I, Alpha), B.1.351 (20H, Beta), P.1 (20J, Gamma), B.1.617.2 (21A, Delta), and B.1.1.529 (21K/ Omicron) have been responsible for a series surges in reported COVID-19 cases (1).",PPR445360
P.1,"The global emergence of SARS-CoV-2 variants of concern (VOC), B.1.1.7 (20I, Alpha), B.1.351 (20H, Beta), P.1 (20J, Gamma), B.1.617.2 (21A, Delta), and B.1.1.529 (21K/ Omicron) have been responsible for a series surges in reported COVID-19 cases (1).",PPR445360
Beta,"The global emergence of SARS-CoV-2 variants of concern (VOC), B.1.1.7 (20I, Alpha), B.1.351 (20H, Beta), P.1 (20J, Gamma), B.1.617.2 (21A, Delta), and B.1.1.529 (21K/ Omicron) have been responsible for a series surges in reported COVID-19 cases (1).",PPR445360
Kappa,"However, we expected that a new assay, which could detect mutations at codon 452 should be able to identify Delta variants, and that our existing codon 484 assay would be able to specifically identify Omicron variants if it was able to distinguish the WT 484 sequence present in both WT and Alpha strains from the E484K mutation present in Beta and Gamma, and the E484Q mutation present in Kappa from the E484A mutation present in Omicron (21).",PPR445360
Beta,Challenge studies suggested that the lethal dose of Delta was higher than Alpha or Beta strains.,PPR444666
Alpha,Challenge studies suggested that the lethal dose of Delta was higher than Alpha or Beta strains.,PPR444666
B.1.1.7,"In September 2020, the B.1.1.7 strain was first identified in the United Kingdom and quickly spread to become the dominant variant worldwide in early 2021 (1).",PPR444666
B.1.351,"Later, in December 2020, two other variants, Beta (B.1.351) and Gamma (P.1) were identified in South Africa and Japan/Brazil, respectively (2–4).",PPR444666
P.1,"Later, in December 2020, two other variants, Beta (B.1.351) and Gamma (P.1) were identified in South Africa and Japan/Brazil, respectively (2–4).",PPR444666
Gamma,"Later, in December 2020, two other variants, Beta (B.1.351) and Gamma (P.1) were identified in South Africa and Japan/Brazil, respectively (2–4).",PPR444666
B.1.617.2,"However, the efficacy of the BNT162b2 vaccine was slightly diminished in the context of the Alpha (93.7% efficacy) (20)..

As Alpha, Beta, and Gamma continued to spread, the Delta variant (B.1.617.2) was identified in India, resulting in a massive surge of COVID-19 cases in the country (21).",PPR444666
Kappa,"Key pathogenic mutations in the B.1.617 SARS-CoV-2 lineage, which includes the Delta (B.1.617.2) and Kappa (B.1.617.1) VOC, occur within the spike protein, which mediates viral attachment and entry into host cells via the ACE2 receptor (25,26).",PPR444666
B.1.617.1,"Key pathogenic mutations in the B.1.617 SARS-CoV-2 lineage, which includes the Delta (B.1.617.2) and Kappa (B.1.617.1) VOC, occur within the spike protein, which mediates viral attachment and entry into host cells via the ACE2 receptor (25,26).",PPR444666
B.1.617,"Key pathogenic mutations in the B.1.617 SARS-CoV-2 lineage, which includes the Delta (B.1.617.2) and Kappa (B.1.617.1) VOC, occur within the spike protein, which mediates viral attachment and entry into host cells via the ACE2 receptor (25,26).",PPR444666
B.1,"These data help to advance pre-clinical models of COVID-19 as well as serve as a benchmark to compare past and future VOC strains..

To date, most K18-hACE2 mouse or Golden Syrian hamster studies have utilized ancestral viral strains of SARS-CoV-2 (e.g., WA-1, D614G, B.1 Wuhan), and few studies have been performed with emergent VOC (2,17,18,33–39).",PPR444666
Gamma,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages.",PMC8769538
Beta,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages.",PMC8769538
Alpha,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages.",PMC8769538
B.1.617.2,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
B.1.1.7,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
B.1.351,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
P.1,"These VOCs include the Alpha (B.1.1.7) lineage first detected in the United Kingdom (29), the Beta (B.1.351) lineage in South Africa (30), the Gamma (P.1) lineage in Brazil (31), and the Delta (B.1.617.2) lineage in India (32) (Fig.",PMC8769538
B.1.351,"In May 2021, the WHO has officially renamed the four VOCs based on the Greek alphabet for purposes of public discourse, in which the UK variant N501Y V1 (i.e., B.1.1.7) was named Alpha, and the South Africa variant N501Y V2 (i.e., B.1.351) was named Beta.",PMC9015543
Alpha,"In May 2021, the WHO has officially renamed the four VOCs based on the Greek alphabet for purposes of public discourse, in which the UK variant N501Y V1 (i.e., B.1.1.7) was named Alpha, and the South Africa variant N501Y V2 (i.e., B.1.351) was named Beta.",PMC9015543
B.1.1.7,"In May 2021, the WHO has officially renamed the four VOCs based on the Greek alphabet for purposes of public discourse, in which the UK variant N501Y V1 (i.e., B.1.1.7) was named Alpha, and the South Africa variant N501Y V2 (i.e., B.1.351) was named Beta.",PMC9015543
P.1,"The two other VOCs were Gamma (i.e., P.1), the variant first identified in Brazil, and Delta (i.e., B.1.617.2) that originated in India.",PMC9015543
B.1.617.2,"The two other VOCs were Gamma (i.e., P.1), the variant first identified in Brazil, and Delta (i.e., B.1.617.2) that originated in India.",PMC9015543
Gamma,"The two other VOCs were Gamma (i.e., P.1), the variant first identified in Brazil, and Delta (i.e., B.1.617.2) that originated in India.",PMC9015543
Beta,"In contrast, neither Gamma nor Delta variants were found in the 261 323 viral genomes by December 25, 2020 in this study, which is plausible since they emerged later than the Alpha and Beta variants..",PMC9015543
B.1.1.529,"More recently, on November 26, 2021, a newly emerging variant B.1.1.529 from South Africa was designated as a novel VOC and named Omicron by WHO.",PMC9015543
Alpha,"One such antibody, NE12, neutralizes an early isolate, the WA-1 strain, as well as the Alpha and Delta variants with half-maximal inhibitory concentrations at picomolar level.",PPR442789
Beta,"A second antibody, NA8, has an unusual breadth of neutralization, with picomolar activity against both the Beta and Omicron variants.",PPR442789
Gamma,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.617.2,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.1.7,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.351,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
P.1,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta).",PPR442789
B.1.1.529,"The most recent VOC, first identified in South Africa and named Omicron (B.1.1.529), is rapidly spreading worldwide
3
.",PPR442789
B.1.529,"Their neutralization spectrum is different and complementary, with NE12 being extremely potent against an early SARS-CoV-2 strain, WA-1, as well as against the B.1.1.7/Alpha and B.1.617.2/Delta variants, and NA8 exhibiting an unusually broad spectrum of action with ultrapotent activity against the two most challenging current VOCs, B.1.351/Beta and B.1.529/Omicron.",PPR442789
B.1.617,"Residues mutated in B.1.1.7, B.1.617 and B.1.351 (g, h) or B.1.1.529/Omicron (i, j) variants of concern are colored in magenta.",PPR442789
Beta,"Wave 1 was characterised by a mixture of the original strains, wave 2 by the beta variant and wave 3 by the Delta variant [28,29].",PMC8778549
B.1.617.1,NextClade analysis as well as multiple sequence alignment (MSA) of the Spike glycoproteins revealed that each of the infections was a Delta variant (B.1.617.1) of SARS-CoV-2.,PMC8778549
B.1.617.2,"AY.4.2 displays three additional mutations (T95I, Y145H and A222V) in the N-terminal domain (NTD) of the spike when compared to the original Delta variant (B.1.617.2) and remains poorly characterized.",PPR441096
B.1,"The spike protein of Delta contains 9 mutations, when compared to the B.1 ancestral strain (D614G), including five changes in the NTD (T19R, G142D, Δ156, Δ157, R158G), two in the receptor binding domain (RBD) (L452R, T478K), one mutation close to the furin cleavage site (P681R) and one in the S2 region (D950N) 
3
.",PPR441096
Alpha,"The mutation is located in close proximity to residue 144, which is deleted in the Alpha variant.",PPR441096
B.1.177,"The A222V mutation was noted in the B.1.177 (or 20A.EU1) lineage that emerged in Spain and spread throughout Europe in summer 2020 
24
.",PPR441096
Kappa,"The T95I substitution was previously detected in the close B.1.617.1 lineage (also termed Kappa) 
26
.",PPR441096
B.1.617.1,"The T95I substitution was previously detected in the close B.1.617.1 lineage (also termed Kappa) 
26
.",PPR441096
Iota,"It was also present in the B.1.526 lineage (also termed Iota) that accounted for up to 30% of sequenced cases in New York City in early 2021 
27
.",PPR441096
B.1.526,"It was also present in the B.1.526 lineage (also termed Iota) that accounted for up to 30% of sequenced cases in New York City in early 2021 
27
.",PPR441096
Beta,"The anti-NTD antibodies bind uncharacterized epitopes within this domain, as assessed by Elisa (not shown)..

We previously assessed the ability of most of these antibodies to recognize the spikes of the Alpha, Beta and Delta variants 
3,30
.",PPR441096
B.1.1,"All 12 samples belonged to the B.1.1(20GR) clade, because they carried the triple mutation GGG28881-28883AAC in the N gene, which did not affect the detection of the test system at the target N. The most common mutation was at position G28851C/T, resulting in the S193T/I amino acid substitution.",PMC8774456
B.1.1.7,"Five samples were identified as B.1.1.7 strain and carried the triple mutation GGG28881-28883AAC along with the mutations GAT28280-28282CTA (D3L) and C28977T (S235F) in gene N. The remaining nonsynonymous and synonymous mutations localized along the entire length of the N gene were found in single samples and are shown in Table 2. .

A total of 57 nonsynonymous and 23 synonymous mutations were found, localized in all functional regions of the N gene and in disordered regions.",PMC8774456
B.1.1.317,"The detection of mutations in the two indicated regions of the N gene (5′ unstructured and linker) and their accumulation in Russian isolates reflects further evolution of the B.1.1 lineage with the formation of new variants, such as the recently reported B.1.1.317 (N: A211V) and B.1.1.397 (N: M234I) [27] and a novel variant (N: S193T and A35T)..",PMC8774456
B.1.1.397,"The detection of mutations in the two indicated regions of the N gene (5′ unstructured and linker) and their accumulation in Russian isolates reflects further evolution of the B.1.1 lineage with the formation of new variants, such as the recently reported B.1.1.317 (N: A211V) and B.1.1.397 (N: M234I) [27] and a novel variant (N: S193T and A35T)..",PMC8774456
B.1.1.529,"After the massive surge due to the delta (B·1·617·2) VoC, the emergence and rapid spread of the Omicron (B.1.1.529) VoC has further caused panic around the world.",PPR439656
Alpha,"The VoC harbouring mutations in the RBD may lead to a decreased neutralising ability of the vaccine-derived antibodies as has been shown against VoCs such as the alpha, beta, gamma and delta variants.",PPR439656
Beta,"The VoC harbouring mutations in the RBD may lead to a decreased neutralising ability of the vaccine-derived antibodies as has been shown against VoCs such as the alpha, beta, gamma and delta variants.",PPR439656
Gamma,"The VoC harbouring mutations in the RBD may lead to a decreased neutralising ability of the vaccine-derived antibodies as has been shown against VoCs such as the alpha, beta, gamma and delta variants.",PPR439656
B.1,Cells were incubated for 24 hours for ancestral (B.1) and Delta (B.1.617.2) variants and for 32 hours for Omicron variant.,PPR439656
B.1.617.2,Cells were incubated for 24 hours for ancestral (B.1) and Delta (B.1.617.2) variants and for 32 hours for Omicron variant.,PPR439656
B.1.617.2,"Since then, SARS-CoV-2 variants of concern (VOC) have swept the globe, displacing parent SARS-CoV-2 strains and, in the case of the Delta variant (B.1.617.2/AY.",PMC8925910
Gamma,"Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize.",PMC8723827
Beta,"Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize.",PMC8723827
Alpha,"Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize.",PMC8723827
Lambda,"Alpha (Supasa et al., 2021) and, more recently, Delta (Liu et al., 2021a), have had the greatest global reach, whilst Beta (Zhou et al., 2021), Gamma (Dejnirattisai et al., 2021b), and Lambda (Colmenares-Mejía et al., 2021), despite causing large outbreaks in Southern Africa and South America, did not become dominant in other parts of the world.",PMC8723827
B.1.1.529,"The rapid emergence of Omicron (https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern) in the background of high Beta immunity implies that the virus may have evolved to escape neutralization by Beta-specific serum (Liu et al., 2021b).",PMC8723827
Kappa,"100978Recombinant DNAVector: pHLsecAricescu et al., 2006N/AVector: pNEOAricescu et al., 2006N/AVector: pHLsec-SARS-CoV-2 spike of OmicronThis paperN/AVector: pNEO-SARS-CoV-2 RBD of OmicronThis paperN/AVector: pCMV-VSV-GStewart et al., 2003Addgene plasmid # 8454pHR-SIN-ACE2Alain TownsendN/AVector: pOPING-ETNettleship et al., 2008N/AVector: human IgG1 heavy chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: human lambda light chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: human kappa light chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: Human FabUniveristy of OxfordN/AVector: pJYDC1AdgeneID: 162458Software and algorithmsCOOT(Emsley et al., 2010)https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/Xia2-dialsWinter et al., 2018https://xia2.github.io/parameters.htmlPHENIXLiebschner et al., 2019https://www.phenix-online.org/PyMOL(Schrödinger and DeLano, 2020)https://pymol.org/Data Acquisition Software 11.1.0.11Fortebiohttps://www.fortebio.com/products/octet-systems-softwareData Analysis Software HT 11.1.0.25Fortebiohttps://www.fortebio.com/products/octet-systems-softwarePrism 8.0GraphPadhttps://www.graphpad.com/scientific-software/prism/Yeast display titration curve fitting were done by the standard non-cooperative Hill equation, fitted by nonlinear least-squares regression with two additional parameters using Python 3.7Zahradnik et al., 2021bN/AIBM SPSS Software 27IBMhttps://www.ibm.commabscapeThis paperhttps://github.com/helenginn/mabscapehttps://snapcraft.io/mabscapeOtherX-ray data were collected at beamline I03, Diamond Light Source, under proposal ib27009 for COVID-19 rapid accessThis paperhttps://www.diamond.ac.uk/covid-19/for-scientists/rapid-access.htmlTALON Superflow Metal Affinity ResinClontechCat#635668HiLoad 16/600 Superdex 200 pgCytivaCat#28-9893-35Superdex 200 increase 10/300 GL columnCytivaCat#28990944HisTrap nickel HP 5-ml columnCytivaCat#17524802HiTrap Heparin HT 5-ml columnCytivaCat#17040703Amine Reactive Second-Generation (AR2G) BiosensorsFortebioCat#18-5092Octet RED96eFortebiohttps://www.fortebio.com/products/label-free-bli-detection/8-channel-octet-systemsBuffer exchange system “QuixStand”GE HealthcareCat#56-4107-78Cartesian dispensing systemGenomic solutionsCat#MIC4000Hydra-96Robbins ScientificCat#Hydra-9696-well crystallization plateGreiner bio-oneCat#E20113NNCrystallization Imaging SystemFormulatrixCat#RI-1000Sonics vibra-cell vcx500 sonicatorVWRCat#432-0137
.",PMC8723827
B.1.1.7,"Participants from the first wave of SARS-CoV2 in the U.K. and those sequence confirmed with B.1.1.7 lineage in December 2020 and February 2021 were recruited through three studies: Sepsis Immunomics [Oxford REC C, reference:19/SC/0296]), ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections [Oxford REC C, reference 13/SC/0149] and the Gastro-intestinal illness in Oxford: COVID sub study [Sheffield REC, reference: 16/YH/0247].",PMC8723827
B.1.351,"We acknowledge the rapid sharing of Victoria, B.1.1.7 and B.1.351, which was isolated by scientists within the National Infection Service at PHE Porton Down, and the B.1.617.2 virus was kindly provided Wendy Barclay and Thushan De Silva.",PMC8723827
B.1.617.2,"We acknowledge the rapid sharing of Victoria, B.1.1.7 and B.1.351, which was isolated by scientists within the National Infection Service at PHE Porton Down, and the B.1.617.2 virus was kindly provided Wendy Barclay and Thushan De Silva.",PMC8723827
P.1,"We thank The Secretariat of National Surveillance, Ministry of Health Brazil for assistance in obtaining P.1 samples.",PMC8723827
B.1.429,"Reports from several countries on the identification of VOCs (United Kingdom—B.1.1.7 [alpha], South Africa—B.1.351 [Beta], Japan/Brazil—P.1 [Gamma], India—B.1.617.2 [Delta]) and variants of interest (Peru—C.37 [Lambda], Colombia—B.1.621 [Mu], U.S.A.—B.1.427 and B.1.429 [Epsilon]), confirm amino acid substitutions and/or deletions acquired in key antigenic sites, such as the RBD and N-terminal domain (NTD) of the S protein, which facilitate viral cell entry [27–32].",PMC8722410
B.1.351,"Evidence has shown that some of these mutations (N501Y, particularly) are convergent, arisen independently in different lineages (B.1.351, P.1 [sublineage of B.1.1.28]) [26].",PMC8722410
P.1,"Evidence has shown that some of these mutations (N501Y, particularly) are convergent, arisen independently in different lineages (B.1.351, P.1 [sublineage of B.1.1.28]) [26].",PMC8722410
B.1.1.7,"Part of these efforts resulted in the creation of two highly efficacious vaccines, BNT162b2 by Pfizer–BioNTech and mRNA-1273 by Moderna; both vaccines use nanotechnology as an essential part of their design to deliver mRNA [87].Table 1Characteristics of SARS-CoV-2 nanotechnology-enabled vaccine candidates.Candidate vaccineDeveloperNanoparticle typeCompositionMolecule deliveredEncoded or delivered SARS-CoV-2 antigenClinical Trial NumberNumber of dosesVaccine efficacyCountryBNT162 (a1, b1, b2, c2)Pfizer–BioNTechLNPRNA, lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3- phosphocholine [DSPC], and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose [177]a1: uRNAb1: modRNAb2: modRNAc2: saRNAa1: RBDb1: RBDb2: S proteinc2: S proteinPhase I/IINCT04380701, EudraCT 2020–001,038-36Phase I/II/IIINCT04368728282% after first dose against symptomatic COVID-19 [178]b2: 95% [179]89.5% against B.1.1.7 [134]75.0% against B.1.351 [134]Germany, USmRNA-1273Moderna/NIAIDLNPMessenger ribonucleic acid (mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose[180]modRNAS proteinPhase INCT04283461Phase IIANCT04405076Phase IIINCT04470427282% after first dose against symptomatic COVID-19 [178]94.1% [178]USNVX-CoV2373NovavaxProtein subunitFull-length recombinant S protein of SARS-CoV-2 combined with saponin-based Matrix-M™ adjuvantProteinS proteinPhase I/IINCT04368988Phase IIA/BNCT04533399Phase IIIEUCTR2020-004,123–16NCT04583995NCT046118022Phase IIB 60.1% inHIV-negative; 51.0% against B.1.351 variant andHIV-negative;49.4% overall [181] Phase III96.4% against original strain; 86.3% against B.1.1.7/501Y.V1 variant;89.7% overall [182]Phase III91% against high-risk populations, 100% against original strain;90.4% overall [183]US, AustraliaLUNAR-COV19/ARCT-021ArcturusLNPLipid-enabled and unlocked nucleomonomer agent modified RNA (LUNAR) composed of50% ionizable amino lipids or MC3, 7% 1,2-distearoyl-sn-glycero-3-phosphocholine, 40% cholesterol, 3% 1,2-dimyristoyl-sn-glycerol and methoxypolyethylene glycolSelf-transcribing and replicating RNA (STARR)S proteinPhase I/IINCT04480957Phase IIANCT04728347––US, SingaporeLNP-nCoV saRNAImperial College LondonLNPIonizable cationic lipid (proprietary to Acuitas), phosphatidylcholine, cholesterol and PEG-lipidsaRNAS proteinPhase IISRCTN17072692––UK, ChinaPlant-derived virus-like particle of SARS-CoV-2Medicago/Glaxo Smith KlineVLNPSARS-CoV-2 antigenic proteinsProteinS proteinPhase INCT04450004Phase II/IIINCT04636697––Canada, USCucumber mosaic virus-derived VLNPSaibaVLNPConjugated SARS-CoV-2 antigenic proteinsProteinS proteinNo clinical trial––SwitzerlandNIAID  National Institute of Allergy and Infectious Diseases, LNP lipid nanoparticle, VLNP virus-like nanoparticle, PEG polyethylene glycol, uRNA uridine containing mRNA, modRNA N1-methyl-pseudouridine (m1Ψ) nucleoside-modified mRNA, saRNA self-amplifying mRNA, RBD receptor-binding domain.",PMC8722410
B.1.427,"directly compared SARS-CoV-2-specific CD4+ and CD8+ T cell responses of COVID-19 convalescent patients previously infected by B.1.1.7, B.1.351, P.1, and CAL.20C (B.1.427/B.1.429) viral lineages, and that were recipients of either mRNA-1273 or BNT162b2 vaccines [168].",PMC8722410
B.1.351,"Notably, it provides protection against infection with prototype and B.1.351 strains in mice.",PMC9106700
Gamma,"Currently, the emergence of five VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-191–8.",PMC9106700
B.1.617.2,"Currently, the emergence of five VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-191–8.",PMC9106700
B.1.1.7,"Currently, the emergence of five VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-191–8.",PMC9106700
B.1.1.529,"Currently, the emergence of five VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-191–8.",PMC9106700
Alpha,"Currently, the emergence of five VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-191–8.",PMC9106700
P.1,"Currently, the emergence of five VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-191–8.",PMC9106700
Beta,"Currently, the emergence of five VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-191–8.",PMC9106700
Eta,"After prime and boost administration, the binding antibody titers in the sera were determined by ELISA against HexaPro of SARS-CoV-2 wild type and a panel of 5 variants (including Alpha, Beta, Gamma, Delta, and Eta).",PMC9106700
Lambda,"3a), indicating that strategies to reduce the number of vaccinations to economize the available vaccine doses might not compromise the resulting titer of neutralizing antibodies when using a HexaPro-based nanoparticle vaccine..

Apart from the SARS-CoV-2 prototype and variants, we also examined the breadth of neutralizing antibodies from cynomolgus macaques immunized with WT NP or Mosaic NP at peak potency (2 weeks after a third vaccination) against pandemic Omicron and Lambda variants and a panel of SARS-CoV-2 pseudoviruses harboring single or combinatorial key residue mutations in the RBD (K417N/T, L452R, T478K, E484K/Q, N501Y) from the circulating pango lineage (Fig.",PMC9106700
B.1.617.3,"For instance, the K417N substitution found in the B.1.351 and AY.1 lineages (median ID50 titer of 104.8 ± 0.2 for WT NP and 105.2 ± 0.5 for Mosaic NP), E484Q present in B.1.617.1, B.1.617.3, and B.1.630 (median ID50 titer of 104.4 ± 0.4 for WT NP and 104.7 ± 0.2 for Mosaic NP) increased it 2.5- (K417N) and 1.0-fold (E484Q) for WT NP, as well as increased it 2.0 (K417N) and reduced it 1.6-fold (484Q) for Mosaic NP.",PMC9106700
B.1.617.1,"For instance, the K417N substitution found in the B.1.351 and AY.1 lineages (median ID50 titer of 104.8 ± 0.2 for WT NP and 105.2 ± 0.5 for Mosaic NP), E484Q present in B.1.617.1, B.1.617.3, and B.1.630 (median ID50 titer of 104.4 ± 0.4 for WT NP and 104.7 ± 0.2 for Mosaic NP) increased it 2.5- (K417N) and 1.0-fold (E484Q) for WT NP, as well as increased it 2.0 (K417N) and reduced it 1.6-fold (484Q) for Mosaic NP.",PMC9106700
B.1.630,"For instance, the K417N substitution found in the B.1.351 and AY.1 lineages (median ID50 titer of 104.8 ± 0.2 for WT NP and 105.2 ± 0.5 for Mosaic NP), E484Q present in B.1.617.1, B.1.617.3, and B.1.630 (median ID50 titer of 104.4 ± 0.4 for WT NP and 104.7 ± 0.2 for Mosaic NP) increased it 2.5- (K417N) and 1.0-fold (E484Q) for WT NP, as well as increased it 2.0 (K417N) and reduced it 1.6-fold (484Q) for Mosaic NP.",PMC9106700
C.1.2,"621, Theta and C.1.2) led to a 1.6-fold decrease in neutralization potency (median ID50 titer of 104.2 ± 0.1 for WT NP and 104.7 for Mosaic NP).",PMC9106700
B.1.427,"The L452R substitution present in B.1.617.2, AY.1, B.1.617, B.1.617.3, B.1.427, B.1.429, C.36.3, and B.1.630 (median ID50 titer of 104.3 ± 0.2 for WT NP and 104.5 ± 0.2 for Mosaic NP) elicited 1.3-fold and 2.5-fold decrease in neutralization potency compared to SARS-CoV-2 wild type (D614G).",PMC9106700
C.36.3,"The L452R substitution present in B.1.617.2, AY.1, B.1.617, B.1.617.3, B.1.427, B.1.429, C.36.3, and B.1.630 (median ID50 titer of 104.3 ± 0.2 for WT NP and 104.5 ± 0.2 for Mosaic NP) elicited 1.3-fold and 2.5-fold decrease in neutralization potency compared to SARS-CoV-2 wild type (D614G).",PMC9106700
B.1.617,"The L452R substitution present in B.1.617.2, AY.1, B.1.617, B.1.617.3, B.1.427, B.1.429, C.36.3, and B.1.630 (median ID50 titer of 104.3 ± 0.2 for WT NP and 104.5 ± 0.2 for Mosaic NP) elicited 1.3-fold and 2.5-fold decrease in neutralization potency compared to SARS-CoV-2 wild type (D614G).",PMC9106700
B.1.429,"The L452R substitution present in B.1.617.2, AY.1, B.1.617, B.1.617.3, B.1.427, B.1.429, C.36.3, and B.1.630 (median ID50 titer of 104.3 ± 0.2 for WT NP and 104.5 ± 0.2 for Mosaic NP) elicited 1.3-fold and 2.5-fold decrease in neutralization potency compared to SARS-CoV-2 wild type (D614G).",PMC9106700
R.1,"However, the E484K substitution present in B.1.351, P.1, B.1.621, B.1.525, Zeta, Theta, R.1, B.1.1.318, C.1.2, and B.1.630 (median ID50 titer of 103.9 ± 0.3 for WT NP and median ID50 titer of 104.6 ± 0.1 for Mosaic NP) elicited 3.2-fold lower neutralization potency for WT NP and 2.0-fold lower neutralization potency for Mosaic NP than SARS-CoV-2 wild type (D614G), indicating that the E484K substitutions exhibited a certain level of resistance for WT NP.",PMC9106700
Zeta,"However, the E484K substitution present in B.1.351, P.1, B.1.621, B.1.525, Zeta, Theta, R.1, B.1.1.318, C.1.2, and B.1.630 (median ID50 titer of 103.9 ± 0.3 for WT NP and median ID50 titer of 104.6 ± 0.1 for Mosaic NP) elicited 3.2-fold lower neutralization potency for WT NP and 2.0-fold lower neutralization potency for Mosaic NP than SARS-CoV-2 wild type (D614G), indicating that the E484K substitutions exhibited a certain level of resistance for WT NP.",PMC9106700
Theta,"However, the E484K substitution present in B.1.351, P.1, B.1.621, B.1.525, Zeta, Theta, R.1, B.1.1.318, C.1.2, and B.1.630 (median ID50 titer of 103.9 ± 0.3 for WT NP and median ID50 titer of 104.6 ± 0.1 for Mosaic NP) elicited 3.2-fold lower neutralization potency for WT NP and 2.0-fold lower neutralization potency for Mosaic NP than SARS-CoV-2 wild type (D614G), indicating that the E484K substitutions exhibited a certain level of resistance for WT NP.",PMC9106700
B.1.621,"However, the E484K substitution present in B.1.351, P.1, B.1.621, B.1.525, Zeta, Theta, R.1, B.1.1.318, C.1.2, and B.1.630 (median ID50 titer of 103.9 ± 0.3 for WT NP and median ID50 titer of 104.6 ± 0.1 for Mosaic NP) elicited 3.2-fold lower neutralization potency for WT NP and 2.0-fold lower neutralization potency for Mosaic NP than SARS-CoV-2 wild type (D614G), indicating that the E484K substitutions exhibited a certain level of resistance for WT NP.",PMC9106700
B.1.525,"However, the E484K substitution present in B.1.351, P.1, B.1.621, B.1.525, Zeta, Theta, R.1, B.1.1.318, C.1.2, and B.1.630 (median ID50 titer of 103.9 ± 0.3 for WT NP and median ID50 titer of 104.6 ± 0.1 for Mosaic NP) elicited 3.2-fold lower neutralization potency for WT NP and 2.0-fold lower neutralization potency for Mosaic NP than SARS-CoV-2 wild type (D614G), indicating that the E484K substitutions exhibited a certain level of resistance for WT NP.",PMC9106700
B.1.1.318,"However, the E484K substitution present in B.1.351, P.1, B.1.621, B.1.525, Zeta, Theta, R.1, B.1.1.318, C.1.2, and B.1.630 (median ID50 titer of 103.9 ± 0.3 for WT NP and median ID50 titer of 104.6 ± 0.1 for Mosaic NP) elicited 3.2-fold lower neutralization potency for WT NP and 2.0-fold lower neutralization potency for Mosaic NP than SARS-CoV-2 wild type (D614G), indicating that the E484K substitutions exhibited a certain level of resistance for WT NP.",PMC9106700
C.37,"A panel of expression plasmids encoding the spike protein of SARS-CoV-2 prototype and variants (Lineages: B.1.1.7, B.1.351, P.1, B.1.525, B.1.617.2, B.1.525, and C.37) with a 19-residue truncation at the C-terminus for SARS-CoV-2 pseudovirus production was constructed by Gibson assembly.",PMC9106700
B.1.1.529,"A new variant, Omicron (B.1.1.529), has recently emerged and was rapidly declared a VOC during the final revision of this paper.",PMC8795541
Gamma,"3A)..

(A) SARS-CoV-2 strains classified in May 2021 as VOCs (red, now also named Alpha [B.1.1.7], Beta [B.1.351], Gamma [P.1], and Delta [B.1.617.2]) and VOIs (green).",PMC8795541
Beta,"3A)..

(A) SARS-CoV-2 strains classified in May 2021 as VOCs (red, now also named Alpha [B.1.1.7], Beta [B.1.351], Gamma [P.1], and Delta [B.1.617.2]) and VOIs (green).",PMC8795541
Alpha,"3A)..

(A) SARS-CoV-2 strains classified in May 2021 as VOCs (red, now also named Alpha [B.1.1.7], Beta [B.1.351], Gamma [P.1], and Delta [B.1.617.2]) and VOIs (green).",PMC8795541
B.1.617,The B.1.617 lineage is divided into three sublineages; the E484Q and T478K (with asterisks) mutations are not shared by all sublineages.,PMC8795541
B.1.526,The same is true for E484K and S477N in the B.1.526 lineage.,PMC8795541
C.37,"In fact, a new variant was declared a VOI in June 2021 (lineage C.37, or Lambda).",PMC8795541
Lambda,"In fact, a new variant was declared a VOI in June 2021 (lineage C.37, or Lambda).",PMC8795541
B.1.351,"Although neutralization of one of these antibodies is abrogated by the mutations of variant B.1.351, it is also possible to produce a bi-valent cocktail of antibodies both of which are resilient to variants B.1.1.7, B.1.351 and B.1.617.2..",PMC8690919
B.1.1.7,"Although neutralization of one of these antibodies is abrogated by the mutations of variant B.1.351, it is also possible to produce a bi-valent cocktail of antibodies both of which are resilient to variants B.1.1.7, B.1.351 and B.1.617.2..",PMC8690919
B.1.617.2,"Finally, we investigate the effects of B.1.1.7, B.1.351 and B.1.617.2 variants of concern on the neutralization properties of these antibodies and explain these effects in terms of their structures..

A panel of plasmablast-derived anti-RBD antibodies efficiently neutralized the SARS-CoV-2 pseudovirus and live virus 14 (Figure 1A) and targeted non-overlapping epitope groups (Figure S1).",PMC8690919
P.1,"Similar histopathological findings of lung and trachea were observed in the therapeutic experiment (Figure 5D, Tables S1 and S2)..

Taken together, the Syrian hamster study shows that the prophylactic or therapeutic treatment with either 40 or 4 mg/kg of antibody cocktail could significantly reduce lung viral load and attenuate SARS-COV-2 virus-induced pulmonary inflammation as judged by histopathological examination..

Several new variants have emerged since late 2020, i.e., the B.1.1.7, B.1.351, P.1, B.1.617.2 lineages, and G614 polymorphism.",PMC8690919
Alpha,"The B.1.1.7 lineage, also known as 20I/501Y.V1 and Alpha, was first identified in the United Kingdom in September 2020 and the spike protein contains characteristic mutations (e.g., N501Y within the RBD) compared with other circulating strains 21.",PMC8690919
Beta,"The B.1.351 lineage, also known as 20H/501Y.V2 and Beta, was first identified in South Africa in late 2020 and arose independently to B.1.1.7 but shares several mutations, including the spike mutation N501Y.",PMC8690919
Gamma,"The P.1 lineage, also known as Gamma, was firstly identified in Brazil and then spread in the Americas and contains three mutations in the RBD (K417T, E484K, and N501Y) 19, 25.",PMC8690919
Kappa,"The VH and VL genes of C121 15, REGN10933 10,33, REGN10987 10,33 and S309 16 were synthesized as cDNA fragments and subcloned into the AbVec Heavy, AbVec Kappa or AbVec Lambda vector as previously described 14.",PMC8690919
Lambda,"The VH and VL genes of C121 15, REGN10933 10,33, REGN10987 10,33 and S309 16 were synthesized as cDNA fragments and subcloned into the AbVec Heavy, AbVec Kappa or AbVec Lambda vector as previously described 14.",PMC8690919
Beta,"Moreover, the magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants, despite Omicron harbouring considerably more mutations.",PPR437022
B.1.1.529,"These peptides (15-mers overlapping by 10 amino acids) spanned the entire spike protein corresponding to the ancestral Wuhan sequence (GenBank: MN908947), Beta (B.1.351; GISAID: EPI_ISL_736932), Delta SARS-CoV-2 variants (B.1.617.2; GISAID: EPI_ISL_2020950) or Omicron (B.1.1.529), carrying in the spike sequence all the 38 currently described mutations (A67V, H69del, V70del, T95l, G142D, V143del, Y144del, Y145del, S152W, N211del, L212l, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F).",PPR437022
Gamma,"Compared to standard phylogenetic distance metrics and overall mutational load, the quantification of distinctive 9-mer polynucleotides provides a higher resolution of separation between VOCs (Reference = 89, IQR: 65-108; Alpha = 166, IQR: 150-182; Beta 130, IQR: 113-147; Gamma = 165, IQR: 152-180; Delta = 234, IQR: 216-253; and Omicron = 294, IQR: 287-315).",PPR436215
Beta,"Compared to standard phylogenetic distance metrics and overall mutational load, the quantification of distinctive 9-mer polynucleotides provides a higher resolution of separation between VOCs (Reference = 89, IQR: 65-108; Alpha = 166, IQR: 150-182; Beta 130, IQR: 113-147; Gamma = 165, IQR: 152-180; Delta = 234, IQR: 216-253; and Omicron = 294, IQR: 287-315).",PPR436215
Alpha,"Compared to standard phylogenetic distance metrics and overall mutational load, the quantification of distinctive 9-mer polynucleotides provides a higher resolution of separation between VOCs (Reference = 89, IQR: 65-108; Alpha = 166, IQR: 150-182; Beta 130, IQR: 113-147; Gamma = 165, IQR: 152-180; Delta = 234, IQR: 216-253; and Omicron = 294, IQR: 287-315).",PPR436215
B.1.640.2,Omicron’s exceptionally high genomic distinctiveness may confer a competitive advantage over both prior VOCs (including Delta) and the recently emerged and highly mutated B.1.640.2 (IHU) lineage.,PPR436215
B.1.617.2,"2
 The PANGO lineages corresponding to these VOCs are as follows: Alpha variant (B.1.1.7 and Q lineages), Beta variant (B.1.351 and descendant lineages), Gamma variant (P.1, which is a descendant of B.1.1.28, and descendant lineages), Delta variant (B.1.617.2 and AY lineages), and Omicron variant (B.1.1.529 and BA lineages).",PPR436215
B.1.1.7,"2
 The PANGO lineages corresponding to these VOCs are as follows: Alpha variant (B.1.1.7 and Q lineages), Beta variant (B.1.351 and descendant lineages), Gamma variant (P.1, which is a descendant of B.1.1.28, and descendant lineages), Delta variant (B.1.617.2 and AY lineages), and Omicron variant (B.1.1.529 and BA lineages).",PPR436215
B.1.1.529,"2
 The PANGO lineages corresponding to these VOCs are as follows: Alpha variant (B.1.1.7 and Q lineages), Beta variant (B.1.351 and descendant lineages), Gamma variant (P.1, which is a descendant of B.1.1.28, and descendant lineages), Delta variant (B.1.617.2 and AY lineages), and Omicron variant (B.1.1.529 and BA lineages).",PPR436215
B.1.1.28,"2
 The PANGO lineages corresponding to these VOCs are as follows: Alpha variant (B.1.1.7 and Q lineages), Beta variant (B.1.351 and descendant lineages), Gamma variant (P.1, which is a descendant of B.1.1.28, and descendant lineages), Delta variant (B.1.617.2 and AY lineages), and Omicron variant (B.1.1.529 and BA lineages).",PPR436215
B.1.351,"2
 The PANGO lineages corresponding to these VOCs are as follows: Alpha variant (B.1.1.7 and Q lineages), Beta variant (B.1.351 and descendant lineages), Gamma variant (P.1, which is a descendant of B.1.1.28, and descendant lineages), Delta variant (B.1.617.2 and AY lineages), and Omicron variant (B.1.1.529 and BA lineages).",PPR436215
P.1,"2
 The PANGO lineages corresponding to these VOCs are as follows: Alpha variant (B.1.1.7 and Q lineages), Beta variant (B.1.351 and descendant lineages), Gamma variant (P.1, which is a descendant of B.1.1.28, and descendant lineages), Delta variant (B.1.617.2 and AY lineages), and Omicron variant (B.1.1.529 and BA lineages).",PPR436215
B.1.1,"3
 All of these variants evolved from the B.1 lineage, while Alpha, Gamma, and Omicron share B.1.1 as an additional parent lineage.",PPR436215
B.1,"3
 All of these variants evolved from the B.1 lineage, while Alpha, Gamma, and Omicron share B.1.1 as an additional parent lineage.",PPR436215
B.1.640,"A recent non-VOC, the IHU variant (B.1.640) that was identified in France also captured interest due to the amount and nature of mutations in this variant.",PPR436215
Gamma,"The members of the SJTRC Study Team are Jeremie H. Estepp, Stacey Schultz-Cherry, Maureen A. McGargill, Aditya Gaur, James Hoffman, Motomi Mori, Li Tang, Elaine Tuomanen, Richard Webby, Randall T. Hayden, Hana Hakim, Diego R. Hijano, Kim J. Allison, E. Kaitlynn Allen, Resha Bajracharya, Walid Awad, Lee-Ann Van de Velde, Brandi L. Clark, Taylor L. Wilson, Aisha Souquette, Ashley Castellaw, Ronald H. Dallas, Ashleigh Gowen, Thomas P. Fabrizio, Chun-Yang Lin, David C. Brice, Sean Cherry, Ericka Kirkpatrick Roubidoux, Valerie Cortez, Pamela Freiden, Nicholas Wohlgemuth, and Kendall Whitt..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD4 Alexa Fluor 700 (clone SK3)BioLegendcat#: 344622; RRID: AB_2563150CD19 PE (clone HIB19)BioLegendcat#: 302208; RRID: AB_314238CXCR5 PE-Dazzle 594 (clone J252D4)BioLegendcat#: 356928; RRID: AB_2563689PD1 BB515 (clone EH12.1)BD Biosciencescat#: 564494; RRID: AB_2738827IgG BV480 (goat polyclonal)Jackson ImmunoResearchcat#: 109-685-098; RRID: AB_2721846IgA FITC (clone M24A)Milliporecat#: CBL114F; RRID: AB_92852CD45 A532 (clone HI30)Thermocat#: 58-0459-42; RRID: AB_11218673CD38 BB700 (clone HIT2)BD Biosciencescat#: 566445; RRID: AB_2744375CD20 Pacific Blue (clone 2H7)BioLegendcat#: 980204; RRID: AB_2632618CD27 BV510 (clone O323)BioLegendcat#: 302836; RRID: AB_2562086CD8 BV570 (clone RPA-T8)BioLegendcat#: 301038; RRID: AB_2563213IgM BV605 (clone MHM-88)BioLegendcat#: 314524; RRID: AB_2562374HLA-DR BV650 (clone L243)BioLegendcat#: 307650; RRID: AB_2563828CD19 BV750 (clone HIB19)BioLegendcat#: 302262; RRID: AB_2810434IgD PE-Cy5 (clone IA6-2)BioLegendcat#: 348250; RRID: AB_2876661CD14 PerCP (clone HCD14)BioLegendcat#: 325632; RRID: AB_2563328CD71 PE-Cy7 (clone CY1G4)BioLegendcat#: 334112; RRID: AB_2563119CD4 Spark 685 (clone SK3)BioLegendcat#: 344658; RRID: AB_2819981CD3 APC-Fire 810 (clone SK7)BioLegendcat#: 344858; RRID: AB_2860895FoxP3 BV421 (clone 206D)BioLegendcat#: 320124; RRID: AB_2565972Ki-67 BV711 (clone Ki-67)BioLegendcat#: 350516; RRID: AB_2563861Tbet BV785 (clone 4B10)BioLegendcat#: 644835; RRID: AB_2721566Bcl6 PE (clone K112-91)BD Biosciencescat#: 561522; RRID: AB_10717126BLIMP1 Alexa Fluor 700 (clone 646702)R&D Systemscat#: IC36081NCD4 Alexa Fluor 700 (clone SK3)BioLegendcat#: 344622; RRID: AB_2563150CD45RO BV650 (clone UCHL1)BioLegendcat#: 304232; RRID: AB_2563462CCR7 BV785 (clone G043H7)BioLegendcat#: 353230; RRID: AB_2563630HLA-DR BV605 (clone L243)BioLegendcat#: 307640; RRID: AB_2561913ICOS BV421 (clone C398.4A)BioLegendcat#: 313524; RRID: AB_2562545IgD PE-Cy7 (clone IA6-2)BioLegendcat#: 348210; RRID: AB_10680462CD3 Alexa Fluor 700 (clone HIT3a)BioLegendcat#: 300324; RRID: AB_493739CD4 PerCP (clone SK3)BioLegendcat#: 344624; RRID: AB_2563326CD45RO APC-Fire 750 (clone UCHL1)BioLegendcat#: 304250; RRID: AB_2616717CXCR3 BV650 (clone G025H7)BioLegendcat#: 353730; RRID: AB_2563870TCR-beta chain APC-Fire 750 (clone H57-597)BioLegendcat#: 109246; RRID: AB_2629697CD3 BV421 (clone SK7)BioLegendcat#: 344834; RRID: AB_2565675anti-human CD28 purified (clone CD28.2)BD Biosciencescat#: 555725; RRID: AB_396068anti-human CD49d purified (clone 9F10)BD Biosciencescat#: 555501; RRID: AB_2130052human Fc block (clone Fc1.3216)BD Biosciencescat#: 564220; RRID: AB_2869554Human TruStain FcXBioLegendcat#: 422302; RRID: AB_2818986CD19 BV510 (clone HIB19)BioLegendcat#: 302242; RRID: AB_2561668CD69 PerCP-eFluor 710 (clone FN50)eBiosciencecat#: 460699-42; RRID: AB_2573694CXCR5 Super Bright 436 (clone MU5UBEE)eBiosciencecat#: 62-9185-42; RRID: AB_2724064CD45RA eFluor 450 (clone HI100)eBiosciencecat#: 48-0458-42; RRID: AB_1272059CD8 BV570 (clone RPA-T8)BioLegendcat#: 301038; RRID: AB_2563213CD3 BV750 (clone SK7)BioLegendcat#: 344846; RRID: AB_2800923CD4 BB515 (clone SK3)BD Biosciencescat#: 565996; RRID: AB_2739447PD-1 FITC (clone EH12.2H7)BioLegendcat#: 329904; RRID: AB_940479ICOS PerCP-Cy5.5 (clone C398.4A)BioLegendcat#: 313518; RRID: AB_10641280CD69 PE-Cy7 (clone FN50)BioLegendcat#: 310912; RRID: AB_314847TCR gamma/delta Alexa Fluor 647 (clone B1)BioLegendcat#: 331214; RRID: AB_1089210anti-human IFN-gamma BV480 (clone B27)BD Biosciencescat#: 566100; RRID: AB_2739503anti-human TNF-alpha BV605 (clone Mab11)BioLegendcat#: 502936; RRID: AB_2563884anti-human IL-17A BV785 (clone BL168)BioLegendcat#: 512338; RRID: AB_2566765anti-human IL-21 PE (clone 3A3-N2)BioLegendcat#: 513004; RRID: AB_2249025anti-human IL-2 APC (clone MQ1-17H12)eBiosciencecat#: 17-7029-82; RRID: AB_469492CD40 (clone HB14)Miltenyi Bioteccat#: 130-094-133; RRID: AB_10839704Co-stimulatory antibodies (CD28/CD49d, clones L293/L25))BD Biosciencescat#: 347690; RRID: AB_647457CD40L BV605 (clone 24-31)BioLegendcat#: 310826; RRID: AB_2563832CD3 FITC (clone SK7)BioLegendcat#: 344804; RRID: AB_2043993CD200 PerCP-Cy5.5 (clone OX-104)BioLegendcat#: 329216; RRID: AB_2563251CD8 APC (clone SK1)BioLegendcat#: 344722; RRID: AB_2075388CD45RA BV421 (clone HI100)BioLegendcat#: 304130; RRID: AB_10965547CD4 BV711 (clone OKT4)BioLegendcat#: 317440; RRID: AB_2562912CD3 PerCP-Cy5.5 (clone OKT3)BioLegendcat#: 317336; RRID: AB_2561628CCR7 FITC (clone G043H7)BioLegendcat#: 353216; RRID: AB_10916386Biological samplesPeripheral blood human samples after SARS-CoV-2 infectionSt.",PMC8695127
Alpha,"Jude Tracking of Viral and Host Factors Associated with COVID-19 study (SJTRC, NCT04362995)N/APeripheral blood and matched lymph node samples after BNT162b2 vaccinationWU-368 study (approval #2020-12-081)N/AChemicals, peptides, and recombinant proteinsRecombinant SARS-CoV-2 Spike protein – Biotin conjugatedStadlbauer et al., 2020N/ARecombinant SARS-CoV-2 Spike protein – Alexa Fluor 647 conjugatedStadlbauer et al., 2020N/ARecombinant SARS-CoV-2 Spike protein – Alexa Fluor 488 conjugatedStadlbauer et al., 2020N/APE-labeled HLA-DPB1∗04:01 S167-180 tetramerThis paperN/ABrilliant Staining bufferBD BiosciencesN/Astreptavidin APC-Fire 750BioLegendcat#: 566349True-Nuclear Transcription Factor Buffer SetBioLegendcat#: 405250Zombie AquaBioLegendcat#: 423106Zombie NIR Fixable Viability KitBioLegendcat#: 424401Lenti-X ConcentratorClontechcat#: 6312321x Cell Stimulation cocktaileBiosciencecat#: 00-4970-93Ghost Dye Violet 510 Viability DyeTonbo Biosciencescat#: 13-0870-T100CTFEYVSQPFLMDLE peptide (>95% purity)This paperN/ATFEYVSQPFLMDLE peptideThis paperN/ASARS-CoV-2 Prot_S Complete PeptivatorMiltenyicat#: 130-127-951NQKLIANQF peptide (>95% purity)Minervina et al., 2020N/AGolgiPlugBD Biosciencescat#: 555029Fixation/Permeabilization Solution kitBD Biosciencescat#: 554715streptavidin PEBioLegendcat#: 405204Critical commercial assaysAllType NGS 11-Loci Amplification KitOne Lambdacat#: ALL-11LXSuperScript VILO cDNA Synthesis kitInvitrogencat#: 11754250SmartScribe Reverse TranscriptaseTakaracat#: 639538Q5 Hot Start High-Fidelity DNA PolymeraseNEBcat#: M0493Deposited dataProcessed TCR repertoire sequencing dataThis paperGEO: GSE183393Raw TCR repertoire sequencing dataThis paperSRA: SRP335569Experimental models: Cell lines293TATCCcat#: CRL-3216Jurkat 76.7 (variant of TCR-null Jurkat 76.7 cells that expresses human CD8 and an NFAT-GFP reporter)gift from Wouter ScheperN/AOligonucleotides5’ – template switch adapter (SmartNNNa): AAGCAGUGGTAUCAACGCAGAGUNNNNUNNNNUNNNNUCTT(rG)4Egorov et al., 2015N/APrimer for cDNA synthesis, human TCR alpha chain mRNA, C-region (ACR_st4): GTCTAGCACAGTTTTGTCEgorov et al., 2015N/APrimer for cDNA synthesis, human TCR beta chain mRNA, C-region (BCR4short):GTATCTGGAGTCATTGAEgorov et al., 2015N/AForward primer for PCR step1, anneals on the switch adapter(M1ss): AAGCAGTGGTATCAACGCAEgorov et al., 2015N/ANested reverse primer for PCR step1, TCR alpha, C-region (ACR_st1):GTCACTGGATTTAGAGTCEgorov et al., 2015N/ANested reverse primer for PCR step1, TCR beta, C-region (BC2uniR):TGCTTCTGATGGCTCAAACACEgorov et al., 2015N/ABarcoded forward PCR step 2 primer (M1s_i): (N)4(XXXXX)CAGTGGTATCAACGCAGAGEgorov et al., 2015N/ABarcoded reverse PCR step 2 primer (TCR alpha): (N)4(XXXXX)GGGTCAGGGTTCTGGATATEgorov et al., 2015N/ABarcoded reverse PCR step 2 primer (TCR beta):(N)4(XXXXX)ACACSTTKTTCAGGTCCTCEgorov et al., 2015N/AhuTRBV2ext: TCGATGATCAATTCTCAGTTGWang et al., 2012N/AhuTRBV3ext: CAAAATACCTGGTCACACAGWang et al., 2012N/AhuTRBV4ext: TCGCTTCTCACCTGAATGWang et al., 2012N/AhuTRBV5-1_4ext: GATTCTCAGGKCKCCAGTTCWang et al., 2012N/AhuTRBV5-5_8ext: GTACCAACAGGYCCTGGGTWang et al., 2012N/AhuTRBV6-1_3,5_9ext: ACTCAGACCCCAAAATTCCWang et al., 2012N/AhuTRBV6-4ext: ACTGGCAAAGGAGAAGTCCWang et al., 2012N/AhuTRBV7-1_3ext: TRTGATCCAATTTCAGGTCAWang et al., 2012N/AhuTRBV7-4_9extnew: CGSWTCTYTGCAGARAGGCWang et al., 2012N/AhuTRBV9ext: GATCACAGCAACTGGACAGWang et al., 2012N/AhuTRBV10-1ext: CAGAGCCCAAGACACAAGWang et al., 2012N/AhuTRBV10-2ext: ACCTTGATGTGTCACCAGACWang et al., 2012N/AhuTRBV10-3ext: CAGAGCCCAAGACACAAGWang et al., 2012N/AhuTRBV11ext: CGATTTTCTGCAGAGACGCWang et al., 2012N/AhuTRBV12ext: ARGTGACAGARATGGGACAAWang et al., 2012N/AhuTRBV13ext: AGCGATAAAGGAAGCATCCWang et al., 2012N/AhuTRBV14ext: CCAACAATCGATTCTTAGCTGWang et al., 2012N/AhuTRBV15extnew: AGTGACCCTGAGTTGTTCTCWang et al., 2012N/AhuTRBV16ext1: GTCTTTGATGAAACAGGTATGCWang et al., 2012N/AhuTRBV17ext_new: CAGACCCCCAGACACAAGWang et al., 2012N/AhuTRBV18ext: CATAGATGAGTCAGGAATGCCWang et al., 2012N/AhuTRBV19ext: AGTTGTGAACAGAATTTGAACCWang et al., 2012N/AhuTRBV20ext: AAGTTTCTCATCAACCATGCWang et al., 2012N/AhuTRBV23ext: GCGATTCTCATCTCAATGCWang et al., 2012N/AhuTRBV24ext: CCTACGGTTGATCTATTACTCCWang et al., 2012N/AhuTRBV25ext: ACTACACCTCATCCACTATTCCWang et al., 2012N/AhuTRBV27,28ext: TGGTATCGACAAGACCCAGWang et al., 2012N/AhuTRBV29ext: TTCTGGTACCGTCAGCAACWang et al., 2012N/AhuTRBV30ext: TCCAGCTGCTCTTCTACTCCWang et al., 2012N/AhuTRBCext: TAGAACTGGACTTGACAGCGWang et al., 2012N/AhuTRAV1ext: AACTGCACGTACCAGACATCWang et al., 2012N/AhuTRAV2ext_new: GATGTGCACCAAGACTCCWang et al., 2012N/AhuTRAV3ext: AAGATCAGGTCAACGTTGCWang et al., 2012N/AhuTRAV4ext: CTCCATGGACTCATATGAAGGWang et al., 2012N/AhuTRAV5ext: CTTTTCCTGAGTGTCCGAGWang et al., 2012N/AhuTRAV6ext: CACCCTGACCTGCAACTATACWang et al., 2012N/AhuTRAV7ext_new: GCAAAATACAGGGATGGGWang et al., 2012N/AhuTRAV8-1ext: CTCACTGGAGTTGGGATGWang et al., 2012N/AhuTRAV8-3ext: CACTGTCTCTGAAGGAGCCWang et al., 2012N/AhuTRAV8-2,4ext: GCCACCCTGGTTAAAGGWang et al., 2012N/AhuTRAV8-6ext: GAGCTGAGGTGCAACTACTCWang et al., 2012N/AhuTRAV8-7ext_new2: CTAACAGAGGCCACCCAGWang et al., 2012N/AhuTRAV9-1_2ext: TGGTATGTCCAATATCCTGGWang et al., 2012N/AhuTRAV10ext: CAAGTGGAGCAGAGTCCTCWang et al., 2012N/AhuTRAV12-1_3ext: CARTGTTCCAGAGGGAGCWang et al., 2012N/AhuTRAV13-1ext: CATCCTTCAACCCTGAGTGWang et al., 2012N/AhuTRAV13-2ext_new: CAGCGCCTCAGACTACTTCWang et al., 2012N/AhuTRAV14ext: AAGATAACTCAAACCCAACCAGWang et al., 2012N/AhuTRAV16ext: AGTGGAGCTGAAGTGCAACWang et al., 2012N/AhuTRAV17ext: GGAGAAGAGGATCCTCAGGWang et al., 2012N/AhuTRAV18ext_new3: TCCAGTATCTAAACAAAGAGCCWang et al., 2012N/AhuTRAV19ext: AGGTAACTCAAGCGCAGACWang et al., 2012N/AhuTRAV20ext: CACAGTCAGCGGTTTAAGAGWang et al., 2012N/AhuTRAV21ext: TTCCTGCAGCTCTGAGTGWang et al., 2012N/AhuTRAV22ext: GTCCTCCAGACCTGATTCTCWang et al., 2012N/AhuTRAV23ext_new: TGCTTATGAGAACACTGCGWang et al., 2012N/AhuTRAV24ext: CTCAGTCACTGCATGTTCAGWang et al., 2012N/AhuTRAV25ext_new: GGACTTCACCACGTACTGCWang et al., 2012N/AhuTRAV26-1ext: GCAAACCTGCCTTGTAATCWang et al., 2012N/AhuTRAV26-2ext: AGCCAAATTCAATGGAGAGWang et al., 2012N/AhuTRAV27ext: TCAGTTTCTAAGCATCCAAGAGWang et al., 2012N/AhuTRAV29ext: GCAAGTTAAGCAAAATTCACCWang et al., 2012N/AhuTRAV30ext: CAACAACCAGTGCAGAGTCWang et al., 2012N/AhuTRAV34ext: AGAACTGGAGCAGAGTCCTCWang et al., 2012N/AhuTRAV35ext: GGTCAACAGCTGAATCAGAGWang et al., 2012N/AhuTRAV36ext: GAAGACAAGGTGGTACAAAGCWang et al., 2012N/AhuTRAV38ext: GCACATATGACACCAGTGAGWang et al., 2012N/AhuTRAV39ext: CTGTTCCTGAGCATGCAGWang et al., 2012N/AhuTRAV40ext_new: GCATCTGTGACTATGAACTGCWang et al., 2012N/AhuTRAV41ext: AATGAAGTGGAGCAGAGTCCWang et al., 2012N/AhuTRACext: GACCAGCTTGACATCACAGWang et al., 2012N/ARecombinant DNApLVX-EF1α-IRES-PuroClontechcat#: 631253TCR_4.1-mCherryThis paperN/ATCR_6.3-mCherryThis paperN/ApsPAX2 packaging plasmidgift from Didier TronoAddgene plasmid #12260; RRID: Addgene_12260pMD2.G envelope plasmidgift from Didier TronoAddgene plasmid #12259; RRID: Addgene_12259Software and algorithmsFlowJo v10.7.1BD Bioscienceshttps://www.flowjo.com/solutions/flowjo/downloadsSpectroFlo v2.2Cytekhttps://cytekbio.com/pages/spectro-floR v. 4.0.1https://www.r-project.orgPrism v9.1.0GraphPad Softwarehttps://graphpad.comBiorenderhttps://biorender.comMiGEC v. 1.2.7Bolotin et al., 2015https://github.com/mikessh/migecMiXCR v. 3.0.3Shugay et al., 2014https://github.com/milaboratory/mixcrdata.table R package v. 1.14.0https://github.com/Rdatatable/data.table/wikistringdist R package v. 0.9.6.3https://github.com/markvanderloo/stringdistigraph R package v. 1.2.6https://igraph.org/r/gephi v. 0.9.2https://gephi.orgggplot2 R package v. 3.3.3https://cran.r-project.org/web/packages/ggplot2/index.html
.",PMC8695127
Beta,"Jude Tracking of Viral and Host Factors Associated with COVID-19 study (SJTRC, NCT04362995)N/APeripheral blood and matched lymph node samples after BNT162b2 vaccinationWU-368 study (approval #2020-12-081)N/AChemicals, peptides, and recombinant proteinsRecombinant SARS-CoV-2 Spike protein – Biotin conjugatedStadlbauer et al., 2020N/ARecombinant SARS-CoV-2 Spike protein – Alexa Fluor 647 conjugatedStadlbauer et al., 2020N/ARecombinant SARS-CoV-2 Spike protein – Alexa Fluor 488 conjugatedStadlbauer et al., 2020N/APE-labeled HLA-DPB1∗04:01 S167-180 tetramerThis paperN/ABrilliant Staining bufferBD BiosciencesN/Astreptavidin APC-Fire 750BioLegendcat#: 566349True-Nuclear Transcription Factor Buffer SetBioLegendcat#: 405250Zombie AquaBioLegendcat#: 423106Zombie NIR Fixable Viability KitBioLegendcat#: 424401Lenti-X ConcentratorClontechcat#: 6312321x Cell Stimulation cocktaileBiosciencecat#: 00-4970-93Ghost Dye Violet 510 Viability DyeTonbo Biosciencescat#: 13-0870-T100CTFEYVSQPFLMDLE peptide (>95% purity)This paperN/ATFEYVSQPFLMDLE peptideThis paperN/ASARS-CoV-2 Prot_S Complete PeptivatorMiltenyicat#: 130-127-951NQKLIANQF peptide (>95% purity)Minervina et al., 2020N/AGolgiPlugBD Biosciencescat#: 555029Fixation/Permeabilization Solution kitBD Biosciencescat#: 554715streptavidin PEBioLegendcat#: 405204Critical commercial assaysAllType NGS 11-Loci Amplification KitOne Lambdacat#: ALL-11LXSuperScript VILO cDNA Synthesis kitInvitrogencat#: 11754250SmartScribe Reverse TranscriptaseTakaracat#: 639538Q5 Hot Start High-Fidelity DNA PolymeraseNEBcat#: M0493Deposited dataProcessed TCR repertoire sequencing dataThis paperGEO: GSE183393Raw TCR repertoire sequencing dataThis paperSRA: SRP335569Experimental models: Cell lines293TATCCcat#: CRL-3216Jurkat 76.7 (variant of TCR-null Jurkat 76.7 cells that expresses human CD8 and an NFAT-GFP reporter)gift from Wouter ScheperN/AOligonucleotides5’ – template switch adapter (SmartNNNa): AAGCAGUGGTAUCAACGCAGAGUNNNNUNNNNUNNNNUCTT(rG)4Egorov et al., 2015N/APrimer for cDNA synthesis, human TCR alpha chain mRNA, C-region (ACR_st4): GTCTAGCACAGTTTTGTCEgorov et al., 2015N/APrimer for cDNA synthesis, human TCR beta chain mRNA, C-region (BCR4short):GTATCTGGAGTCATTGAEgorov et al., 2015N/AForward primer for PCR step1, anneals on the switch adapter(M1ss): AAGCAGTGGTATCAACGCAEgorov et al., 2015N/ANested reverse primer for PCR step1, TCR alpha, C-region (ACR_st1):GTCACTGGATTTAGAGTCEgorov et al., 2015N/ANested reverse primer for PCR step1, TCR beta, C-region (BC2uniR):TGCTTCTGATGGCTCAAACACEgorov et al., 2015N/ABarcoded forward PCR step 2 primer (M1s_i): (N)4(XXXXX)CAGTGGTATCAACGCAGAGEgorov et al., 2015N/ABarcoded reverse PCR step 2 primer (TCR alpha): (N)4(XXXXX)GGGTCAGGGTTCTGGATATEgorov et al., 2015N/ABarcoded reverse PCR step 2 primer (TCR beta):(N)4(XXXXX)ACACSTTKTTCAGGTCCTCEgorov et al., 2015N/AhuTRBV2ext: TCGATGATCAATTCTCAGTTGWang et al., 2012N/AhuTRBV3ext: CAAAATACCTGGTCACACAGWang et al., 2012N/AhuTRBV4ext: TCGCTTCTCACCTGAATGWang et al., 2012N/AhuTRBV5-1_4ext: GATTCTCAGGKCKCCAGTTCWang et al., 2012N/AhuTRBV5-5_8ext: GTACCAACAGGYCCTGGGTWang et al., 2012N/AhuTRBV6-1_3,5_9ext: ACTCAGACCCCAAAATTCCWang et al., 2012N/AhuTRBV6-4ext: ACTGGCAAAGGAGAAGTCCWang et al., 2012N/AhuTRBV7-1_3ext: TRTGATCCAATTTCAGGTCAWang et al., 2012N/AhuTRBV7-4_9extnew: CGSWTCTYTGCAGARAGGCWang et al., 2012N/AhuTRBV9ext: GATCACAGCAACTGGACAGWang et al., 2012N/AhuTRBV10-1ext: CAGAGCCCAAGACACAAGWang et al., 2012N/AhuTRBV10-2ext: ACCTTGATGTGTCACCAGACWang et al., 2012N/AhuTRBV10-3ext: CAGAGCCCAAGACACAAGWang et al., 2012N/AhuTRBV11ext: CGATTTTCTGCAGAGACGCWang et al., 2012N/AhuTRBV12ext: ARGTGACAGARATGGGACAAWang et al., 2012N/AhuTRBV13ext: AGCGATAAAGGAAGCATCCWang et al., 2012N/AhuTRBV14ext: CCAACAATCGATTCTTAGCTGWang et al., 2012N/AhuTRBV15extnew: AGTGACCCTGAGTTGTTCTCWang et al., 2012N/AhuTRBV16ext1: GTCTTTGATGAAACAGGTATGCWang et al., 2012N/AhuTRBV17ext_new: CAGACCCCCAGACACAAGWang et al., 2012N/AhuTRBV18ext: CATAGATGAGTCAGGAATGCCWang et al., 2012N/AhuTRBV19ext: AGTTGTGAACAGAATTTGAACCWang et al., 2012N/AhuTRBV20ext: AAGTTTCTCATCAACCATGCWang et al., 2012N/AhuTRBV23ext: GCGATTCTCATCTCAATGCWang et al., 2012N/AhuTRBV24ext: CCTACGGTTGATCTATTACTCCWang et al., 2012N/AhuTRBV25ext: ACTACACCTCATCCACTATTCCWang et al., 2012N/AhuTRBV27,28ext: TGGTATCGACAAGACCCAGWang et al., 2012N/AhuTRBV29ext: TTCTGGTACCGTCAGCAACWang et al., 2012N/AhuTRBV30ext: TCCAGCTGCTCTTCTACTCCWang et al., 2012N/AhuTRBCext: TAGAACTGGACTTGACAGCGWang et al., 2012N/AhuTRAV1ext: AACTGCACGTACCAGACATCWang et al., 2012N/AhuTRAV2ext_new: GATGTGCACCAAGACTCCWang et al., 2012N/AhuTRAV3ext: AAGATCAGGTCAACGTTGCWang et al., 2012N/AhuTRAV4ext: CTCCATGGACTCATATGAAGGWang et al., 2012N/AhuTRAV5ext: CTTTTCCTGAGTGTCCGAGWang et al., 2012N/AhuTRAV6ext: CACCCTGACCTGCAACTATACWang et al., 2012N/AhuTRAV7ext_new: GCAAAATACAGGGATGGGWang et al., 2012N/AhuTRAV8-1ext: CTCACTGGAGTTGGGATGWang et al., 2012N/AhuTRAV8-3ext: CACTGTCTCTGAAGGAGCCWang et al., 2012N/AhuTRAV8-2,4ext: GCCACCCTGGTTAAAGGWang et al., 2012N/AhuTRAV8-6ext: GAGCTGAGGTGCAACTACTCWang et al., 2012N/AhuTRAV8-7ext_new2: CTAACAGAGGCCACCCAGWang et al., 2012N/AhuTRAV9-1_2ext: TGGTATGTCCAATATCCTGGWang et al., 2012N/AhuTRAV10ext: CAAGTGGAGCAGAGTCCTCWang et al., 2012N/AhuTRAV12-1_3ext: CARTGTTCCAGAGGGAGCWang et al., 2012N/AhuTRAV13-1ext: CATCCTTCAACCCTGAGTGWang et al., 2012N/AhuTRAV13-2ext_new: CAGCGCCTCAGACTACTTCWang et al., 2012N/AhuTRAV14ext: AAGATAACTCAAACCCAACCAGWang et al., 2012N/AhuTRAV16ext: AGTGGAGCTGAAGTGCAACWang et al., 2012N/AhuTRAV17ext: GGAGAAGAGGATCCTCAGGWang et al., 2012N/AhuTRAV18ext_new3: TCCAGTATCTAAACAAAGAGCCWang et al., 2012N/AhuTRAV19ext: AGGTAACTCAAGCGCAGACWang et al., 2012N/AhuTRAV20ext: CACAGTCAGCGGTTTAAGAGWang et al., 2012N/AhuTRAV21ext: TTCCTGCAGCTCTGAGTGWang et al., 2012N/AhuTRAV22ext: GTCCTCCAGACCTGATTCTCWang et al., 2012N/AhuTRAV23ext_new: TGCTTATGAGAACACTGCGWang et al., 2012N/AhuTRAV24ext: CTCAGTCACTGCATGTTCAGWang et al., 2012N/AhuTRAV25ext_new: GGACTTCACCACGTACTGCWang et al., 2012N/AhuTRAV26-1ext: GCAAACCTGCCTTGTAATCWang et al., 2012N/AhuTRAV26-2ext: AGCCAAATTCAATGGAGAGWang et al., 2012N/AhuTRAV27ext: TCAGTTTCTAAGCATCCAAGAGWang et al., 2012N/AhuTRAV29ext: GCAAGTTAAGCAAAATTCACCWang et al., 2012N/AhuTRAV30ext: CAACAACCAGTGCAGAGTCWang et al., 2012N/AhuTRAV34ext: AGAACTGGAGCAGAGTCCTCWang et al., 2012N/AhuTRAV35ext: GGTCAACAGCTGAATCAGAGWang et al., 2012N/AhuTRAV36ext: GAAGACAAGGTGGTACAAAGCWang et al., 2012N/AhuTRAV38ext: GCACATATGACACCAGTGAGWang et al., 2012N/AhuTRAV39ext: CTGTTCCTGAGCATGCAGWang et al., 2012N/AhuTRAV40ext_new: GCATCTGTGACTATGAACTGCWang et al., 2012N/AhuTRAV41ext: AATGAAGTGGAGCAGAGTCCWang et al., 2012N/AhuTRACext: GACCAGCTTGACATCACAGWang et al., 2012N/ARecombinant DNApLVX-EF1α-IRES-PuroClontechcat#: 631253TCR_4.1-mCherryThis paperN/ATCR_6.3-mCherryThis paperN/ApsPAX2 packaging plasmidgift from Didier TronoAddgene plasmid #12260; RRID: Addgene_12260pMD2.G envelope plasmidgift from Didier TronoAddgene plasmid #12259; RRID: Addgene_12259Software and algorithmsFlowJo v10.7.1BD Bioscienceshttps://www.flowjo.com/solutions/flowjo/downloadsSpectroFlo v2.2Cytekhttps://cytekbio.com/pages/spectro-floR v. 4.0.1https://www.r-project.orgPrism v9.1.0GraphPad Softwarehttps://graphpad.comBiorenderhttps://biorender.comMiGEC v. 1.2.7Bolotin et al., 2015https://github.com/mikessh/migecMiXCR v. 3.0.3Shugay et al., 2014https://github.com/milaboratory/mixcrdata.table R package v. 1.14.0https://github.com/Rdatatable/data.table/wikistringdist R package v. 0.9.6.3https://github.com/markvanderloo/stringdistigraph R package v. 1.2.6https://igraph.org/r/gephi v. 0.9.2https://gephi.orgggplot2 R package v. 3.3.3https://cran.r-project.org/web/packages/ggplot2/index.html
.",PMC8695127
B.1.1.529,"The novel SARS-CoV-2 variant, Omicron (B.1.1.529) contains an unusually high number of mutations (>30) in the spike protein, raising concerns of escape from vaccines, convalescent sera and therapeutic drugs.",PPR436135
Alpha,Convalescent sera from Alpha and Delta patients allow similar levels of breakthrough by Omicron.,PPR436135
Beta,Phylogenetic analysis of the full-length spike protein demonstrated that the spike protein of the Omicron strain was relatively close to gamma and beta strains compared to other VOC and VOI (Fig.,PPR436135
Gamma,Phylogenetic analysis of the full-length spike protein demonstrated that the spike protein of the Omicron strain was relatively close to gamma and beta strains compared to other VOC and VOI (Fig.,PPR436135
Mu,"In addition to Alpha, Beta, and Gamma variants that were previously reported (5), engineered ACE2 (3N39v4) showed similar or better efficacy to Delta, Epsilon, Lambda and Mu, as compared with the original Wuhan strain (Fig.",PPR436135
Epsilon,"In addition to Alpha, Beta, and Gamma variants that were previously reported (5), engineered ACE2 (3N39v4) showed similar or better efficacy to Delta, Epsilon, Lambda and Mu, as compared with the original Wuhan strain (Fig.",PPR436135
Lambda,"In addition to Alpha, Beta, and Gamma variants that were previously reported (5), engineered ACE2 (3N39v4) showed similar or better efficacy to Delta, Epsilon, Lambda and Mu, as compared with the original Wuhan strain (Fig.",PPR436135
Alpha,Previous work indicated that the nucleocapsid 203 mutation increase the virulence and transmission of the SARS-CoV-2 Alpha variant.,PPR435662
Gamma,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
B.1.617.2,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
B.1.617.1,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
B.1.1.7,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
B.1.1.529,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
B.1.1.28,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
B.1.351,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
P.1,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
Kappa,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
Beta,"The resulting genomic variations enabled selection of several distinct variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1/B.1.1.28), Kappa (B.1.617.1), Delta (B.1.617.2) and the newly emerging Omicron (B.1.1.529)..

SARS-CoV-2 is an enveloped, positive-stranded RNA virus.",PPR435662
Epsilon,"1J, K, S1D), suggesting a positive selection for the R203M/L452R mutations..

For the identified lineages, Epsilon and Lota-452R bear the L452R mutation only, while Delta and Kappa bear both R203M and L452R mutations (Fig 1L).",PPR435662
Mu,"According to the annotation from GISAID, we identified the mutations of VOCs, including Alpha, Beta, Gamma, Epsilon, Eta, Lambda, Mu, Kappa, Delta and Omicron.",PPR435662
Eta,"According to the annotation from GISAID, we identified the mutations of VOCs, including Alpha, Beta, Gamma, Epsilon, Eta, Lambda, Mu, Kappa, Delta and Omicron.",PPR435662
Lambda,"According to the annotation from GISAID, we identified the mutations of VOCs, including Alpha, Beta, Gamma, Epsilon, Eta, Lambda, Mu, Kappa, Delta and Omicron.",PPR435662
Gamma,"Earlier this year, the emergence of variants such as Beta and Gamma that showed resistance to several mAbs, including bamlanivimab, led to EUA revocation by the FDA (Food and Drug Administration, 2021).",PMC8692065
Beta,"Earlier this year, the emergence of variants such as Beta and Gamma that showed resistance to several mAbs, including bamlanivimab, led to EUA revocation by the FDA (Food and Drug Administration, 2021).",PMC8692065
B.1,"An original strain of SARS-CoV-2 (Pango lineage B/B.1) relinquished its global dominance to the Alpha (B.1.1.1, first described in the United Kingdom) around April 2021.",PMC8692065
B.1.1.1,"An original strain of SARS-CoV-2 (Pango lineage B/B.1) relinquished its global dominance to the Alpha (B.1.1.1, first described in the United Kingdom) around April 2021.",PMC8692065
Alpha,"An original strain of SARS-CoV-2 (Pango lineage B/B.1) relinquished its global dominance to the Alpha (B.1.1.1, first described in the United Kingdom) around April 2021.",PMC8692065
Lambda,"Next, to design sAb templates for Cas9-induced HDR integration into nPnP cells, the following 5 gene modules were assembled: (1) the 5′ homology arm containing a partial VH1-82 promoter, followed by (2) each VL chain region (V-J) matched with its respective constant human light chain, either constant kappa (IGKC) or constant lambda (IGLC1); (iii) a flexible 57-amino acid linker, containing 3 tandem Strep-Tag(II) motifs providing both a connection to the HC as well as a peptide tag for phenotypic detection of HDR integration and antibody expression (Moffett et al., 2019); (4) the VH chain region (V-D-J), followed by (5) a 3′ homology arm (consisting of the downstream intron).",PMC8692065
Kappa,"Next, to design sAb templates for Cas9-induced HDR integration into nPnP cells, the following 5 gene modules were assembled: (1) the 5′ homology arm containing a partial VH1-82 promoter, followed by (2) each VL chain region (V-J) matched with its respective constant human light chain, either constant kappa (IGKC) or constant lambda (IGLC1); (iii) a flexible 57-amino acid linker, containing 3 tandem Strep-Tag(II) motifs providing both a connection to the HC as well as a peptide tag for phenotypic detection of HDR integration and antibody expression (Moffett et al., 2019); (4) the VH chain region (V-D-J), followed by (5) a 3′ homology arm (consisting of the downstream intron).",PMC8692065
Epsilon,"Therefore, we tested 3 of our mAbs (mAb-50, -64, and -82) for binding to SARS-CoV-2 RBD proteins derived from several variants: Alpha, Beta, Gamma, Delta, Delta+, Epsilon and Kappa (see key resources table).",PMC8692065
B.1.1.529,"A newly emerged SARS-CoV-2 variant B.1.1.529 has worried the health policy makers worldwide due to the presence of a large number of mutations in its genomic sequence, especially in the spike protein region.",PPR435130
Alpha,Omicron showed the closest nucleotide and protein sequence homology with Alpha variant for the complete sequence as well as for RBM.,PPR435130
Beta,"The analysis of genomic and protein sequence homology of Omicron with the reference strain and current global VOCs/VOIs (as per WHO) showed the highest similarity of Omicron with the Alpha variant for the complete sequence as well as RBM, however, the highest similarity for the complete nucleotide and protein sequences for the spike protein were noted with Beta and Delta variants, respectively (Table S1)..",PPR435130
B.1,"4)..

Our analysis of the SARS-CoV-2 genomic sequences coupled with epidemiological data from SA unravels multiple observations regarding host-virus interactions which may help predicting the epidemiological potentials of the Omicron..

Our analyses showed that Omicron has significantly greater variantions than current VOCs and VOIs in comparisons with the wild type strains (Wuhan strain and B.1).",PPR435130
B.1.621,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
Q.1,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
P.1,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
B.1.1.7,"P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants
30
.",PPR435130
A.1,"Here, we evaluated the immunogenicity of a single dose COVID-19 replicon RNA vaccine expressing Spike protein (A.1) from SARS-CoV-2 (repRNA-CoV2S) in immunocompromised, SIV infected and immune competent, naïve pigtail macaques.",PMC8724308
Kappa,The emergence of SARS-CoV-2 Kappa and Beta variants with enhanced transmissibility and resistance to neutralizing antibodies has created new challenges for the control of the ongoing COVID-19 pandemic.,PMC8688474
Beta,The emergence of SARS-CoV-2 Kappa and Beta variants with enhanced transmissibility and resistance to neutralizing antibodies has created new challenges for the control of the ongoing COVID-19 pandemic.,PMC8688474
Gamma,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.617.2,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.617.1,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.1.7,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
Alpha,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.351,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
P.1,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
Alpha,"Several reports also showed a lack of similarity and cross reactivity between alpha coronaviruses and SARS-CoVs [18, 32, 38, 56].",PPR434684
Beta,"The common human and animal coronaviruses (both alpha and beta coronavirus families) individually do not generate cross-reactive antibodies against this protein, presumably making it a SARS-specific response [30, 32, 33, 38, 46, 49].",PPR434684
Gamma,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.617.2,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.1.7,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.1.529,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
Alpha,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
B.1.351,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
P.1,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
Beta,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PPR432949
A.3,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figure 1A and C. The “other” category also contains B lineages and was used for any lineage with 12 or less representatives.",PPR432949
A.1,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figure 1A and C. The “other” category also contains B lineages and was used for any lineage with 12 or less representatives.",PPR432949
B.1,The large European lineage B.1 was detected in six samples in April 2020.,PPR432949
Iota,"The former VOC, B.1.526 (Iota), which is a lineage predominantly circulating in New York, was detected from March to June 2021 in 29 samples.",PPR432949
B.1.526,"The former VOC, B.1.526 (Iota), which is a lineage predominantly circulating in New York, was detected from March to June 2021 in 29 samples.",PPR432949
B.1.351,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
P.1,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
B.1.617.2,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
B.1.1.7,"While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a, 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a, 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PMC8673750
B.1.617.1,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.525,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.429,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.526,"Moreover, since many antibodies that bind S are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι), and B.1.617.1 (κ).",PMC8673750
B.1.351,Here we report a direct contact transmission of SARS-CoV-2 variant B.1.351 in wild-type mice.,PMC8669038
Gamma,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
B.1.427,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
B.1.617.2,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
C.37,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
B.1.617.1,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
B.1.525,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
B.1.1.7,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
Kappa,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
Lambda,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
Alpha,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
P.1,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
Epsilon,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
Eta,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
Beta,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
B.1.526,"The lineage B.1.1.7 (also named Alpha) emerged in the UK,2 B.1.351 (Beta) emerged in South Africa,3 P.1 (Gamma) emerged in Brazil,4 B.1.427/B.1.429 (Epsilon) emerged in California of USA, B.1.525 (Eta) emerged in Nigeria,5 B.1.526 (Lota) emerged in New York of USA,6 B.1.617.1 (Kappa) and B.1.617.2 (Delta) emerged in India,7 and C.37 (Lambda) emerged in Peru.8 Many mutations lie in the Spike glycoprotein and the corresponding receptor-binding domain (RBD) of these variants, which may compromise Spike- or RBD-based therapeutic antibodies, vaccines, and other countermeasures.",PMC8669038
B.1.429,"Meanwhile, we constructed various plasmids expressing the Spike proteins of D614, G614, B.1.1.7, B.1.351, P.1, B.1.429, B.1.525, B.1.617.1, B.1.617.2, and C.37 strains of SARS-CoV-2 (Fig.",PMC8669038
Alpha,"In this report, we evaluated an alphavirus-based replicating RNA vaccine expressing Spike proteins from the original SARS-CoV-2 Alpha strain and recent VoCs delivered in vivo via a lipid inorganic nanoparticle.",PPR431927
A.1,"Previously, we reported the development of an Venezuelan Equine Encephalitis Virus (VEEV)-based replicating RNA (repRNA) vaccine encoding the spike protein of the original A.1 lineage of SARS-CoV2, delivered by a Lipid InOrganic Nanoparticle (LION) (Erasmus et al., 2020a).",PPR431927
B.1.351,"In this report we evaluated repRNA vaccine expressing the SARS-CoV2 spike protein of the SARS-CoV2 variants, B.1.1.7 and B.1.351 in mice and hamsters, using LION to mediate delivery via intramuscular injection.",PPR431927
B.1.1.7,"In this report we evaluated repRNA vaccine expressing the SARS-CoV2 spike protein of the SARS-CoV2 variants, B.1.1.7 and B.1.351 in mice and hamsters, using LION to mediate delivery via intramuscular injection.",PPR431927
B.1,"The SARS-CoV-2 Isolate hCoV-19/Germany/BavPat1/2020 (B.1)(NR-52370, BEI Resources), hCoV-19/England/204820464/2020 (B.1.1.7)(NR-54000, BEI Resources), and hCoV-19/USA/PHC658/2021 (B.1.617.2) (NR-55612, BEI Resources) were obtained from BEI Resources.",PPR431927
B.1.617.2,"The SARS-CoV-2 Isolate hCoV-19/Germany/BavPat1/2020 (B.1)(NR-52370, BEI Resources), hCoV-19/England/204820464/2020 (B.1.1.7)(NR-54000, BEI Resources), and hCoV-19/USA/PHC658/2021 (B.1.617.2) (NR-55612, BEI Resources) were obtained from BEI Resources.",PPR431927
B.1,"The genome sequence of UF-40 conforms to Phylogenetic Assignment of Named Global Outbreak Lineages (PANGO) (Rambaut et al., 2020) lineage B.1 (version: 2021-04-21), which is a large European lineage that originated in Northern Italy in 2020 and one that was detected in the United States early in 2020 [https://cov-lineages.org/lineages/lineage_B.1.html].",PMC8820684
B.1.375,"SARS-CoV-2 UF-39 and -40 fall within clades B.1.375 and B.1, and their genomes differ from SARS-CoV-2 Wuhan-1 by 27 and 14 rnt, respectively, and from IME-WH01 by 30 and 17 nt.Fig.",PMC8820684
B.1.1.7,"This virus variant (designated as UF-39) was likely spread to Cedar Key by a visitor from another state, since its PANGO genetic lineage is more closely related to that of the UK variant of concern (VOC) designated B.1.1.7 that was first detected in mid-2020 in other states.",PMC8820684
Alpha,"Most common lineages observed were Delta, followed by Kappa, Alpha and B.1.36, seen in 65.82%, 9.96%, 6.83% and 4.68%, respectively in the study population.",PPR432454
Kappa,"Most common lineages observed were Delta, followed by Kappa, Alpha and B.1.36, seen in 65.82%, 9.96%, 6.83% and 4.68%, respectively in the study population.",PPR432454
B.1.36,"Most common lineages observed were Delta, followed by Kappa, Alpha and B.1.36, seen in 65.82%, 9.96%, 6.83% and 4.68%, respectively in the study population.",PPR432454
Beta,"The World Health Organization (WHO) has labeled these variants using the Greek alphabets (alpha, beta, gamma, delta and so on) based on their reporting dates (6).",PPR432454
Gamma,"The World Health Organization (WHO) has labeled these variants using the Greek alphabets (alpha, beta, gamma, delta and so on) based on their reporting dates (6).",PPR432454
B.1.617.3,"1.1.7 (Alpha), B.1.351 (Beta) and B.1.1.28.1 (Gamma), B.1.1.28.2 (Zeta), B.1.617.1 (Kappa), B.1.617.2 (Delta) and Delta derivatives as well as B.1.617.3 (7–9)..",PPR432454
Zeta,"1.1.7 (Alpha), B.1.351 (Beta) and B.1.1.28.1 (Gamma), B.1.1.28.2 (Zeta), B.1.617.1 (Kappa), B.1.617.2 (Delta) and Delta derivatives as well as B.1.617.3 (7–9)..",PPR432454
B.1.617.2,"1.1.7 (Alpha), B.1.351 (Beta) and B.1.1.28.1 (Gamma), B.1.1.28.2 (Zeta), B.1.617.1 (Kappa), B.1.617.2 (Delta) and Delta derivatives as well as B.1.617.3 (7–9)..",PPR432454
B.1.617.1,"1.1.7 (Alpha), B.1.351 (Beta) and B.1.1.28.1 (Gamma), B.1.1.28.2 (Zeta), B.1.617.1 (Kappa), B.1.617.2 (Delta) and Delta derivatives as well as B.1.617.3 (7–9)..",PPR432454
B.1.351,"1.1.7 (Alpha), B.1.351 (Beta) and B.1.1.28.1 (Gamma), B.1.1.28.2 (Zeta), B.1.617.1 (Kappa), B.1.617.2 (Delta) and Delta derivatives as well as B.1.617.3 (7–9)..",PPR432454
Iota,"Yonker et al showed the detection of SARS-CoV-2 variants belonging to the Alpha and B.1.526.2 lineages (derivatives of Iota), identified in the age group below 21 years (11)..",PPR432454
B.1.617,"A separate cluster of B.1.617 lineage was observed that segregated into Kappa, Delta and B.1.617.3 lineages as depicted in Figure 4..

India after the completion of massive immunization of 1 billion doses of COVID-19 in the adult population has recently approved two vaccines for pediatric use namely Covaxin/BBV152 (inactivated virus vaccine) and ZyCoV-D (DNA vaccine), both vaccines are being manufactured in India.",PPR432454
C.37,"The second wave of the COVID-19 in the world witnessed the emergence of variants of concern (Alpha, Beta, Gamma, Delta) and VOIs (Kappa, Zeta, Lambda (C.37)] in the adults.",PPR432454
Lambda,"The second wave of the COVID-19 in the world witnessed the emergence of variants of concern (Alpha, Beta, Gamma, Delta) and VOIs (Kappa, Zeta, Lambda (C.37)] in the adults.",PPR432454
Gamma,"Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize.",PPR429543
Beta,"Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize.",PPR429543
Alpha,"Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize.",PPR429543
Lambda,"Since the end of 2020 a series of viral variants have emerged in different regions where some have caused large outbreaks, Alpha (Supasa et al., 2021) and more recently Delta (Liu et al., 2021a) have had the greatest global reach, whilst Beta (Zhou et al., 2021), Gamma (Dejnirattisai et al., 2021b) and Lambda (Colmenares-Mejia et al., 2021), although causing large outbreaks in Southern Africa and South America, did not become dominant in other parts of the World.",PPR429543
B.1.1.7,"Participants from the first wave of SARS-CoV2 in the U.K. and those sequence confirmed with B.1.1.7 lineage in December 2020 and February 2021 were recruited through three studies: Sepsis Immunomics [Oxford REC C, reference:19/SC/0296]), ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections [Oxford REC C, reference 13/SC/0149] and the Gastro-intestinal illness in Oxford: COVID sub study [Sheffield REC, reference: 16/YH/0247].",PPR429543
P.1,"Briefly, serially diluted Ab or plasma was mixed with SARS-CoV-2 strain Victoria or P.1 and incubated for 1 hr at 37 °C.",PPR429543
B.1.351,"We acknowledge the rapid sharing of Victoria, B.1.1.7 and B.1.351 which was isolated by scientists within the National Infection Service at PHE Porton Down, and the B.1.617.2 virus was kindly provided Wendy Barclay and Thushan De Silva.",PPR429543
B.1.617.2,"We acknowledge the rapid sharing of Victoria, B.1.1.7 and B.1.351 which was isolated by scientists within the National Infection Service at PHE Porton Down, and the B.1.617.2 virus was kindly provided Wendy Barclay and Thushan De Silva.",PPR429543
P.1,"The P.1 variant with N501Y, E484K, and K417T mutations was detected on January 9, 2021, by the Japanese authorities in the airport from four travellers returning from Brazil 
43
.",PPR429243
B.1.1.7,"These are lineage B.1.1.7 variant identified in the UK with N501Y mutation (which has now evolved to include the E484K mutation in UK) 
48
; lineage B.",PPR429243
C.37,"Health authorities are also currently investigating another strain called C.37, which first emerged in Peru in August 2020, and has raised public health concerns, especially among the neighbouring countries such as Argentina, Chile, and Ecuador 
55
.",PPR429243
B.1.351,"Here, we found that the propagation of a B.1.351 SARS-CoV-2 stock on Calu-3 cells eliminated viruses that previously accumulated mutations in the furin cleavage site.",PMC8704555
Beta,"In the present study, we evaluated how the propagation of a B.1.351-related (beta variant) SARS-CoV-2 isolate in two cell types, Vero/hSLAM and Calu-3 cells, affected viral genome sequences both within and outside of the furin cleavage site of the spike gene.",PMC8704555
B.1.617.2,Future studies will need to evaluate whether other SARS-CoV-2 lineage variants (such as B.1.617.2) would acquire the same nucleotide variants when grown on Calu-3 cells or whether the nucleotide variants described here are restricted to the B.1.351 lineage..,PMC8704555
Epsilon,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.427,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.617.2,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.1.7,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.1.28,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
Alpha,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
Beta,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
B.1.351,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
Gamma,"NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs.",PMC8675084
Kappa,"Spike is directed to cell membranes via an N-terminal Ig kappa secretion signal and a C-terminal PDGFR-β transmembrane domain (Lim et al., 2013).",PMC8675084
B.1.429,"Mutations S13I and W152C for B1.427/B.1.429 synergistically reduce 4A8 binding, which recapitulates recent findings of nAb evasion through novel disulfide bond formation and NTD structural remodeling (McCallum et al., 2021a).",PMC8675084
Lambda,"Using pooled libraries and fluoresce-assisted cell sorting will further increase the experimental throughput of this platform..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesMouse anti-FLAG M2Sigma-AldrichF3165Goat anti-Mouse IgG(H+L), Human ads-Alexa Fluor 488SouthernBiotech1031-30Goat anti-Human IgG Fc-Alexa Fluor 647SouthernBiotech2048-31Goat anti-Mouse IgG H&L (IRDYe 680RD)abcamab216776Beta Tubulin Loading Control Monoclonal Antibody (BT7R)Thermo FisherMA5-16308Bacterial strainsNEB 5-alpha Competent E. coli (High Efficiency)NEBC2987HMix & Go Competent Cells - Strain Zymo 10BZymo ResearchT3019Rosetta (DE3) Competent CellsSigma-Aldrich70954Chemicals, peptides, and recombinant proteinsSuperior BrothAthenaES0105Expi293 Expression MediumSigma-AldrichA1435101DMEM, high glucose, pyruvateGIBCO11995065Fetal Bovine SerumGIBCO26140079Opti-MEM I Reduced Serum Medium, GlutaMAX SupplementGIBCO51985091Penicillin-Streptomycin (5,000 U/mL)Thermo Fisher15070063Lipofectamine 3000 Transfection ReagentThermo FisherL3000015Bovine Serum AlbuminSigma-AldrichA3294EZCut TEV Protease, RecombinantBioVision7847-100ACE2 Fc Chimera, HumanGenscriptZ03484Hoechst stainThermo Fisher62249Odyssey Blocking Buffer (PBS)LI-COR927-40000Surfactant P20CytivaBR100054cOmplete, EDTA-free Protease Inhibitor CocktailSigma-Aldrich11873580001Nano-W (Methylamine Tungstate)Nanoprobes#2018Commercial kits and enzymesNEBuilder HiFi DNA Assembly Master MixNEBE2621SEsp3INEBR0734T7 DNA LigaseNEBM0318SAarI (2 U/μL)Thermo FisherER1582T4 DNA LigaseNEBB0202SPromega Wizard SV 96 Plasmid DNA Purification KitPromegaA2250Expi293 Transfection kitSigma-AldrichL3287Mycoplasma Detection KitSouthernBiotech13100-01Pierce HRV 3C Protease Solution KitThermo Fisher88946Bright-Glo Luciferase Assay SystemPromegaE2610qPCR Lentivirus Titer KitApplied Biological Materials (abm)LV900Deposited dataRaw imagesThis paper; Mendeley Datahttps://doi.org/10.17632/k2kbt5gs6y.1Spike Display dataThis paperData S1Experimental models: Cell linesHEK293TATCCCRL-3216Expi293F CellsThermo FisherA14527OligonucleotidesSynthetic DNA sequences for cloning, see Table S3Integrated DNA TechnlologiesN/ARecombinant DNASARS-CoV-2 S HexaProHsieh et al., 2020Addgene #154754pcDNA5/FRT/TO/intron/GFPShelton et al., 2018Addgene #113547pYTK001Lee et al., 2015Addgene #65108HDM-Hgpm2BEI ResourcesNR-52516pRC-CMV-Rev1bBEI ResourcesNR-52519HDM-tat1bBEI ResourcesNR-5251Vector pHAGE2 Containing the ZsGreen GeneBEI ResourcesNR-52520pCMV-VSV-G Envelope VectorCell BiolabsRV-110Software and algorithmsFlowJo v9BDN/ANIS-Elements DNikonMQS33000cryoSPARC v3.1.0cryoSPARCN/ACisTEMhttps://cistem.org/softwareN/ASA3800 Spectral Cell Analyzer SoftwareSONYN/AR Tidyversehttps://www.tidyverse.org/N/Aggplot2 (v3.3.5)https://ggplot2.tidyverse.org/N/AChimeraX 1.1UCSFN/AGraphPad PrismGraphPadN/AOctet Data Analysis software (v11.1)FortéBioN/APublic datasetsExpression summary of variants with single substitutionsHsieh et al., 2020Table S1Yeast display RBD expression, ACE2 binding, and mAb escape dataStarr et al., 2020, 2021https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/Other384-well Echo Source PlateBiolabPP-020096-well Clear Round Bottom 2.2 mL Polypropylene Deep Well Plate (Sterile)AxygenP-2ML-SQ-C-SNunc OmniTray Single-Well PlateThermo Fisher140156Protein G magnetic beadsPromegaG7471Protein A AgaroseThermo Fisher15918014Strep-Tactin Superflow resinIBA2-1206-025Superose 6 increase 10/300GE healthcareGE29-0915-96Cell Culture Dishes (10 cm)VWR10062-880Cell Culture Plate (6-well)VWR10861-696Cell Culture Plate (12-well)VWR10861-698LUNA-II Automated Cell CounterLogos biosystemsL40002SA3800 Spectral AnalyzerSONYN/A5 mL HisTrap HP columnGE healthcare17524802Cell Imaging Dish, 35 × 10 mmEppendorf0030740009Ts2R-FL inverted research microscopeNikonMFA51010CF160 Plan Apochromat Lambda 60x oil immersion objectiveNikonMRD01605C-FL AT DAPI/HOECHST/ALEXA FLUOR 350; Filter CubeChroma96221C-FL AT EGFP/FITC/CY2/ALEXA FLUOR 488; Filter CubeChroma96226C-FL AT TEXAS RED/mCHERY/ALEXA FLUOR 594; Filter CubeChroma96231SOLA SM II 365 LIGHT ENGINELumencor77060075PCO.PANDA USB3.1 SCMOS CAMERAPCO77067012Mini-PROTEAN TGX Precast Protein GelBio-Rad4561084Trans-Blot SD.",PMC8675084
Alpha,The alpha/B.1.1.7 SARS-CoV-2 lineage emerged in autumn 2020 in the United Kingdom and transmitted rapidly until winter 2021 when it was responsible for most new COVID-19 cases in many European countries.,PMC8635972
B.1.1.7,The alpha/B.1.1.7 SARS-CoV-2 lineage emerged in autumn 2020 in the United Kingdom and transmitted rapidly until winter 2021 when it was responsible for most new COVID-19 cases in many European countries.,PMC8635972
B.1.351,"The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains.",PMC8635972
P.1,"The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains.",PMC8635972
Beta,"The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains.",PMC8635972
Gamma,"The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains.",PMC8635972
Theta,"Some of these residue substitutions, including the N501Y mutation, seem to have arisen independently by convergent evolution and selection and are found in the B.1.1.7 (alpha), the South African B.1.351 (beta), and the Brazilian P.1 (gamma) variants of concern (VOC) (Rambaut, 2020; Faria et al., 2021; Tegally et al., 2021) as well as the variant of interest (VOI) B.1.621 (mu), first identified in Colombia (Laiton-Donato et al., 2021), and the former VOI P.3 (theta) from The Philippines (Tablizo et al., 2021).",PMC8635972
B.1.621,"Some of these residue substitutions, including the N501Y mutation, seem to have arisen independently by convergent evolution and selection and are found in the B.1.1.7 (alpha), the South African B.1.351 (beta), and the Brazilian P.1 (gamma) variants of concern (VOC) (Rambaut, 2020; Faria et al., 2021; Tegally et al., 2021) as well as the variant of interest (VOI) B.1.621 (mu), first identified in Colombia (Laiton-Donato et al., 2021), and the former VOI P.3 (theta) from The Philippines (Tablizo et al., 2021).",PMC8635972
Mu,"Some of these residue substitutions, including the N501Y mutation, seem to have arisen independently by convergent evolution and selection and are found in the B.1.1.7 (alpha), the South African B.1.351 (beta), and the Brazilian P.1 (gamma) variants of concern (VOC) (Rambaut, 2020; Faria et al., 2021; Tegally et al., 2021) as well as the variant of interest (VOI) B.1.621 (mu), first identified in Colombia (Laiton-Donato et al., 2021), and the former VOI P.3 (theta) from The Philippines (Tablizo et al., 2021).",PMC8635972
P.3,"Some of these residue substitutions, including the N501Y mutation, seem to have arisen independently by convergent evolution and selection and are found in the B.1.1.7 (alpha), the South African B.1.351 (beta), and the Brazilian P.1 (gamma) variants of concern (VOC) (Rambaut, 2020; Faria et al., 2021; Tegally et al., 2021) as well as the variant of interest (VOI) B.1.621 (mu), first identified in Colombia (Laiton-Donato et al., 2021), and the former VOI P.3 (theta) from The Philippines (Tablizo et al., 2021).",PMC8635972
B.1.617.2,"All the above VOC/VOI have been for the most part replaced by the B.1.617.2 (delta), which emerged in India in December 2020 (Cherian et al., 2021; Yadav, 2021) and has become the dominant variant globally (http://www.gisaid.org/, accessed October 2021).",PMC8635972
B.1,"In order to examine whether the increased affinity of the N501Y variant for ACE-2 was associated with a more efficient establishment of infection and development of disease, we challenged transgenic ACE-2 humanized K18-hACE2 mice with the early 2020 SARS-CoV2 B.1 (Freiburg isolate, FR-4248 Miladi, 2020) and the B1.1.7 (alpha) strains.",PMC8635972
P.2,"20
 In Brazil, 69.4% of the strains were identified as P.2 lineage variant
and 30.6% were identified as Wuhan-H1 variant D614G.",PMC8637774
B.1.351,"66
 Since then, there have been many viral lineages to note, most notable VOC
include the B.1.1.7/20I/501.Y.V1 variant that was first detected in the United
Kingdom in October 2020, the B.1.351/20 H/501Y.V2 variant that was detected in South
Africa in December 2020, and the Lineage P.1.",PMC8637774
B.1.1.7,"66
 Since then, there have been many viral lineages to note, most notable VOC
include the B.1.1.7/20I/501.Y.V1 variant that was first detected in the United
Kingdom in October 2020, the B.1.351/20 H/501Y.V2 variant that was detected in South
Africa in December 2020, and the Lineage P.1.",PMC8637774
B.1.351,"SARS-CoV-2 genomic diversity profiles were also examined from daily sampling of culture experiments for three SARS-CoV-2 variants (Lineage A, B.1.351, and B.1.617.2) cultured in VeroE6 C1008 cells (n = 33)..

ISNVs were detected in 83% (19/23) of the mild cohort cases and 100% (16/16) of the severe cohort cases.",PPR425039
B.1.617.2,"SARS-CoV-2 genomic diversity profiles were also examined from daily sampling of culture experiments for three SARS-CoV-2 variants (Lineage A, B.1.351, and B.1.617.2) cultured in VeroE6 C1008 cells (n = 33)..

ISNVs were detected in 83% (19/23) of the mild cohort cases and 100% (16/16) of the severe cohort cases.",PPR425039
Beta,"Governance and human ethics approval for clinical metadata and use of specimens from cases positive for SARS-CoV-2 in New South Wales was obtained (2020/ETH02426 and 2020/ETH02282)..

Daily sampling was conducted to determine the fifty percent tissue culture infective dose (TCID50) of SARS-CoV-2 viral stocks from three lineages of SARS-CoV-2 (Lineage A – referred to as Wuhan, Beta – B.1.351, and Delta – B.1.617.2).",PPR425039
B.1,"The majority of cases were designated to lineage B.1.617.2 or Delta VOC (n=20, cases; P601, P603, P608, P611, P612, P614, P615, P622, P624, P626, P629, P604, P606, P618, P620, P621, PG27, P628), followed by B.1 (n=13 cases P0332, P0570, P0495, P0676, P1384, P1434, and P1494), D.2 genomes (n=11, cases; P0340, P0341, P0417, P0642, P0858, P1149, P2099, P2152, P1498 and P1551) and B.6 (n=4, case P0105).",PPR425039
D.2,"The majority of cases were designated to lineage B.1.617.2 or Delta VOC (n=20, cases; P601, P603, P608, P611, P612, P614, P615, P622, P624, P626, P629, P604, P606, P618, P620, P621, PG27, P628), followed by B.1 (n=13 cases P0332, P0570, P0495, P0676, P1384, P1434, and P1494), D.2 genomes (n=11, cases; P0340, P0341, P0417, P0642, P0858, P1149, P2099, P2152, P1498 and P1551) and B.6 (n=4, case P0105).",PPR425039
B.6,"The majority of cases were designated to lineage B.1.617.2 or Delta VOC (n=20, cases; P601, P603, P608, P611, P612, P614, P615, P622, P624, P626, P629, P604, P606, P618, P620, P621, PG27, P628), followed by B.1 (n=13 cases P0332, P0570, P0495, P0676, P1384, P1434, and P1494), D.2 genomes (n=11, cases; P0340, P0341, P0417, P0642, P0858, P1149, P2099, P2152, P1498 and P1551) and B.6 (n=4, case P0105).",PPR425039
B.1.1,"Single genomes from lineage A.2.2 (case P1727) lineage A genome (case P1811) and lineage B.1.1 (P1020) (Figure 1, Table 1).",PPR425039
A.2.2,"Single genomes from lineage A.2.2 (case P1727) lineage A genome (case P1811) and lineage B.1.1 (P1020) (Figure 1, Table 1).",PPR425039
B.1.617,"Group’s three to five were all in lineage B.1.617, and of those groups, groups four and five had no shared iSNVs between cases.",PPR425039
Alpha,"The evolutionary rate of SARS-CoV-2 has been estimated at 1.1 x 10-3 substitutions/site/year (Smith et al., 2014, Day et al., 2020), however, some variants, such as Alpha (Lineage B.1.1.7) and Delta (Lineage B.1.617.2) have developed a higher percentage of nucleotide changes (Duchene et al., 2020, Rambaut, 2020).",PPR425039
B.1.1.7,"The evolutionary rate of SARS-CoV-2 has been estimated at 1.1 x 10-3 substitutions/site/year (Smith et al., 2014, Day et al., 2020), however, some variants, such as Alpha (Lineage B.1.1.7) and Delta (Lineage B.1.617.2) have developed a higher percentage of nucleotide changes (Duchene et al., 2020, Rambaut, 2020).",PPR425039
B.1,"Indeed, only seven (3%) of all 204 sequenced COVID-19 cases were of B.1 lineage, with the others caused by 14 different variants.",PMC8610426
Gamma,"In Europe, 45 (92%) of 49 cases were caused by the alpha variant of concern (B.1.1.7), compared with Latin America where 20 (13%) of 155 cases were caused by the alpha variant and 35 (23%) cases were caused by the gamma variant of concern (P.1).",PMC8610426
Alpha,"In Europe, 45 (92%) of 49 cases were caused by the alpha variant of concern (B.1.1.7), compared with Latin America where 20 (13%) of 155 cases were caused by the alpha variant and 35 (23%) cases were caused by the gamma variant of concern (P.1).",PMC8610426
P.1,"In Europe, 45 (92%) of 49 cases were caused by the alpha variant of concern (B.1.1.7), compared with Latin America where 20 (13%) of 155 cases were caused by the alpha variant and 35 (23%) cases were caused by the gamma variant of concern (P.1).",PMC8610426
B.1.1.7,"In Europe, 45 (92%) of 49 cases were caused by the alpha variant of concern (B.1.1.7), compared with Latin America where 20 (13%) of 155 cases were caused by the alpha variant and 35 (23%) cases were caused by the gamma variant of concern (P.1).",PMC8610426
Mu,"We show the cumulative incidence of symptomatic COVID-19 starting on day 43 in the primary efficacy analysis set for all participants (figure 2A
) and those aged 18–60 years (figure 2B).Table 2Efficacy of CVnCoV against virologically confirmed COVID-19 occurring 15 days or more after the second dose in the primary efficacy analysis setCVnCoVPlaceboVaccine efficacy (95% CI)n/NPerson-yearsn/NPerson-yearsCOVID-19 of any severityOverall83/12 8511735·29145/12 2111569·8748·2% (31·0–61·4)*18–60 years71/11 5321591·47136/11 0311449·2352·5% (36·2–64·8)≥61 years12/1319143·829/1180120·64..†COVID-19 of any severity by region‡Europe21/4091684·2233/3919604·8343·7% (−0·2 to 69·1)Latin America62/87601051·07112/8292965·0349·2% (30·1–63·3)COVID-19 of any severity by strain§Alpha variant (B.1.1.7/501Y.V2)20/11 5321591·4742/11 0311449·2355·1% (23·5–73·6)Gamma variant (P.1/501Y.V3)9/11 5321591·4726/11 0311449·2367·1% (29·8–84·6)Lambda variant (C.37)13/11 5321591·4726/11 0311449·2352·8% (8·2–75·8)Mu variant (B.1.621)11/11 5321591·4717/11 0311449·23..†Other7/11 5321591·4713/11 0311449·23..†Moderate-to-severe COVID-19Overall12/12 8511735·2937/12 2111569·8770·7% (42·5–86·1)18–60 years9/11 5321591·4736/11 0311449·2377·2% (51·8–90·4)≥61 years3/1319143·821/1180120·64..†Severe COVID-19Overall4/12 8511735·2910/12 2111569·87..†18–60 years2/11 5321591·479/11 0311449·23..†≥61 years2/1319143·821/1180120·64..†*For COVID-19 of any severity, the 95·826% CI is provided (due to adjustment for multiplicity across interim analyses).†Not reported; the number of cases was too low to be statistically meaningful.‡Vaccine efficacy by region was evaluated post-hoc.§Efficacy against strains was evaluated in adjudicated and sequenced cases in participants aged 18–60 years; other strains includes B.1 lineage SARS-CoV-2.Figure 2Kaplan-Meier cumulative incidence of virologically confirmed COVID-19 of any severity in the primary efficacy analysis set(A) Overall study population.",PMC8610426
B.1.621,"We show the cumulative incidence of symptomatic COVID-19 starting on day 43 in the primary efficacy analysis set for all participants (figure 2A
) and those aged 18–60 years (figure 2B).Table 2Efficacy of CVnCoV against virologically confirmed COVID-19 occurring 15 days or more after the second dose in the primary efficacy analysis setCVnCoVPlaceboVaccine efficacy (95% CI)n/NPerson-yearsn/NPerson-yearsCOVID-19 of any severityOverall83/12 8511735·29145/12 2111569·8748·2% (31·0–61·4)*18–60 years71/11 5321591·47136/11 0311449·2352·5% (36·2–64·8)≥61 years12/1319143·829/1180120·64..†COVID-19 of any severity by region‡Europe21/4091684·2233/3919604·8343·7% (−0·2 to 69·1)Latin America62/87601051·07112/8292965·0349·2% (30·1–63·3)COVID-19 of any severity by strain§Alpha variant (B.1.1.7/501Y.V2)20/11 5321591·4742/11 0311449·2355·1% (23·5–73·6)Gamma variant (P.1/501Y.V3)9/11 5321591·4726/11 0311449·2367·1% (29·8–84·6)Lambda variant (C.37)13/11 5321591·4726/11 0311449·2352·8% (8·2–75·8)Mu variant (B.1.621)11/11 5321591·4717/11 0311449·23..†Other7/11 5321591·4713/11 0311449·23..†Moderate-to-severe COVID-19Overall12/12 8511735·2937/12 2111569·8770·7% (42·5–86·1)18–60 years9/11 5321591·4736/11 0311449·2377·2% (51·8–90·4)≥61 years3/1319143·821/1180120·64..†Severe COVID-19Overall4/12 8511735·2910/12 2111569·87..†18–60 years2/11 5321591·479/11 0311449·23..†≥61 years2/1319143·821/1180120·64..†*For COVID-19 of any severity, the 95·826% CI is provided (due to adjustment for multiplicity across interim analyses).†Not reported; the number of cases was too low to be statistically meaningful.‡Vaccine efficacy by region was evaluated post-hoc.§Efficacy against strains was evaluated in adjudicated and sequenced cases in participants aged 18–60 years; other strains includes B.1 lineage SARS-CoV-2.Figure 2Kaplan-Meier cumulative incidence of virologically confirmed COVID-19 of any severity in the primary efficacy analysis set(A) Overall study population.",PMC8610426
C.37,"We show the cumulative incidence of symptomatic COVID-19 starting on day 43 in the primary efficacy analysis set for all participants (figure 2A
) and those aged 18–60 years (figure 2B).Table 2Efficacy of CVnCoV against virologically confirmed COVID-19 occurring 15 days or more after the second dose in the primary efficacy analysis setCVnCoVPlaceboVaccine efficacy (95% CI)n/NPerson-yearsn/NPerson-yearsCOVID-19 of any severityOverall83/12 8511735·29145/12 2111569·8748·2% (31·0–61·4)*18–60 years71/11 5321591·47136/11 0311449·2352·5% (36·2–64·8)≥61 years12/1319143·829/1180120·64..†COVID-19 of any severity by region‡Europe21/4091684·2233/3919604·8343·7% (−0·2 to 69·1)Latin America62/87601051·07112/8292965·0349·2% (30·1–63·3)COVID-19 of any severity by strain§Alpha variant (B.1.1.7/501Y.V2)20/11 5321591·4742/11 0311449·2355·1% (23·5–73·6)Gamma variant (P.1/501Y.V3)9/11 5321591·4726/11 0311449·2367·1% (29·8–84·6)Lambda variant (C.37)13/11 5321591·4726/11 0311449·2352·8% (8·2–75·8)Mu variant (B.1.621)11/11 5321591·4717/11 0311449·23..†Other7/11 5321591·4713/11 0311449·23..†Moderate-to-severe COVID-19Overall12/12 8511735·2937/12 2111569·8770·7% (42·5–86·1)18–60 years9/11 5321591·4736/11 0311449·2377·2% (51·8–90·4)≥61 years3/1319143·821/1180120·64..†Severe COVID-19Overall4/12 8511735·2910/12 2111569·87..†18–60 years2/11 5321591·479/11 0311449·23..†≥61 years2/1319143·821/1180120·64..†*For COVID-19 of any severity, the 95·826% CI is provided (due to adjustment for multiplicity across interim analyses).†Not reported; the number of cases was too low to be statistically meaningful.‡Vaccine efficacy by region was evaluated post-hoc.§Efficacy against strains was evaluated in adjudicated and sequenced cases in participants aged 18–60 years; other strains includes B.1 lineage SARS-CoV-2.Figure 2Kaplan-Meier cumulative incidence of virologically confirmed COVID-19 of any severity in the primary efficacy analysis set(A) Overall study population.",PMC8610426
Lambda,"We show the cumulative incidence of symptomatic COVID-19 starting on day 43 in the primary efficacy analysis set for all participants (figure 2A
) and those aged 18–60 years (figure 2B).Table 2Efficacy of CVnCoV against virologically confirmed COVID-19 occurring 15 days or more after the second dose in the primary efficacy analysis setCVnCoVPlaceboVaccine efficacy (95% CI)n/NPerson-yearsn/NPerson-yearsCOVID-19 of any severityOverall83/12 8511735·29145/12 2111569·8748·2% (31·0–61·4)*18–60 years71/11 5321591·47136/11 0311449·2352·5% (36·2–64·8)≥61 years12/1319143·829/1180120·64..†COVID-19 of any severity by region‡Europe21/4091684·2233/3919604·8343·7% (−0·2 to 69·1)Latin America62/87601051·07112/8292965·0349·2% (30·1–63·3)COVID-19 of any severity by strain§Alpha variant (B.1.1.7/501Y.V2)20/11 5321591·4742/11 0311449·2355·1% (23·5–73·6)Gamma variant (P.1/501Y.V3)9/11 5321591·4726/11 0311449·2367·1% (29·8–84·6)Lambda variant (C.37)13/11 5321591·4726/11 0311449·2352·8% (8·2–75·8)Mu variant (B.1.621)11/11 5321591·4717/11 0311449·23..†Other7/11 5321591·4713/11 0311449·23..†Moderate-to-severe COVID-19Overall12/12 8511735·2937/12 2111569·8770·7% (42·5–86·1)18–60 years9/11 5321591·4736/11 0311449·2377·2% (51·8–90·4)≥61 years3/1319143·821/1180120·64..†Severe COVID-19Overall4/12 8511735·2910/12 2111569·87..†18–60 years2/11 5321591·479/11 0311449·23..†≥61 years2/1319143·821/1180120·64..†*For COVID-19 of any severity, the 95·826% CI is provided (due to adjustment for multiplicity across interim analyses).†Not reported; the number of cases was too low to be statistically meaningful.‡Vaccine efficacy by region was evaluated post-hoc.§Efficacy against strains was evaluated in adjudicated and sequenced cases in participants aged 18–60 years; other strains includes B.1 lineage SARS-CoV-2.Figure 2Kaplan-Meier cumulative incidence of virologically confirmed COVID-19 of any severity in the primary efficacy analysis set(A) Overall study population.",PMC8610426
Beta,"Seven (3%; two in the CVnCoV group and five in the placebo group) of these cases in the overall population were wild-type, defined as WT/D614G lineages A.1/B.1 without the B.1.1.7 (alpha), B.1.351 (beta), and B.",PMC8610426
A.1,"Seven (3%; two in the CVnCoV group and five in the placebo group) of these cases in the overall population were wild-type, defined as WT/D614G lineages A.1/B.1 without the B.1.1.7 (alpha), B.1.351 (beta), and B.",PMC8610426
B.1.351,"Seven (3%; two in the CVnCoV group and five in the placebo group) of these cases in the overall population were wild-type, defined as WT/D614G lineages A.1/B.1 without the B.1.1.7 (alpha), B.1.351 (beta), and B.",PMC8610426
Epsilon,1.429 (epsilon) variants of concern.,PMC8610426
P.2,"The remaining cases were caused by alpha (20 [13%]), B.1.526 (iota; one [1%]), wild-type (seven [5%]), P.2 (zeta; one [1%]), and other (20 [13%]).",PMC8610426
B.1.526,"The remaining cases were caused by alpha (20 [13%]), B.1.526 (iota; one [1%]), wild-type (seven [5%]), P.2 (zeta; one [1%]), and other (20 [13%]).",PMC8610426
B.1.1.7,"Alpha as known as B.1.1.7 and new Q sub-lineages in Pango lineage (9), 20I (V1) in next strain clade, GRY (formerly GR/501Y.V1) in GISAID clade, was first identified in United Kingdom, in September 2020.",PMC8645832
B.1.351,"Beta, known as B.1.351 in Pango lineage (10), 20H (V2) in nextstrain clade, GH/501Y.V2 in GISAID clade, was first identified in South Africa, in May 2020.",PMC8645832
P.1,"Gamma, known as P.1 in Pango lineage (11), 20J (V3) in nextstrain clade, GR/501Y.V3 in GISAID clade, was first identified in Brazil, in November 2020.",PMC8645832
B.1.617.2,"Delta, known as B.1.617.2 and new AY sub-lineages in Pango lineage (12), 21A in next strain clade, G/478K.V1 in GISAID clade, was first identified in India, in October 2020..",PMC8645832
Mu,"The mutations on the spike of VOC and VOI..

VOC, Variants of concern; VOI, Interested variants..

All mutation sites are based on Wuhan-Hu-1 (GenBank: NC_045512) as the reference sequence..

*detected in some sequences but not all..

VOI contain Lambda (a.k.a., C.37) from Peru (13) and Mu (a.k.a., B.1.621) from Colombia (14).",PMC8645832
B.1.621,"The mutations on the spike of VOC and VOI..

VOC, Variants of concern; VOI, Interested variants..

All mutation sites are based on Wuhan-Hu-1 (GenBank: NC_045512) as the reference sequence..

*detected in some sequences but not all..

VOI contain Lambda (a.k.a., C.37) from Peru (13) and Mu (a.k.a., B.1.621) from Colombia (14).",PMC8645832
C.37,"The mutations on the spike of VOC and VOI..

VOC, Variants of concern; VOI, Interested variants..

All mutation sites are based on Wuhan-Hu-1 (GenBank: NC_045512) as the reference sequence..

*detected in some sequences but not all..

VOI contain Lambda (a.k.a., C.37) from Peru (13) and Mu (a.k.a., B.1.621) from Colombia (14).",PMC8645832
Lambda,"The mutations on the spike of VOC and VOI..

VOC, Variants of concern; VOI, Interested variants..

All mutation sites are based on Wuhan-Hu-1 (GenBank: NC_045512) as the reference sequence..

*detected in some sequences but not all..

VOI contain Lambda (a.k.a., C.37) from Peru (13) and Mu (a.k.a., B.1.621) from Colombia (14).",PMC8645832
B.1.526,"In addition, several variants such as B.1.427/429, B.1.525, B.1.526, and B.1.617.1, previously designated as VOI have finally proven to no longer pose a significant risk to global public health (15)..

Frequencies of VOC and VOI in relevant positions.",PMC8645832
B.1.617.1,"In addition, several variants such as B.1.427/429, B.1.525, B.1.526, and B.1.617.1, previously designated as VOI have finally proven to no longer pose a significant risk to global public health (15)..

Frequencies of VOC and VOI in relevant positions.",PMC8645832
B.1.427,"In addition, several variants such as B.1.427/429, B.1.525, B.1.526, and B.1.617.1, previously designated as VOI have finally proven to no longer pose a significant risk to global public health (15)..

Frequencies of VOC and VOI in relevant positions.",PMC8645832
B.1.525,"In addition, several variants such as B.1.427/429, B.1.525, B.1.526, and B.1.617.1, previously designated as VOI have finally proven to no longer pose a significant risk to global public health (15)..

Frequencies of VOC and VOI in relevant positions.",PMC8645832
Beta,"Even so, neutralization antibody (nAb) titers of sera from immunized individuals or convalescent patients against B.1.1.7 lineage only slightly decreased, based on the pseudovirus neutralization assay (29)..

B.1.351 lineage (a.k.a., Beta or 20H/501Y.V2) first identified in South Africa has been detected in at least 114 countries and 51 states of USA (30).",PMC8645832
Gamma,"Interestingly, the serum of convalescent patients infected with the B.1.351 variant showed effective cross-neutralization against other variants (35)..

P.1 lineage (a.k.a., Gamma) was first identified in Brazil with several mutations of biological significance such as E484K, N501Y and K417T in the RBD and five mutations in the NTD (
Figure 2E
) (32, 33).",PMC8645832
Alpha,"Other studies showed that the vaccine efficacies were approximately 88%, 93%, and 75.0% against the Delta, Alpha, and Beta variants, respectively (41, 62).",PMC8645832
B.1,"On the other hand, the vaccine-induced antibodies showed neutralizing activity against four variants, including nCoV/USA_WA1/2020 (line A.1), EHC-083E (line B.1), B.1.1.7, and N501Y (95), but the neutralization activity against B.1.351 variant was significantly lost (96).",PMC8645832
A.1,"On the other hand, the vaccine-induced antibodies showed neutralizing activity against four variants, including nCoV/USA_WA1/2020 (line A.1), EHC-083E (line B.1), B.1.1.7, and N501Y (95), but the neutralization activity against B.1.351 variant was significantly lost (96).",PMC8645832
P.2,"In particular, vaccine-induced serum nAb remained effective against D614G, B.1.1.7 and B.1.429 variants (107), but that was significantly less effective against B.1.351 (107), P.1 and P.2 variants (68).",PMC8645832
B.1.429,"In particular, vaccine-induced serum nAb remained effective against D614G, B.1.1.7 and B.1.429 variants (107), but that was significantly less effective against B.1.351 (107), P.1 and P.2 variants (68).",PMC8645832
B.1.315,"observed that the sera of individuals who had received NVX-CoV2373 still contained high levels of nAb against the B.1.1.7 variant (126), but these nAb levels were significantly reduced 14.5-fold against B.1.315 (127).",PMC8645832
Eta,"Based on these studies, World Health organization has announced variants of concern (VOC) (alpha, beta, gamma, and delta) and variants of interest (VOI) (eta, lota, kappa, lambda, and mu) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8606321
Kappa,"Based on these studies, World Health organization has announced variants of concern (VOC) (alpha, beta, gamma, and delta) and variants of interest (VOI) (eta, lota, kappa, lambda, and mu) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8606321
Alpha,"Based on these studies, World Health organization has announced variants of concern (VOC) (alpha, beta, gamma, and delta) and variants of interest (VOI) (eta, lota, kappa, lambda, and mu) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8606321
Lambda,"Based on these studies, World Health organization has announced variants of concern (VOC) (alpha, beta, gamma, and delta) and variants of interest (VOI) (eta, lota, kappa, lambda, and mu) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8606321
Beta,"Based on these studies, World Health organization has announced variants of concern (VOC) (alpha, beta, gamma, and delta) and variants of interest (VOI) (eta, lota, kappa, lambda, and mu) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8606321
Mu,"Based on these studies, World Health organization has announced variants of concern (VOC) (alpha, beta, gamma, and delta) and variants of interest (VOI) (eta, lota, kappa, lambda, and mu) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8606321
Gamma,"Based on these studies, World Health organization has announced variants of concern (VOC) (alpha, beta, gamma, and delta) and variants of interest (VOI) (eta, lota, kappa, lambda, and mu) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8606321
B.1.617.2,"According to the pangolin lineages, out of 20,086 strains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2, and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2
).",PMC8606321
B.1.617.1,"According to the pangolin lineages, out of 20,086 strains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2, and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2
).",PMC8606321
B.1.525,"According to the pangolin lineages, out of 20,086 strains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2, and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2
).",PMC8606321
B.1.351,"According to the pangolin lineages, out of 20,086 strains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2, and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2
).",PMC8606321
P.1,"According to the pangolin lineages, out of 20,086 strains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2, and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2
).",PMC8606321
B.1.617.2,"We present new insight into key mutations in SARS‐CoV‐2 variants B.1.1.7 (P681H) and B.1.617.2 (P681R), which may impact on neuropilin 1 (NRP1) binding and CNS invasion.",PMC8652524
B.1.1.7,"We present new insight into key mutations in SARS‐CoV‐2 variants B.1.1.7 (P681H) and B.1.617.2 (P681R), which may impact on neuropilin 1 (NRP1) binding and CNS invasion.",PMC8652524
Alpha,"Recently, additional lineages such as B.1.1.7 (or alpha variant) in the United Kingdom, B.1.351 (or beta variant) in South Africa, and P.1 (or gamma variant) in Brazil have been described based on mutations at various genes [87, 88, 89].",PMC8652524
Beta,"Recently, additional lineages such as B.1.1.7 (or alpha variant) in the United Kingdom, B.1.351 (or beta variant) in South Africa, and P.1 (or gamma variant) in Brazil have been described based on mutations at various genes [87, 88, 89].",PMC8652524
B.1.351,"Recently, additional lineages such as B.1.1.7 (or alpha variant) in the United Kingdom, B.1.351 (or beta variant) in South Africa, and P.1 (or gamma variant) in Brazil have been described based on mutations at various genes [87, 88, 89].",PMC8652524
P.1,"Recently, additional lineages such as B.1.1.7 (or alpha variant) in the United Kingdom, B.1.351 (or beta variant) in South Africa, and P.1 (or gamma variant) in Brazil have been described based on mutations at various genes [87, 88, 89].",PMC8652524
Gamma,"Recently, additional lineages such as B.1.1.7 (or alpha variant) in the United Kingdom, B.1.351 (or beta variant) in South Africa, and P.1 (or gamma variant) in Brazil have been described based on mutations at various genes [87, 88, 89].",PMC8652524
B.1.617.3,"At the time of writing, the B.1.617 lineage, first discovered in India [90, 91, 92, 93, 94], divided into the three sublineages B.1.617.1 (or kappa variant), B.1.617.2 (or delta variant), and B.1.617.3, which have fallen into the international spotlight (particularly the B.1.617.2 sublineage), has increased potential to evade antibody and overall immune action, posing an increased potential for infecting individuals already vaccinated against the initial SARS‐CoV‐2 strain [95].",PMC8652524
B.1.617.1,"At the time of writing, the B.1.617 lineage, first discovered in India [90, 91, 92, 93, 94], divided into the three sublineages B.1.617.1 (or kappa variant), B.1.617.2 (or delta variant), and B.1.617.3, which have fallen into the international spotlight (particularly the B.1.617.2 sublineage), has increased potential to evade antibody and overall immune action, posing an increased potential for infecting individuals already vaccinated against the initial SARS‐CoV‐2 strain [95].",PMC8652524
B.1.617,"At the time of writing, the B.1.617 lineage, first discovered in India [90, 91, 92, 93, 94], divided into the three sublineages B.1.617.1 (or kappa variant), B.1.617.2 (or delta variant), and B.1.617.3, which have fallen into the international spotlight (particularly the B.1.617.2 sublineage), has increased potential to evade antibody and overall immune action, posing an increased potential for infecting individuals already vaccinated against the initial SARS‐CoV‐2 strain [95].",PMC8652524
Kappa,"At the time of writing, the B.1.617 lineage, first discovered in India [90, 91, 92, 93, 94], divided into the three sublineages B.1.617.1 (or kappa variant), B.1.617.2 (or delta variant), and B.1.617.3, which have fallen into the international spotlight (particularly the B.1.617.2 sublineage), has increased potential to evade antibody and overall immune action, posing an increased potential for infecting individuals already vaccinated against the initial SARS‐CoV‐2 strain [95].",PMC8652524
Gamma,"As of November 11, 2021, the World Health Organization recognizes four VOCs: Alpha (lineage B.1.1.7), which was first identified in the United Kingdom; Beta (B.1.351), first reported in South Africa; Gamma (P.1), believed to have originated in Brazil; and Delta (B.1.617.2 and AY.x sub-lineages), first detected in India.",PMC8603072
B.1.617.2,"As of November 11, 2021, the World Health Organization recognizes four VOCs: Alpha (lineage B.1.1.7), which was first identified in the United Kingdom; Beta (B.1.351), first reported in South Africa; Gamma (P.1), believed to have originated in Brazil; and Delta (B.1.617.2 and AY.x sub-lineages), first detected in India.",PMC8603072
B.1.1.7,"As of November 11, 2021, the World Health Organization recognizes four VOCs: Alpha (lineage B.1.1.7), which was first identified in the United Kingdom; Beta (B.1.351), first reported in South Africa; Gamma (P.1), believed to have originated in Brazil; and Delta (B.1.617.2 and AY.x sub-lineages), first detected in India.",PMC8603072
Alpha,"As of November 11, 2021, the World Health Organization recognizes four VOCs: Alpha (lineage B.1.1.7), which was first identified in the United Kingdom; Beta (B.1.351), first reported in South Africa; Gamma (P.1), believed to have originated in Brazil; and Delta (B.1.617.2 and AY.x sub-lineages), first detected in India.",PMC8603072
B.1.351,"As of November 11, 2021, the World Health Organization recognizes four VOCs: Alpha (lineage B.1.1.7), which was first identified in the United Kingdom; Beta (B.1.351), first reported in South Africa; Gamma (P.1), believed to have originated in Brazil; and Delta (B.1.617.2 and AY.x sub-lineages), first detected in India.",PMC8603072
P.1,"As of November 11, 2021, the World Health Organization recognizes four VOCs: Alpha (lineage B.1.1.7), which was first identified in the United Kingdom; Beta (B.1.351), first reported in South Africa; Gamma (P.1), believed to have originated in Brazil; and Delta (B.1.617.2 and AY.x sub-lineages), first detected in India.",PMC8603072
Beta,"As of November 11, 2021, the World Health Organization recognizes four VOCs: Alpha (lineage B.1.1.7), which was first identified in the United Kingdom; Beta (B.1.351), first reported in South Africa; Gamma (P.1), believed to have originated in Brazil; and Delta (B.1.617.2 and AY.x sub-lineages), first detected in India.",PMC8603072
B.1.351,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters.",PMC8646660
P.1,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters.",PMC8646660
B.1.617.2,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters.",PMC8646660
B.1.1.7,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters.",PMC8646660
Gamma,"Various SARS‐CoV‐2 strains, including the Alpha, Beta, Gamma, and Delta variants, and naturally occurring epitope mutants, can be neutralized by FD20 with similar potency.
.



EMBO Mol Med (2021) 13: e14544.
.

SARS‐CoV‐2 has caused a global pandemic with more than 200 million confirmed infections so far and the efficacy of the current vaccines is greatly challenged by the emergence of Variants of Concern (VOCs) such as the Delta.",PMC8646660
Beta,"Various SARS‐CoV‐2 strains, including the Alpha, Beta, Gamma, and Delta variants, and naturally occurring epitope mutants, can be neutralized by FD20 with similar potency.
.



EMBO Mol Med (2021) 13: e14544.
.

SARS‐CoV‐2 has caused a global pandemic with more than 200 million confirmed infections so far and the efficacy of the current vaccines is greatly challenged by the emergence of Variants of Concern (VOCs) such as the Delta.",PMC8646660
Alpha,"Various SARS‐CoV‐2 strains, including the Alpha, Beta, Gamma, and Delta variants, and naturally occurring epitope mutants, can be neutralized by FD20 with similar potency.
.



EMBO Mol Med (2021) 13: e14544.
.

SARS‐CoV‐2 has caused a global pandemic with more than 200 million confirmed infections so far and the efficacy of the current vaccines is greatly challenged by the emergence of Variants of Concern (VOCs) such as the Delta.",PMC8646660
B.1.1.298,"Y453F increases the ACE2 binding affinity, and with A475V and F490L, is found in independent mink‐related SARS‐CoV‐2 variants (Larsen et al, 2021; Oude Munnink et al, 2021) identified in Denmark and the Netherlands (B1.1 and B.1.1.298) that may escape human antisera and REG10933 (Starr et al, 2021).",PMC8646660
B.1.177,"A222V and S477N are described in 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) that emerged in early summer 2020 and subsequently spread to multiple locations in Europe at the end of 2020 (Lemey et al, 2021).",PMC8646660
B.1.160,"A222V and S477N are described in 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) that emerged in early summer 2020 and subsequently spread to multiple locations in Europe at the end of 2020 (Lemey et al, 2021).",PMC8646660
B.1.258,"N439K is in B.1.141, B.1.258, and in mink strains; it increases affinity to ACE2 and reduces neutralization of sera from convalescent patients (Thomson et al, 2021).",PMC8646660
B.1.617.2,"Despite this, we identified 12 neutralizing mAbs against three distinct regions of the spike protein that neutralize SARS-CoV-2 and variants of concern (VOCs), including B.1.1.7 (alpha), P.1 (gamma), and B.1.617.2 (delta).",PMC8593667
B.1.1.7,"Despite this, we identified 12 neutralizing mAbs against three distinct regions of the spike protein that neutralize SARS-CoV-2 and variants of concern (VOCs), including B.1.1.7 (alpha), P.1 (gamma), and B.1.617.2 (delta).",PMC8593667
Alpha,"Despite this, we identified 12 neutralizing mAbs against three distinct regions of the spike protein that neutralize SARS-CoV-2 and variants of concern (VOCs), including B.1.1.7 (alpha), P.1 (gamma), and B.1.617.2 (delta).",PMC8593667
P.1,"Despite this, we identified 12 neutralizing mAbs against three distinct regions of the spike protein that neutralize SARS-CoV-2 and variants of concern (VOCs), including B.1.1.7 (alpha), P.1 (gamma), and B.1.617.2 (delta).",PMC8593667
Gamma,"Despite this, we identified 12 neutralizing mAbs against three distinct regions of the spike protein that neutralize SARS-CoV-2 and variants of concern (VOCs), including B.1.1.7 (alpha), P.1 (gamma), and B.1.617.2 (delta).",PMC8593667
R.1,"Of the greatest concern is the substitution at position 484 in the RBD, which is exclusively shared by the VOCs, variants of interest (VOIs), and variants under monitoring (VUMs) originally identified in South Africa (B.1.351 [beta]), Brazil (P.1 [gamma]), Texas (R.1), Colombia (B.1.621 [mu]), New York (B.1.526 [iota]), and India (B.1.617.1 [kappa]) (2, 3, 11–15).",PMC8593667
B.1.621,"Of the greatest concern is the substitution at position 484 in the RBD, which is exclusively shared by the VOCs, variants of interest (VOIs), and variants under monitoring (VUMs) originally identified in South Africa (B.1.351 [beta]), Brazil (P.1 [gamma]), Texas (R.1), Colombia (B.1.621 [mu]), New York (B.1.526 [iota]), and India (B.1.617.1 [kappa]) (2, 3, 11–15).",PMC8593667
B.1.617.1,"Of the greatest concern is the substitution at position 484 in the RBD, which is exclusively shared by the VOCs, variants of interest (VOIs), and variants under monitoring (VUMs) originally identified in South Africa (B.1.351 [beta]), Brazil (P.1 [gamma]), Texas (R.1), Colombia (B.1.621 [mu]), New York (B.1.526 [iota]), and India (B.1.617.1 [kappa]) (2, 3, 11–15).",PMC8593667
B.1.351,"Of the greatest concern is the substitution at position 484 in the RBD, which is exclusively shared by the VOCs, variants of interest (VOIs), and variants under monitoring (VUMs) originally identified in South Africa (B.1.351 [beta]), Brazil (P.1 [gamma]), Texas (R.1), Colombia (B.1.621 [mu]), New York (B.1.526 [iota]), and India (B.1.617.1 [kappa]) (2, 3, 11–15).",PMC8593667
B.1.526,"Of the greatest concern is the substitution at position 484 in the RBD, which is exclusively shared by the VOCs, variants of interest (VOIs), and variants under monitoring (VUMs) originally identified in South Africa (B.1.351 [beta]), Brazil (P.1 [gamma]), Texas (R.1), Colombia (B.1.621 [mu]), New York (B.1.526 [iota]), and India (B.1.617.1 [kappa]) (2, 3, 11–15).",PMC8593667
Epsilon,"Other emerging variants have acquired a mutation of L452R within the RBD, which is found in B.1.1.298, a variant capable of interspecies transmission between humans and minks, and B.1.427/B.1.429 (epsilon) isolated in southern California (19).",PMC8593667
B.1.427,"Other emerging variants have acquired a mutation of L452R within the RBD, which is found in B.1.1.298, a variant capable of interspecies transmission between humans and minks, and B.1.427/B.1.429 (epsilon) isolated in southern California (19).",PMC8593667
B.1.1.298,"Other emerging variants have acquired a mutation of L452R within the RBD, which is found in B.1.1.298, a variant capable of interspecies transmission between humans and minks, and B.1.427/B.1.429 (epsilon) isolated in southern California (19).",PMC8593667
Kappa,"Moreover, B.1.617.1 (kappa) found in India possesses both L452R and E484Q mutations within the RBD (15, 20).",PMC8593667
A.23.1,"Intriguingly, the B.1.617 lineages contain P681R, a mutation that enhances and accelerates viral fusion (24) and is also present in the dominant variant in Uganda, A.23.1 (25).",PMC8593667
B.1.617,"Intriguingly, the B.1.617 lineages contain P681R, a mutation that enhances and accelerates viral fusion (24) and is also present in the dominant variant in Uganda, A.23.1 (25).",PMC8593667
P.2,"This is in line with previous studies that showed that the E484K and E484Q mutations are the key escaping residues responsible for neutralization resistance by P.1, P.2, B.1.351, and B.1.617.1 VOCs (2, 4, 38).",PMC8593667
Lambda,The synthesized fragments for heavy and light chains with 5′ and 3′ Gibson overhangs were then cloned into human IgG1 and human kappa or lambda light chain expression vectors by Gibson assembly as previously described (53).,PMC8593667
Alpha,R203K/G204R incur positive selection and associate with the emergence of B.1.1.7 (Alpha).,PMC8590493
B.1.1.7,R203K/G204R incur positive selection and associate with the emergence of B.1.1.7 (Alpha).,PMC8590493
Gamma,"These mutations are carried by the increasingly frequent lineages B.1.1.7 (Alpha) (Collier et al., 2021; C. Caserta et al., 2021) and P.1 (Gamma) (Dejnirattisai et al., 2021; Faria et al., 2021).",PMC8590493
P.1,"These mutations are carried by the increasingly frequent lineages B.1.1.7 (Alpha) (Collier et al., 2021; C. Caserta et al., 2021) and P.1 (Gamma) (Dejnirattisai et al., 2021; Faria et al., 2021).",PMC8590493
P.3,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
Zeta,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
Theta,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
C.37,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
P.2,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
Lambda,"The lineages showing rapid increases (Figures S4A–S4H), including B.1.1.7, P.1, P.2 (Zeta), P.3 (Theta), and C.37 (Lambda), are all carrying R203K/G204R mutations (Tables S3A and S3B).",PMC8590493
B.1.617.2,"The recently evolved Indian lineages B.1.617.1 (Kappa) (Yadav et al., 2021), B.1.617.2 (Delta), and AY.1 (Delta-plus) also carry a point mutation at 28,881, which is a novel N mutation, R203M, instead of R203K/G204R (Table S3A).",PMC8590493
Kappa,"The recently evolved Indian lineages B.1.617.1 (Kappa) (Yadav et al., 2021), B.1.617.2 (Delta), and AY.1 (Delta-plus) also carry a point mutation at 28,881, which is a novel N mutation, R203M, instead of R203K/G204R (Table S3A).",PMC8590493
B.1.617.1,"The recently evolved Indian lineages B.1.617.1 (Kappa) (Yadav et al., 2021), B.1.617.2 (Delta), and AY.1 (Delta-plus) also carry a point mutation at 28,881, which is a novel N mutation, R203M, instead of R203K/G204R (Table S3A).",PMC8590493
B.1.351,"The AYR variants mostly belong to the B.1.351 (Beta) (Mwenda et al., 2021) lineage (1211/1379, 87.8%)..",PMC8590493
Beta,"The AYR variants mostly belong to the B.1.351 (Beta) (Mwenda et al., 2021) lineage (1211/1379, 87.8%)..",PMC8590493
Gamma,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
B.1.617.2,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
B.1.1.7,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
Alpha,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
P.1,"Sequences for three infectious variants of SARS-CoV-2 including SARS-CoV-2/B.1.617.2 (Delta variant), SARS-CoV-2/ B.1.1.7 (Alpha variant) and SARS-CoV-2/ P.1 (Gamma variant) were also included in analysis.",PMC8592051
P.1,"Hierarchical clustering provided phylogenetic and evolutionary analysis of the lineages, and we tracked the P.1 (Gamma) variant origin.",PPR417998
Gamma,"Hierarchical clustering provided phylogenetic and evolutionary analysis of the lineages, and we tracked the P.1 (Gamma) variant origin.",PPR417998
B.1.1.28,"Instead, we found evidence pointing to its external source and a possible recombinant event that may relate P.1 to the B.1.1.28 variant subset.",PPR417998
B.1.617.2,"Brazil was the pandemic’s epicenter at the peak of its second wave, around April 2021..

New variants continually emerge, many of them considered Variants of Concern (VOC) such as the British B.1.1.7 (Alpha), the South African B.1.351 (Beta), the Indian B.1.617.2 (Delta), and the P.1 (Gamma), first identified in Brazil in November 2020 (2).",PPR417998
B.1.1.7,"Brazil was the pandemic’s epicenter at the peak of its second wave, around April 2021..

New variants continually emerge, many of them considered Variants of Concern (VOC) such as the British B.1.1.7 (Alpha), the South African B.1.351 (Beta), the Indian B.1.617.2 (Delta), and the P.1 (Gamma), first identified in Brazil in November 2020 (2).",PPR417998
Alpha,"Brazil was the pandemic’s epicenter at the peak of its second wave, around April 2021..

New variants continually emerge, many of them considered Variants of Concern (VOC) such as the British B.1.1.7 (Alpha), the South African B.1.351 (Beta), the Indian B.1.617.2 (Delta), and the P.1 (Gamma), first identified in Brazil in November 2020 (2).",PPR417998
B.1.351,"Brazil was the pandemic’s epicenter at the peak of its second wave, around April 2021..

New variants continually emerge, many of them considered Variants of Concern (VOC) such as the British B.1.1.7 (Alpha), the South African B.1.351 (Beta), the Indian B.1.617.2 (Delta), and the P.1 (Gamma), first identified in Brazil in November 2020 (2).",PPR417998
Beta,"Brazil was the pandemic’s epicenter at the peak of its second wave, around April 2021..

New variants continually emerge, many of them considered Variants of Concern (VOC) such as the British B.1.1.7 (Alpha), the South African B.1.351 (Beta), the Indian B.1.617.2 (Delta), and the P.1 (Gamma), first identified in Brazil in November 2020 (2).",PPR417998
P.4,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
B.1.195,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
B.1.1,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
N.9,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
P.1.2,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
P.2,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
B.1,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
B.1.1.33,"The main lineages identified in Brazil according to the PANGO nomenclature are: P.1 (3572 – 40.9%), P.4 (1274 – 14.6%), P.2 (1132 – 13.0%), B.1.1.33 (909 – 10.4%), B.1.1.28 (864 – 9.9%), B.1.1.7 (248 – 2.8%), B.1.1 (186 – 2.1%), P.1.2 (153 – 1.7%), N.9 (81 – 0.9%), B.1 (65 – 0.7%), B.1.195 (54 – 0.6%), other (178 – 2.0%).",PPR417998
A.2,"Cluster 2 is composed of lineages less frequent in Brazil, including the basal lineages A.1, A.2, and B and B.1, which have 1,3,3 and 59 samples, respectively.",PPR417998
A.1,"Cluster 2 is composed of lineages less frequent in Brazil, including the basal lineages A.1, A.2, and B and B.1, which have 1,3,3 and 59 samples, respectively.",PPR417998
N.10,"The group is mainly composed of B.1.1, B.1.1.28, B.1.1.33, P.2, N.9, and N.10 (Table S2).",PPR417998
P.1.1,"The Brazilian B.1.1.33 sequences are closer to the B.1.1 sequences found in Switzerland (EPI_ISL_415454, EPI_ISL_524474, EPI_ISL_415700, EPI_ISL_415457, EPI_ISL_429203), Czech Republic (EPI_ISL_416743, EPIJSL_895731) and Netherlands (EPI_ISL_454750), corroborating its European origin (9)..

TP1 comprises clusters within variants P.1, P.4, P.1.1, and P.1.2 (clusters 3,7,9,10,12,14 and 15).",PPR417998
B.1.617.1,"Cluster-based methods reached higher bootstrap values compared to those based on the lineage (Figure 5)..

Kappa variant B.1.617.1 samples appear together within the TP1 group in the DNA and the protein trees (Figures 5b and d), which probably consists of annotation errors once these samples have the characteristic mutations of the P.1 variant rather than B.1.617.1 (Table S1)..

We investigated three hypotheses for the P.1 variant origin: a) it evolved locally, i.e., from T0, b) it had a later entry external origin (came from abroad); and c) P.1 is derived from some recombination event..

From each of the 50 P.1 samples (Brazilian), we take the 70 closest vectors in the set of World proteomes of 2020.",PPR417998
B.1.1.198,The P.1 group achieved a bootstrap of 100% in its branch (Figure S7) and is a sister group of a branch divided into a consistent branch of B.1.1.198 and another branch that includes samples of B.1.1 and B.1.1.192.,PPR417998
B.1.561,"The proteomes closest to the origin of P.1, from those identified by the network, are one from USA (EPI_ISL_803019) labeled B.1.561, and one from India (EPI_ISL_728326) identified as B.1.1.306..",PPR417998
B.1.1.10,"The RDP4 found one possible recombinant event: hCoV-19/Lithuania/MR-LUHS-Eilnr352/2020 (EPIJSL_636871 – B.1.1.280) as a recombinant sample, hCoV-19/Brazil/AM-CD1739/ 2020 (EPI_ISL_2233906 – P.4) as minor parental, and hCoV-19/England/OXON-AD15D/2020 (EPI_ISL_448567 – B.1.1.10) as major parental.",PPR417998
B.1.1.280,"The RDP4 found one possible recombinant event: hCoV-19/Lithuania/MR-LUHS-Eilnr352/2020 (EPIJSL_636871 – B.1.1.280) as a recombinant sample, hCoV-19/Brazil/AM-CD1739/ 2020 (EPI_ISL_2233906 – P.4) as minor parental, and hCoV-19/England/OXON-AD15D/2020 (EPI_ISL_448567 – B.1.1.10) as major parental.",PPR417998
B.1.1.1,"The methods applied by RDP4, and their respective p-values are RDP (3.92E-04), GENECONV (6.26E-03), Bootscan (2.46E-03), Maxchi (1.35E-02), Chimaera (6.28E-03), 3Seq (1.36E-05)..

RAPR results (Table S9) suggested the hypothesis that the proximity between P.1 to few samples of B.1.1.28 from cluster 6 may be due to a recombination event between a Brazilian P.1 and a foreign strain, close to hCoV-19/USA/NC-UNC-0017/2020 (EPI_ISL_831339 – B.1.1.1), which originated this group of B.1.1.28.",PPR417998
P.7,"Also, concerning the T0 group, cluster 5 has 77 samples of B.1.1.28 consistently separated from the others, which had its designation updated to variant P.7, which agrees with our analysis.",PPR417998
B.3,"Finally, tree d) obtains BP of 100% for the branch of the TP1 group and inserts as basal the variants A.1, A.2, B, B.3, B.6, and B.39 consistently..

Sequences similar to P.1 detected by the neural network ensemble.",PPR417998
B.39,"Finally, tree d) obtains BP of 100% for the branch of the TP1 group and inserts as basal the variants A.1, A.2, B, B.3, B.6, and B.39 consistently..

Sequences similar to P.1 detected by the neural network ensemble.",PPR417998
B.6,"Finally, tree d) obtains BP of 100% for the branch of the TP1 group and inserts as basal the variants A.1, A.2, B, B.3, B.6, and B.39 consistently..

Sequences similar to P.1 detected by the neural network ensemble.",PPR417998
Alpha,Our results show that in Vero E6 cells the B.1.1.7 strain (aka Alpha Variant of Concern) is associated with much faster kinetics of endocytic uptake compared to its ancestor B.1.177.,PMC8562013
B.1.1.7,Our results show that in Vero E6 cells the B.1.1.7 strain (aka Alpha Variant of Concern) is associated with much faster kinetics of endocytic uptake compared to its ancestor B.1.177.,PMC8562013
B.1.177,"Conversely, in TMPRSS2-negative cell lines, CoVs internalize by the late pathway and fusion is triggered by the Cathepsin B/L proteases [13].Scheme 1Structure of SARS-CoV-2 and differences between B.1.177, B.1.1.7, and B.1Δ in the Spike protein.",PMC8562013
B.1,"B.1Δ originated from a B.1 strain (hCoV-19/Italy/LOM-UniSR1/2020, GISAID Accession ID: EPI_ISL_413489) whose passaging in VeroE6 yielded a CS devoid of 685RS686 sequence (Scheme 1).",PMC8562013
P.2,"From 720 SARS-CoV-2 genome sequences, we found few sites under positive selection pressure, such as the D614G (98.5 %) in the spike, that has replaced the old variant; the V1167F in the spike (41 %), identified in the P.2 variant that emerged from Brazil during the period of analysis; and I292T (39 %) in the N protein.",PMC8743548
B.1.1,"The proposal is labelled considering the major lineages (A and B), and the descendant lineages assigned by numerical values (B.1, B.1.1, B.1.1.28, among others) [10].",PMC8743548
B.1,"The proposal is labelled considering the major lineages (A and B), and the descendant lineages assigned by numerical values (B.1, B.1.1, B.1.1.28, among others) [10].",PMC8743548
B.1.1.28,"The proposal is labelled considering the major lineages (A and B), and the descendant lineages assigned by numerical values (B.1, B.1.1, B.1.1.28, among others) [10].",PMC8743548
A.3,"There are six lineages derived from lineage A (denoted A.1–A.6), two sublineages of A.1 (A.1.1 and A.3), and 16 lineages derived from lineage B.",PMC8743548
A.1,"There are six lineages derived from lineage A (denoted A.1–A.6), two sublineages of A.1 (A.1.1 and A.3), and 16 lineages derived from lineage B.",PMC8743548
Gamma,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
B.1.617.2,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
B.1.1.7,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
Alpha,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
B.1.351,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
P.1,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
Beta,"According to the new labels, VOCs Alpha, Beta, Gamma, and Delta correspond to, respectively, lineages B.1.1.7 (and B.1.1.7+E484K), B.1.351, P.1, and B.1.617.2 [18].",PMC8743548
B.1.427,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
Zeta,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
Theta,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
C.37,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.617.1,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.525,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
Kappa,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
Lambda,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
P.3,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
Epsilon,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
Eta,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.526,"VOIs Epsilon, Zeta, Eta, Theta, Iota, Kappa, and Lambda correspond to, respectively, lineages B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, and C.37 [18].",PMC8743548
B.1.1.33,"The most common sublineage was B.1.1.28 with 38.6% of prevalence (IC 95 % 42.2–35.1 %), followed by sublineage B.1.1.33, with 37.4 % (IC 95 % 41–33.9 %), and 15.8 % of B.1.1 (IC 95 % 15.8–13.3 %).",PMC8743548
N.4,We also identified sequences from lineages P.2 and N.4 (Fig.,PMC8743548
B.1.429,"Moreover, the variants of concern B.1.351, B.1.427, and B.1.429 feature the T205I substitution, which were identified in 0.69% of our sequences from May to September (Table S1) [62].",PMC8743548
P.4,"This can be evidenced by the emergence of the variants P.3 and P.4 in the Philippines and Mexico, respectively, which possess mutations that were identified in the P.2 variant, such as the V1176F [80, 81].",PMC8743548
B.1.351,"In humans, the spike mutation D215G is characteristic of the beta variant lineage (B.1.351, South Africa) (42).",PMC8612357
Beta,"In humans, the spike mutation D215G is characteristic of the beta variant lineage (B.1.351, South Africa) (42).",PMC8612357
P.1,"D138Y is a defining mutation of the gamma variant lineage (P.1, Brazil) (44)..",PMC8612357
Gamma,"D138Y is a defining mutation of the gamma variant lineage (P.1, Brazil) (44)..",PMC8612357
Alpha,"The cooccurrence of spikes 69–70del and N501Y has been recorded in the alpha variant lineage (B.1.1.7, UK) in humans (25, 50).",PMC8612357
B.1.1.7,"The cooccurrence of spikes 69–70del and N501Y has been recorded in the alpha variant lineage (B.1.1.7, UK) in humans (25, 50).",PMC8612357
B.1.177,"The main results of the present work showed that (i) GENPAT and GISAID detected the same PANGO lineages, (ii) the PANGO lineages B.1.177 (i.e.",PMC8556844
B.1.1.7,historical in Italy) and B.1.1.7 (i.e.,PMC8556844
B.1.1,"These multiple MST-based clusters were also observed for other less common PANGO lineages, such like B.1.1, B.1.177.8, B.1.1.420, B.1, P.1 and B.1.160 (Fig.",PMC8556844
B.1.160,"These multiple MST-based clusters were also observed for other less common PANGO lineages, such like B.1.1, B.1.177.8, B.1.1.420, B.1, P.1 and B.1.160 (Fig.",PMC8556844
B.1.177.8,"These multiple MST-based clusters were also observed for other less common PANGO lineages, such like B.1.1, B.1.177.8, B.1.1.420, B.1, P.1 and B.1.160 (Fig.",PMC8556844
B.1.1.420,"These multiple MST-based clusters were also observed for other less common PANGO lineages, such like B.1.1, B.1.177.8, B.1.1.420, B.1, P.1 and B.1.160 (Fig.",PMC8556844
B.1,"These multiple MST-based clusters were also observed for other less common PANGO lineages, such like B.1.1, B.1.177.8, B.1.1.420, B.1, P.1 and B.1.160 (Fig.",PMC8556844
P.1,"These multiple MST-based clusters were also observed for other less common PANGO lineages, such like B.1.1, B.1.177.8, B.1.1.420, B.1, P.1 and B.1.160 (Fig.",PMC8556844
B.1.351,"Numerous lineages of SARS-CoV-2 emerged since the beginning of pandemic and, at the time of the manuscript preparation, three of them are today considered as global variants of concern: B.1.1.7, B.1.351, and P.1 (i.e.",PMC8556844
B.1.1.207,"In addition, GENPAT did not identified many samples corresponding to variants of concern named “South Africa” (B.1.351) [75, 83, 87, 88], “Japan-Brazil” (B.1.1.248 reclassified to B.1.1.28.1 - alias P.1) [75, 83, 87–90], “Nigeria” (B.1.1.207) [75, 91], “Denmark” (Y453F, 69–70deltaHV) [92, 93], “UK-Nigeria” (B.1.525) [94], and “Indian” (B.1.617) [95], neither in the Abruzzo region (Fig.",PMC8556844
B.1.617,"In addition, GENPAT did not identified many samples corresponding to variants of concern named “South Africa” (B.1.351) [75, 83, 87, 88], “Japan-Brazil” (B.1.1.248 reclassified to B.1.1.28.1 - alias P.1) [75, 83, 87–90], “Nigeria” (B.1.1.207) [75, 91], “Denmark” (Y453F, 69–70deltaHV) [92, 93], “UK-Nigeria” (B.1.525) [94], and “Indian” (B.1.617) [95], neither in the Abruzzo region (Fig.",PMC8556844
B.1.525,"In addition, GENPAT did not identified many samples corresponding to variants of concern named “South Africa” (B.1.351) [75, 83, 87, 88], “Japan-Brazil” (B.1.1.248 reclassified to B.1.1.28.1 - alias P.1) [75, 83, 87–90], “Nigeria” (B.1.1.207) [75, 91], “Denmark” (Y453F, 69–70deltaHV) [92, 93], “UK-Nigeria” (B.1.525) [94], and “Indian” (B.1.617) [95], neither in the Abruzzo region (Fig.",PMC8556844
A.1,"Then, the dynamic nomenclature assigns a numerical value for each descending lineage from either lineage A or B (e.g A.1 or B.2) following roles with corresponding criteria [34]..

Keeping in mind the objective to build phylogenomic trees matching the PANGO lineages, with high discriminatory power, and as fast as possible, we replaced the slow substitution model-based phylogenomic inference [53–55] by MST inferred with the algorithm “MSTree V2” implemented in GrapeTree (version 2.2, default parameters) [68] (Fig.",PMC8556844
Alpha,"New preliminary evidence on cross-reactivity of Mala S 1 allergen with skin will be showed..


Mouhamadou Ndiaye 1,2, Rosalie Sacheli 3,4, Khadim Diongue 1,2, Caroline Adjetey 3, Rajae Darfouf 3,4, Mame Cheikh Seck 1,2, Aida Sadikh Badiane 1,2, Mamadou Alpha Diallo Diallo 2, Thérése Dieng 1, Marie-Pierre Hayette 3,4 and Daouda Ndiaye 1,2
1 University Cheikh Anta Diop2 Laboratory of Parasitology, University Hospital of Aristide Le Dantec3 Department of Clinical Microbiology, Center for Interdisciplinary Research on Medicines (CIRM), University Hospital of Liege4 National Reference Center for Mycosis, University Hospital of Liege
.",PMC8624133
Kappa,The agreement between different laboratory methods in measuring the same variable was estimated by Cohen’s kappa test (K).,PMC8624133
Lambda,"Objectives: Identification of proteins recognized by antibodies that react with superficial antigens of Candida albicans germ tubes (CAGTA), expressed in a cDNA phage library of Candida albicans growing as mycelia..

Materials & Methods: The mycelial C. albicans SC5314 cDNA library was harboured in Lambda Zap II phage, and was kindly provided by Dr P. Sundstrom and Dr W. Fonzi.",PMC8624133
Gamma,"More than half of the 53 phages with in-frame coded proteins matched the hyphally-regulated cell wall protein (Hyr1), while others corresponded to enolase 1 (Eno1), cystathionine γ-lyase (Cys3), aminopeptidase 2 (Ape2) and the coatomer subunit gamma (Sec21) of C. albicans..",PMC8624133
Zeta,"Initially, the fusogenic system was characterized using dynamic light scattering (DLS), zeta potential, anisotropy and differential scanning calorimetry (DSC).",PMC8551951
Alpha,Escherichia coli alpha hemolysin (HlyA) is a pore-forming protein which belongs to the 'Repeat in toxins' (RTX) family.,PMC8551951
Beta,"The enzyme has three subunits: The alfa subunit, responsible for catalytic activity and ionic transport; The beta subunit, responsible for the normal activity of NKA and contains several glycosylation sites; And the gama (or FXYD2) subunit that has a modulating function and influences the kinetic properties of the enzyme.",PMC8551951
M.1,"Ali M.H1, Shuma M.S1, Dohra H2, Yamazaki, M.1,3.",PMC8551951
D.2,"Calaça G. N.1, Lima, D.2, Santos, C. S.3, Manica, G.C.M4, Klassen, G4, Pessôa, C.A.2, Wohnrath, K.2, Juliana Inaba
1.",PMC8551951
N.1,"Calaça G. N.1, Lima, D.2, Santos, C. S.3, Manica, G.C.M4, Klassen, G4, Pessôa, C.A.2, Wohnrath, K.2, Juliana Inaba
1.",PMC8551951
K.2,"Calaça G. N.1, Lima, D.2, Santos, C. S.3, Manica, G.C.M4, Klassen, G4, Pessôa, C.A.2, Wohnrath, K.2, Juliana Inaba
1.",PMC8551951
A.1,"The RhCl3/pCD was more potent to reduce the NF-κB expression in RAW 264.7 and J774 A.1, than RhCl3, at all tested concentrations.",PMC8551951
Lambda,"One of them is the insecticide ZEUS® (Ihara), a combination of dinotefuran and lambda cyhalothrin, produced in order to reduce their environmental impacts..",PMC8551951
Gamma,This protein is classified as a gamma type based on its characteristic structural domains.,PMC8551951
V.2,"Adeline Neiverth-Chagas1,2, Souza , S. G. H.3, Zingali , R.B.4, Rezende H. K.2, Fernandes, B. V.2, Klein, M.K.2, Klein, N. K.2, Vendruscolo, E. C. G.2, Marise Fonseca dos Santos 1.",PMC8551951
Iota,"By means of biophysical computational methods (Constant-pH Monte Carlo simulations), the stability of several spike (S) trimeric structures at different conformational states and pH conditions was investigated, as well as the free energy of interactions between the receptor binding domain (RBD) and the Angiotensin Converting Enzyme 2 (ACE2) for the most common variants of concern (Alfa, Beta, Gamma, Kappa, Epsilon, and Iota).",PMC8551951
Epsilon,"By means of biophysical computational methods (Constant-pH Monte Carlo simulations), the stability of several spike (S) trimeric structures at different conformational states and pH conditions was investigated, as well as the free energy of interactions between the receptor binding domain (RBD) and the Angiotensin Converting Enzyme 2 (ACE2) for the most common variants of concern (Alfa, Beta, Gamma, Kappa, Epsilon, and Iota).",PMC8551951
Kappa,"By means of biophysical computational methods (Constant-pH Monte Carlo simulations), the stability of several spike (S) trimeric structures at different conformational states and pH conditions was investigated, as well as the free energy of interactions between the receptor binding domain (RBD) and the Angiotensin Converting Enzyme 2 (ACE2) for the most common variants of concern (Alfa, Beta, Gamma, Kappa, Epsilon, and Iota).",PMC8551951
Theta,"Additionally, the fractality observed in the different brain waves present in ECoG is characterized by higher FD values associated with faster waves, as beta (I= 2.943 ± 0.006; II= 2.942 ± 0.005; III= 2.942 ± 0.008) and alpha (I= 2.695 ± 0.025; II= 2.697 ± 0.024; III= 2.699 ± 0.014), followed by slower theta (I= 2.280 ± 0.030; II= 2.283 ± 0.032; III= 2.280 ± 0.018) and delta (I= 1.472 ± 0.024; II= 1.452 ± 0.049; III= 1.463 ± 0.031) rhythms.",PMC8551951
B.1.617.2,"The most recent strain of concern of SARS-CoV-2 is Delta (B.1.617.2), responsible for an increase in infections in India and reported with a large increase in viral transmissibility..",PMC8551951
A.2,"Carneiro, G. C.1, Parmera, J. B.2, Almeida, I. J.3, Oliveira, M. C. B2,4, Silagi, M. L.5, Studart-Neto, A.2, Ono, C. R1, Barbosa, E. R.2, Nitrini, R.2, Buchpiguel, C. A.1, Brucki, S. M. D.2, Coutinho, A. M.1.",PMC8551951
R.2,"Carneiro, G. C.1, Parmera, J. B.2, Almeida, I. J.3, Oliveira, M. C. B2,4, Silagi, M. L.5, Studart-Neto, A.2, Ono, C. R1, Barbosa, E. R.2, Nitrini, R.2, Buchpiguel, C. A.1, Brucki, S. M. D.2, Coutinho, A. M.1.",PMC8551951
C.1,"Carneiro, G. C.1, Parmera, J. B.2, Almeida, I. J.3, Oliveira, M. C. B2,4, Silagi, M. L.5, Studart-Neto, A.2, Ono, C. R1, Barbosa, E. R.2, Nitrini, R.2, Buchpiguel, C. A.1, Brucki, S. M. D.2, Coutinho, A. M.1.",PMC8551951
B.1.1.7,The B.1.1.7 refers to a mutation in the SARS-CoV-2 RNA that renders the virus more contagious up to 70% with a vast number of genetic variations in the S protein.,PMC8545698
B.1.351,"For instance, the identified B.1.351 variant has acquired mutations in the ACE2 interaction surface of the RBD that led to increased transmissibility [126].",PMC8545698
B.1.427,The new variant of concern (VOC) named as CAL.20C (B.1.427/B.1.429) was originally detected in California and is currently spreading throughout the US and other countries.,PMC8545698
B.1.429,"As of March 26, 2021, the sequenced genomes reported in GISAID for the B.1.427 and B.1.429 lineages are 4292 and 10,934, respectively.",PMC8545698
B.1.526,"Nearly all of the newly identified B.1.526 variants have a set of common mutations in the spike protein such as L5F, T95I, D253G, E484K, D614G and A701V [131].",PMC8545698
P.1,"The P.1 or Brazilian variant, also known as 20 J/501Y·V3, is one of the SARS-CoV-2 variant emerged from Brazil.",PMC8545698
B.1.1.28,"The genome sequencing revealed that the emergence of Lineage P.1 contains 10-lineage-defining amino acid mutations in the virus spike protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y and T1207I) when compared to its immediate ancestor (B.1.1.28).",PMC8545698
Beta,"NoDrug nameTargetMechanism of actionAdverse effectStatusRef.1Chloroquine and HydroxychloroquineACE2viral cell entryLysosomeGlycosylate inhibition of host cell receptors to block viral entry, acidification of endosomal and proteolytic process.Immunomodulatory effects through inhibition of cytokine production, autophagy and lysosomal activity in host cells.Overdose may present with respiratory arrest, cardiac arrest and hypokalemia and patients may also be given epinephrinePhase 4Completed[348], [349]2Lopinavir/RitonavirEnzyme3CL proteaseInhibition of 3CL protease.Resists viral cell entryRisk to Pediatric PatientsPhase 4Active, Not Recruiting[350]3RibavirinNucleotide analogue remdesivi (RDV)Inhibits HVC polymeraseRNA dependentRNA polymerase inhibitorViral RNA synthesis and mRNA capping inhibitorHepatotoxicity andhypersensitivityPhase 4Active, Not Recruiting[351], [352]4RemdesivirRNA polymeraseRNA dependentRNA polymerase inhibitor.Block viral replicationOver dose - remdesivir are not readily available.Phase 4Not yet recruiting[353]5FavipiravirRNA-dependent RNA polymerase (RdRp)RNA polymerase inhibitor which prevents RNA replication and transcriptionNot recommended, if the pregnancy is confirmed or suspectedPhase 4Not Yet Recruiting[354]6TocilizumabCytokine stormInhibition IL-6 receptor.Block cytokine storm reductionMonoclonal antibodyOver dose - neutropeniaPhase 4Not yet recruiting[355], [356]7Sarilumabinterleukin-6 inhibitormonoclonal antibodiesInhibition of IL-6 ReceptorDecrease in neutophil count and a reversible decrease in fibrinogenPhase 4Completed[357]8FingolimodEnzyme dihydroorotate dehydrogenaseinactivating IL-6/STAT3 pathwayCardiac effects (bradycardia and heart block)Phase 4Completed[358]9Canakinumabinterleukin-1 (IL-1)monoclonal antibody which acts against IL-1-βAdverse reaction InfluenzaPhase 3Active, not Recruiting[359]10Anakinrainterleukin-1 (IL-1)monoclonal antibody which acts against IL-1 ReceptorRheumatoid arthritisAEs (incidence > 10%)Phase 4Completed[360]11Gimsilumabgranulocyte macrophage-colony stimulating factor (GM-CSF)monoclonal antibody which acts against GM-CSFNot availablePhase 2Completed[361]12HeparinVero E6 cellsAnticoagulant and anti-inflammatoryPlatelet counts usually do not fall until between days 5 and 12Phase 4Active, not Recruiting[362], [363], [364]13BaricitinibJAK1/2Antiviral activityClathrin-mediated endocytosis inhibitorJanus kinases 1 and 2 (JAK1/2 inhibitorMany adverse reactionsPhase 4Active, not Recruiting[365], [366]14RuxolitinibJAK1/2Inhibition of Janus kinase (JAK)Myelosuppression, including leukopenia, anemia, and thrombocytopenia.Phase 4Completed[367]15UmifenovirSpike protein /ACE2Cell membraneHost cell membrane fusion, DNA and RNA inhibitorPathological changesPhase 4Completed[368]16PirfenidoneSpike protein/ACE2Inhibition of collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferationInhibition of TNF – α and IL – 1 βPhotosensitivity rash and gastrointestinal symptoms.Phase 4Completed[369]17Camostat MesilateProtease inhibitorTMPRSS2 inhibitor which prevents the viral replicationBlock viral mutationRash, pruritus, nausea, abnormal laboratory test values, and diarrheaPhase 4Withdrawn[370]18Darunavir/CobicistatProteaseViral entry inhibitorInhibits HIV replicationJaundice (13%), ocular icterus (15%), and nausea (12%).Phase 4Active, not Recruiting/ Phase 4Active, not Recruiting[370]19Aerosolized interferon -αcytokinesStimulate antiviral immunity––[371]20OseltamivirNeuraminidaseViral replication inhibitorNo adverse reactionsPhase 4Completed[372]21Baloxivir marboxilViral endonucleaseViral multiplication inhibitor––[373]22The SARS-Cov-2 specific protease drug candidateProtease inhibitorPrevent the viral infectivityInhibitor of ACE2, S protein and TMPRSS2 serine protease––[374], [375]23SARS-Cov-2 specific antibodiesAntibodyBind with viral cell, and inhibit the viral entry and improve immune system––[372], [376]Table 6Developed nasal drugs, its mechanism and current status.Table 6Product NameDeveloperMechanismCurrent StatusRefNitric Oxide Nasal Spray (NONS)SaNOtizeReduces Viral RNA generation and fusion of S proteinPhase-III completed[378]Nebulizer suspension powderAPEPTICOBy restoring endothelial-epithelial barrier of pulmonary alveoliPhase II[379]Inhaled mRNA antibodiesNeurimmune and EthrisEncoded with mRNA and helps in neutralizing the anti SARS-CoV-2 antibodiesPhase I[380]AlvescoCovis PharmaRestrains viral replicationPhase III[381]Neuroactive nasal sprayVistaGen TherapeuticsBy reducing anxiety through enabling synaptic pathwaysPhase III[382]Interferon beta for nebulizationSynairgenEnhances pulmonary antiviral defensesPhase II[383]LeukinesargramostimnebulizerPartner therapeuticsTreating acute hypoxemiaPhase II[384]Table 7Plant based SARS-CoV-2 vaccine candidates.Table 7VaccinePlant HostVaccine AntigenTrial status/IDReferencesCoVLPTransient expression in N. benthamianaSARS-CoV-2 S protein/ Viral like particle based vaccinePhase 3NCT04636697[435]KBP-201Transient expression in N. benthamianaSARS-CoV-2 RBD-based vaccinePhase 1/2NCT04473690[436]IBIO-200Transient expression in N. benthamianaSARS-CoV-2 Viral like particle based vaccinePre-clinical study[437]IBIO-201Transient expression in N. benthamianaSARS-CoV-2 Spike-based sub-unit vaccinePre-clinical study[437]IBIO-202Transient expression in N. benthamianaSARS-CoV-2 nucleocapsid protein-based sub-unit vaccinePre-clinical study[437]Recombinant SARS-CoV-2 and RBD proteinTransient expression in N. benthamianaRBDResearch[438]Recombinant SARS-CoV-2 and N proteinTransient expression in N. benthamianaN proteinResearch[438]N/M protein based vaccineTransient expression in N. benthamianaRecombinant SARS-CoV N and M proteinResearch[439]Baiya SARS-CoV-2 Vax 1Transient expression in N. benthamianaProtein subunit vaccine/ SARS-CoV N and M proteinPre-clinical study[440]Nucleocapsid SARS-CoVTransient expression in N. benthamianaSARS-CoV nucleocapsid proteinPre-clinical study[441]SARS-CoV S1 protein fusionTransient expression in N. benthamianaSARS-CoV S1-GFP fusion proteinResearch[442]SARS-CoV S1 protein based vaccineStable expression in tomatoSARS-CoV S1 proteinPre-clinical study[443]RBD - receptor binding domain (RBD), GFP - green fluorescent protein.Table 8Overview of the vaccine production for SARS-CoV-2 treatment.",PMC8545698
Gamma,"Hence, IVM causes hyperpolarization by triggering gamma amino butyric acid (GABA)-gated-Cl− channels and paralyses the infesting organism [340].",PMC8545698
Beta,"We show, in macaques immunized with Wu-Hu-1 spike, that a single dose of adjuvanted beta variant receptor binding domain (RBD) protein broadens neutralizing antibody responses to heterologous VOCs.",PMC8536561
B.1.351,"Of particular concern is the surge of variants harboring spike mutations that confer resistance to prior immunity, such as 501Y.V2 (B.1.351, “beta”).8, 9, 10, 11 This underpins the substantially reduced vaccine efficacies observed in trials in South Africa, where this variant was circulating at high frequency.12,13 Recently, significant numbers of vaccine breakthrough infections have been observed during infection waves dominated by the delta (B.1.617.2) variant, which also displays reduced sensitivity to neutralization.14, 15, 16 Updated vaccines are likely required to protect against current and future mutated variants.",PMC8536561
B.1.617.2,"Of particular concern is the surge of variants harboring spike mutations that confer resistance to prior immunity, such as 501Y.V2 (B.1.351, “beta”).8, 9, 10, 11 This underpins the substantially reduced vaccine efficacies observed in trials in South Africa, where this variant was circulating at high frequency.12,13 Recently, significant numbers of vaccine breakthrough infections have been observed during infection waves dominated by the delta (B.1.617.2) variant, which also displays reduced sensitivity to neutralization.14, 15, 16 Updated vaccines are likely required to protect against current and future mutated variants.",PMC8536561
Alpha,"(C) Heterotypic RBD boost also restored the reduced neutralizing antibody titers against VOCs alpha (green), gamma (yellow), and delta (orange) as well as improved the neutralization of the more distantly related SARS-CoV-1 (open circles).",PMC8536561
Gamma,"(C) Heterotypic RBD boost also restored the reduced neutralizing antibody titers against VOCs alpha (green), gamma (yellow), and delta (orange) as well as improved the neutralization of the more distantly related SARS-CoV-1 (open circles).",PMC8536561
P.1,"Thus, although a heterotypic RBD boost elicits potent cross-neutralizing responses, further work is required to quantify the benefits of this approach over a third homotypic spike (or RBD) boost..


REAGENT or RESOURCESOURCEIDENTIFIERBacterial and virus strainsWild-type SARS-CoV-2 isolateJonas KlingströmN/A501Y.V2 isolateAlex SigalCele et al.34Biological samplesPlasma from NHPsThis studyN/AChemicals, peptides, and recombinant proteinsRecombinant SARS-CoV-2 WT SpikeThis studyN/ARecombinant SARS-CoV-2 501Y.V2 RBDThis studyN/APolyethylenimineSigma-AldrichCat# 764604Matrix-MNovavax ABN/ALipofectamine 3000InvitrogenCat# L3000075Bright-Glo Luciferase Assay SystemPromegaCat# E2620TRIzol ReagentThermo Fisher ScientificCat# 15596026GlycoBlue CoprecipitantThermo Fisher ScientificCat# AM9515SuperScript III One-Step RT-PCR System with Platinum Taq DNA PolymeraseThermo Fisher ScientificCat# 12574018mMESSAGE mMACHINE T7 Transcription KitThermo Fisher ScientificCat# AM1344GIBCO FreeStyle MAX ReagentThermo Fisher ScientificCat# 16447100Gibson Assembly MastermixNew England BiolabsCat# E2611SDeposited dataSARS-CoV-2 lineage metadataGISAIDhttps://www.gisaid.orgExperimental models: cell linesHuman: GIBCO FreeStyle 293-F cellsThermo Fisher ScientificCat# R79009Human: HEK293T-ACE2Hanke et al.35N/AHuman: Calu-3Jonas KlingströmN/AAfrican Green Monkey: Vero E6 cellATCCCat# CRL-1586; RRID: CVCL_0574Experimental models: organisms/strainsNHP: Macaca mulattaN/AN/AMouse: K18-hACE2Jackson Laboratory, McCray et al.24Cat# 034860; RRID: MSR_JAX:034860OligonucleotidesgBlocks Gene FragmentsIntegrated DNA TechnologiesN/ARecombinant DNASARS-CoV-2 Spike ectodomain plasmid (expression)Hsieh et al.36Addgene: 154754; RRID: Addgene_154754SARS-CoV-2 B.1.351/501Y.V2 RBD plasmidThis studyN/ASARS-CoV-2 WT Spike plasmidJames VossRogers et al.37SARS-CoV-2 B.1.1.7 Spike plasmidDavid NemazeeAddgene: 170451; RRID: Addgene_170451SARS-CoV-2 B.1.351 Spike plasmidPenny MooreWibmer et al.38SARS-CoV-2 P.1 Spike plasmidDavid NemazeeAddgene: 170450; RRID: Addgene_170450SARS-CoV-2 B.1.617.2 Spike plasmidG2P-UK National Virology consortiumSpencer et al.39SARS-CoV-1 Spike plasmidJames VossRogers et al.37Lentiviral backbone: pCMV delta R8.2Bob WeinbergAddgene: 8455; RRID: Addgene_8455Luciferase transfer plasmidJames VossRogers et al.37Software and algorithmsGraphPad Prism v9.0.0GraphPad Software Inc.https://www.graphpad.com/scientific-software/prism/; RRID: SCR_002798Julia v1.6The Julia Programming Languagehttps://julialang.org/Non-linear Multinomial Regression for VOC frequency estimationThis studyhttps://github.com/MurrellGroup/VOCfreq; https://doi.org/10.5281/zenodo.5562800OtherHiLoad® 16/600 Superdex® 200 pgCytiviaCat# 28-9893-35His-Pur Ni-NTA resinThermo Fisher ScientificCat# 88222
.",PMC8536561
B.1.1.7,"Thus, although a heterotypic RBD boost elicits potent cross-neutralizing responses, further work is required to quantify the benefits of this approach over a third homotypic spike (or RBD) boost..


REAGENT or RESOURCESOURCEIDENTIFIERBacterial and virus strainsWild-type SARS-CoV-2 isolateJonas KlingströmN/A501Y.V2 isolateAlex SigalCele et al.34Biological samplesPlasma from NHPsThis studyN/AChemicals, peptides, and recombinant proteinsRecombinant SARS-CoV-2 WT SpikeThis studyN/ARecombinant SARS-CoV-2 501Y.V2 RBDThis studyN/APolyethylenimineSigma-AldrichCat# 764604Matrix-MNovavax ABN/ALipofectamine 3000InvitrogenCat# L3000075Bright-Glo Luciferase Assay SystemPromegaCat# E2620TRIzol ReagentThermo Fisher ScientificCat# 15596026GlycoBlue CoprecipitantThermo Fisher ScientificCat# AM9515SuperScript III One-Step RT-PCR System with Platinum Taq DNA PolymeraseThermo Fisher ScientificCat# 12574018mMESSAGE mMACHINE T7 Transcription KitThermo Fisher ScientificCat# AM1344GIBCO FreeStyle MAX ReagentThermo Fisher ScientificCat# 16447100Gibson Assembly MastermixNew England BiolabsCat# E2611SDeposited dataSARS-CoV-2 lineage metadataGISAIDhttps://www.gisaid.orgExperimental models: cell linesHuman: GIBCO FreeStyle 293-F cellsThermo Fisher ScientificCat# R79009Human: HEK293T-ACE2Hanke et al.35N/AHuman: Calu-3Jonas KlingströmN/AAfrican Green Monkey: Vero E6 cellATCCCat# CRL-1586; RRID: CVCL_0574Experimental models: organisms/strainsNHP: Macaca mulattaN/AN/AMouse: K18-hACE2Jackson Laboratory, McCray et al.24Cat# 034860; RRID: MSR_JAX:034860OligonucleotidesgBlocks Gene FragmentsIntegrated DNA TechnologiesN/ARecombinant DNASARS-CoV-2 Spike ectodomain plasmid (expression)Hsieh et al.36Addgene: 154754; RRID: Addgene_154754SARS-CoV-2 B.1.351/501Y.V2 RBD plasmidThis studyN/ASARS-CoV-2 WT Spike plasmidJames VossRogers et al.37SARS-CoV-2 B.1.1.7 Spike plasmidDavid NemazeeAddgene: 170451; RRID: Addgene_170451SARS-CoV-2 B.1.351 Spike plasmidPenny MooreWibmer et al.38SARS-CoV-2 P.1 Spike plasmidDavid NemazeeAddgene: 170450; RRID: Addgene_170450SARS-CoV-2 B.1.617.2 Spike plasmidG2P-UK National Virology consortiumSpencer et al.39SARS-CoV-1 Spike plasmidJames VossRogers et al.37Lentiviral backbone: pCMV delta R8.2Bob WeinbergAddgene: 8455; RRID: Addgene_8455Luciferase transfer plasmidJames VossRogers et al.37Software and algorithmsGraphPad Prism v9.0.0GraphPad Software Inc.https://www.graphpad.com/scientific-software/prism/; RRID: SCR_002798Julia v1.6The Julia Programming Languagehttps://julialang.org/Non-linear Multinomial Regression for VOC frequency estimationThis studyhttps://github.com/MurrellGroup/VOCfreq; https://doi.org/10.5281/zenodo.5562800OtherHiLoad® 16/600 Superdex® 200 pgCytiviaCat# 28-9893-35His-Pur Ni-NTA resinThermo Fisher ScientificCat# 88222
.",PMC8536561
B.1.617.2,Epidemiological data demonstrate that SARS-CoV-2 variants of concern (VOC) B.1.1.7 and B.1.617.2 are more transmissible and infections are associated with a higher mortality than non-VOC virus infections.,PPR416637
B.1.1.7,Epidemiological data demonstrate that SARS-CoV-2 variants of concern (VOC) B.1.1.7 and B.1.617.2 are more transmissible and infections are associated with a higher mortality than non-VOC virus infections.,PPR416637
B.1,"B.1.1.7 virus isolates displayed inferior or equivalent spread in most cell lines and primary cells compared to an ancestral B.1 SARS-CoV-2, and were outcompeted by the latter.",PPR416637
Alpha,"The B.1.1.7 lineage was labeled Alpha as it was the first variant of concern (VOC) (O’Toole et al., 2021).",PPR416637
B.1.351,"In accordance with reports by others (Bates et al., 2021; Supasa et al., 2021; Widera et al., 2021), B.1 infection- and vaccination-induced antibodies efficiently neutralized both B.1 and B.1.1.7 in a plaque reduction neutralization test, whereas such antibodies failed to effectively neutralize B.1.351 (Fig.",PPR416637
P.3,"Briefly, cells were expanded using the conditionally reprogrammed cell (CRC) culture method, then p.2 or p.3 cells were seeded on porous Transwell or Snapwell 1.1 cm2 supports (Corning) in UNC-ALI medium and differentiated at air-liquid interface for at least three weeks prior to infection.",PPR416637
P.2,"Briefly, cells were expanded using the conditionally reprogrammed cell (CRC) culture method, then p.2 or p.3 cells were seeded on porous Transwell or Snapwell 1.1 cm2 supports (Corning) in UNC-ALI medium and differentiated at air-liquid interface for at least three weeks prior to infection.",PPR416637
B.1.351,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
P.1,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
B.1.617,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
B.1.1.7,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with comparable potency.",PMC8528426
Alpha,"One such variant, B.1.1.7 (World Health Organization classification: Alpha), emerged from southeast England in October 2020 and accounted for two-thirds of new infections in London in December 2020, with a higher transmission rate (43 to 90%) and risk of mortality (32 to 104%) than previously circulating strains (7, 8).",PMC8528426
Beta,"Other variants, such as B.1.351 (Beta) and P.1 (Gamma), also became prevalent in three provinces in South Africa and Manaus, Brazil, respectively (6, 9, 10).",PMC8528426
Gamma,"Other variants, such as B.1.351 (Beta) and P.1 (Gamma), also became prevalent in three provinces in South Africa and Manaus, Brazil, respectively (6, 9, 10).",PMC8528426
B.1.617.2,"The B.1.617.2 (Delta) variant, which was initially identified in India, has become a dominant strain in many countries (11, 12) and responsible for most of the new COVID-19 cases.",PMC8528426
Alpha,"Specifically, investigative criteria include a positive RT-PCR test more than 90 days after the initial test in healed patients or a positive RT-PCR test more than 45 days after the initial test that is accompanied by compatible symptoms or epidemiological exposure, after confirmed healing..

Another emerging problem that can influence the possibility of reinfection and the vaccination efficacity is the new variants of SARS-CoV-2, such us alpha, beta, gamma and delta.",PMC8535385
Beta,"Specifically, investigative criteria include a positive RT-PCR test more than 90 days after the initial test in healed patients or a positive RT-PCR test more than 45 days after the initial test that is accompanied by compatible symptoms or epidemiological exposure, after confirmed healing..

Another emerging problem that can influence the possibility of reinfection and the vaccination efficacity is the new variants of SARS-CoV-2, such us alpha, beta, gamma and delta.",PMC8535385
Gamma,"Specifically, investigative criteria include a positive RT-PCR test more than 90 days after the initial test in healed patients or a positive RT-PCR test more than 45 days after the initial test that is accompanied by compatible symptoms or epidemiological exposure, after confirmed healing..

Another emerging problem that can influence the possibility of reinfection and the vaccination efficacity is the new variants of SARS-CoV-2, such us alpha, beta, gamma and delta.",PMC8535385
B.1.617.2,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
B.1.1.7,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
B.1.351,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
P.1,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176].",PMC8535385
Alpha,"The dynamics of SARS-CoV-2 alpha variant shedding and immune responses at the nasal mucosa remain poorly characterised..

We measured infectious viral release, antibodies and cytokines in 426 PCR+ nasopharyngeal swabs from individuals harboring non-alpha or alpha variants..

With both lineages, viral titers were variable, ranging from 0 to >106 infectious units.",PMC8526063
B.1.1.7,"The alpha variant (B.1.1.7), initially detected in UK at the end of 2020, displayed a 43-90% higher reproduction number than pre-existing variants.",PMC8526063
B.1.617.2,"Currently, four variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) and several variants of interests (B.1.526, B.1.525, and P.2) are characterized and are essential for close monitoring.",PMC8537675
B.1.525,"Currently, four variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) and several variants of interests (B.1.526, B.1.525, and P.2) are characterized and are essential for close monitoring.",PMC8537675
B.1.1.7,"Currently, four variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) and several variants of interests (B.1.526, B.1.525, and P.2) are characterized and are essential for close monitoring.",PMC8537675
P.2,"Currently, four variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) and several variants of interests (B.1.526, B.1.525, and P.2) are characterized and are essential for close monitoring.",PMC8537675
B.1.351,"Currently, four variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) and several variants of interests (B.1.526, B.1.525, and P.2) are characterized and are essential for close monitoring.",PMC8537675
P.1,"Currently, four variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) and several variants of interests (B.1.526, B.1.525, and P.2) are characterized and are essential for close monitoring.",PMC8537675
B.1.526,"Currently, four variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) and several variants of interests (B.1.526, B.1.525, and P.2) are characterized and are essential for close monitoring.",PMC8537675
A.1,"The additional SAR-CoV-2 genomes, which descend from either lineage A or lineage B, are designated a numerical value, for example, lineage A.1 or lineage B.2.",PMC8537675
C.2,"These designations can proceed for a maximum of three sublevels (e.g., A.1.1.1), after which new descendent lineages are given a letter (in English alphabetical sequence from C, so A.1.1.1.1 would become C.1 and A.1.1.1.2 would become C.2).",PMC8537675
C.1,"These designations can proceed for a maximum of three sublevels (e.g., A.1.1.1), after which new descendent lineages are given a letter (in English alphabetical sequence from C, so A.1.1.1.1 would become C.1 and A.1.1.1.2 would become C.2).",PMC8537675
B.1,"Demonstrate a bootstrap value >70% for the lineage-defining node..

As of September 2021, lineage B and its sub-lineage B.1 appears to be the most prevalent worldwide.",PMC8537675
B.1.427,"The other variants include B.1.351, P.1 (B.1.1.28.1), and B.1.617.2 (the B.1.427 and B.1.429 variants have been de-escalated due to low prevalence).",PMC8537675
B.1.429,"The other variants include B.1.351, P.1 (B.1.1.28.1), and B.1.617.2 (the B.1.427 and B.1.429 variants have been de-escalated due to low prevalence).",PMC8537675
Alpha,"The B.1.1.7 variant, also known as Alpha, VOC 202012/01, or 20B/501Y.V1, was first reported as a new SARS-CoV-2 variant by the United Kingdom in December 2020 [63,64].",PMC8537675
Beta,"The B.1.351 variant, also recognized as Beta or 20H/501Y.V2, was initially identified in December 2020 in South Africa and became the dominant circulating variant in the region.",PMC8537675
Gamma,"The P.1 variant, also known as Gamma or B.1.1.28.1, was initially first detected in Japan and was later identified in Brazil in January 2021, where it has become the dominant circulating virus [89].",PMC8537675
B.1.1.28,The P.1 variant belongs to the B.1.1.28 lineage.,PMC8537675
B.1.617,"The B.1.617 variant, also known as G/452R.V3, was first detected in India and has been become the dominant strain across India, other Southeast Asian countries, and the United Kingdom.",PMC8537675
B.1.617.1,"This variant contains three sublineages, including B.1.617.1, B.1.617.2 (Delta), and B.1.617.3.",PMC8537675
B.1.617.3,"The B.1.617.3 was the first sublineage to be identified in October 2020 in India and is relatively uncommon compared to the other two sub-lineages, B.1.617.1 and B.1.617.2, which were first detected in December 2020.",PMC8537675
Kappa,"Interim immunogenicity data for the Ad26.COV2.S vaccine showed humoral neutralizing antibody responses against wild type as well as B.1.1.7, B.1.617.1 (kappa), B.1.617.2, P.1, B.1.429, and B.1.351 to be similar after eight months of Ad26.COV2.S vaccine. .

B.1.351 variant: The B.1.351 variants containing the Spike K417N/T, E484K, and N501Y RBD mutations showed significantly decreased neutralization even in fully vaccinated individuals [84].",PMC8537675
Eta,"Classification of SARS-CoV-2 Variants..

• B.1.525 (Eta).",PMC8537675
Iota,• B.1.526 (Iota).,PMC8537675
C.37,• C.37 (Lambda) ^.,PMC8537675
Lambda,• C.37 (Lambda) ^.,PMC8537675
Mu,• B.1.621 (Mu) #.,PMC8537675
B.1.621,• B.1.621 (Mu) #.,PMC8537675
Gamma,"As a proof-of-concept, we incorporated BrCas12b into an RT-LAMP-mediated one-pot reaction system, coined CRISPR-SPADE (CRISPR Single Pot Assay for Detecting Emerging VOCs) to enable rapid, differential detection of SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) in 205 clinical samples.",PPR408586
B.1.617.2,"As a proof-of-concept, we incorporated BrCas12b into an RT-LAMP-mediated one-pot reaction system, coined CRISPR-SPADE (CRISPR Single Pot Assay for Detecting Emerging VOCs) to enable rapid, differential detection of SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) in 205 clinical samples.",PPR408586
B.1.1.7,"As a proof-of-concept, we incorporated BrCas12b into an RT-LAMP-mediated one-pot reaction system, coined CRISPR-SPADE (CRISPR Single Pot Assay for Detecting Emerging VOCs) to enable rapid, differential detection of SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) in 205 clinical samples.",PPR408586
Alpha,"As a proof-of-concept, we incorporated BrCas12b into an RT-LAMP-mediated one-pot reaction system, coined CRISPR-SPADE (CRISPR Single Pot Assay for Detecting Emerging VOCs) to enable rapid, differential detection of SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) in 205 clinical samples.",PPR408586
B.1.351,"As a proof-of-concept, we incorporated BrCas12b into an RT-LAMP-mediated one-pot reaction system, coined CRISPR-SPADE (CRISPR Single Pot Assay for Detecting Emerging VOCs) to enable rapid, differential detection of SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) in 205 clinical samples.",PPR408586
P.1,"As a proof-of-concept, we incorporated BrCas12b into an RT-LAMP-mediated one-pot reaction system, coined CRISPR-SPADE (CRISPR Single Pot Assay for Detecting Emerging VOCs) to enable rapid, differential detection of SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) in 205 clinical samples.",PPR408586
Beta,"As a proof-of-concept, we incorporated BrCas12b into an RT-LAMP-mediated one-pot reaction system, coined CRISPR-SPADE (CRISPR Single Pot Assay for Detecting Emerging VOCs) to enable rapid, differential detection of SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) in 205 clinical samples.",PPR408586
Beta,"Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta).",PMC8556155
Alpha,"Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta).",PMC8556155
B.1.1.7,"Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta).",PMC8556155
B.1.617.2,"We also compared the cross-neutralizing activity of wave 1 sera with sera from individuals infected with the Alpha, the Beta or the B.1.617.2 (Delta) variants up to 79 days post onset of symptoms.",PMC8556155
Gamma,"In the absence of current long-term COVID-19 vaccine follow-up, knowledge of the longevity of the neutralizing antibody response acquired through natural infection with ancestral SARS-CoV-2 during wave 1 of the COVID-19 pandemic at late time points (up to 10 months POS) may provide important indicators for the durability of vaccine-induced humoral immunity..

SARS-CoV-2 variants encoding mutations in the spike protein have been identified and include B.1.1.7 (Alpha variant, initially reported in the United Kingdom)13, P.1 (Gamma variant, first reported in Brazil), B.1.351 (Beta variant, first reported in South Africa)14 and B.1.617.2 (Delta variant, first reported in India)15, which have been associated with more efficient transmission16–18.",PMC8556155
B.1.351,"In the absence of current long-term COVID-19 vaccine follow-up, knowledge of the longevity of the neutralizing antibody response acquired through natural infection with ancestral SARS-CoV-2 during wave 1 of the COVID-19 pandemic at late time points (up to 10 months POS) may provide important indicators for the durability of vaccine-induced humoral immunity..

SARS-CoV-2 variants encoding mutations in the spike protein have been identified and include B.1.1.7 (Alpha variant, initially reported in the United Kingdom)13, P.1 (Gamma variant, first reported in Brazil), B.1.351 (Beta variant, first reported in South Africa)14 and B.1.617.2 (Delta variant, first reported in India)15, which have been associated with more efficient transmission16–18.",PMC8556155
P.1,"In the absence of current long-term COVID-19 vaccine follow-up, knowledge of the longevity of the neutralizing antibody response acquired through natural infection with ancestral SARS-CoV-2 during wave 1 of the COVID-19 pandemic at late time points (up to 10 months POS) may provide important indicators for the durability of vaccine-induced humoral immunity..

SARS-CoV-2 variants encoding mutations in the spike protein have been identified and include B.1.1.7 (Alpha variant, initially reported in the United Kingdom)13, P.1 (Gamma variant, first reported in Brazil), B.1.351 (Beta variant, first reported in South Africa)14 and B.1.617.2 (Delta variant, first reported in India)15, which have been associated with more efficient transmission16–18.",PMC8556155
B.1.351,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
P.1,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
B.1.427,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
B.1.526,"We and others have shown that some variants such as B.1.351 [6], P.1 [7], B.1.526 [8] and B.1.427/B.1.429 [9] are more resistant to neutralization by some mAbs, as well as by sera from convalescent patients and vaccinees.",PPR407661
B.1.1.7,"The SARS-CoV-2 viruses USA-WA1/2020 (WA1), hC0V-19/USA/CACDC_5574/2020 (B.1.1.7), hCoV-19/South Africa/KRISP-K005325/2020 (B.1.351), hCoV-19/Japan/TY7-503/2021 (P.1), and hCoV-19/USA/NY-NP-DOH1/2021 (B.1.526) were obtained from BEI Resources (NIAID, NIH).",PPR407661
B.1.1.1,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
R.1,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.617.2,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.617.1,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.525,"Here we assessed 2-36 activity on more variants, including pseudoviruses representing the combination of key spike mutations of B.1.427/B.1.429, R.1, B.1.1.1, B.1.525, B.1.617.1, B.1.617.2 and B.1.1.7 with E484K, as well as many pseudoviruses with single spike mutations which are naturally circulating in COVID-19 patients with high frequency and located in the N-terminal domain, RBD, or S2.",PPR407661
B.1.1.7,In vitro mutagenesis assays show that mutant residues found in the emerging new lineage B.1.1.7 of SARS-CoV-2 do not affect nCoV617 binding to the S-RBD.,PMC8515945
B.1.617,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html).",PMC8515945
B.1.1.28,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html).",PMC8515945
B.1.351,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html).",PMC8515945
P.1,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html).",PMC8515945
B.1.617.2,"Our results have revealed the neutralizing mechanism of the NAb nCoV617, which may benefit both prophylactic and therapeutic interventions for the newly emerging SARS-CoV-2 lineage B.1.1.7 and provide effective options for comprehensive antibody therapy, but for the lineages B.1.351, B.1.1.28, B.1.617, and B.1.617.2, the effect of nCoV617 may be greatly reduced.",PMC8515945
Lambda,"HEK-293T cells in 12-well plates were transfected with the assembled Ig heavy- and light-chain pairs derived from the same single individual plasma cells using Effectene (Qiagen) as the transfection reagent (45)..

For production of purified full-length IgG1 antibodies, the VHDJH and VL genes were cloned into the pCDNA3.1+ (Invitrogen) mammalian expression vector containing either the human IgG1 constant region gene, the human lambda light-chain constant region, or the lambda light-chain constant region gene using standard recombinant DNA technology (45).",PMC8515945
Beta,"Fold-change (relative to beta actin) for IA mRNA in M0, M1 and M2 cells from C5024T (n=4) and WT (n=4) mice (right-hand panel).",PPR404842
Kappa,The E484Q mutation was detected in 10 specimens of the Kappa variant (B.1.627.1).,PMC8487322
Alpha,"In September 2020, the B.1.1.7 lineage emerged as a variant of concern in the United Kingdom (UK), subsequently termed the alpha variant, with 9 spike protein mutations (del69/70HV, del144Y, N501Y, A570D, D614G, P681H, T761I, S982A, and D1118H) [4,5].",PMC8487322
B.1.1.7,"In September 2020, the B.1.1.7 lineage emerged as a variant of concern in the United Kingdom (UK), subsequently termed the alpha variant, with 9 spike protein mutations (del69/70HV, del144Y, N501Y, A570D, D614G, P681H, T761I, S982A, and D1118H) [4,5].",PMC8487322
B.1.351,"Two subsequent variants of concern, B.1.351 (beta variant), first identified in South Africa, and P.1 (gamma variant), first identified in Brazil, were found to harbor the D614G and N501Y mutations, as well as 2 additional key mutations in the receptor binding domain (RBD), K417N/T and E484K, which increase binding affinity to the ACE2 receptor [14].",PMC8487322
P.1,"Two subsequent variants of concern, B.1.351 (beta variant), first identified in South Africa, and P.1 (gamma variant), first identified in Brazil, were found to harbor the D614G and N501Y mutations, as well as 2 additional key mutations in the receptor binding domain (RBD), K417N/T and E484K, which increase binding affinity to the ACE2 receptor [14].",PMC8487322
Beta,"Two subsequent variants of concern, B.1.351 (beta variant), first identified in South Africa, and P.1 (gamma variant), first identified in Brazil, were found to harbor the D614G and N501Y mutations, as well as 2 additional key mutations in the receptor binding domain (RBD), K417N/T and E484K, which increase binding affinity to the ACE2 receptor [14].",PMC8487322
Gamma,"Two subsequent variants of concern, B.1.351 (beta variant), first identified in South Africa, and P.1 (gamma variant), first identified in Brazil, were found to harbor the D614G and N501Y mutations, as well as 2 additional key mutations in the receptor binding domain (RBD), K417N/T and E484K, which increase binding affinity to the ACE2 receptor [14].",PMC8487322
B.1.617.2,"Recently, variant delta (B.1.617.2), first identified in India, has rapidly spread in England and Scotland where it has outcompeted the variant alpha [19], [20], [21], [22].",PMC8487322
Iota,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
C.37,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
B.1.617.1,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
B.1.525,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
B.1.526,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
Eta,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
Lambda,"Other lineages, such as variant of interest (VOI) B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda) also harbor mutations that are predicted to affect transmission, replication, and escape immunity [5,24].",PMC8487322
P.2,This class includes B.1.427/B.1.429 and P.2 variants.,PMC8487322
B.1.427,This class includes B.1.427/B.1.429 and P.2 variants.,PMC8487322
B.1.438.1,The occasional mutation E484K reported in multiple lineages was only detected in the B.1.438.1 lineage where 8 out of 15 specimens had that specific mutation.,PMC8487322
R.1,"This adds to existing literature, with only one other recent study reporting use of the Allplex™ SARS-CoV-2 Variants I assay on 30 nasopharyngeal swab specimens, where 4 variants belonging to R.1 lineage were detected [29].",PMC8487322
P.3,"The SARS-CoV-2 mutations targeted by the Allplex assay are currently found in VOC lineages B.1.1.7, P1, B.1.351 and VOI lineages P.2, P.3, B.1.525, B.1.526 and R.1.",PMC8487322
B.1.177.50,"All lineages that were identified belonged to lineage B.1, of these 37 (42%) belonged to lineage B.1.221, 10 (11.3%) to lineage B.1.177.50, and nine (10.2%) to lineage B.1.160..

Phylogenetic analysis of conjunctival samples (C) and nasopharyngeal samples (N) from eight matched individuals..

Conjunctival and nasopharyngeal samples of subjects 116, 310, 312, and 394 were grouped in clade 20E (EU1) and carried no mutations between matched samples.",PMC8543390
B.1,"All lineages that were identified belonged to lineage B.1, of these 37 (42%) belonged to lineage B.1.221, 10 (11.3%) to lineage B.1.177.50, and nine (10.2%) to lineage B.1.160..

Phylogenetic analysis of conjunctival samples (C) and nasopharyngeal samples (N) from eight matched individuals..

Conjunctival and nasopharyngeal samples of subjects 116, 310, 312, and 394 were grouped in clade 20E (EU1) and carried no mutations between matched samples.",PMC8543390
B.1.221,"All lineages that were identified belonged to lineage B.1, of these 37 (42%) belonged to lineage B.1.221, 10 (11.3%) to lineage B.1.177.50, and nine (10.2%) to lineage B.1.160..

Phylogenetic analysis of conjunctival samples (C) and nasopharyngeal samples (N) from eight matched individuals..

Conjunctival and nasopharyngeal samples of subjects 116, 310, 312, and 394 were grouped in clade 20E (EU1) and carried no mutations between matched samples.",PMC8543390
B.1.177,"Identified lineages from these samples belonged to lineages B.1.177, B.1.177.50, W.2 (alias B.1.177.53.2), and B.1.177.36, respectively.",PMC8543390
B.1.177.36,"Identified lineages from these samples belonged to lineages B.1.177, B.1.177.50, W.2 (alias B.1.177.53.2), and B.1.177.36, respectively.",PMC8543390
W.2,"Identified lineages from these samples belonged to lineages B.1.177, B.1.177.50, W.2 (alias B.1.177.53.2), and B.1.177.36, respectively.",PMC8543390
B.1.258,"The nasopharyngeal sample of subject 159 was included in lineage B.1.258, whereas the analysis for the conjunctival sample failed.",PMC8543390
B.1.160,"The most common lineages from these samples correspond to lineages B.1.221 (49.3%), B.1.177 (19.2%), and B.1.160 (9.6%).",PMC8543390
Alpha,"Vaccine breakthrough by a highly transmissible SARS-CoV-2 strain is a risk to global public health..

Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) by qPCR (quantitative polymerase chain reaction) for Wuhan-Hu1 and alpha variant.",PMC8483940
B.1.617.2,Viral sequencing revealed an infection cluster of 6 vaccinated patients infected with the delta (B.1.617.2) SARS-CoV-2 variant.,PMC8483940
Epsilon,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.617.1,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
Iota,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.1.7,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
Kappa,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
P.1,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
Beta,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
Gamma,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.351,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.429,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.526,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
Alpha,"We found that the COVID-19 global epidemic clearly featured increasing circulation of Alpha since the start of 2021, which was rapidly replaced by the Delta variant starting around May 2021.",PPR401806
Gamma,"Some SARS-CoV-2 variants disappeared immediately, while others characterized by several key mutations adapted well, enabling their rapid spread
1
. WHO has designated four Variants of Concern (VOCs) associated with increased transmissibility and various extents of immune escape
2–4
, namely the Alpha, Beta, Gamma, and Delta variants, first detected in the UK, South Africa, Brazil, and India, respectively
5
.",PPR401806
Beta,"Some SARS-CoV-2 variants disappeared immediately, while others characterized by several key mutations adapted well, enabling their rapid spread
1
. WHO has designated four Variants of Concern (VOCs) associated with increased transmissibility and various extents of immune escape
2–4
, namely the Alpha, Beta, Gamma, and Delta variants, first detected in the UK, South Africa, Brazil, and India, respectively
5
.",PPR401806
Iota,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 20 September 2021
5
.",PPR401806
Mu,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 20 September 2021
5
.",PPR401806
Eta,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 20 September 2021
5
.",PPR401806
Kappa,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 20 September 2021
5
.",PPR401806
Lambda,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 20 September 2021
5
.",PPR401806
A.1,"Reference strains includes lineage A, A.1, B, and B.1; the sub-lineages of four VOCs are aggregated with the parent lineages.",PPR401806
B.1.621,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR401806
C.37,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR401806
B.1.617.1,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR401806
B.1.525,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR401806
B.1.526,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR401806
Beta,"Thus, 20C for some time appeared well on its way to becoming the dominant variant in North America, and may have been at a competitive advantage compared to other early descendants of A1, but it has been losing ground to the well-documented Greek-letter variants (Alpha, Beta, Delta, etc.)",PPR401603
Alpha,"Thus, 20C for some time appeared well on its way to becoming the dominant variant in North America, and may have been at a competitive advantage compared to other early descendants of A1, but it has been losing ground to the well-documented Greek-letter variants (Alpha, Beta, Delta, etc.)",PPR401603
B.1.1.7,"The revisions have greatly improved the manuscript, and the reviewers and I ask only that small changes be made for clarity, to help future readers..

1) As suggested by reviewer 2, please mention the lack of information on face mask usage in index cases and the impact this might have on the results..

2) As suggested by reviewer 1 (point 2), please reconsider whether the data have sufficient power to demonstrate saturation and revise accordingly..

3) Please also consider the conflicting evidence on B.1.1.7 viral loads (reviewer 1, point 3)..


Reviewer #1:
.",PMC8476126
P.1,"Naveca, F. G. et al., COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence.",PMC8476126
B.1.1.7,"This is a variant of B.1.1.7 strain and most of the new mutations in this variant occurred in the S gene. .

During uncontrolled viral replication, as found in a large pandemic, viral variants can emerge if they provide either increased infectivity, immune escape, or both.",PMC8537260
Alpha,"Four notable variants of concern have been described to date, including the alpha variant (also known as B.1.1.7, 20I/501Y.V1, VOC 202012/01, or the UK variant), the beta variant (also known as B.1.351, 20H/501Y.V2, or the South African variant), the gamma variant (also known as P.1, GR/501Y.V3 or the Brazilian variant), and the delta variant (also known as B.1.671.2, G/478K.V1 or the Indian variant (Table 1 and Table 2). .",PMC8537260
Beta,"Four notable variants of concern have been described to date, including the alpha variant (also known as B.1.1.7, 20I/501Y.V1, VOC 202012/01, or the UK variant), the beta variant (also known as B.1.351, 20H/501Y.V2, or the South African variant), the gamma variant (also known as P.1, GR/501Y.V3 or the Brazilian variant), and the delta variant (also known as B.1.671.2, G/478K.V1 or the Indian variant (Table 1 and Table 2). .",PMC8537260
B.1.351,"Four notable variants of concern have been described to date, including the alpha variant (also known as B.1.1.7, 20I/501Y.V1, VOC 202012/01, or the UK variant), the beta variant (also known as B.1.351, 20H/501Y.V2, or the South African variant), the gamma variant (also known as P.1, GR/501Y.V3 or the Brazilian variant), and the delta variant (also known as B.1.671.2, G/478K.V1 or the Indian variant (Table 1 and Table 2). .",PMC8537260
P.1,"Four notable variants of concern have been described to date, including the alpha variant (also known as B.1.1.7, 20I/501Y.V1, VOC 202012/01, or the UK variant), the beta variant (also known as B.1.351, 20H/501Y.V2, or the South African variant), the gamma variant (also known as P.1, GR/501Y.V3 or the Brazilian variant), and the delta variant (also known as B.1.671.2, G/478K.V1 or the Indian variant (Table 1 and Table 2). .",PMC8537260
Gamma,"Four notable variants of concern have been described to date, including the alpha variant (also known as B.1.1.7, 20I/501Y.V1, VOC 202012/01, or the UK variant), the beta variant (also known as B.1.351, 20H/501Y.V2, or the South African variant), the gamma variant (also known as P.1, GR/501Y.V3 or the Brazilian variant), and the delta variant (also known as B.1.671.2, G/478K.V1 or the Indian variant (Table 1 and Table 2). .",PMC8537260
B.1.617.2,"In May 2021 the delta variant (B.1.617.2) emerged in India, where it is now the most frequent strain, with a reported 97% increase in transmissibility (Table 2).",PMC8537260
B.1.1.28,"E484K has been linked to cases of reinfection in Brazilian patients who had previously been infected with B.1.1.33 variant (E484) and were reinfected with variant B.1.1.28, which contains the E484K mutation [96,97].",PMC8537260
B.1.1.33,"E484K has been linked to cases of reinfection in Brazilian patients who had previously been infected with B.1.1.33 variant (E484) and were reinfected with variant B.1.1.28, which contains the E484K mutation [96,97].",PMC8537260
Theta,"Another important RBD mutation is the N501Y mutation that has been reported in alpha, beta, gamma, and other variants such as theta (P.3), B.1.x, B1.621 and A.27 variants.",PMC8537260
P.3,"Another important RBD mutation is the N501Y mutation that has been reported in alpha, beta, gamma, and other variants such as theta (P.3), B.1.x, B1.621 and A.27 variants.",PMC8537260
A.27,"Another important RBD mutation is the N501Y mutation that has been reported in alpha, beta, gamma, and other variants such as theta (P.3), B.1.x, B1.621 and A.27 variants.",PMC8537260
B.1.617.1,"on convalescent and post-vaccination (mRNA-1273 or BNT162b2) sera, reported that the majority (79%) of convalescent sera and all post-vaccination sera were able to neutralise the B.1.617.1 variant.",PMC8537260
Epsilon,"In a pseudovirus neutralisation assay, they found a 2- and 2.5-fold reduction in the neutralisation of epsilon (B.1.429) variant by sera post vaccination with mRNA-1273 or NVX-CoV2373, respectively, compared with an ancestral variant containing D614G.",PMC8537260
B.1.429,"In a pseudovirus neutralisation assay, they found a 2- and 2.5-fold reduction in the neutralisation of epsilon (B.1.429) variant by sera post vaccination with mRNA-1273 or NVX-CoV2373, respectively, compared with an ancestral variant containing D614G.",PMC8537260
B.1,"examined the ability of sera from convalescent COVID-19 patients who had subsequently been given one dose of BNT162b2 to neutralise the original B.1 virus, and the alpha, beta, and gamma variants in live virus neutralisation assays.",PMC8537260
B.1.427,"Compared with mRNA-1273, a primary two-dose vaccination course with mRNA-1273.351 resulted in a small (1.4-fold) increase in neutralising antibody tires against the beta variant but a 6.1-fold decrease in neutralising antibody titres against the wild-type (Wuhan with D614G mutation), a 2.6-fold decrease against the gamma variant, and a 3.8 fold decrease against B.1.427/B.1.429.",PMC8537260
B.1.357,"Spike protein monomer ribbon structures from (D) B.1.1.7 (UK variant/Alpha) spike structure in monomer, (E) P.1 (Brazil variant/Gamma) spike structure in monomer, (F) B.1.357 (South African variant/Beta) spike structure in monomer, and (G) B.1.617.2 (Indian variant/Delta) spike structure in monomer.",PMC8537260
B.1.35,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PMC8458290
Beta,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PMC8458290
Alpha,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PMC8458290
B.1.1.7,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PMC8458290
B.1.351,"We have explored their binding to and neutralisation of two newly emergent variants (B.1.1.7 and B.1.351), identifying a potent cross-reactive agent.",PMC8458290
P.1,"The B.1.351 (Beta variant) and P.1 (Gamma variant) lineages are characterised by three mutations (K417N, E484K and N501Y) in the RBD, which, although less prevalent, are a serious concern as they are associated with immune evasion30.",PMC8458290
Gamma,"The B.1.351 (Beta variant) and P.1 (Gamma variant) lineages are characterised by three mutations (K417N, E484K and N501Y) in the RBD, which, although less prevalent, are a serious concern as they are associated with immune evasion30.",PMC8458290
Alpha,The secondary structure prediction also suggested that the 82–94 region is a disordered structure surrounded by two alpha helices.,PMC8488371
Gamma,"Amino acid residues in common with the emerging variants of concern (Alpha (UK, B.1.1.7), Gamma (Brazil, P.1); and Beta (South Africa, B.1.351) are highlighted by a star.",PMC8496873
B.1.1.7,"Amino acid residues in common with the emerging variants of concern (Alpha (UK, B.1.1.7), Gamma (Brazil, P.1); and Beta (South Africa, B.1.351) are highlighted by a star.",PMC8496873
Alpha,"Amino acid residues in common with the emerging variants of concern (Alpha (UK, B.1.1.7), Gamma (Brazil, P.1); and Beta (South Africa, B.1.351) are highlighted by a star.",PMC8496873
B.1.351,"Amino acid residues in common with the emerging variants of concern (Alpha (UK, B.1.1.7), Gamma (Brazil, P.1); and Beta (South Africa, B.1.351) are highlighted by a star.",PMC8496873
P.1,"Amino acid residues in common with the emerging variants of concern (Alpha (UK, B.1.1.7), Gamma (Brazil, P.1); and Beta (South Africa, B.1.351) are highlighted by a star.",PMC8496873
Beta,"Amino acid residues in common with the emerging variants of concern (Alpha (UK, B.1.1.7), Gamma (Brazil, P.1); and Beta (South Africa, B.1.351) are highlighted by a star.",PMC8496873
A.27,"H655Y has been observed by others in vitro [57], associated with adaption to cats and hamsters [54,58] antibody escape [59] and, identified in the sequence of super spreaders [60] as well as arising by convergent evolution in circulating lineages (eg., P1 and A.27 lineages).",PMC8496873
Gamma,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
B.1.1.7,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
Alpha,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
B.1.351,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
P.1,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
Beta,"Some of the most consequential amino acid substitutions observed so far have occurred in the RBD, particularly N501Y in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, and the additional combination of K417N/T and E484K in the Gamma and Beta lineages.",PMC8443366
B.1.429,"The L452R substitution, detected in both the B.1.429 (Epsilon) and B.1.617.2 (Delta) variants also permits escape to monoclonal antibodies and a reduction in neutralization titer in comparison to USA-WA1 in vaccinees as well as individuals recovered from COVID-19 infection (McCallum et al., 2021; Mlcochova et al., 2021).",PMC8443366
Epsilon,"The L452R substitution, detected in both the B.1.429 (Epsilon) and B.1.617.2 (Delta) variants also permits escape to monoclonal antibodies and a reduction in neutralization titer in comparison to USA-WA1 in vaccinees as well as individuals recovered from COVID-19 infection (McCallum et al., 2021; Mlcochova et al., 2021).",PMC8443366
B.1.617.2,"The L452R substitution, detected in both the B.1.429 (Epsilon) and B.1.617.2 (Delta) variants also permits escape to monoclonal antibodies and a reduction in neutralization titer in comparison to USA-WA1 in vaccinees as well as individuals recovered from COVID-19 infection (McCallum et al., 2021; Mlcochova et al., 2021).",PMC8443366
B.1.617,"For example, RBD residue Asn501 (present as Tyr501 in several VOCs, including Alpha, Beta, and Gamma) lies just outside of the 54042-4 epitope, whereas the Cα atoms of Glu484 (present as Lys484 or Gln484 in, e.g., Beta, Gamma, and B.1.617 [Kappa]) and Leu452 (present as Arg452 in Epsilon and Delta) are ∼18 Å and ∼14 Å away from the Cα atoms of the nearest 54042-4 residue, respectively (Figure 3B).",PMC8443366
B.1.258,"These substitutions included K417N found in many isolates in the Beta lineage, as well as E484K (Beta, Gamma), N501Y (Alpha, Beta, Gamma), L452R (Delta, Epsilon), and N439K found in lineages B.1.141 and B.1.258 (Thomson et al., 2021).",PMC8443366
Lambda,"Finally, we determined the LIBRA-seq score for each antigen in the library for every cell as previously described (Setliff et al., 2019)..

For each antibody, variable genes were inserted into custom plasmids encoding the constant region for the IgG1 heavy chain as well as respective lambda and kappa light chains (pTwist CMV BetaGlobin WPRE Neo vector, Twist Bioscience).",PMC8443366
Kappa,"Finally, we determined the LIBRA-seq score for each antigen in the library for every cell as previously described (Setliff et al., 2019)..

For each antibody, variable genes were inserted into custom plasmids encoding the constant region for the IgG1 heavy chain as well as respective lambda and kappa light chains (pTwist CMV BetaGlobin WPRE Neo vector, Twist Bioscience).",PMC8443366
Gamma,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
B.1.617.2,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
B.1.617.1,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
B.1.351,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
P.1,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
Kappa,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
Beta,"Here we report 38 cryo-EM structures, corresponding to the spike protein of the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Kappa (B.1.617.1) variants in different functional states with and without its receptor, ACE2.",PPR394177
Alpha,"The Alpha (B.1.1.7) variant was the first VOC, was identified in the United Kingdom in September 2020 and emerged to global dominance that peaked in mid-March 2021.",PPR394177
B.1.1.7,"The Alpha (B.1.1.7) variant was the first VOC, was identified in the United Kingdom in September 2020 and emerged to global dominance that peaked in mid-March 2021.",PPR394177
B.1.617,"In early 2021, the B.1.617 lineage was reported in India.",PPR394177
B.1.617.3,"The higher order assembly of S-Kappa can be attributed to the unique E484Q substitution that is primarily found in the Kappa (B.1.617.1), B.1.617.3, B.1.630 and P5 variants per PANGO lineage but not in other VOCs and VOIs1.",PPR394177
B.1.630,"The higher order assembly of S-Kappa can be attributed to the unique E484Q substitution that is primarily found in the Kappa (B.1.617.1), B.1.617.3, B.1.630 and P5 variants per PANGO lineage but not in other VOCs and VOIs1.",PPR394177
B.1.617.2,"These authors contributed equally to this work..

A novel variant of SARS-CoV-2, the Delta variant of concern (VOC, also known as lineage B.1.617.2), is fast becoming the dominant strain globally.",PMC8435265
Gamma,"To date, there have been four main lineages that are identified as the variants of concern (VOC) by the World Health Organization (WHO), including Alpha (known as B.1.1.7 strain), Beta (known as B.1.351 strain), Gamma (known as P.1 strain) and Delta (known as B.1.617.2 strain) [1].",PMC8435265
B.1.1.7,"To date, there have been four main lineages that are identified as the variants of concern (VOC) by the World Health Organization (WHO), including Alpha (known as B.1.1.7 strain), Beta (known as B.1.351 strain), Gamma (known as P.1 strain) and Delta (known as B.1.617.2 strain) [1].",PMC8435265
Alpha,"To date, there have been four main lineages that are identified as the variants of concern (VOC) by the World Health Organization (WHO), including Alpha (known as B.1.1.7 strain), Beta (known as B.1.351 strain), Gamma (known as P.1 strain) and Delta (known as B.1.617.2 strain) [1].",PMC8435265
B.1.351,"To date, there have been four main lineages that are identified as the variants of concern (VOC) by the World Health Organization (WHO), including Alpha (known as B.1.1.7 strain), Beta (known as B.1.351 strain), Gamma (known as P.1 strain) and Delta (known as B.1.617.2 strain) [1].",PMC8435265
P.1,"To date, there have been four main lineages that are identified as the variants of concern (VOC) by the World Health Organization (WHO), including Alpha (known as B.1.1.7 strain), Beta (known as B.1.351 strain), Gamma (known as P.1 strain) and Delta (known as B.1.617.2 strain) [1].",PMC8435265
Beta,"To date, there have been four main lineages that are identified as the variants of concern (VOC) by the World Health Organization (WHO), including Alpha (known as B.1.1.7 strain), Beta (known as B.1.351 strain), Gamma (known as P.1 strain) and Delta (known as B.1.617.2 strain) [1].",PMC8435265
B.1.617,"The data showed the Ct kept falling from March to April 2021, with an increasing proportion of B.1.617 stain, compared to the baseline between Dec 2020 to Feb 2021 in Delhi, India [16].",PMC8435265
Gamma,"The havoc intensified with the emergence of SARS-CoV-2 variants (B.1.1.7; Alpha, B.1.351; Beta, P.1; Gamma, B.1.617; Delta, B.1.617.2; Delta-plus, B.1.525; Eta, and B.1.429; Epsilon etc.)",PMC8461057
Alpha,"The havoc intensified with the emergence of SARS-CoV-2 variants (B.1.1.7; Alpha, B.1.351; Beta, P.1; Gamma, B.1.617; Delta, B.1.617.2; Delta-plus, B.1.525; Eta, and B.1.429; Epsilon etc.)",PMC8461057
Epsilon,"The havoc intensified with the emergence of SARS-CoV-2 variants (B.1.1.7; Alpha, B.1.351; Beta, P.1; Gamma, B.1.617; Delta, B.1.617.2; Delta-plus, B.1.525; Eta, and B.1.429; Epsilon etc.)",PMC8461057
Eta,"The havoc intensified with the emergence of SARS-CoV-2 variants (B.1.1.7; Alpha, B.1.351; Beta, P.1; Gamma, B.1.617; Delta, B.1.617.2; Delta-plus, B.1.525; Eta, and B.1.429; Epsilon etc.)",PMC8461057
Beta,"The havoc intensified with the emergence of SARS-CoV-2 variants (B.1.1.7; Alpha, B.1.351; Beta, P.1; Gamma, B.1.617; Delta, B.1.617.2; Delta-plus, B.1.525; Eta, and B.1.429; Epsilon etc.)",PMC8461057
Theta,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.427,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
C.37,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.617.1,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.617,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.525,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.1.7,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
Kappa,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
P.1,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
Lambda,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.351,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.429,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.526,"The Wuhan strain of SARS-CoV-2 has undergone various mutations, resulting in B.1.1.7/alpha (United Kingdom), B.1.351/beta (South Africa), P.1/gamma (Brazil), B.1.617/delta (India), B.1.429 and B.1.427/epsilon (United States/California), B.1.525/eta (United Kingdom, Nigeria), P3/theta (Philippines), B.1.526/lota (United States/New York), B.1.617.1/kappa (India) and C.37/lambda (Peru) lineages (https://www.gisaid.org/hcov19-variants/).",PMC8461057
B.1.258,"The variant was first identified in March 2020 in Scotland, and as of January 2021, a second lineage B.1.258 has independently emerged in other European countries (Table 3).",PMC8461057
B.1.351,The TF-RBD multivalent vaccine produced broad-spectrum neutralizing antibodies against Alpha (B.1.1.7) and Beta (B.1.351) variants.,PMC8426336
Beta,The TF-RBD multivalent vaccine produced broad-spectrum neutralizing antibodies against Alpha (B.1.1.7) and Beta (B.1.351) variants.,PMC8426336
Alpha,The TF-RBD multivalent vaccine produced broad-spectrum neutralizing antibodies against Alpha (B.1.1.7) and Beta (B.1.351) variants.,PMC8426336
B.1.1.7,The TF-RBD multivalent vaccine produced broad-spectrum neutralizing antibodies against Alpha (B.1.1.7) and Beta (B.1.351) variants.,PMC8426336
Iota,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
Gamma,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
B.1.427,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
B.1.617.2,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
C.37,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
Lambda,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
P.1,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
B.1.526,"The mRNA vaccine platform is substantially advantageous in terms of the potency of the delivered antigen, which is the most natural modification of the viral protein encoded by the host.34 Therefore, it is necessary to explore whether an mRNA vaccine encoding the nanoparticle-based trimeric RBD has good immune effects..

SARS-CoV-2 is well-known to mutate rapidly, with the main variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Iota (B.1.526), B.1.427/B.1.429/CAL.20C, Delta (B.1.617.2), and Lambda (C.37) being reported thus far.35–38 In particular, the Alpha and Beta lineages have been studied and reported most frequently.",PMC8426336
Zeta,The zeta potential measurement of the LNPs was −6.33 mV in PBS (pH 7.2).,PMC8426336
Alpha,"Since the start of 2021, the COVID-19 global epidemic clearly featured increasing circulation of Alpha, which was rapidly replaced by the Delta variant starting around May 2021 and reaching a global prevalence of 96.6% at the end of July 2021.",PPR392097
Gamma,"Some SARS-CoV-2 variants disappeared immediately, while others characterized by several key mutations adapted well, enabling their rapid spread
1
. WHO has designated four Variants of Concern (VOCs) associated with increased transmissibility and various extents of immune escape
2–4
, namely the Alpha, Beta, Gamma, and Delta variants, first detected in the UK, South Africa, Brazil, and India, respectively
5
.",PPR392097
Beta,"Some SARS-CoV-2 variants disappeared immediately, while others characterized by several key mutations adapted well, enabling their rapid spread
1
. WHO has designated four Variants of Concern (VOCs) associated with increased transmissibility and various extents of immune escape
2–4
, namely the Alpha, Beta, Gamma, and Delta variants, first detected in the UK, South Africa, Brazil, and India, respectively
5
.",PPR392097
Iota,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 2 September 2021
5
.",PPR392097
Mu,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 2 September 2021
5
.",PPR392097
Eta,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 2 September 2021
5
.",PPR392097
Kappa,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 2 September 2021
5
.",PPR392097
Lambda,"Details of data sources and data completeness are shown in Appendix (Table S1–S2, S4–S5)..

We used the variant naming system proposed by WHO, where four VOCs and five Variants of Interest (VOIs, included Eta, Iota, Kappa, Lambda, and Mu) had been designated as of 2 September 2021
5
.",PPR392097
A.1,"Reference strains includes lineage A, A.1, B, and B.1; the sub-lineages of four VOCs are aggregated with the parent lineages.",PPR392097
B.1.621,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR392097
C.37,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR392097
B.1.617.1,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR392097
B.1.525,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR392097
B.1.526,"The sub-lineages of four VOCs are aggregated with the parent lineages; designated Variants of Interest (VOIs) included lineage B.1.525, B.1.526, B.1.617.1, C.37, B.1.621 and their sub-lineages; other lineages included reference strains and other variants.",PPR392097
Alpha,"The genetic landscape obtained visualizes the relevant mutations in a lineage-specific fashion and provides developmental paths in genetic state space from early lineages towards the variants of concern alpha, beta, gamma and delta.",PMC8472651
Beta,"The genetic landscape obtained visualizes the relevant mutations in a lineage-specific fashion and provides developmental paths in genetic state space from early lineages towards the variants of concern alpha, beta, gamma and delta.",PMC8472651
Gamma,"The genetic landscape obtained visualizes the relevant mutations in a lineage-specific fashion and provides developmental paths in genetic state space from early lineages towards the variants of concern alpha, beta, gamma and delta.",PMC8472651
Eta,"Most of the variants from each of the PATs occupy a separate side branch of the similarity tree which virtually agree with VOC/VOI and partly GISAID lineages, namely, PAT C with beta (β, B.1.351, ‘South-African’ variant), PAT B with eta (η, B.1.525, ‘Nigerian’ variant) and PAT D with epsilon (ε, B.1.427 and B.1.429, ‘Californian’ variant, since July 2021 not further considered as VOI by WHO) (Figure 4b).",PMC8472651
Epsilon,"Most of the variants from each of the PATs occupy a separate side branch of the similarity tree which virtually agree with VOC/VOI and partly GISAID lineages, namely, PAT C with beta (β, B.1.351, ‘South-African’ variant), PAT B with eta (η, B.1.525, ‘Nigerian’ variant) and PAT D with epsilon (ε, B.1.427 and B.1.429, ‘Californian’ variant, since July 2021 not further considered as VOI by WHO) (Figure 4b).",PMC8472651
B.1.427,"Most of the variants from each of the PATs occupy a separate side branch of the similarity tree which virtually agree with VOC/VOI and partly GISAID lineages, namely, PAT C with beta (β, B.1.351, ‘South-African’ variant), PAT B with eta (η, B.1.525, ‘Nigerian’ variant) and PAT D with epsilon (ε, B.1.427 and B.1.429, ‘Californian’ variant, since July 2021 not further considered as VOI by WHO) (Figure 4b).",PMC8472651
B.1.525,"Most of the variants from each of the PATs occupy a separate side branch of the similarity tree which virtually agree with VOC/VOI and partly GISAID lineages, namely, PAT C with beta (β, B.1.351, ‘South-African’ variant), PAT B with eta (η, B.1.525, ‘Nigerian’ variant) and PAT D with epsilon (ε, B.1.427 and B.1.429, ‘Californian’ variant, since July 2021 not further considered as VOI by WHO) (Figure 4b).",PMC8472651
B.1.351,"Most of the variants from each of the PATs occupy a separate side branch of the similarity tree which virtually agree with VOC/VOI and partly GISAID lineages, namely, PAT C with beta (β, B.1.351, ‘South-African’ variant), PAT B with eta (η, B.1.525, ‘Nigerian’ variant) and PAT D with epsilon (ε, B.1.427 and B.1.429, ‘Californian’ variant, since July 2021 not further considered as VOI by WHO) (Figure 4b).",PMC8472651
B.1.429,"Most of the variants from each of the PATs occupy a separate side branch of the similarity tree which virtually agree with VOC/VOI and partly GISAID lineages, namely, PAT C with beta (β, B.1.351, ‘South-African’ variant), PAT B with eta (η, B.1.525, ‘Nigerian’ variant) and PAT D with epsilon (ε, B.1.427 and B.1.429, ‘Californian’ variant, since July 2021 not further considered as VOI by WHO) (Figure 4b).",PMC8472651
B.1.117,"PAT A splits into two VOCs (alpha and gamma), and GISAID clades (GRY and GR), referring to ‘British’ and ‘Brazilian’ Pangolin lineages B.1.117 and P1, respectively.",PMC8472651
Iota,"PAT EF (non-VOC) splits into two major portraits, referring, e.g., to lineage B.1.526 (Iota, ι), expressing spot F and of lineage B.1.617.1 (kappa, κ), expressing spot E. VOCs/VOIs and MOCs cluster together in the heatmap after two-way hierarchical clustering, thus indicating mutual impact of MOCs and VOCs, where the latter ones accumulate in the spots (Figure 5a).",PMC8472651
B.1.526,"PAT EF (non-VOC) splits into two major portraits, referring, e.g., to lineage B.1.526 (Iota, ι), expressing spot F and of lineage B.1.617.1 (kappa, κ), expressing spot E. VOCs/VOIs and MOCs cluster together in the heatmap after two-way hierarchical clustering, thus indicating mutual impact of MOCs and VOCs, where the latter ones accumulate in the spots (Figure 5a).",PMC8472651
B.1.617.1,"PAT EF (non-VOC) splits into two major portraits, referring, e.g., to lineage B.1.526 (Iota, ι), expressing spot F and of lineage B.1.617.1 (kappa, κ), expressing spot E. VOCs/VOIs and MOCs cluster together in the heatmap after two-way hierarchical clustering, thus indicating mutual impact of MOCs and VOCs, where the latter ones accumulate in the spots (Figure 5a).",PMC8472651
Kappa,"PAT EF (non-VOC) splits into two major portraits, referring, e.g., to lineage B.1.526 (Iota, ι), expressing spot F and of lineage B.1.617.1 (kappa, κ), expressing spot E. VOCs/VOIs and MOCs cluster together in the heatmap after two-way hierarchical clustering, thus indicating mutual impact of MOCs and VOCs, where the latter ones accumulate in the spots (Figure 5a).",PMC8472651
Beta,"(F) Parental peptides’ aa sequence (top) with 3D structure determined by X-ray crystallography in the middle row (c: coil, b: beta strand, t: turn, h: α helix), modified peptides’ aa sequence bottom in bold letters and their 3D structure determined by ¹H-NMR, highlighting specific LL-LiViNAbI, ST-LiViNAbI and promiscuous peptides..

SARS-CoV-2 uses 3 membrane proteins for invading host cells; the spike (S), membrane (M) and viroporin envelop (E) proteins have been the most studied and are, perhaps, the most relevant..

All ∼162 SARS-CoV-2 vaccines to date in preclinical phase, plus 212 candidate vaccines in development (1), have been biologically produced, i.e.",PMC8446425
B.1.351,"We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50).",PMC8442901
P.1,"We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50).",PMC8442901
B.1.1.7,"We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50).",PMC8442901
B.1,"Last, all these variants have the D614G mutation that defines the B.1 lineage and became dominant throughout 2020, now being present in the large majority of sequenced SARS-CoV-2 variants (>99%) (Fig.",PMC8442901
Gamma,"Initially, this designation included lineage B.1.1.7 (corresponding to WHO designation Alpha), B.1.351 (Beta), and P.1 (Gamma).",PPR390035
B.1.1.7,"Initially, this designation included lineage B.1.1.7 (corresponding to WHO designation Alpha), B.1.351 (Beta), and P.1 (Gamma).",PPR390035
Alpha,"Initially, this designation included lineage B.1.1.7 (corresponding to WHO designation Alpha), B.1.351 (Beta), and P.1 (Gamma).",PPR390035
B.1.351,"Initially, this designation included lineage B.1.1.7 (corresponding to WHO designation Alpha), B.1.351 (Beta), and P.1 (Gamma).",PPR390035
P.1,"Initially, this designation included lineage B.1.1.7 (corresponding to WHO designation Alpha), B.1.351 (Beta), and P.1 (Gamma).",PPR390035
Beta,"Initially, this designation included lineage B.1.1.7 (corresponding to WHO designation Alpha), B.1.351 (Beta), and P.1 (Gamma).",PPR390035
B.1.429,"In early 2021, CDC added two new variants to this list: B.1.427 and B.1.429 (Epsilon), both of which were first identified in California
4,5
.",PPR390035
Epsilon,"In early 2021, CDC added two new variants to this list: B.1.427 and B.1.429 (Epsilon), both of which were first identified in California
4,5
.",PPR390035
B.1.427,"In early 2021, CDC added two new variants to this list: B.1.427 and B.1.429 (Epsilon), both of which were first identified in California
4,5
.",PPR390035
B.1.526,"For B.1.526, both clinical and wastewater abundance is relatively stable over time.",PPR390035
Beta,OP 02 Deep and shallow looks at human beta cell gene expression.,PMC8408311
Alpha,"The collection contains 3,046 single cells classified in 7 different cell types (alpha, beta, delta, PP, ductal, stellate and acinar) based on expression of marker genes.",PMC8408311
Gamma,This analysis pinpointed CCAAT Enhancer Binding Protein Gamma (CEBPG) as a node gene in a GRN of unfolded protein response (UPR) in the beta cells.,PMC8408311
Mu,"If so, this would suggest that mitochondrial function might be the main determinant of metabolic flexibility..

Materials and methods: Twenty-five (11 males and 14 females) overweight and obese individuals (BMI 31.7 ± 3.3 kg/m2; 64.7 ± 7.0 years) underwent an incremental submaximal cycling test at 30%, 50%, and 70% of the predetermined maximal power output (Wmax) and a two-step hyperinsulinemic-euglycemic clamp (10 and 40 mU/m2/min).",PMC8408311
B.1.1.7,"Interestingly, the RBD N501Y mutation, present in emerging variants of concern (VOCs) that are fueling the pandemic worldwide (including the B.1.1.7 (α) lineage), bypassed this requirement.",PMC8406544
B.1.351,"Over the 2019 to 2020 period, no major sequence variations were observed except for the N501Y mutation (4.4%), which started to arise at the end of the year in at least three independent lineages of interest (B.1.1.7, B.1.351, P.1) (27, 28, 29).",PMC8406544
P.1,"Over the 2019 to 2020 period, no major sequence variations were observed except for the N501Y mutation (4.4%), which started to arise at the end of the year in at least three independent lineages of interest (B.1.1.7, B.1.351, P.1) (27, 28, 29).",PMC8406544
Alpha,"Among them, the B.1.1.7 lineage (also known as alpha variant), which was first identified in the United Kingdom, was shown to have increased infectivity and transmissibility (31, 32).",PMC8406544
B.1.617.2,"The majority of them bound better to ACE2 at physiological temperature, notably for lineages harboring the N501Y mutation (B.1.1.7, B.1.351, and P.1) or the L452R mutation (B.1.617.2 and B.1.429).",PMC8406544
B.1.429,"The majority of them bound better to ACE2 at physiological temperature, notably for lineages harboring the N501Y mutation (B.1.1.7, B.1.351, and P.1) or the L452R mutation (B.1.617.2 and B.1.429).",PMC8406544
Gamma,"Coronaviruses were categorized into four genera, including Alpha, Beta, Gamma, and Delta coronaviruses.",PMC8470645
Beta,"Coronaviruses were categorized into four genera, including Alpha, Beta, Gamma, and Delta coronaviruses.",PMC8470645
Alpha,"Coronaviruses were categorized into four genera, including Alpha, Beta, Gamma, and Delta coronaviruses.",PMC8470645
B.1.1.7,The B.1.1.7 variant was first detected in the United Kingdom on 14 December 2020 and found with 23 mutations and 17 amino acid changes.,PMC8470645
B.1.351,The mutant variant B.1.351 (23 mutations and 17 amino acid changes) was detected in South Africa and the Brazilian mutant variant was detected in Brazil (approximately 35 mutations with 17 amino acid changes).,PMC8470645
P.1,"Furthermore, additional receptor binding domain mutations E484K and K417T were found in variants P.1 and 501Y.V2 known to increase the affinity of the RBD to the angiotensin-converting enzyme 2 (ACE2) receptor [48]..",PMC8470645
B.1.617.3,"As of May 2021, three sublineages including B.1.617.3 (first detected in October 2020) relatively uncommon compared with the B.1.617.1 and B.1.617.2 both detected in December 2020.",PMC8470645
B.1.617.2,"As of May 2021, three sublineages including B.1.617.3 (first detected in October 2020) relatively uncommon compared with the B.1.617.1 and B.1.617.2 both detected in December 2020.",PMC8470645
B.1.617.1,"As of May 2021, three sublineages including B.1.617.3 (first detected in October 2020) relatively uncommon compared with the B.1.617.1 and B.1.617.2 both detected in December 2020.",PMC8470645
B.1.351,"Ongoing genomic-based COVID-19 surveillance has recently been highlighted as a critical public health tool to detect novel SARS-CoV-2 variants, such as the B.1.1.7, B.1.351, and P.1 variants31,32.",PMC8405798
P.1,"Ongoing genomic-based COVID-19 surveillance has recently been highlighted as a critical public health tool to detect novel SARS-CoV-2 variants, such as the B.1.1.7, B.1.351, and P.1 variants31,32.",PMC8405798
B.1.1.7,"Ongoing genomic-based COVID-19 surveillance has recently been highlighted as a critical public health tool to detect novel SARS-CoV-2 variants, such as the B.1.1.7, B.1.351, and P.1 variants31,32.",PMC8405798
P.3,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
B.1.427,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
B.1.617.2,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
B.1.525,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
B.1.1.7,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
P.2,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
B.1.351,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
P.1,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
B.1.526,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1.",PMC8404189
B.1.429,B.1.427/B.1.429 variant was first identified in California.,PMC8404189
B.1.617.1,"Recently in India, SARS-CoV-2 variants were reported that belongs to the B.1.617 lineage: B.1.617.1 and B.1.617.2 (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8404189
B.1.617,"Recently in India, SARS-CoV-2 variants were reported that belongs to the B.1.617 lineage: B.1.617.1 and B.1.617.2 (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PMC8404189
Iota,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Gamma,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Zeta,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Theta,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Kappa,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Alpha,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Epsilon,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Eta,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
Beta,"B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) are presently grouped in VOCs, while B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (Eta), P.3 (Theta), B.1.526 (Iota), B.1.617.1 (Kappa) are mentioned as VOIs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

Serological or nucleic acid detection based assays may be used for the diagnosis of COVID-19.",PMC8404189
B.1.351,"The variant B.1.1.7 of SARS-CoV-2 (UK variant), also named as 501Y.V1 or variant of concern 202012/01, first emerged in England, has caused a surge in COVID-19 cases.115 This variant has been reported to be spread to >50 countries and seems to become virulent in the future.116–118 It has eight S protein mutations except for D614G.119 SARS-CoV-2 B.1.351 (501Y.V2) and P.1 (501Y.V3), also termed as South Africa variant and Brazil variant, respectively, were claimed to have more strong infectious ability.",PMC8390046
P.1,"The variant B.1.1.7 of SARS-CoV-2 (UK variant), also named as 501Y.V1 or variant of concern 202012/01, first emerged in England, has caused a surge in COVID-19 cases.115 This variant has been reported to be spread to >50 countries and seems to become virulent in the future.116–118 It has eight S protein mutations except for D614G.119 SARS-CoV-2 B.1.351 (501Y.V2) and P.1 (501Y.V3), also termed as South Africa variant and Brazil variant, respectively, were claimed to have more strong infectious ability.",PMC8390046
B.1.1.7,"The variant B.1.1.7 of SARS-CoV-2 (UK variant), also named as 501Y.V1 or variant of concern 202012/01, first emerged in England, has caused a surge in COVID-19 cases.115 This variant has been reported to be spread to >50 countries and seems to become virulent in the future.116–118 It has eight S protein mutations except for D614G.119 SARS-CoV-2 B.1.351 (501Y.V2) and P.1 (501Y.V3), also termed as South Africa variant and Brazil variant, respectively, were claimed to have more strong infectious ability.",PMC8390046
B.1.429,"In early January 2021, a novel variant of concern (VOC) designated B.1.429 comprising 2 lineages, B.1.427 and B.1.429, was originally detected in California (CA) and shown to enhance infectivity in vitro and decrease antibody neutralization by plasma from convalescent patients and vaccine recipients.",PPR387280
B.1.427,"In early January 2021, a novel variant of concern (VOC) designated B.1.429 comprising 2 lineages, B.1.427 and B.1.429, was originally detected in California (CA) and shown to enhance infectivity in vitro and decrease antibody neutralization by plasma from convalescent patients and vaccine recipients.",PPR387280
B.1,"We find that both strains exhibit enhanced virulence as measured by increased body weight loss compared to hamsters infected with ancestral B.1 (614G), with B.1.429 causing the most body weight loss among all 3 lineages.",PPR387280
Epsilon,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
Zeta,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
B.1.1.7,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
P.2,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
Alpha,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
Beta,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
B.1.351,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
P.1,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
Gamma,"In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs.",PPR387280
A.1,"Thus, prior infection with ancestral B.1 (614G) protects hamsters from challenge 21 days later with either B.1.427 or B.1.429, with protection defined as no virus replication in lungs..

To determine if the airborne transmission of B.1.427 and B1.429 between hamsters is more efficient than B.1 (614G) airborne transmission, four groups of eight “donor” hamsters (Table 1) were inoculated intranasally with 104 PFU of either B.1 (614G), A.1 (WA-1), B.1.427, B.1.429 (Figure 9).",PPR387280
B.1.617.2,"The B.1.427/B.1.429 variant is no longer the predominant circulating strain in California, as it was replaced first by the B.1.1.7 (alpha) variant, which has since been replaced by the B.1.617.2 (delta) variant.",PPR387280
B.1.247,"This makes it difficult to unambiguously identify B.1.429 and B.1.427 in mixtures and thus we reported the results as the frequency of the “epsilon”, the arrogate of the B.1.429 and B.1.427 frequencies..

As previously reported with ancestral B.1 and other VOC [11,25,26], in this study intranasal inoculation of hamsters with the SARS-CoV-2 B.1 (614G) or epsilon variants (B.1.247/B.1.249) induced progressive moderate to severe broncho-interstitial pneumonia with vasculitis, beginning as early as day 2 PI.",PPR387280
B.1.351,"Considering the critical role of the RBD in mediating viral entry; the tendency of the RBD of SARS coronaviruses to be highly variable (21); and the recent emergence of new variants B.1.1.7, P.1, and B.1.351 (6–8, 22); increasing interest has been directed toward the surveillance of SARS-CoV-2 RBD mutations.",PMC8409985
P.1,"Considering the critical role of the RBD in mediating viral entry; the tendency of the RBD of SARS coronaviruses to be highly variable (21); and the recent emergence of new variants B.1.1.7, P.1, and B.1.351 (6–8, 22); increasing interest has been directed toward the surveillance of SARS-CoV-2 RBD mutations.",PMC8409985
B.1.1.7,"Considering the critical role of the RBD in mediating viral entry; the tendency of the RBD of SARS coronaviruses to be highly variable (21); and the recent emergence of new variants B.1.1.7, P.1, and B.1.351 (6–8, 22); increasing interest has been directed toward the surveillance of SARS-CoV-2 RBD mutations.",PMC8409985
B.1.1.70,"Figure 3A illustrates the position of these variants on the RBD, and Figure 3B displays the more recently observed frequency of these variants according to the GISAID repository, with variant N501Y, currently the most frequent RBD variant worldwide (a key mutation present in the newly emergent B.1.1.7, B.1.351, B.1.1.70, and P.1 strains).",PMC8409985
B.1.258,"Based on the relative EC50 values observed in our multiplex assay, we selected these high -affinity variants, and the emerging N439K variant present in currently circulating lineage B.1.258, as well as E484K, which is a mutation shared by B.1.351, B.1.525, and P.1 lineages, to be profiled and compared for their binding kinetics to ACE2 using bio-layer interferometry (BLI).",PMC8409985
B.1.525,"Based on the relative EC50 values observed in our multiplex assay, we selected these high -affinity variants, and the emerging N439K variant present in currently circulating lineage B.1.258, as well as E484K, which is a mutation shared by B.1.351, B.1.525, and P.1 lineages, to be profiled and compared for their binding kinetics to ACE2 using bio-layer interferometry (BLI).",PMC8409985
B.1.617.2,"Two protective mAbs, SARS2-02 and SARS2-38, showed variable capacity to neutralize variants of concern (VOC) and variants of interest (VOI): SARS2-02 binds an epitope that includes residues E484 and L452 and shows reduced potency against strains (B.1.351 [Beta], B.1.617.2 [Delta], B.1.429 [Epsilon], B.1.1.28/P.1 [Gamma], B.1.526 [Iota], and B.1.617.1 [Kappa]) encoding these mutations.",PMC8373659
B.1.617.1,"Two protective mAbs, SARS2-02 and SARS2-38, showed variable capacity to neutralize variants of concern (VOC) and variants of interest (VOI): SARS2-02 binds an epitope that includes residues E484 and L452 and shows reduced potency against strains (B.1.351 [Beta], B.1.617.2 [Delta], B.1.429 [Epsilon], B.1.1.28/P.1 [Gamma], B.1.526 [Iota], and B.1.617.1 [Kappa]) encoding these mutations.",PMC8373659
P.1,"Two protective mAbs, SARS2-02 and SARS2-38, showed variable capacity to neutralize variants of concern (VOC) and variants of interest (VOI): SARS2-02 binds an epitope that includes residues E484 and L452 and shows reduced potency against strains (B.1.351 [Beta], B.1.617.2 [Delta], B.1.429 [Epsilon], B.1.1.28/P.1 [Gamma], B.1.526 [Iota], and B.1.617.1 [Kappa]) encoding these mutations.",PMC8373659
B.1.1.28,"Two protective mAbs, SARS2-02 and SARS2-38, showed variable capacity to neutralize variants of concern (VOC) and variants of interest (VOI): SARS2-02 binds an epitope that includes residues E484 and L452 and shows reduced potency against strains (B.1.351 [Beta], B.1.617.2 [Delta], B.1.429 [Epsilon], B.1.1.28/P.1 [Gamma], B.1.526 [Iota], and B.1.617.1 [Kappa]) encoding these mutations.",PMC8373659
B.1.351,"Two protective mAbs, SARS2-02 and SARS2-38, showed variable capacity to neutralize variants of concern (VOC) and variants of interest (VOI): SARS2-02 binds an epitope that includes residues E484 and L452 and shows reduced potency against strains (B.1.351 [Beta], B.1.617.2 [Delta], B.1.429 [Epsilon], B.1.1.28/P.1 [Gamma], B.1.526 [Iota], and B.1.617.1 [Kappa]) encoding these mutations.",PMC8373659
B.1.429,"Two protective mAbs, SARS2-02 and SARS2-38, showed variable capacity to neutralize variants of concern (VOC) and variants of interest (VOI): SARS2-02 binds an epitope that includes residues E484 and L452 and shows reduced potency against strains (B.1.351 [Beta], B.1.617.2 [Delta], B.1.429 [Epsilon], B.1.1.28/P.1 [Gamma], B.1.526 [Iota], and B.1.617.1 [Kappa]) encoding these mutations.",PMC8373659
B.1.526,"Two protective mAbs, SARS2-02 and SARS2-38, showed variable capacity to neutralize variants of concern (VOC) and variants of interest (VOI): SARS2-02 binds an epitope that includes residues E484 and L452 and shows reduced potency against strains (B.1.351 [Beta], B.1.617.2 [Delta], B.1.429 [Epsilon], B.1.1.28/P.1 [Gamma], B.1.526 [Iota], and B.1.617.1 [Kappa]) encoding these mutations.",PMC8373659
B.1.1.7,"We also tested viral isolates B.1.1.7 (with and without E484K), B.1.429, B.1.1.298, B.1.222, B.1.617.1, and B.1.617.2 and two B.1.526 isolates (with E484K or S477N mutation).",PMC8373659
B.1.1.298,"We also tested viral isolates B.1.1.7 (with and without E484K), B.1.429, B.1.1.298, B.1.222, B.1.617.1, and B.1.617.2 and two B.1.526 isolates (with E484K or S477N mutation).",PMC8373659
B.1.222,"We also tested viral isolates B.1.1.7 (with and without E484K), B.1.429, B.1.1.298, B.1.222, B.1.617.1, and B.1.617.2 and two B.1.526 isolates (with E484K or S477N mutation).",PMC8373659
Alpha,"In addition, we examined the competition of two SARS-CoV-2 isolates, representatives of the ancestral lineage A (SARS-CoV-2/human/USA/WA1/2020) and the alpha variant of concern (VOC) B.1.1.7 (SARS-CoV-2/human/USA/CA_CDC_5574/2020), through co-infection of white-tailed deer.",PPR383487
B.1.1.7,"In addition, we examined the competition of two SARS-CoV-2 isolates, representatives of the ancestral lineage A (SARS-CoV-2/human/USA/WA1/2020) and the alpha variant of concern (VOC) B.1.1.7 (SARS-CoV-2/human/USA/CA_CDC_5574/2020), through co-infection of white-tailed deer.",PPR383487
A.2,"In January, February and March 2020, the L84S mutation was present in 35%, 18% and 11% of the available GISAID sequences (Table S1, Figure S1), corresponding to Nextstrain clade 19B, GISAID Clade S (98% of L84S sequences) or several Pango A lineages (20% A[basal], 37% A.1, 18% A.2 of L84S sequences).",PPR382902
A.1,"In January, February and March 2020, the L84S mutation was present in 35%, 18% and 11% of the available GISAID sequences (Table S1, Figure S1), corresponding to Nextstrain clade 19B, GISAID Clade S (98% of L84S sequences) or several Pango A lineages (20% A[basal], 37% A.1, 18% A.2 of L84S sequences).",PPR382902
A.3,"The majority (87%) of the V62L mutations co-occur with L84S in Clade S or Pango lineage A[basal] (70%) and A.3 (28%) for the period December 2019-March 2020 (Figure S1), and these sequences with both L84S and V62L were mostly (86%) detected in North America (Figure S2)..",PPR382902
Alpha,"However, with the subsequent rise of the Variant of Concern (VOC) Alpha (B.1.1.7) in autumn 2020, viruses with truncated ORF8 (mutation Q27*) have been circulating.",PPR382902
B.1.1.7,"However, with the subsequent rise of the Variant of Concern (VOC) Alpha (B.1.1.7) in autumn 2020, viruses with truncated ORF8 (mutation Q27*) have been circulating.",PPR382902
B.1.617.2,"During Spring 2021, the VOC Delta (B.1.617.2 and others) strains which have mostly L84 and V62 have risen to dominance, and by June 2021 less than 0.1% of available sequences have L84S in an intact ORF8 polypeptide.",PPR382902
B.1.1.7,Several severe acute respiratory syndrome coronavirus 2 variants of concern (VOCs) emerged in late 2020; lineage B.1.1.7 initially dominated globally.,PMC8544957
B.1.351,"However, lineages B.1.351 and P.1 represent potentially greater risk for transmission and immune escape.",PMC8544957
P.1,"However, lineages B.1.351 and P.1 represent potentially greater risk for transmission and immune escape.",PMC8544957
Gamma,"Globally, the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages represented the 3 main actively circulating VOCs in late 2020 and early 2021 (6).",PMC8544957
Alpha,"Globally, the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages represented the 3 main actively circulating VOCs in late 2020 and early 2021 (6).",PMC8544957
Beta,"Globally, the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages represented the 3 main actively circulating VOCs in late 2020 and early 2021 (6).",PMC8544957
Eta,"In accordance with the mutation rate, variants of concern (alpha, beta, gamma and delta) and interest (eta and kappa) also started appearing in the first wave (1.5% of the genomes), which dominated the second (~96% of genomes) and post-second wave (100% of genomes) phases.",PPR382067
Kappa,"In accordance with the mutation rate, variants of concern (alpha, beta, gamma and delta) and interest (eta and kappa) also started appearing in the first wave (1.5% of the genomes), which dominated the second (~96% of genomes) and post-second wave (100% of genomes) phases.",PPR382067
Alpha,"In accordance with the mutation rate, variants of concern (alpha, beta, gamma and delta) and interest (eta and kappa) also started appearing in the first wave (1.5% of the genomes), which dominated the second (~96% of genomes) and post-second wave (100% of genomes) phases.",PPR382067
Beta,"In accordance with the mutation rate, variants of concern (alpha, beta, gamma and delta) and interest (eta and kappa) also started appearing in the first wave (1.5% of the genomes), which dominated the second (~96% of genomes) and post-second wave (100% of genomes) phases.",PPR382067
Gamma,"In accordance with the mutation rate, variants of concern (alpha, beta, gamma and delta) and interest (eta and kappa) also started appearing in the first wave (1.5% of the genomes), which dominated the second (~96% of genomes) and post-second wave (100% of genomes) phases.",PPR382067
Lambda,"On the basis of these studies, World Health Organisation have announced variants of concern (VOC) (alpha, beta, gamma and delta) and variants of interest (VOI) (eta, lota, kappa and lambda) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).",PPR382067
B.1.617.2,"According to the pangolin lineages out of 20,086 stains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2 and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2).",PPR382067
B.1.617.1,"According to the pangolin lineages out of 20,086 stains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2 and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2).",PPR382067
B.1.525,"According to the pangolin lineages out of 20,086 stains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2 and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2).",PPR382067
B.1.351,"According to the pangolin lineages out of 20,086 stains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2 and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2).",PPR382067
P.1,"According to the pangolin lineages out of 20,086 stains used in the present study, 7421 were delta variants (B.1.617.2, AY.1, AY.2 and AY.3), 95 were beta (B.1.351) and 1 gamma (P.1) constituting VOCs and 42 eta (B.1.525), 2300 kappa (B.1.617.1) constituting VOIs (Table 2).",PPR382067
B.1.1.7,Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance.,PMC8552604
B.1.351,"A prospective comparison of the VOC assays to genome sequencing for the detection of B.1.1.7, combined detection of P.1 and B.1.351, and wild-type (i.e., non-VOC) lineages showed sensitivities of 98.2 to 100%, specificities of 98.9 to 100%, positive predictive values of 76.9% to 100%, and negative predictive values of 96 to 100%.",PMC8552604
P.1,"A prospective comparison of the VOC assays to genome sequencing for the detection of B.1.1.7, combined detection of P.1 and B.1.351, and wild-type (i.e., non-VOC) lineages showed sensitivities of 98.2 to 100%, specificities of 98.9 to 100%, positive predictive values of 76.9% to 100%, and negative predictive values of 96 to 100%.",PMC8552604
Gamma,"While it is anticipated that the majority of these mutations have no biological implications, the emergence of lineages with different phenotypic characteristics has been observed..

To date, there are four variants of concern (VOCs) that have been declared as such by the World Health Organization (WHO): B.1.1.7 (Alpha) (with and without the spike [S] gene E484K mutation), B.1.351 (Beta), P.1 (Gamma), and more recently B.1.617.2 (Delta) (4, 5).",PMC8552604
B.1.617.2,"While it is anticipated that the majority of these mutations have no biological implications, the emergence of lineages with different phenotypic characteristics has been observed..

To date, there are four variants of concern (VOCs) that have been declared as such by the World Health Organization (WHO): B.1.1.7 (Alpha) (with and without the spike [S] gene E484K mutation), B.1.351 (Beta), P.1 (Gamma), and more recently B.1.617.2 (Delta) (4, 5).",PMC8552604
Alpha,"While it is anticipated that the majority of these mutations have no biological implications, the emergence of lineages with different phenotypic characteristics has been observed..

To date, there are four variants of concern (VOCs) that have been declared as such by the World Health Organization (WHO): B.1.1.7 (Alpha) (with and without the spike [S] gene E484K mutation), B.1.351 (Beta), P.1 (Gamma), and more recently B.1.617.2 (Delta) (4, 5).",PMC8552604
Beta,"While it is anticipated that the majority of these mutations have no biological implications, the emergence of lineages with different phenotypic characteristics has been observed..

To date, there are four variants of concern (VOCs) that have been declared as such by the World Health Organization (WHO): B.1.1.7 (Alpha) (with and without the spike [S] gene E484K mutation), B.1.351 (Beta), P.1 (Gamma), and more recently B.1.617.2 (Delta) (4, 5).",PMC8552604
B.1.160,"During this time, 585 samples with the H69/V70 deletion alone (without the N501Y mutation) were detected, which were found to be lineages B.1.525 (n = 574), B.1 (n = 5), B.1.160 (n = 3), B.1.258 (n = 2), and B.1.280 (n = 1).",PMC8552604
B.1.525,"During this time, 585 samples with the H69/V70 deletion alone (without the N501Y mutation) were detected, which were found to be lineages B.1.525 (n = 574), B.1 (n = 5), B.1.160 (n = 3), B.1.258 (n = 2), and B.1.280 (n = 1).",PMC8552604
B.1.258,"During this time, 585 samples with the H69/V70 deletion alone (without the N501Y mutation) were detected, which were found to be lineages B.1.525 (n = 574), B.1 (n = 5), B.1.160 (n = 3), B.1.258 (n = 2), and B.1.280 (n = 1).",PMC8552604
B.1,"During this time, 585 samples with the H69/V70 deletion alone (without the N501Y mutation) were detected, which were found to be lineages B.1.525 (n = 574), B.1 (n = 5), B.1.160 (n = 3), B.1.258 (n = 2), and B.1.280 (n = 1).",PMC8552604
B.1.280,"During this time, 585 samples with the H69/V70 deletion alone (without the N501Y mutation) were detected, which were found to be lineages B.1.525 (n = 574), B.1 (n = 5), B.1.160 (n = 3), B.1.258 (n = 2), and B.1.280 (n = 1).",PMC8552604
B.1.438,"Also during this prospective comparison, a total of 152 samples tested positive for N501Y alone (without the H69/70 deletion); these belonged to the B.1 (n = 27), B.1.351 (n = 17), B.1.438 (n = 2), and P.1 (n = 106) lineages..

Daily number of VOC positive samples detected in late 2020 to early 2021.",PMC8552604
Alpha,"Here we investigated the relative efficiency of aerosol transmission of two variants of SARS-CoV-2, B.1.1.7 (alpha) and lineage A, in the Syrian hamster.",PPR380669
B.1.1.7,"Here we investigated the relative efficiency of aerosol transmission of two variants of SARS-CoV-2, B.1.1.7 (alpha) and lineage A, in the Syrian hamster.",PPR380669
B.1.351,"C. BHK cells expressing either human ACE2 or hamster ACE2 were infected with pseudotyped VSV reporter particles with the spike proteins of WA1 and B.1.1.7 and B.1.351, luciferase was measured and normalized to no spike controls as a readout for cell entry Relative entry to no spike control for human and hamster ACE2 is depicted.",PPR380669
Iota,"We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune‐escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages.",PMC8420576
Gamma,"We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune‐escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages.",PMC8420576
Alpha,"We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune‐escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages.",PMC8420576
Epsilon,"We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune‐escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages.",PMC8420576
Kappa,"We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune‐escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages.",PMC8420576
Beta,"We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune‐escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages.",PMC8420576
B.1.1.7,"The situation worsened with the occurrence of even more virulent and transmissible strains, such as Alpha/UK/B.1.1.7 carrying the strain‐charactering N501Y Spike mutation or the Beta/South African strain B.1.351.",PMC8420576
B.1.617.3,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.617.2,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.617.1,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.617,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
P.1,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.351,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.429,"These mutations can occur singly, e.g., in the Epsilon/Californian B.1.429 strain (L452R), or in combination, for example, in the Gamma/Brazilian P.1 strain (K417T, E484K, N501Y), in the Beta/South African B.1.351 strain (K417N, E484K, N501Y) or the Indian B.1.617 lineage (L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage).",PMC8420576
B.1.526,"These include the Alpha/UK B.1.1.7 variant with an N501Y mutation in the RBD, the Beta/South African B.1.351 variant (K417N, E484K, N501Y), Gamma/Brazilian P.1 (K417T, E484K, N501Y), Iota/New York City B.1.526 (E484K), Epsilon/Californian B.1.429 (L452R), and the Indian B.1.617 lineage (with L452R and E484Q in the Kappa/B.1.617.1 and B.1.617.3 variants, or L452R and T478K in the Delta/B.1.617.2 sub‐lineage)..",PMC8420576
B.1.427,"For low‐affinity measurements, biotinylated RBD (see above) was immobilized on the sensors, dipped into wells containing 60, 30, 15, 7.5, 3.75, or 1.875 nM VHH for 300 s, followed by buffer for 600 s. For high‐affinity measurements, biotinylated nanobodies were immobilized, incubated with 20, 10, 5, 2.5, 1.25 nM RBD (Z03479, GenScript) for 600 s, and followed by dissociation with buffer for 1 h. For RBD variant experiments, biotinylated nanobodies were immobilized, incubated with 20, 6.66, and 2.22 nM RBD wt (Z03479, GenScript) and mutants (Sino Biological; B.1.1.7/Alpha/""UK"" 40592‐V08H82, B.1.351/Beta/""South African"" 40592‐V085H85, P.1/Gamma/""Brazilian"" 40592‐V08H86, and B.1.427/B.1.429/Epsilon/Californian 40592‐V08H28) for 450 s and then with buffer for 900 s. For testing the quadruple mutant (a combination of the Gamma/Brazilian and Epsilon/Californian variants), biotinylated RBD K417T, L452R, E484K, N501Y was immobilized and incubated with 100 nM nanobodies for 450 s, followed by buffer for 900 s. For thermostability BLI experiments, VHH antibodies (1 µM) were incubated at room temperature (RT) or at 90°C for 5 min and centrifuged for 20 min at 20,000 g. The supernatants were recovered and diluted 50‐fold in running buffer (corresponding to 20 nM of the starting material).",PMC8420576
B.1.351,"However, from the end of 2020, three divergent SARS-CoV-2 lineages evolved into fast-spreading variants that became known as variants of concern: B.1.1.7 [United Kingdom (UK)] [20], B.1.351 [South Africa (SA)] [21] and P.1 (Brazil) [22].",PMC8341613
P.1,"However, from the end of 2020, three divergent SARS-CoV-2 lineages evolved into fast-spreading variants that became known as variants of concern: B.1.1.7 [United Kingdom (UK)] [20], B.1.351 [South Africa (SA)] [21] and P.1 (Brazil) [22].",PMC8341613
B.1.1.7,"However, from the end of 2020, three divergent SARS-CoV-2 lineages evolved into fast-spreading variants that became known as variants of concern: B.1.1.7 [United Kingdom (UK)] [20], B.1.351 [South Africa (SA)] [21] and P.1 (Brazil) [22].",PMC8341613
B.1.427,"More recently, other lineages were added to this list: B.1.427, B.1.429 [California, United States of America (USA)], B.1.617 or B.1.617.1–3 (India) [20,23,24], as well as several lineages of interest that carry the mutation E484K, including P.2 [25] and B.1.1.7 containing E484K.",PMC8341613
B.1.617,"More recently, other lineages were added to this list: B.1.427, B.1.429 [California, United States of America (USA)], B.1.617 or B.1.617.1–3 (India) [20,23,24], as well as several lineages of interest that carry the mutation E484K, including P.2 [25] and B.1.1.7 containing E484K.",PMC8341613
P.2,"More recently, other lineages were added to this list: B.1.427, B.1.429 [California, United States of America (USA)], B.1.617 or B.1.617.1–3 (India) [20,23,24], as well as several lineages of interest that carry the mutation E484K, including P.2 [25] and B.1.1.7 containing E484K.",PMC8341613
B.1.429,"More recently, other lineages were added to this list: B.1.427, B.1.429 [California, United States of America (USA)], B.1.617 or B.1.617.1–3 (India) [20,23,24], as well as several lineages of interest that carry the mutation E484K, including P.2 [25] and B.1.1.7 containing E484K.",PMC8341613
B.1.258,"A two amino acid deletion in positions 69 and 70 of spike is observed in cluster 5 and lineages B.1.1.7, B.1.525 and B.1.258 [40].",PMC8341613
B.1.525,"A two amino acid deletion in positions 69 and 70 of spike is observed in cluster 5 and lineages B.1.1.7, B.1.525 and B.1.258 [40].",PMC8341613
B.1.617.2,"The appearance of shared mutations in distinct and rapidly spreading SARS-CoV-2 lineages suggests that these mutations, either alone or in combination, may provide fitness advantage, as recently observed with the acquisition of S417N by B.1.617.2 lineage.",PMC8341613
B.1.1,"During this period, the variant B.1.1, encoding the WT spike protein, was prevalent in Portugal..",PMC8341613
B.1.351,"Several VOCs has been detected and include lineage B.1.1.7 first identified in the UK, linage B.1.351 in South Africa, and lineage P.1 (B.1.1.28.1) in Brazil.",PPR378218
P.1,"Several VOCs has been detected and include lineage B.1.1.7 first identified in the UK, linage B.1.351 in South Africa, and lineage P.1 (B.1.1.28.1) in Brazil.",PPR378218
B.1.1.7,"Several VOCs has been detected and include lineage B.1.1.7 first identified in the UK, linage B.1.351 in South Africa, and lineage P.1 (B.1.1.28.1) in Brazil.",PPR378218
B.1.177,"Results of SARS-CoV-2 variant after qPCR analysis was compared with NGS sequenced data of all 77 SARS-CoV-2 positive samples, and after Pangolin classification (github.com/cov-lineages/pangolin) we showed a concordance of 100% (CI 95% 95.3–100%) between NGS sequenced data and qPCR data for the B.1.1.7, B.1.351, P.1, and other variants not investigated (B.1.177, B.1.258, B.1.545) (Table 1).",PPR378218
B.1.545,"Results of SARS-CoV-2 variant after qPCR analysis was compared with NGS sequenced data of all 77 SARS-CoV-2 positive samples, and after Pangolin classification (github.com/cov-lineages/pangolin) we showed a concordance of 100% (CI 95% 95.3–100%) between NGS sequenced data and qPCR data for the B.1.1.7, B.1.351, P.1, and other variants not investigated (B.1.177, B.1.258, B.1.545) (Table 1).",PPR378218
B.1.258,"Results of SARS-CoV-2 variant after qPCR analysis was compared with NGS sequenced data of all 77 SARS-CoV-2 positive samples, and after Pangolin classification (github.com/cov-lineages/pangolin) we showed a concordance of 100% (CI 95% 95.3–100%) between NGS sequenced data and qPCR data for the B.1.1.7, B.1.351, P.1, and other variants not investigated (B.1.177, B.1.258, B.1.545) (Table 1).",PPR378218
B.1,"Pangolin submission produced 6 B.1.1.7 calls, 2 P.1 calls, 1 B.1.351 call, 13 A variants, 2 B variants and 58 B.1 variants with other sub-lineages (different from B.1.1.7, B1.351 and P.1).",PPR378218
A.1,"The developed custom genotyping panel probes differentiate between the B.1.1.7, B.1.351, P.1 and all B.1 derived variants (all carrying D614G mutation) from the A.1 (Wuhan) lineage.",PPR378218
B.1.525,"Among the 77 sequenced clinical samples we identified an already reported B.1.525 variant, since this new variant was reported on PANGO lineage his frequency in Italy was less than 0,9 % (supplementary table 1).",PPR378218
B.1.351,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
P.1,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
B.1.617.2,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
B.1.1.7,"While over ~1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021).",PPR377777
B.1.617.1,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.525,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.429,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.526,"Moreover, since many antibodies that bind spike are non-neutralizing, our work suggests that agonist features that prematurely trigger and thereby irreversibly inactivate S, or inhibition of membrane fusion, contribute to the ability of neutralizing antibodies to block SARS-CoV-2 infection..

We first tested the ability of CV3-1 and CV3-25 to recognize and neutralize the emerging variants of concern, B.1.1.7 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), B.1.617.2 (δ) as well as variants of interest B.1.429 (ε), B.1.525 (η), B.1.526 (ι) and B.1.617.1 (κ).",PPR377777
B.1.351,"The emergence of novel SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern with
increased transmission dynamics has raised questions regarding stability and
disinfection of these viruses.",PMC8243362
B.1.1.7,"The emergence of novel SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern with
increased transmission dynamics has raised questions regarding stability and
disinfection of these viruses.",PMC8243362
B.1.1,"Indeed, all patient S samples form a single clade within the B.1.1 lineage on the global SARS-CoV-2 phylogeny, with the patient A sample as its ancestor (Fig.",PPR375612
B.1.1.7,"This is consistent with the hypothesis that immunocompromised patients represent a hotspot of viral adaptation, causing “saltations” in the otherwise clock-like evolutionary rate of SARS-CoV-2
1
; notably, such a jump could have happened at the origin of the B.1.1.7 (“alpha”) variant which has attained global dominance in early 2021
1,37
..",PPR375612
B.1,"FFPE (black dot), patient A sample (the presumed source of infection for patient S)..

Neutralizing activity of serum obtained from 16 convalescent donors against patient S virus samples obtained on August 20, 2020 and February 19, 2021, as well as a reference viral strain of the B.1 lineage isolated from a swab sample in the beginning of the pandemic in Russia in March 2020.",PPR375612
B.1.617.2,"Rows, from top to bottom: VOCs Delta (B.1.617.2), Beta (B.1.351), Alpha (B.1.1.7); Cluster 5 variant; immunosuppressed individual with persistent infection for 290 days (Williamson et al., 2021); three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 (Truong et al., 2021); immunosuppressed individual treated with immunoglobulin (Sepulcri et al.",PPR375612
Alpha,"Rows, from top to bottom: VOCs Delta (B.1.617.2), Beta (B.1.351), Alpha (B.1.1.7); Cluster 5 variant; immunosuppressed individual with persistent infection for 290 days (Williamson et al., 2021); three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 (Truong et al., 2021); immunosuppressed individual treated with immunoglobulin (Sepulcri et al.",PPR375612
B.1.351,"Rows, from top to bottom: VOCs Delta (B.1.617.2), Beta (B.1.351), Alpha (B.1.1.7); Cluster 5 variant; immunosuppressed individual with persistent infection for 290 days (Williamson et al., 2021); three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 (Truong et al., 2021); immunosuppressed individual treated with immunoglobulin (Sepulcri et al.",PPR375612
Beta,"Rows, from top to bottom: VOCs Delta (B.1.617.2), Beta (B.1.351), Alpha (B.1.1.7); Cluster 5 variant; immunosuppressed individual with persistent infection for 290 days (Williamson et al., 2021); three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 (Truong et al., 2021); immunosuppressed individual treated with immunoglobulin (Sepulcri et al.",PPR375612
P.1,We have screened a library of chitosan derivatives by site-specific docking at not only spike protein Receptor Binding Domain (RBD) of wild type SARS-CoV-2 but also on RBD of B.1.1.7 (UK) and P.1 (Brazil) SARS-CoV-2 variants.,PMC8313795
B.1.1.7,We have screened a library of chitosan derivatives by site-specific docking at not only spike protein Receptor Binding Domain (RBD) of wild type SARS-CoV-2 but also on RBD of B.1.1.7 (UK) and P.1 (Brazil) SARS-CoV-2 variants.,PMC8313795
Beta,"Later it was determined to be caused by SARS-CoV-2 virus, a beta-coronavirus closely related to the other CoVs such as SARS and Bat coronavirus RaTG13 [1] in lineage B subtype of beta coronaviruses belonging to the Coronavirinae subfamily, covered under the broad umbrella of the Coronaviridae family [2].",PMC8313795
B.1.351,"Furthermore, recent developments of highly contagious new variants such as the B.1.1.7, B.1.351, and P.1 lineage have surfaced with new concerns.",PMC8313795
Eta,"6Table 3Comparision of the residue of RBD and ACE2; PDB ID 7NXC P.1 a lineage (Brazil variant) and PDB ID 6M0J wild type at ≤3.5 Å.Table 3Interaction overview at ≤3.5 ÅChemical bondsSARS-CoV-2 P.1 lineageSARS-CoV-2 wild-typeResiduesLength (Å)ResiduesLength (Å)Hydrogen bondsTYR 449 (OH)2.99ASN487 (ND2)2.6TYR 501 (CE1)3.3LYS417 (NZ)3.0TYR 505 (CD2)3.37GLN493 (NE2)2.8THR 500 (OG1)2.45TYR505 (OH)3.2ASN 487 (ND2)2.42TYR449 (OH)2.7GLN 498 (OE1)3.45THR500 (OG1)2.6GLN 493 (NE2)3.1ASN501 (N)3.7ASN 487 (OD1)2.77TYR449 (OH)3.0TYR 501 (OH)3.32TYR489 (OH)3.5THR 500 (CB)3.45ASN487 (OD1)2.7TYR 453 (OH)3.17GLY 502 (N)2.8TYR 489 (OH)3.41TYR505 (OH)3.7GLN 498 (OE1)3.1GLN 498 (OE1)⁎3.58Other bondsLYS417 (NZ)a3.9LYS417 (NZ)a3.0aSalt bridge, HH: hydrogen eta, OD1: oxygen delta 1, OG1: oxygen gamma 1, O: oxygen, HN: nitrogen eta, NZ: nitrogen zeta, CD: carbon delta, CA: carbon alpha, HH11: hydrogen eta 11, HH12: hydrogen eta 12, HE22:hydrogen epsilon 22, HG1: hydrogen gamma 1, OE1: oxygen epsilon 1, ND2: nitrogen delta 2, NE2: nitrogen epsilon 2, OH: oxygen eta, N: nitrogen.⁎To highlight the presence of a higher bond length (≤ 3.5 Å.)",PMC8313795
Epsilon,"6Table 3Comparision of the residue of RBD and ACE2; PDB ID 7NXC P.1 a lineage (Brazil variant) and PDB ID 6M0J wild type at ≤3.5 Å.Table 3Interaction overview at ≤3.5 ÅChemical bondsSARS-CoV-2 P.1 lineageSARS-CoV-2 wild-typeResiduesLength (Å)ResiduesLength (Å)Hydrogen bondsTYR 449 (OH)2.99ASN487 (ND2)2.6TYR 501 (CE1)3.3LYS417 (NZ)3.0TYR 505 (CD2)3.37GLN493 (NE2)2.8THR 500 (OG1)2.45TYR505 (OH)3.2ASN 487 (ND2)2.42TYR449 (OH)2.7GLN 498 (OE1)3.45THR500 (OG1)2.6GLN 493 (NE2)3.1ASN501 (N)3.7ASN 487 (OD1)2.77TYR449 (OH)3.0TYR 501 (OH)3.32TYR489 (OH)3.5THR 500 (CB)3.45ASN487 (OD1)2.7TYR 453 (OH)3.17GLY 502 (N)2.8TYR 489 (OH)3.41TYR505 (OH)3.7GLN 498 (OE1)3.1GLN 498 (OE1)⁎3.58Other bondsLYS417 (NZ)a3.9LYS417 (NZ)a3.0aSalt bridge, HH: hydrogen eta, OD1: oxygen delta 1, OG1: oxygen gamma 1, O: oxygen, HN: nitrogen eta, NZ: nitrogen zeta, CD: carbon delta, CA: carbon alpha, HH11: hydrogen eta 11, HH12: hydrogen eta 12, HE22:hydrogen epsilon 22, HG1: hydrogen gamma 1, OE1: oxygen epsilon 1, ND2: nitrogen delta 2, NE2: nitrogen epsilon 2, OH: oxygen eta, N: nitrogen.⁎To highlight the presence of a higher bond length (≤ 3.5 Å.)",PMC8313795
Zeta,"6Table 3Comparision of the residue of RBD and ACE2; PDB ID 7NXC P.1 a lineage (Brazil variant) and PDB ID 6M0J wild type at ≤3.5 Å.Table 3Interaction overview at ≤3.5 ÅChemical bondsSARS-CoV-2 P.1 lineageSARS-CoV-2 wild-typeResiduesLength (Å)ResiduesLength (Å)Hydrogen bondsTYR 449 (OH)2.99ASN487 (ND2)2.6TYR 501 (CE1)3.3LYS417 (NZ)3.0TYR 505 (CD2)3.37GLN493 (NE2)2.8THR 500 (OG1)2.45TYR505 (OH)3.2ASN 487 (ND2)2.42TYR449 (OH)2.7GLN 498 (OE1)3.45THR500 (OG1)2.6GLN 493 (NE2)3.1ASN501 (N)3.7ASN 487 (OD1)2.77TYR449 (OH)3.0TYR 501 (OH)3.32TYR489 (OH)3.5THR 500 (CB)3.45ASN487 (OD1)2.7TYR 453 (OH)3.17GLY 502 (N)2.8TYR 489 (OH)3.41TYR505 (OH)3.7GLN 498 (OE1)3.1GLN 498 (OE1)⁎3.58Other bondsLYS417 (NZ)a3.9LYS417 (NZ)a3.0aSalt bridge, HH: hydrogen eta, OD1: oxygen delta 1, OG1: oxygen gamma 1, O: oxygen, HN: nitrogen eta, NZ: nitrogen zeta, CD: carbon delta, CA: carbon alpha, HH11: hydrogen eta 11, HH12: hydrogen eta 12, HE22:hydrogen epsilon 22, HG1: hydrogen gamma 1, OE1: oxygen epsilon 1, ND2: nitrogen delta 2, NE2: nitrogen epsilon 2, OH: oxygen eta, N: nitrogen.⁎To highlight the presence of a higher bond length (≤ 3.5 Å.)",PMC8313795
Alpha,"6Table 3Comparision of the residue of RBD and ACE2; PDB ID 7NXC P.1 a lineage (Brazil variant) and PDB ID 6M0J wild type at ≤3.5 Å.Table 3Interaction overview at ≤3.5 ÅChemical bondsSARS-CoV-2 P.1 lineageSARS-CoV-2 wild-typeResiduesLength (Å)ResiduesLength (Å)Hydrogen bondsTYR 449 (OH)2.99ASN487 (ND2)2.6TYR 501 (CE1)3.3LYS417 (NZ)3.0TYR 505 (CD2)3.37GLN493 (NE2)2.8THR 500 (OG1)2.45TYR505 (OH)3.2ASN 487 (ND2)2.42TYR449 (OH)2.7GLN 498 (OE1)3.45THR500 (OG1)2.6GLN 493 (NE2)3.1ASN501 (N)3.7ASN 487 (OD1)2.77TYR449 (OH)3.0TYR 501 (OH)3.32TYR489 (OH)3.5THR 500 (CB)3.45ASN487 (OD1)2.7TYR 453 (OH)3.17GLY 502 (N)2.8TYR 489 (OH)3.41TYR505 (OH)3.7GLN 498 (OE1)3.1GLN 498 (OE1)⁎3.58Other bondsLYS417 (NZ)a3.9LYS417 (NZ)a3.0aSalt bridge, HH: hydrogen eta, OD1: oxygen delta 1, OG1: oxygen gamma 1, O: oxygen, HN: nitrogen eta, NZ: nitrogen zeta, CD: carbon delta, CA: carbon alpha, HH11: hydrogen eta 11, HH12: hydrogen eta 12, HE22:hydrogen epsilon 22, HG1: hydrogen gamma 1, OE1: oxygen epsilon 1, ND2: nitrogen delta 2, NE2: nitrogen epsilon 2, OH: oxygen eta, N: nitrogen.⁎To highlight the presence of a higher bond length (≤ 3.5 Å.)",PMC8313795
Gamma,"6Table 3Comparision of the residue of RBD and ACE2; PDB ID 7NXC P.1 a lineage (Brazil variant) and PDB ID 6M0J wild type at ≤3.5 Å.Table 3Interaction overview at ≤3.5 ÅChemical bondsSARS-CoV-2 P.1 lineageSARS-CoV-2 wild-typeResiduesLength (Å)ResiduesLength (Å)Hydrogen bondsTYR 449 (OH)2.99ASN487 (ND2)2.6TYR 501 (CE1)3.3LYS417 (NZ)3.0TYR 505 (CD2)3.37GLN493 (NE2)2.8THR 500 (OG1)2.45TYR505 (OH)3.2ASN 487 (ND2)2.42TYR449 (OH)2.7GLN 498 (OE1)3.45THR500 (OG1)2.6GLN 493 (NE2)3.1ASN501 (N)3.7ASN 487 (OD1)2.77TYR449 (OH)3.0TYR 501 (OH)3.32TYR489 (OH)3.5THR 500 (CB)3.45ASN487 (OD1)2.7TYR 453 (OH)3.17GLY 502 (N)2.8TYR 489 (OH)3.41TYR505 (OH)3.7GLN 498 (OE1)3.1GLN 498 (OE1)⁎3.58Other bondsLYS417 (NZ)a3.9LYS417 (NZ)a3.0aSalt bridge, HH: hydrogen eta, OD1: oxygen delta 1, OG1: oxygen gamma 1, O: oxygen, HN: nitrogen eta, NZ: nitrogen zeta, CD: carbon delta, CA: carbon alpha, HH11: hydrogen eta 11, HH12: hydrogen eta 12, HE22:hydrogen epsilon 22, HG1: hydrogen gamma 1, OE1: oxygen epsilon 1, ND2: nitrogen delta 2, NE2: nitrogen epsilon 2, OH: oxygen eta, N: nitrogen.⁎To highlight the presence of a higher bond length (≤ 3.5 Å.)",PMC8313795
Alpha,"Here we investigated the relative efficiency of aerosol transmission of two variants of SARS-CoV-2, B.1.1.7 (alpha) and lineage A, in the Syrian hamster.",PPR374984
B.1.1.7,"Here we investigated the relative efficiency of aerosol transmission of two variants of SARS-CoV-2, B.1.1.7 (alpha) and lineage A, in the Syrian hamster.",PPR374984
B.1.351,"C. BHK cells expressing either human ACE2 or hamster ACE2 were infected with pseudotyped VSV reporter particles with the spike proteins of WA1 and B.1.1.7 and B.1.351, luciferase was measured and normalized to no spike controls as a readout for cell entry Relative entry to no spike control for human and hamster ACE2 is depicted.",PPR374984
Gamma,"Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma).",PMC8310664
Alpha,"Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma).",PMC8310664
P.1,"Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma).",PMC8310664
B.1.1.7,"Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma).",PMC8310664
Beta,"The most relevant variants emerged in United Kingdom (known as 20I/501Y.V1, VOC 202,012/01, B.1.1.7, or alpha), South Africa (known as 20H/501Y.V2, B.1.351, or beta) and Brazil (known as P.1, or gamma) during 2020 but started to spread all around the world between December 2020 and January 2021.2 These variants possess different mutations on the receptor-binding domain (RBD) of the spike protein responsible for binding to the ACE2 receptor on the human cell surface.",PMC8310664
B.1.351,"The most relevant variants emerged in United Kingdom (known as 20I/501Y.V1, VOC 202,012/01, B.1.1.7, or alpha), South Africa (known as 20H/501Y.V2, B.1.351, or beta) and Brazil (known as P.1, or gamma) during 2020 but started to spread all around the world between December 2020 and January 2021.2 These variants possess different mutations on the receptor-binding domain (RBD) of the spike protein responsible for binding to the ACE2 receptor on the human cell surface.",PMC8310664
B.1,"In Italy, the SARS-CoV-2 lineage B.1, clade 20A.EU1 circulating across Europe was first identified in March 2020 and remained dominant up to November 2020.4 By the end of February 2021, surveillance data of Umbria region, Italy, revealed the SARS-CoV-2 variants B.1.1.7 and P.1 as accounting for 36.2% and 51.1% of the total cases analyzed, respectively.5
.",PMC8310664
A.1,"found significant differences only from A.1 to B.1 and B.1.1.7, but not from B.1 and B.1.1.7.16 In our study, no differences were found in post-vaccination sera for NT-Abs titers to the 20A.EU1 and B.1.1.7 strains..",PMC8310664
B.1.35,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PPR372615
Beta,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PPR372615
Alpha,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PPR372615
B.1.1.7,"C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa).",PPR372615
B.1.351,"We have explored their binding to and neutralization of two newly emergent variants (B.1.1.7 and B.1.351), identifying a potent cross-reactive agent.",PPR372615
P.1,"The B.1.351 (Beta variant) and P.1 (Gamma variant) lineages are characterized by three mutations (K417N, E484K and N501Y) in the RBD, which, although less prevalent, are a serious concern as they are associated with immune evasion
30
.",PPR372615
Gamma,"The B.1.351 (Beta variant) and P.1 (Gamma variant) lineages are characterized by three mutations (K417N, E484K and N501Y) in the RBD, which, although less prevalent, are a serious concern as they are associated with immune evasion
30
.",PPR372615
Beta,"DL4 and a more potent, rationally designed mutant, neutralizes the Alpha variant as potently as the original strain but only displays marginal activity against the Beta variant.",PPR372255
Alpha,"DL4 and a more potent, rationally designed mutant, neutralizes the Alpha variant as potently as the original strain but only displays marginal activity against the Beta variant.",PPR372255
B.1,"Of the 131 Uganda full SARS-CoV-2 genomes analysed in December 2020, 50 (38%) belonged to lineage A and the rest belonged to a variety of B lineages with the majority lineages being B.1 (N = 30; 23%) and B.1.5 (N = 17; 13%) which were found predominantly in cross border truck drivers seeking to enter the country.",PMC8378408
B.1.351,"8
We sequenced samples collected after September 2020 to increase the chances of detecting any of the emerging circulating SARS-CoV-2 variants including the high mortality
9 variant originally referred to as the UK variant or B.1.1.7, and the highly transmissible
10 variant originally referred to as the South Africa variant or B.1.351/501Y.V2 which had been reported on 14 December and 18 December, 2020 respectively.",PMC8378408
B.1.1.7,"8
We sequenced samples collected after September 2020 to increase the chances of detecting any of the emerging circulating SARS-CoV-2 variants including the high mortality
9 variant originally referred to as the UK variant or B.1.1.7, and the highly transmissible
10 variant originally referred to as the South Africa variant or B.1.351/501Y.V2 which had been reported on 14 December and 18 December, 2020 respectively.",PMC8378408
Iota,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
P.3,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Gamma,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
B.1.427,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Zeta,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Theta,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
B.1.617.2,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
B.1.617.1,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
B.1.525,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
P.2,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Alpha,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
P.1,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Epsilon,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Kappa,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Beta,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
B.1.526,"WGS of SARS-CoV-2 remains vital in elucidating COVID-19 disease
26 for the unforeseeable future as researchers globally continue to identify new SARS-CoV-2 variants of concern and interests such as B.1.1.7 (Alpha), B.1351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.427/B.1.429 (Epsilon), P.2 (Zeta), B.1.525 (B.1.525), P.3 (Theta), B.1.526 (Iota), and B.1.617.1 (Kappa) respectively.",PMC8378408
Alpha,"Specifically, the B.1.1.7 lineage (Alpha variant, or variant V1/20I Nextstrain clade; 17 amino-acid substitutions) emerged in southeast England in November 2020 and rapidly spread towards fixation.",PMC8282437
B.1.1.7,"Specifically, the B.1.1.7 lineage (Alpha variant, or variant V1/20I Nextstrain clade; 17 amino-acid substitutions) emerged in southeast England in November 2020 and rapidly spread towards fixation.",PMC8282437
B.1.351,"The B.1.351 lineage (Beta variant, V2/20H Nextstrain clade; 17 amino-acid substitutions) was initially reported in South Africa in December 2020.",PMC8282437
Beta,"The B.1.351 lineage (Beta variant, V2/20H Nextstrain clade; 17 amino-acid substitutions) was initially reported in South Africa in December 2020.",PMC8282437
P.1,"Additionally, the P.1 lineage (Gamma variant, V3/20 J Nextstrain clade; 17 amino-acid substitutions) was reported in Brazil in January 2021 (Abdool Karim and de Oliveira, 2021).",PMC8282437
Gamma,"Additionally, the P.1 lineage (Gamma variant, V3/20 J Nextstrain clade; 17 amino-acid substitutions) was reported in Brazil in January 2021 (Abdool Karim and de Oliveira, 2021).",PMC8282437
Iota,"Most importantly, besides the aforementioned VOCs, the substitution E484K has been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in variants/lineages P.2 (20B), Eta (21D), Iota (21F) and B.1.620 (20A/S:126A) (CoVariants, 2021).",PMC8282437
P.2,"Most importantly, besides the aforementioned VOCs, the substitution E484K has been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in variants/lineages P.2 (20B), Eta (21D), Iota (21F) and B.1.620 (20A/S:126A) (CoVariants, 2021).",PMC8282437
B.1.620,"Most importantly, besides the aforementioned VOCs, the substitution E484K has been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in variants/lineages P.2 (20B), Eta (21D), Iota (21F) and B.1.620 (20A/S:126A) (CoVariants, 2021).",PMC8282437
Eta,"Most importantly, besides the aforementioned VOCs, the substitution E484K has been reported to emerge independently in several other SARS-CoV-2 lineages worldwide, such as in variants/lineages P.2 (20B), Eta (21D), Iota (21F) and B.1.620 (20A/S:126A) (CoVariants, 2021).",PMC8282437
B.1.526,"with the Iota variant (lineage B.1.526), which have been reported to rapidly spread in New York (Annavajhala et al., 2021).",PMC8282437
B.1.1.318,"The B.1.1.318 lineage, now also listed under the Iota variant (European Centre for Disease Prevention and Control (ECDC), 2021b), which was reported by Public Health England and designated as variant under monitoring is also characterized by only the 484K phenotype in the absence of 501Y substitution (Public Health England, 2021).",PMC8282437
B.1.621,"It should be also noted that, besides Beta and Gamma variants, both aforementioned MOCs are also present in strains belonging to the B.1.621 lineage (Nextstrain clade 21H).",PMC8282437
B.1.177,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.1.305,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.1,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.258,"of samplesVariantFluorescence channelFAMHEXTexas RedCy5HumanNegativeN/A20N/A––––Positive (A)Obtained in September 2020, before the emergence of the targeting mutations20WT++––ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument4WT++––21Alpha (B.1.177)+––+1Beta (B.1.351)––++Positive (B)NGS (Illumina MiSeq)16WT (B.1.177)++––2WT (B.1.258)++––29Alpha (B.1.1.7)+––+12Beta (B.1.351)––++1Other (B.1.1.318)–++–VeterinaryNegativeN/A3 cats, 3 minksN/A––––PositiveNGS (Ion Torrent GeneStudio S5)2 catsWT (B.1.1)++––NGS (Illumina MiSeq)3 minksWT (B.1.1.305)++––N/A: not applicable; WT: wild type; NGS: next-generation sequencing..",PMC8282437
B.1.285,"The viral strains from Northern Greece were characterized by whole genome sequencing using the NGS technology (Illumina MiSeq) and were classified as follows: 29 as Alpha variant (B.1.1.7), 12 as Beta variant (B.1.351) and 18 as WT strains (B.1.285 & B.1.177).",PMC8282437
Gamma,"Maximum likelihood trees were calculated with the best-fit substitution model General Time Reversible with Gamma distribution (GTR+G) for HPIV-1, the Tamura 3-parameter model with Gamma distribution (TN92+G) for HPIV-2, the Tamura-Nei model with Gamma distribution and invariant sites (GTR+G+I) for HPIV-3, and the Tamura 3-parameter model with Gamma distribution and invariant sites (T92+G+I) for HPIV-4, respectively, in MEGA version X [52].",PMC8307145
B.1.351,"Since the end of 2020, there has been a great deal of international concern about the variants of SARS-COV-2 B.1.1.7, identified in the United Kingdom; B.1.351 discovered in South Africa and P.1, originating from the Brazilian state of Amazonas.",PMC8421758
P.1,"Since the end of 2020, there has been a great deal of international concern about the variants of SARS-COV-2 B.1.1.7, identified in the United Kingdom; B.1.351 discovered in South Africa and P.1, originating from the Brazilian state of Amazonas.",PMC8421758
B.1.1.7,"Since the end of 2020, there has been a great deal of international concern about the variants of SARS-COV-2 B.1.1.7, identified in the United Kingdom; B.1.351 discovered in South Africa and P.1, originating from the Brazilian state of Amazonas.",PMC8421758
Alpha,"There was no funding for this study..


Research in ContextEvidence before this study Previous studies reported a higher case fatality rate among patients with COVID-19 caused by Variant of Concern B.1.1.7 (VOC Alpha) when compared to patients who had become infected with the previous strains.",PMC8421758
Beta,"There is very limited information available about the case fatality rate associated with other VOCs, such as B.1.351 (Beta) and P.1 (Gamma).",PMC8421758
Gamma,"There is very limited information available about the case fatality rate associated with other VOCs, such as B.1.351 (Beta) and P.1 (Gamma).",PMC8421758
B.1.1.28,"There was an increase in the proportion of patients without pre-existing risk conditions among severe cases and deaths in the second wave compared to the first.Implications of all the available evidence The P.1 variant has a significantly different virulence and epidemiological profile from the lineages previously established in the state of Amazonas during the first wave of the pandemic, namely B.1.1.28, B.1.1.29, B.1.1.33.",PMC8421758
B.1.1.29,"There was an increase in the proportion of patients without pre-existing risk conditions among severe cases and deaths in the second wave compared to the first.Implications of all the available evidence The P.1 variant has a significantly different virulence and epidemiological profile from the lineages previously established in the state of Amazonas during the first wave of the pandemic, namely B.1.1.28, B.1.1.29, B.1.1.33.",PMC8421758
B.1.1.33,"The analysis of mortality data suggests that there was a change in the mortality profile by sex and age group when comparing the first wave of the COVID-19 pandemic in Amazonas, in which strains B.1.1.28, B.1.1.29 predominated and B.1.1.33 of SARS-CoV-2, and the second pandemic wave, in which the emerging P.1 strain predominated.",PMC8421758
B.1.351,"Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern.",PMC8310330
P.1,"Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern.",PMC8310330
B.1.617,"Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern.",PMC8310330
B.1.1.7,"Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern.",PMC8310330
B.1.617.3,"Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed.",PMC8310330
B.1.1.317,"Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed.",PMC8310330
B.1.1.141,"Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed.",PMC8310330
B.1.617.2,"Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed.",PMC8310330
B.1.617.1,"At the beginning of 2021, the list of variants of concern (VOC) included the B.1.1.7, B.1.351, P.1; currently, this list already contains ten records including linages B.1.617.1, B.1.617.2, B.1.617.3 [9].",PMC8310330
B.1.1.28,"The neutralizing effect of serum samples obtained from patients vaccinated with Pfizer/BNT162b2 was reduced for the B.1.351, B.1.1.28, and B.1.617 variants by 7.85, 5.12, and 3 times, respectively, in comparison to the wild-type virus [11,12].",PMC8310330
B.1.1.1,"Virus isolation and sequencing were carried out in separate aliquots..

Vero E6 (ATCC CRL-1586), 293T, and 293T/ACE2[16] cells were maintained in complete Dulbecco’s modified Eagle’s medium (DMEM), containing 10% fetal bovine serum (FBS, HyClone|Cytiva, Logan, UT, USA), L-glutamine (4 mM) and penicillin/streptomycin solution (100 IU/mL; 100 μg/mL) (PanEco, Moscow, Russia)..

SARS-CoV-2 strains B.1.1.1 or PMVL-1 (GISAID EPI_ISL_421275), B.1.1.141 (T385I) or PMVL-31 (GISAID EPI_ISL_1710849) and B.1.1.317 (S477N, A522S) or PMVL-43 (GISAID EPI_ISL_1710861), B.1.617.2 (T19R G142D E156G F157del R158del L452R T478K D614G P681R D950N) and B.1.617.3 (T19R G142D E156G F157del R158del L452R E484Q D614G P681R D950N) were isolated from a nasopharyngeal swab.",PMC8310330
B.1.1,"In March 2020, the diversity was limited to a few genetic lineages, of which B.1 and B.1.1 were dominant (35.5% and 46.3% respectively).",PMC8310330
B.1,"In March 2020, the diversity was limited to a few genetic lineages, of which B.1 and B.1.1 were dominant (35.5% and 46.3% respectively).",PMC8310330
B.1.1.336,"Currently the dominant lineages consist of B.1.1, B.1.1.141, B.1.1.336, B.1.1.373 and particularly rising B.1.1.317 and B.1.1.397, which together accounted for 82.4% of the diversity in February 2021..

We then focused on the most common RBD mutations and evaluated their combinations in the main genetic lineages.",PMC8310330
B.1.1.397,"Currently the dominant lineages consist of B.1.1, B.1.1.141, B.1.1.336, B.1.1.373 and particularly rising B.1.1.317 and B.1.1.397, which together accounted for 82.4% of the diversity in February 2021..

We then focused on the most common RBD mutations and evaluated their combinations in the main genetic lineages.",PMC8310330
B.1.1.373,"Currently the dominant lineages consist of B.1.1, B.1.1.141, B.1.1.336, B.1.1.373 and particularly rising B.1.1.317 and B.1.1.397, which together accounted for 82.4% of the diversity in February 2021..

We then focused on the most common RBD mutations and evaluated their combinations in the main genetic lineages.",PMC8310330
B.1.1.294,"The emergence of mutations in RBD is noted for B.1.1, B.1.1.141, B.1.1.294, B.1.1.317, and B.1.1.397 genetic lineages (Figure S2)..",PMC8310330
Gamma,"The most discussed VOC in academic literature and media are Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta (lineage B.1.617.2) and initially found in United Kingdom, South Africa, Brazilia, and India, respectively.",PMC8310330
Alpha,"The most discussed VOC in academic literature and media are Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta (lineage B.1.617.2) and initially found in United Kingdom, South Africa, Brazilia, and India, respectively.",PMC8310330
Beta,"The most discussed VOC in academic literature and media are Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta (lineage B.1.617.2) and initially found in United Kingdom, South Africa, Brazilia, and India, respectively.",PMC8310330
P.2,"The E484K mutation is currently found in VOC B.1.351, P.1, P.2, and in the newly emerged Alpha strain B.1.1.7 with an additional E484K mutation.",PMC8310330
P.1,"We found that all trimeric S proteins induced a T cell response and long-lived, strongly neutralizing antibody responses against 2019 SARS-CoV-2 and variants of concern P.1 and B.1.351.",PMC8274612
B.1.351,"However, recently emerged variants of concern (VOCs) first reported in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) are partially resistant to neutralizing antibodies generated against approved vaccines based on the S protein from 2019 strains (17–21).",PMC8274612
B.1.1.7,"However, recently emerged variants of concern (VOCs) first reported in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) are partially resistant to neutralizing antibodies generated against approved vaccines based on the S protein from 2019 strains (17–21).",PMC8274612
Gamma,"These are substantially higher than endpoint titers from a standard high-antibody-titer convalescent human sera control (NIBSC 20/130, see Materials and Methods), which ranged from 1,600 to 6,400, with an average of 3,466..

To assess whether immunization led to the development of S-protein-specific T cells, we stimulated splenocytes from vaccinated mice with peptide pools covering the complete S protein and analyzed the response using a gamma interferon (IFN-γ) ELISpot assay (Fig.",PMC8274612
B.1.351,"Genomic surveillance studies have shown that such mutations led to the emergence of SARS-CoV-2 variants around the globe such as B.1.1.7 (UK) and B.1.351 (South Africa) (Rambaut et al., 2020; Tegally et al., 2021).",PMC8270730
B.1.1.7,"Genomic surveillance studies have shown that such mutations led to the emergence of SARS-CoV-2 variants around the globe such as B.1.1.7 (UK) and B.1.351 (South Africa) (Rambaut et al., 2020; Tegally et al., 2021).",PMC8270730
P.1,"Whole genome sequencing revealed that this surge was related to a new SARS-CoV-2 VOC called P.1 (Faria et al., 2021).",PMC8270730
P.2,"We show for the first time six vaccinees infected with P.1 and P.2 lineages as well as two cases of reinfection by these lineages among vaccinees of the study..

For this study we selected 72 SARS-CoV-2 recently tested positive individuals with nasopharyngeal swabs collected between mid-January and March 2021 with SARS-CoV-2 RT-qPCR Ct values <30.",PMC8270730
Alpha,Access to sequencing data generated in this study is available at GISAID under IDs EPI_ISL_1608103–1608122 and EPI_ISL_2375848–2375899.Table 1Signature mutations of SARS-CoV-2 variants of concern/interest analyzed.Table 1SARS-CoV-2 lineageMutations outside S geneMutations in S geneMutations covered by Sanger sequencingB.1.1.7 (alpha)orf1a:T1001IS:del69/70S:N501Yorf1a:A1708DS:del144/145S:A570Dorf1a:I2230TS:N501YS:D614Gorf1a:del3675/3677S:A570DS:P681Horf1b:P314LS:D614GS:T716IOrf8:Q27*S:P681HOrf8:R52IS:T716IOrf8:Y73CS:S982AN:D3LS:D1118HN:R203KN:G204RN:S235FB.1.351 (beta)ORF1a:T265IS:D80AS:K417NORF1a:K1655NS:D215GS:E484KORF1a:K3353RS:del241/243S:N501YORF1a:del3675/3677S:D614GORF1b:P314LS:A701VORF3a:Q57HORF3a:S171LE:P71LN:T205IP.1 (gamma)orf1a:S1188LS:L18FS:K417Torf1a:K1795QS:T20NS:E484Korf1a:del3675/3677S:P26SS:N501Yorf1b:P314LS:D138YS:D614Gorf1b:E1264DS:R190SS:H655Yorf3a:S253PS:K417Torf8:E92KS:E484KN:P80RS:N501YN:R203KS:D614GN:G204RS:H655YS:T1027IS:V1176FP.2 (zeta)orf1a:L3468VS:E484KS:E484Korf1a:L3930FS:D614GS:D614Gorf1b:P314LS:V1176FN:A119SN:R203KN:G204RN:M234IB.1.617.2 (delta)ORF1b:P314LS:T19RS:L452RORF1b:G662SS:del157/158S:T478KORF1b:P1000LS:D950NS:D614GORF3a:S26LS:P681RM:I82TORF7a:V82AORF7a:T120IORF8:del119/120N:D63GN:R203MN:D377Y.,PMC8270730
Zeta,Access to sequencing data generated in this study is available at GISAID under IDs EPI_ISL_1608103–1608122 and EPI_ISL_2375848–2375899.Table 1Signature mutations of SARS-CoV-2 variants of concern/interest analyzed.Table 1SARS-CoV-2 lineageMutations outside S geneMutations in S geneMutations covered by Sanger sequencingB.1.1.7 (alpha)orf1a:T1001IS:del69/70S:N501Yorf1a:A1708DS:del144/145S:A570Dorf1a:I2230TS:N501YS:D614Gorf1a:del3675/3677S:A570DS:P681Horf1b:P314LS:D614GS:T716IOrf8:Q27*S:P681HOrf8:R52IS:T716IOrf8:Y73CS:S982AN:D3LS:D1118HN:R203KN:G204RN:S235FB.1.351 (beta)ORF1a:T265IS:D80AS:K417NORF1a:K1655NS:D215GS:E484KORF1a:K3353RS:del241/243S:N501YORF1a:del3675/3677S:D614GORF1b:P314LS:A701VORF3a:Q57HORF3a:S171LE:P71LN:T205IP.1 (gamma)orf1a:S1188LS:L18FS:K417Torf1a:K1795QS:T20NS:E484Korf1a:del3675/3677S:P26SS:N501Yorf1b:P314LS:D138YS:D614Gorf1b:E1264DS:R190SS:H655Yorf3a:S253PS:K417Torf8:E92KS:E484KN:P80RS:N501YN:R203KS:D614GN:G204RS:H655YS:T1027IS:V1176FP.2 (zeta)orf1a:L3468VS:E484KS:E484Korf1a:L3930FS:D614GS:D614Gorf1b:P314LS:V1176FN:A119SN:R203KN:G204RN:M234IB.1.617.2 (delta)ORF1b:P314LS:T19RS:L452RORF1b:G662SS:del157/158S:T478KORF1b:P1000LS:D950NS:D614GORF3a:S26LS:P681RM:I82TORF7a:V82AORF7a:T120IORF8:del119/120N:D63GN:R203MN:D377Y.,PMC8270730
Beta,Access to sequencing data generated in this study is available at GISAID under IDs EPI_ISL_1608103–1608122 and EPI_ISL_2375848–2375899.Table 1Signature mutations of SARS-CoV-2 variants of concern/interest analyzed.Table 1SARS-CoV-2 lineageMutations outside S geneMutations in S geneMutations covered by Sanger sequencingB.1.1.7 (alpha)orf1a:T1001IS:del69/70S:N501Yorf1a:A1708DS:del144/145S:A570Dorf1a:I2230TS:N501YS:D614Gorf1a:del3675/3677S:A570DS:P681Horf1b:P314LS:D614GS:T716IOrf8:Q27*S:P681HOrf8:R52IS:T716IOrf8:Y73CS:S982AN:D3LS:D1118HN:R203KN:G204RN:S235FB.1.351 (beta)ORF1a:T265IS:D80AS:K417NORF1a:K1655NS:D215GS:E484KORF1a:K3353RS:del241/243S:N501YORF1a:del3675/3677S:D614GORF1b:P314LS:A701VORF3a:Q57HORF3a:S171LE:P71LN:T205IP.1 (gamma)orf1a:S1188LS:L18FS:K417Torf1a:K1795QS:T20NS:E484Korf1a:del3675/3677S:P26SS:N501Yorf1b:P314LS:D138YS:D614Gorf1b:E1264DS:R190SS:H655Yorf3a:S253PS:K417Torf8:E92KS:E484KN:P80RS:N501YN:R203KS:D614GN:G204RS:H655YS:T1027IS:V1176FP.2 (zeta)orf1a:L3468VS:E484KS:E484Korf1a:L3930FS:D614GS:D614Gorf1b:P314LS:V1176FN:A119SN:R203KN:G204RN:M234IB.1.617.2 (delta)ORF1b:P314LS:T19RS:L452RORF1b:G662SS:del157/158S:T478KORF1b:P1000LS:D950NS:D614GORF3a:S26LS:P681RM:I82TORF7a:V82AORF7a:T120IORF8:del119/120N:D63GN:R203MN:D377Y.,PMC8270730
Gamma,Access to sequencing data generated in this study is available at GISAID under IDs EPI_ISL_1608103–1608122 and EPI_ISL_2375848–2375899.Table 1Signature mutations of SARS-CoV-2 variants of concern/interest analyzed.Table 1SARS-CoV-2 lineageMutations outside S geneMutations in S geneMutations covered by Sanger sequencingB.1.1.7 (alpha)orf1a:T1001IS:del69/70S:N501Yorf1a:A1708DS:del144/145S:A570Dorf1a:I2230TS:N501YS:D614Gorf1a:del3675/3677S:A570DS:P681Horf1b:P314LS:D614GS:T716IOrf8:Q27*S:P681HOrf8:R52IS:T716IOrf8:Y73CS:S982AN:D3LS:D1118HN:R203KN:G204RN:S235FB.1.351 (beta)ORF1a:T265IS:D80AS:K417NORF1a:K1655NS:D215GS:E484KORF1a:K3353RS:del241/243S:N501YORF1a:del3675/3677S:D614GORF1b:P314LS:A701VORF3a:Q57HORF3a:S171LE:P71LN:T205IP.1 (gamma)orf1a:S1188LS:L18FS:K417Torf1a:K1795QS:T20NS:E484Korf1a:del3675/3677S:P26SS:N501Yorf1b:P314LS:D138YS:D614Gorf1b:E1264DS:R190SS:H655Yorf3a:S253PS:K417Torf8:E92KS:E484KN:P80RS:N501YN:R203KS:D614GN:G204RS:H655YS:T1027IS:V1176FP.2 (zeta)orf1a:L3468VS:E484KS:E484Korf1a:L3930FS:D614GS:D614Gorf1b:P314LS:V1176FN:A119SN:R203KN:G204RN:M234IB.1.617.2 (delta)ORF1b:P314LS:T19RS:L452RORF1b:G662SS:del157/158S:T478KORF1b:P1000LS:D950NS:D614GORF3a:S26LS:P681RM:I82TORF7a:V82AORF7a:T120IORF8:del119/120N:D63GN:R203MN:D377Y.,PMC8270730
B.1.1.28,"The phylogenetic tree depicts that most of the sequences characterized herein belonged to P.1 (33; 46%) or P.2 (33; 46%) variants, followed by B.1.1.7 (4; 5.5%) and by B.1.1.28 (2; 2.5%), this latter one of the original variants found in the first wave of the pandemic in Brazil.Fig.",PMC8270730
B.1.351,"However, virus escape analysis identifies a single natural mutation in RBD, namely K417N found in B.1.351 variant from South Africa, abolished the neutralizing activity of these public antibodies.",PMC8270942
P.1,"Mutations at position 417 have recently been identified in SA501Y.V2 (B.1.351) variant from South Africa and in BR501Y.V3 (P.1) from Brazil and found capable of substantially reducing antibody and vaccine efficacy including those already approved for emergence use28,36–40.",PMC8270942
Lambda,"Recent reports have also recognized disproportionally high prevalence of IGHV3-53/3-66 with limited somatic mutations among SARS-CoV-2 patients11,25.Table 1Binding capacity, neutralizing activity, and gene family analysis of 13 monoclonal Abs isolated from Patient #5, Patient #2, and Patient #22.PatientmAbsBinding to RBDPseudovirus (μg/ml)Live virus (μg/ml)Heavy chainKappa chain (K) or Lambda chain (L)Kd (nM)Competing w/ ACE2IC50IC80IC50IC80IGHVHCDR3HCDR3 lengthSHM (%)IGK(L)VK(L)CDR3K(L)CDR3 lengthSHM (%)P#5P5A-1B93.41+++0.00140.00530.00430.04414-59*01ASNGQYYDILTGQPPDYWYFDL220.70K4-1*01QQYYSTPLT90.00P#22P22A-1D15.79+++0.00380.06250.01980.13213-53*01ARDRDYYGMDV110.00K1-9*01LHLNSYRT80.38P#5P5A-2G73.95+++0.00440.02870.18140.83554-61*01ARERCYYGSGRAPRCVWFDP200.34L2-14*01SSYTSSSTLVV110.74P#5P5A-1D16.83+++0.00960.06910.01890.07433-53*01ARDLYYYGMDV110.35K1-9*01QQLNSYPT80.76P#5P5A-1B84.28+++0.01150.05010.01680.08573-53*01ARETLAFDY91.40K1-9*01QQLNSYPPA90.00P#5P5A-2G915.94+++0.01580.14660.01130.11873–33*01,3–33*06ARWFHTGGYFDY120.00L5-37*01MIWPSNALYV100.35P#5P5A-1D214.02+++0.01860.10250.02730.43253-53*01ARALQVGATSDYFDY151.40L1-40*01QSCDSSLSVVV111.11P#5P5A-3C81.30+++0.02060.10310.01120.14993-53*01ARDLQEHGMDV111.05K1-9*01QHLNSYPPGYT111.14P#2P2C-1F11*3.64+++0.02860.11950.03230.17793-66*01,3-66*04ARDLVVYGMDV111.75K3-20*01QQYGSSPT80.00P#2P2B-2F6*5.57+++0.05000.60740.40742.43094-38-2*02ARAVVGIVVVPAAGRRAFDI200.69L2-8*01SSYAGSNNLV100.00P#2P2B-1A1038.41+++0.09740.74460.06390.30533-53*01AREGPKSITGTAFDI150.35K1-33*01,K1D-33*01QQYDNLPMYT100.38P#5P5A-3B41.16+0.09931.06570.05611.00805-51*01ARRDSTYGGNTDY130.35L1-44*01AAWDDSLNGVV110.00P#5P5A-3C128.47+++0.09960.46790.26362.67832–5*02AHSLFLTVGYSSSWSPFDY190.00K4-1*01QQYYSTPHT90.00The program IMGT/V-QUEST was applied to analyze gene germline, complementarity determining region (CDR) 3 length, and somatic hypermutation (SHM).",PMC8270942
Beta,"Neutralization assays against live SARS-CoV-2 were conducted using a clinical isolate (Beta/Shenzhen/SZTH-003/2020, EPI_ISL_406594 at the Global Initiative on Sharing All Influenza Data (GISAID) database) previously obtained from a nasopharyngeal swab of an infected patient.",PMC8270942
B.1.1.7,"Lineagespot was able to record the evolution and rapid domination of the B.1.1.7 lineage in the community, and allowed for a robust inference between the variants evident through our approach and the variants observed in patients from the same area time periods.",PPR367843
A.1,"As an example, for lineage A.1, the output produced by using the freebayes variant caller tool in the first step of the methodology, returns n

d
 = 2 and n

t
 = 10 rules satisfied, while the output of the GATK Mutect2 tool returns n

d
 = 1 and n

t
 = 4 rules satisfied.",PPR367843
B.1.351,"To this end, two Variants of Concern were selected; the B.1.1.7 (UK) and the B.1.351 (South Africa) lineages which are shown in Figure 3..",PPR367843
B.1.177.17,"As an example, suppose that a group of reads satisfy only the first two rules from lineage B.1.177.17 (28931!=’A’, 25613!=’G’), and another group of reads satisfy the next two rules from the same lineage (407!=’-’, 22087!=’A’).",PPR367843
Gamma,"Reverse genetics systems and recombinant techniques are being used to develop new vaccines to target specific antigens of the AHSV, including several viral and nonstructural proteins of the virus, including the capsid proteins VP2 and VP5, as well as NS1, which may elicit an interferon gamma host antiviral response [10,11,12,16,43].",PMC8300273
B.1.1.7,"Although there are several variants emerging from the original Wuhan strain, the following three lineages have been identified to be more infectious: lineage B.1.1.7 (WHO label: Alpha variant) identified in the UK, the B.1.351 (WHO label: Beta variant) in South Africa, and the P.1 (WHO label: Alpha variant) from Brazil (3).",PMC8297464
Alpha,"Although there are several variants emerging from the original Wuhan strain, the following three lineages have been identified to be more infectious: lineage B.1.1.7 (WHO label: Alpha variant) identified in the UK, the B.1.351 (WHO label: Beta variant) in South Africa, and the P.1 (WHO label: Alpha variant) from Brazil (3).",PMC8297464
B.1.351,"Although there are several variants emerging from the original Wuhan strain, the following three lineages have been identified to be more infectious: lineage B.1.1.7 (WHO label: Alpha variant) identified in the UK, the B.1.351 (WHO label: Beta variant) in South Africa, and the P.1 (WHO label: Alpha variant) from Brazil (3).",PMC8297464
P.1,"Although there are several variants emerging from the original Wuhan strain, the following three lineages have been identified to be more infectious: lineage B.1.1.7 (WHO label: Alpha variant) identified in the UK, the B.1.351 (WHO label: Beta variant) in South Africa, and the P.1 (WHO label: Alpha variant) from Brazil (3).",PMC8297464
Beta,"Although there are several variants emerging from the original Wuhan strain, the following three lineages have been identified to be more infectious: lineage B.1.1.7 (WHO label: Alpha variant) identified in the UK, the B.1.351 (WHO label: Beta variant) in South Africa, and the P.1 (WHO label: Alpha variant) from Brazil (3).",PMC8297464
P.1.1,"We read with interest the recently published manuscript of Dimeglio et al., exploring the SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.1 and here we report a case of SARS-CoV-2 infection with a P.1.1 variant lacking the Y501 mutation in a vaccinated individual in Italy..

COVID-19 vaccines are very effective in preventing infections, hospitalizations and deaths.",PMC8257417
P.1,1Genomic detection of the SARS-CoV-2 P.1 variant of concern in a vaccine breakthrough case in Italy.,PMC8257417
B.1.427,"Notably, B.1.427 became dominant in Western New York, before it was displaced by B.1.1.7.",PPR365689
B.1.1.7,"Our hierarchical cluster analysis of B.1.1.7 lineages, which by May 2021 made up ~ 80% of all cases, indicated both multiple introductions and community spread.",PPR365689
B.1.351,"B.1.1.7, B.1.351, P.1, and so forth, are so-called variants of concern (VOC), as defined by WHO and the CDC.",PPR365689
P.1,"B.1.1.7, B.1.351, P.1, and so forth, are so-called variants of concern (VOC), as defined by WHO and the CDC.",PPR365689
B.1.429,Two B.1.429 samples were collected on Jan. 20; the genomic sequences were identical.,PPR365689
P.2,"We also identified one P.2 variant, currently designated a variant of interest by WHO and the CDC, originally identified in Brazil..",PPR365689
B.1.526,"This is in direct contrast to the variant profiles seen in NYC, where cases were dominated by B.1.526 lineages in addition to B.1.1.7.",PPR365689
B.1.617,The recent emergence of B.1.617 lineage has created grave public health problem in India.,PPR365005
B.1.617.2,"The lineage further mutated to generate sub-lineages B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3.",PPR365005
Kappa,"The lineage further mutated to generate sub-lineages B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3.",PPR365005
B.1.617.1,"The lineage further mutated to generate sub-lineages B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3.",PPR365005
B.1.617.3,"The SARS-CoV-2 lineage B.1.617 was initially detected from India during October 2020 and since then further mutated as sub lineages B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3 variant.",PPR365005
Alpha,The Delta variant has been reported to be 60% more transmissible than the Alpha variant (B.111.7) and the WHO has designated Delta variant as a Variant of Concern (VOC).,PPR365005
B.1.351,"4
 Reduced efficacy against B.1.351 was also reported for the NVX-CoV237 (Novavax) and Ad26.COV2-S (Johnson & Johnson) vaccines.",PPR365005
B.1,"7
 Here, we have assessed the NAb response of individuals immunized with Covishield™ (first dose and second dose), COVID-19 recovered individuals who were vaccinated (first dose and second dose) and breakthrough infections (due to Kappa and the Delta variant)..

A comparative assessment of Covishield™ vaccinated individuals’ (n=116) sera in different categories was performed against prototype strain B.1 (D614G) and Delta variant.",PPR365005
B.1.1.7,"According to the data of a phylogenetic analysis, this
strain forms a distinct phylogenetic cluster (lineage B.1.1.7) [84].",PMC8526184
B.1.351,"It is necessary to note the emergence of
convergent mutations common to the P1, B.1.1.7, and B.1.351 lineages
(Table 1).",PMC8526184
A.3,"Six lineages derived from lineage A (A.1–A.6) and two
descendant sublineages of A.1 (A.1.1 and A.3) are identified.",PMC8526184
A.1,"Six lineages derived from lineage A (A.1–A.6) and two
descendant sublineages of A.1 (A.1.1 and A.3) are identified.",PMC8526184
B.1,"Also, there are
16 lineages derived from lineage B. Lineage B.1, comprising 70 sublineages as
of April 2020, is predominant.",PMC8526184
B.1.1,"A phylogenetic analysis of SARS-CoV-2 isolates from
Russia showed that most samples correspond to the B.1, B.1.1, and B.1* lineages
(PANGOLIN nomenclature) or to the G, GR, and GH clades (GISAID nomenclature),
which are widespread in Europe [106].",PMC8526184
B.1.351,"Overall, our mutational fingerprinting and nomenclature provide a simple way to glean the ancestry of new variants compared with phylogenetic designations, such as B.1.351 and B.1.1.7 (Rambaut, Loman, et al.",PMC8135569
B.1.1.7,"Overall, our mutational fingerprinting and nomenclature provide a simple way to glean the ancestry of new variants compared with phylogenetic designations, such as B.1.351 and B.1.1.7 (Rambaut, Loman, et al.",PMC8135569
A.1,"This includes all small- and medium-sized phylogenetic groups (up to 488 genomes) and two large groups (A.1 with 1,377 genomes and B.1.2 with 749 genomes).",PMC8135569
B.1.2,"This includes all small- and medium-sized phylogenetic groups (up to 488 genomes) and two large groups (A.1 with 1,377 genomes and B.1.2 with 749 genomes).",PMC8135569
B.1.1,"One large group, B.1.1, predominately connects with ε3 node (79%, 4,832 genomes), but some of its members belong to ε3 offshoots because they contain respective diagnostic mutations.",PMC8135569
B.1.1.1,"For group B.1.1.1, two other ε3 offshoots are mixed up almost equally.",PMC8135569
B.1.351,"Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen..

Development of multiple safe and effective vaccines to control the ongoing COVID-19 pandemic (Cucinotta and Vanelli, 2020; World Health Organization, 2020b) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; Wu et al., 2020; Zhu et al., 2020) is a global priority, and several vaccines have already been authorized or approved for use in humans to fight the pandemic (Voysey et al., 2021; Baden et al., 2021; Polack et al., 2020).",PMC8085771
B.1.1.7,"Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen..

Development of multiple safe and effective vaccines to control the ongoing COVID-19 pandemic (Cucinotta and Vanelli, 2020; World Health Organization, 2020b) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; Wu et al., 2020; Zhu et al., 2020) is a global priority, and several vaccines have already been authorized or approved for use in humans to fight the pandemic (Voysey et al., 2021; Baden et al., 2021; Polack et al., 2020).",PMC8085771
B.1,"(A) Correlation between Leiden-0008 strain (B.1 lineage; LUMC) and Wuhan-Hu-1 (A lineage, Nexelis).",PMC8085771
Beta,SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold.,PMC8278575
B.1.1.7,"The B.1.1.7, lineage, originated in the U.K, it soon spread to other countries after its discovery in December 2020 and grew at an exponential pace.",PMC8278575
B.1.351,"The B.1.351 Lineage, first reported in South Africa in December 2020, this variant, also known as 20H/501Y.V2 carries a mutation (N501Y) in the spike protein’s RBD, which lead to increased transmission, with estimates ranging between 40% and 70%; K417N, which also aids the virus in binding to human cells more closely; and E484K, a mutation that may aid the virus in evading certain types of antibodies (84)..

After spreading from South Africa into neighboring countries, it has expanded to at least 68 nations.",PMC8278575
P.1,The P.1 lineage was discovered in four people in Japan who contracted P.1 while on vacation in Brazil.,PMC8278575
B.1.429,"The CAL.20C variant was originated in California, in late 2020, from the B.1.427 and B.1.429 lineages.",PMC8278575
B.1.427,"The CAL.20C variant was originated in California, in late 2020, from the B.1.427 and B.1.429 lineages.",PMC8278575
B.1.617,"The B.1.617 variant, also known as G/452.V3, was first detected in Maharashtra, India, in October 2020.",PMC8278575
B.1.617.2,Recent studies shows that B.1.617.2 is at least as transmissible as the B.1.1.7 variant.,PMC8278575
B.10,"Table 1Comparison of corresponding nomenclature of SARS-CoV-2Corresponding nomenclature/clade/lineageNotable variantshCoV-19/ Wuhan/WIV04/2019B.1 clades: D614GB.1.351 lineageB.1.1.7 Lineage and B.1.1.207Andrew Rambaut, et alA.1-A.6B.3-B.7 B.9, B.10 B.13-B.16B.2`B.1Nextstrain.org/ncov19B19A20A20C20B20EGISAIDSL and OVGGHGRGV.",PMC8237041
A.6,"Further six lineages, A.1 to A.6 were recognized from lineage A and two descendant sublineages, A.1.1 and A.3 were recognized from A.1.",PMC8237041
A.3,"Further six lineages, A.1 to A.6 were recognized from lineage A and two descendant sublineages, A.1.1 and A.3 were recognized from A.1.",PMC8237041
A.1,"Further six lineages, A.1 to A.6 were recognized from lineage A and two descendant sublineages, A.1.1 and A.3 were recognized from A.1.",PMC8237041
B.1,"So far, lineage B.1 is the major recognized lineage and it additionally subclassified into more than 70 sublineages [18].According to Nextstrain.org/ncov: Total 11 major clades were distinguished on the basis of analysis of clades.nextstrain.org.",PMC8237041
B.1.1.7,"Variants from this lineage are associated with multiple amino acid changes in the spike protein, including a deletion at 69/70, mutation in ORF8, P681H, N501Y and E484K mutation.A.N501Y: The N501Y (substitution of Asparagine to Tyrosine at 501 amino acid position) mutation is of major concern of B.1.1.7 lineage, as it is present in Receptor Binding Motif of Receptor Binding Domain (RBD) in Spike glycoprotein.",PMC8237041
B.1.351,E484K mutation is also deemed to be responsible for the reduced efficacy of both vaccine and convalescent sera [33].Lineage B.1.351 or 501.2 variant: It is also known as 20C/501Y.V2 or South African Covid Variant and was first detected in South Africa during mid-December 2020.,PMC8237041
B.1.258,Transmission and virulence of this variant is unclear [37].Lineage B.1.258∆: It has been identified within B.1.258 clade in Czech Republic and Slovakia during September-December 2020.,PMC8237041
B.1.1.28,"This variant belongs to B.1.1.28 lineage and contains 17 non-synonymous mutations, 11 in S protein viz L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F; 3 in ORF1ab viz S1188L, K1795Q, and E5665D; one in ORF8 namely E92K, and one P80K in N protein; 1 deletion namely SGF 3675-3677del in ORF1ab; and 4 synonymous mutations.",PMC8237041
B.1.429,"Functional effect of this variant regarding antigenicity and transmissibility of SARS-CoV-2 is uncertain [42].CAL.20C: It arises from lineage B.1.429 and was first identified in Europe and Los Angeles of United states in the year 2020, then it rapidly escalated in California during January 2021.",PMC8237041
B.1.617,"However, most of the commercially available PCR protocols are using multiple targets and presumably no significant impact on diagnosis [48].Faster transmissibility in the population: D614G [49], B.1.1.7 [31], and B.1.617 [45] variant of SARS-CoV-2 has been associated with faster transmissibility compared to 614D variant (wild type).",PMC8237041
B.1.168,"Lineage B.1.617 and Lineage B.1.168 are responsible for recent quick surge of SARS-CoV-2 cases in India.
.

Genomics evaluate the particular virology in real time.",PMC8237041
Gamma,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.617.2,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.1.7,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
Alpha,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.351,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
P.1,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
Beta,"These VOCs include lineages identified in the UK (B.1.1.7, Alpha) [348], in South Africa (B.1.351, Beta) [349], in Brazil/Japan (P.1, Gamma) [350], and more recently in India (B.1.617.2, Delta) [351,352].",PMC8307803
B.1.617.3,"More recently, there was a massive outbreak of B.1.617 in India, a lineage characterized by the combination of L452R and E484Q spike mutations in sublineages B.1.617.1 and B.1.617.3 or L452R and T478K in B.1.617.2 [351,352,390].",PMC8307803
B.1.617.1,"More recently, there was a massive outbreak of B.1.617 in India, a lineage characterized by the combination of L452R and E484Q spike mutations in sublineages B.1.617.1 and B.1.617.3 or L452R and T478K in B.1.617.2 [351,352,390].",PMC8307803
B.1.617,"More recently, there was a massive outbreak of B.1.617 in India, a lineage characterized by the combination of L452R and E484Q spike mutations in sublineages B.1.617.1 and B.1.617.3 or L452R and T478K in B.1.617.2 [351,352,390].",PMC8307803
B.1.177,"Furthermore, variants 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) increased in dominance, the latter one carrying the S477N mutation in RBD that might have resulted from selective pressure exerted by the host nAb response and possibly increases RBD’s affinity for ACE2 [371,417].",PMC8307803
B.1.160,"Furthermore, variants 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) increased in dominance, the latter one carrying the S477N mutation in RBD that might have resulted from selective pressure exerted by the host nAb response and possibly increases RBD’s affinity for ACE2 [371,417].",PMC8307803
B.1.429,"In the US, two Californian lineages (B.1.427 and B.1.429) gained dominance in the second year of the pandemic, characterized, again, by recurring spike mutations [418].",PMC8307803
B.1.427,"In the US, two Californian lineages (B.1.427 and B.1.429) gained dominance in the second year of the pandemic, characterized, again, by recurring spike mutations [418].",PMC8307803
B.1.526,"In New York, B.1.526 variants were detected frequently carrying either the S477N or E484K mutation (Table 2, Figure 6) [423,424].",PMC8307803
B.1.525,"Since E484K is known to impair nAb efficacy as described for B.1.351 and P.1, these variants pose a possible bias to vaccines. .

More recently, lineage B.1.525 was detected in the UK and in Nigeria and rapidly spread over more than 20 countries in the world.",PMC8307803
B.1.1.28,"On the Philippines, variant P.3 was identified, which stems from the same lineage B.1.1.28 as P.1 and harbors N501Y, E484K, and P681H mutations [428].",PMC8307803
P.3,"On the Philippines, variant P.3 was identified, which stems from the same lineage B.1.1.28 as P.1 and harbors N501Y, E484K, and P681H mutations [428].",PMC8307803
C.37,"In Peru and Chile, a new sublineage within B.1.1.1 is expanding, designated C.37, with the novel spike deletion Δ246–252 [429].",PMC8307803
B.1.1.1,"In Peru and Chile, a new sublineage within B.1.1.1 is expanding, designated C.37, with the novel spike deletion Δ246–252 [429].",PMC8307803
B.1.1.7,Efficacy against B.1.1.7 lineage.,PMC8373118
B.1.351,"SARS‐2‐S mutations have occurred in the P1 lineage (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, and D614G), the B.1.1.7 lineage (del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, and D1118H), and the B.1.351 lineage (K417N, E484K, N501Y, D614G, and A701V).",PMC8373118
B.1.427,"Indeed, in humans, SARS-CoV-2 variants of concern were described since October 2020 in the United Kingdom (lineage B.1.1.7), Brazil and Japan (P.1), United States of America (B.1.427 and B.1.429), and South Africa (B.1.351) (Public Health England, 2020; Faria et al., 2021; Tegally et al., 2021).",PMC8267889
B.1.1.7,"Indeed, in humans, SARS-CoV-2 variants of concern were described since October 2020 in the United Kingdom (lineage B.1.1.7), Brazil and Japan (P.1), United States of America (B.1.427 and B.1.429), and South Africa (B.1.351) (Public Health England, 2020; Faria et al., 2021; Tegally et al., 2021).",PMC8267889
P.1,"Indeed, in humans, SARS-CoV-2 variants of concern were described since October 2020 in the United Kingdom (lineage B.1.1.7), Brazil and Japan (P.1), United States of America (B.1.427 and B.1.429), and South Africa (B.1.351) (Public Health England, 2020; Faria et al., 2021; Tegally et al., 2021).",PMC8267889
B.1.351,"Indeed, in humans, SARS-CoV-2 variants of concern were described since October 2020 in the United Kingdom (lineage B.1.1.7), Brazil and Japan (P.1), United States of America (B.1.427 and B.1.429), and South Africa (B.1.351) (Public Health England, 2020; Faria et al., 2021; Tegally et al., 2021).",PMC8267889
B.1.429,"Indeed, in humans, SARS-CoV-2 variants of concern were described since October 2020 in the United Kingdom (lineage B.1.1.7), Brazil and Japan (P.1), United States of America (B.1.427 and B.1.429), and South Africa (B.1.351) (Public Health England, 2020; Faria et al., 2021; Tegally et al., 2021).",PMC8267889
B.1.1.298,(B) Phylogenetic grouping of mink-associated variant transmission Clusters 1–5 (lineage B.1.1.298).,PMC8267889
B.1.1.7,"The more infectious SARS-CoV-2 lineage B.1.1.7 rapidly spread in Europe after December, 2020, and a concern that B.1.1.7 could cause more severe disease has been raised.",PMC8219488
B.1.351,"The proportion of the study population with variants of concern other than B.1.1.7 (34 [0·1%] with B.1.351, and three [<0·1%] with P.1) or with variants of interest (257 [0·8%] with B.1.525) was very low, and proportions for the remaining circulating lineages during the study period (19 734 [64·5%]) are described by DCGC online.",PMC8219488
P.1,"The proportion of the study population with variants of concern other than B.1.1.7 (34 [0·1%] with B.1.351, and three [<0·1%] with P.1) or with variants of interest (257 [0·8%] with B.1.525) was very low, and proportions for the remaining circulating lineages during the study period (19 734 [64·5%]) are described by DCGC online.",PMC8219488
B.1.525,"The proportion of the study population with variants of concern other than B.1.1.7 (34 [0·1%] with B.1.351, and three [<0·1%] with P.1) or with variants of interest (257 [0·8%] with B.1.525) was very low, and proportions for the remaining circulating lineages during the study period (19 734 [64·5%]) are described by DCGC online.",PMC8219488
B.1.351,All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain.,PMC8216847
Lambda,"A total of 341 heavy chains (HCs), 353 kappa light chains (κLCs), and 303 lambda light chains (λLCs) were successfully sequenced from the four SARS-CoV-2-positive donors (Table S1; Figure S1), from which 228 paired HC/LCs were generated, and 198 Abs were successfully produced and characterized.",PMC8216847
Kappa,"A total of 341 heavy chains (HCs), 353 kappa light chains (κLCs), and 303 lambda light chains (λLCs) were successfully sequenced from the four SARS-CoV-2-positive donors (Table S1; Figure S1), from which 228 paired HC/LCs were generated, and 198 Abs were successfully produced and characterized.",PMC8216847
Alpha,"Additional BLI data and comparison to number of amino acid mutations in Figure S3..

We also determined the abilities of these Abs to recognize SARS-CoV-1; MERS; the two endemic human beta coronaviruses, OC43 and HKU1; and the two endemic human alpha coronaviruses, NL63 and 229E (Figure 3B).",PMC8216847
Beta,"Additional BLI data and comparison to number of amino acid mutations in Figure S3..

We also determined the abilities of these Abs to recognize SARS-CoV-1; MERS; the two endemic human beta coronaviruses, OC43 and HKU1; and the two endemic human alpha coronaviruses, NL63 and 229E (Figure 3B).",PMC8216847
P.1,"Recently, lineages of viral variants have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (Davies et al., 2020; Faria et al., 2021; Rambaut et al., 2020; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021).",PMC8216847
B.1.1.7,"Recently, lineages of viral variants have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (Davies et al., 2020; Faria et al., 2021; Rambaut et al., 2020; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021).",PMC8216847
B.1.617.2,"The SARS-CoV-2 B.1.617.2 (Delta) variant was first identified in the state of Maharashtra in late 2020 and has spread throughout India, displacing the B.1.1.7 (Alpha) variant and other pre-existing lineages.",PPR360151
Alpha,"The SARS-CoV-2 B.1.617.2 (Delta) variant was first identified in the state of Maharashtra in late 2020 and has spread throughout India, displacing the B.1.1.7 (Alpha) variant and other pre-existing lineages.",PPR360151
B.1.1.7,"The SARS-CoV-2 B.1.617.2 (Delta) variant was first identified in the state of Maharashtra in late 2020 and has spread throughout India, displacing the B.1.1.7 (Alpha) variant and other pre-existing lineages.",PPR360151
B.1.617.1,"In an analysis of vaccine breakthrough in over 100 healthcare workers across three centres in India, the Delta variant not only dominates vaccine-breakthrough infections with higher respiratory viral loads compared to non-delta infections (Ct value of 16.5 versus 19), but also generates greater transmission between HCW as compared to B.1.1.7 or B.1.617.1 (mean cluster size 1.1 versus 3.3 p=0.03).",PPR360151
B.1.617,"The B.1.617 variant emerged in the state of Maharashtra in late 2020/early 2021
3
, spreading throughout India and to at least 60 countries.",PPR360151
B.1.351,"Importantly in the same assay, the Beta variant (B.1.351) that emerged in South Africa demonstrated an 8.2 fold loss of neutralisation sensitivity relative to WT..

We next sought biological evidence for the higher transmissibility predicted from the modelling.",PPR360151
Beta,"Importantly in the same assay, the Beta variant (B.1.351) that emerged in South Africa demonstrated an 8.2 fold loss of neutralisation sensitivity relative to WT..

We next sought biological evidence for the higher transmissibility predicted from the modelling.",PPR360151
B.1.1.7,"The genome sequence of the Wuhan-Hu-1 isolate (NC_045512.2) was used as the SARS-CoV-2 reference sequence.Table 1Sequences of primers used for synthesis of PCR amplicons that include SARS-CoV-2 genome sequence variations of interesta.Table 1Amplicon no.Genomic region within ampliconPrimer sequences (5ˈ- 3ˈ)bTarget Tag SNV/haplotypeOther sequence variations of interest within the amplicon113961–14601F: TATACGCCAACTTAGGTGAACG14408C>T/H1R: TAGATTACCAGAAGCAGCGTG221770–22446F: GTCTCTGGGACCAATGGTAC22227C>T/H1r21991-21993delTTA/B.1.1.7R: GGGTCAAGTGCACAGTCTAC322855–23562F: CTGCGTTATAGCTTGGAATTCT23403A>G/H123012G>A/B.1.351; 23063A>T/B.1.1.7 & B.1.351; 23271C>A/B.1.1.7R: CCAATGGGTATGTCACACTCA425318–25940F: CTGCTGCAAATTTGATGAAGAC25563G>T/H1bR: TCATGTTCAGAAATAGGACTTGT528497–29161F: ACACCAATAGCAGTCCAGATG28881_28883GGG>AAC/H1a28688T>C/H5; 28932C>T/H1r; 28977C>T/B.1.1.7R: AGTTCCTTGTCTGATTAGTTCCTa, The cDNAs pertaining to amplicons 1 and 3 were usually synthesized together in a single cDNA synthesis reaction, as were the cDNAs pertaining to amplicons 4 and 5.bReverse (R) primers were used in all of the cDNA synthesis reactions.Fig.",PMC8214199
B.1.36,Genome type C may correspond to the very recently described B.1.36 lineage of the Phylogenetic Assignment Named Global Outbreak (PANGO) Lineages (GISAID).,PMC8214199
B.1.617.2,"With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom.",PMC8218332
B.1.617.1,"Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants.",PMC8218332
B.1.351,"However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2.",PMC8218332
P.1,"However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2.",PMC8218332
B.1.1.7,"This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations..

•Vaccine/convalescent sera show reduced neutralization of B.1.617.1 and B.1.617.2•Sera from B.1.351and P.1 show markedly reduced neutralization of B.1.617.2•B.1.351, P.1, and B.1.617.2 are antigenically divergent•Vaccines based on B.1.1.7 may protect broadly against current variants.",PMC8218332
B.1.617,"The B.1.617 lineage of SARS-CoV-2, especially the delta strain, which is B.1.617.2, has contributed to the wave of infection in the Indian subcontinent.",PMC8218332
Beta,"Structural and serological analyses show some evidence of antibody escape, and individuals infected previously with the B.1.351 (beta) and P.1 (gamma) variants are likely more susceptible to reinfection by the delta strain.",PMC8218332
Gamma,"Structural and serological analyses show some evidence of antibody escape, and individuals infected previously with the B.1.351 (beta) and P.1 (gamma) variants are likely more susceptible to reinfection by the delta strain.",PMC8218332
Alpha,Vaccines based on B.1.1.7 (alpha) are likely to provide the broadest protection against current variants..,PMC8218332
B.1.429,"L452R has also been identified in B.1.427 and B.1.429 (Deng et al., 2021), and T478K is found in B.1.1.519.",PMC8218332
B.1.427,"L452R has also been identified in B.1.427 and B.1.429 (Deng et al., 2021), and T478K is found in B.1.1.519.",PMC8218332
B.1.1.519,"Finally, we performed neutralization assays on a pseudotyped lentivirus expressing B.1.1.519 S, which contains the single T478K substitution in the RBD, and saw no significant changes in neutralization (Figure S1; Table S1).Figure S1Neutralization curves of human mAbs against SARS-CoV-2 pseudotyped lentiviruses expressing full-length S of the B.1.617.1, B.1.617.2, B.1.1.519, and B.1.429 variants, related to Figure 2FRNT50 titers are given in Table S2..

Neutralization curves of human mAbs against SARS-CoV-2 pseudotyped lentiviruses expressing full-length S of the B.1.617.1, B.1.617.2, B.1.1.519, and B.1.429 variants, related to Figure 2.",PMC8218332
B.1.315,"Although, in some cases, neutralization was knocked out for B.1.617.2, some sera showed almost no change in neutralization between B.1.315 or P.1 and the Victoria strain; determining at an epitope level how sera from these individuals differentially recognize variant viruses will be interesting.",PMC8218332
Lambda,"Finally, the mechanism of neutralization of antibodies binding to the NTD and dissection of the role of antibodies to the NTD in neutralization are worthy of further investigation..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesFabDejnirattisai et al., 2021aN/AIgGDejnirattisai et al., 2021aN/AHuman anti-NP (mAb 206)Dejnirattisai et al., 2021aN/ARegeneron mAbsAstraZenecaCat#REGN10933, and REGN10987AstraZeneca mAbsAstraZenecaCat#AZD1061, AZD8895Vir mAbsAdagioCat#S309Lilly mAbsAdagioCat#Ly-CoV555, and Cat#Ly-CoV16Adagio mAbsAdagioCat#ADG10, Cat#ADG20, and Cat#ADG30Anti-Human IgG (Fc specific)-PeroxidaseSigmaCat#A0170Polyclonal Goat Anti- human ACE2R&DCat#AF933Polyclonal Rabbit Anti-Goat Immunoglobulins/FITCDAKOCat#F0250Bacterial and virus strainsSARS-CoV-2 (Australia/VIC01/2020)Caly et al., 2020N/ASARS-CoV-2/B.1.1.7Public Health EnglandN/ASARS-CoV-2/B.1.351Public Health EnglandN/ASARS-CoV-2/P.1This paperN/ADH5α bacteriaIn VitrogenCat#18263012Biological samplesSerum from Pfizer-vaccinated individualsUniversity of OxfordN/ASerum from AstraZeneca-Oxford-vaccinated individualsUniversity of OxfordN/APlasma from SARS-CoV-2 patientsJohn Radcliffe Hospital in Oxford UKN/AChemicals, peptides, and recombinant proteinsHis-tagged SARS-CoV-2 RBDDejnirattisai et al., 2021aN/AHis-tagged SARS-CoV-2 RBD L452R, E484Q, T478KThis paperN/AHis-tagged SARS-CoV-2 RBD L452R E484Q, L452R T478KThis paperN/AHis-tagged human ACE2This paperN/AHuman ACE2-hIgG1FcThis paperN/APhosphate buffered saline tabletsSigma-AldrichCat#P4417Dulbecco’s Modified Eagle Medium, high glucoseSigma-AldrichCat#D5796Dulbecco’s Modified Eagle Medium, low glucoseSigma-AldrichCat#D6046FreeStyle 293 Expression MediumGIBCOCat#12338018L-Glutamine–Penicillin–Streptomycin solutionSigma-AldrichCat#G1146GlutaMAX SupplementGIBCOCat#35050061UltraDOMA PF Protein-free MediumLonzaCat#12-727FOpti-MEMGIBCOCat#11058021Fetal Bovine SerumGIBCOCat#12676029Polyethylenimine, branchedSigma-AldrichCat#408727Carboxymethyl celluloseSigmaCat#C4888Strep-Tactin®XTIBA LifesciencesCat#2-1206-025HEPESMelfordCat#34587-39108Sodium ChlorideHoneywellCat#SZBF3340HLB brothFisher Scientific UKCat#51577-51656Mem Neaa (100X)GIBCOCat#2203945Trypsin-EDTAGIBCOCat#2259288TrypLE Express EnzymeGIBCOCat#12604013L-Glutamine 200 mM (100X)GIBCOCat#2036885SYPROorange (5000X in DMSO)ThermoCat#S6651Isopropyl β-d-1-thiogalactopyranosideMeridian BioscienceCat#BIO-37036KanamycinMelfordCat#K22000LysozymeSigma-AldrichCat#L6876Tris-baseMelfordCat#T60040ImidazoleSigma-AldrichCat#56750Triton X-100Sigma-AldrichCat#8787TurbonucleaseSigma-AldrichCat#T4330RNase AQIAGENCat#158922NaClSigma-AldrichCat#S9888MgSO4Sigma-AldrichCat#746452Na2HPO4MelfordCat#S23100NaH2PO4MelfordCat#S23185Critical commercial assaysBright-Glo Luciferase Assay SystemPromegaCat#E2620HIV Type 1 p24 Antigen ELISA 2.0ZeptoMetrixCat#0801002Deposited dataCrystal structures of SARS-CoV-2 RBD/Fab complexesThis paperPDBs:7OR9,7ORA,7ORBExperimental models: Cell linesHEK293S GnTI- cellsATCCCat#CRL-3022HEK293 cellsATCCCat#CRL-3216Expi293F CellsGIBCO,Cat#A14527HEK293T/17 cellsATCCCat#CRL-11268HEK293T cellsATCCCat#CRL-11268Hamster: ExpiCHO cellsThermo FisherCat#A29133Vero cellsATCCCat#CCL-81Recombinant DNAVector: pHLsecAricescu et al., 2006N/AVector: pNEOAricescu et al., 2006N/AVector: p8.91di Genova et al., 2020Nigel TempertonVector: pCSFLWdi Genova et al., 2020Nigel TempertonVector: pcDNA-SARS-CoV-2 spikedi Genova et al., 2020Nigel TempertonVector: pcDNA-SARS-CoV-2 spike of Victoria strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.1A strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.1B strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.1C strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.2 strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.1.519This paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.429This paperN/AVector: pCMV-VSV-GStewart et al., 2003Addgene plasmid # 8454pHR-SIN-ACE2Alain TownsendN/AVector: pOPING-ETNettleship et al., 2008N/Ahuman ACE2 cDNASourcebiosciencesCat#5297380Vector: human IgG1 heavy chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: human lambda light chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: human kappa light chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: Human FabUniveristy of OxfordN/AVector: Human scFvUniversity of Oxford, NDM (G. Screaton)N/ASoftware and algorithmsCOOTEmsley and Cowtan, 2004https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/Xia2-dialsWinter et al., 2018https://xia2.github.io/parameters.htmlPHENIXLiebschner et al., 2019https://phenix-online.org/PyMOLSchrodingerhttps://pymol.org/2/Data Acquisition Software 11.1.0.11Fortebiohttps://www.sartorius.com/en/products/protein-analysis/octet-systems-softwareData Analysis Software HT 11.1.0.25Fortebiohttps://www.sartorius.com/en/products/protein-analysis/octet-systems-softwarePrism 8.0GraphPadhttps://www.graphpad.com/scientific-software/prism/IBM SPSS Software 26IBMhttps://www.ibm.com/us-en/?ar=1MabscapeThis paperhttps://github.com/helenginn/mabscape;https://snapcraft.io/mabscapeOtherX-ray data were collected at beamline I03, Diamond Light Source, under proposal ib27009 for COVID-19 rapid accessThis paperhttps://www.diamond.ac.uk/covid-19/for-scientists/rapid-access.htmlTALON Superflow Metal Affinity ResinClontechCat#635668HiLoad 16/600 Superdex 200 pgCytivaCat#28-9893-35Superdex 200 increase 10/300 GL columnCytivaCat#28990944HisTrap HP 5-ml columnCytivaCat#17524802HiTrap Heparin HT 5-ml columnCytivaCat#17040703Amine Reactive Second-Generation (AR2G) BiosensorsFortebioCat#18-5092Octet RED96eFortebiohttps://www.sartorius.com/en/products/protein-analysis/octet-label-free-detection-systemsBuffer exchange system “QuixStand”GE HealthcareCat#56-4107-78Cartesian dispensing systemGenomic solutionsCat#MIC4000Hydra-96Robbins ScientificCat#Hydra-9696-well crystallization plateGreiner bio-oneCat#E20113NNCrystallization Imaging SystemFormulatrixCat#RI-1000Sonics vibra-cell vcx500 sonicatorVWRCat#432-0137
.",PMC8218332
Kappa,"Finally, the mechanism of neutralization of antibodies binding to the NTD and dissection of the role of antibodies to the NTD in neutralization are worthy of further investigation..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesFabDejnirattisai et al., 2021aN/AIgGDejnirattisai et al., 2021aN/AHuman anti-NP (mAb 206)Dejnirattisai et al., 2021aN/ARegeneron mAbsAstraZenecaCat#REGN10933, and REGN10987AstraZeneca mAbsAstraZenecaCat#AZD1061, AZD8895Vir mAbsAdagioCat#S309Lilly mAbsAdagioCat#Ly-CoV555, and Cat#Ly-CoV16Adagio mAbsAdagioCat#ADG10, Cat#ADG20, and Cat#ADG30Anti-Human IgG (Fc specific)-PeroxidaseSigmaCat#A0170Polyclonal Goat Anti- human ACE2R&DCat#AF933Polyclonal Rabbit Anti-Goat Immunoglobulins/FITCDAKOCat#F0250Bacterial and virus strainsSARS-CoV-2 (Australia/VIC01/2020)Caly et al., 2020N/ASARS-CoV-2/B.1.1.7Public Health EnglandN/ASARS-CoV-2/B.1.351Public Health EnglandN/ASARS-CoV-2/P.1This paperN/ADH5α bacteriaIn VitrogenCat#18263012Biological samplesSerum from Pfizer-vaccinated individualsUniversity of OxfordN/ASerum from AstraZeneca-Oxford-vaccinated individualsUniversity of OxfordN/APlasma from SARS-CoV-2 patientsJohn Radcliffe Hospital in Oxford UKN/AChemicals, peptides, and recombinant proteinsHis-tagged SARS-CoV-2 RBDDejnirattisai et al., 2021aN/AHis-tagged SARS-CoV-2 RBD L452R, E484Q, T478KThis paperN/AHis-tagged SARS-CoV-2 RBD L452R E484Q, L452R T478KThis paperN/AHis-tagged human ACE2This paperN/AHuman ACE2-hIgG1FcThis paperN/APhosphate buffered saline tabletsSigma-AldrichCat#P4417Dulbecco’s Modified Eagle Medium, high glucoseSigma-AldrichCat#D5796Dulbecco’s Modified Eagle Medium, low glucoseSigma-AldrichCat#D6046FreeStyle 293 Expression MediumGIBCOCat#12338018L-Glutamine–Penicillin–Streptomycin solutionSigma-AldrichCat#G1146GlutaMAX SupplementGIBCOCat#35050061UltraDOMA PF Protein-free MediumLonzaCat#12-727FOpti-MEMGIBCOCat#11058021Fetal Bovine SerumGIBCOCat#12676029Polyethylenimine, branchedSigma-AldrichCat#408727Carboxymethyl celluloseSigmaCat#C4888Strep-Tactin®XTIBA LifesciencesCat#2-1206-025HEPESMelfordCat#34587-39108Sodium ChlorideHoneywellCat#SZBF3340HLB brothFisher Scientific UKCat#51577-51656Mem Neaa (100X)GIBCOCat#2203945Trypsin-EDTAGIBCOCat#2259288TrypLE Express EnzymeGIBCOCat#12604013L-Glutamine 200 mM (100X)GIBCOCat#2036885SYPROorange (5000X in DMSO)ThermoCat#S6651Isopropyl β-d-1-thiogalactopyranosideMeridian BioscienceCat#BIO-37036KanamycinMelfordCat#K22000LysozymeSigma-AldrichCat#L6876Tris-baseMelfordCat#T60040ImidazoleSigma-AldrichCat#56750Triton X-100Sigma-AldrichCat#8787TurbonucleaseSigma-AldrichCat#T4330RNase AQIAGENCat#158922NaClSigma-AldrichCat#S9888MgSO4Sigma-AldrichCat#746452Na2HPO4MelfordCat#S23100NaH2PO4MelfordCat#S23185Critical commercial assaysBright-Glo Luciferase Assay SystemPromegaCat#E2620HIV Type 1 p24 Antigen ELISA 2.0ZeptoMetrixCat#0801002Deposited dataCrystal structures of SARS-CoV-2 RBD/Fab complexesThis paperPDBs:7OR9,7ORA,7ORBExperimental models: Cell linesHEK293S GnTI- cellsATCCCat#CRL-3022HEK293 cellsATCCCat#CRL-3216Expi293F CellsGIBCO,Cat#A14527HEK293T/17 cellsATCCCat#CRL-11268HEK293T cellsATCCCat#CRL-11268Hamster: ExpiCHO cellsThermo FisherCat#A29133Vero cellsATCCCat#CCL-81Recombinant DNAVector: pHLsecAricescu et al., 2006N/AVector: pNEOAricescu et al., 2006N/AVector: p8.91di Genova et al., 2020Nigel TempertonVector: pCSFLWdi Genova et al., 2020Nigel TempertonVector: pcDNA-SARS-CoV-2 spikedi Genova et al., 2020Nigel TempertonVector: pcDNA-SARS-CoV-2 spike of Victoria strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.1A strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.1B strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.1C strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.617.2 strainThis paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.1.519This paperN/AVector: pcDNA-SARS-CoV-2 spike of B.1.429This paperN/AVector: pCMV-VSV-GStewart et al., 2003Addgene plasmid # 8454pHR-SIN-ACE2Alain TownsendN/AVector: pOPING-ETNettleship et al., 2008N/Ahuman ACE2 cDNASourcebiosciencesCat#5297380Vector: human IgG1 heavy chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: human lambda light chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: human kappa light chainGerman Cancer Research Center, Heidelberg, Germany (H. WardemannN/AVector: Human FabUniveristy of OxfordN/AVector: Human scFvUniversity of Oxford, NDM (G. Screaton)N/ASoftware and algorithmsCOOTEmsley and Cowtan, 2004https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/Xia2-dialsWinter et al., 2018https://xia2.github.io/parameters.htmlPHENIXLiebschner et al., 2019https://phenix-online.org/PyMOLSchrodingerhttps://pymol.org/2/Data Acquisition Software 11.1.0.11Fortebiohttps://www.sartorius.com/en/products/protein-analysis/octet-systems-softwareData Analysis Software HT 11.1.0.25Fortebiohttps://www.sartorius.com/en/products/protein-analysis/octet-systems-softwarePrism 8.0GraphPadhttps://www.graphpad.com/scientific-software/prism/IBM SPSS Software 26IBMhttps://www.ibm.com/us-en/?ar=1MabscapeThis paperhttps://github.com/helenginn/mabscape;https://snapcraft.io/mabscapeOtherX-ray data were collected at beamline I03, Diamond Light Source, under proposal ib27009 for COVID-19 rapid accessThis paperhttps://www.diamond.ac.uk/covid-19/for-scientists/rapid-access.htmlTALON Superflow Metal Affinity ResinClontechCat#635668HiLoad 16/600 Superdex 200 pgCytivaCat#28-9893-35Superdex 200 increase 10/300 GL columnCytivaCat#28990944HisTrap HP 5-ml columnCytivaCat#17524802HiTrap Heparin HT 5-ml columnCytivaCat#17040703Amine Reactive Second-Generation (AR2G) BiosensorsFortebioCat#18-5092Octet RED96eFortebiohttps://www.sartorius.com/en/products/protein-analysis/octet-label-free-detection-systemsBuffer exchange system “QuixStand”GE HealthcareCat#56-4107-78Cartesian dispensing systemGenomic solutionsCat#MIC4000Hydra-96Robbins ScientificCat#Hydra-9696-well crystallization plateGreiner bio-oneCat#E20113NNCrystallization Imaging SystemFormulatrixCat#RI-1000Sonics vibra-cell vcx500 sonicatorVWRCat#432-0137
.",PMC8218332
B.1.1.7,"Then, a second N501Y mutant 501Y Variant 2 (also named 20B/501Y·V1, SARS-CoV-2 VOC 202012/01, or lineage B.1.1.7) appeared in England in late September 2020 and became the dominant lineage in December 2020 (Leung et al., 2021).",PMC8213438
B.1.351,"It is worth noting that N501Y mutation was detected in four SARS-CoV-2 mutants, which appeared almost simultaneously in different countries, including B.1.1.7 (UK, mid-December 2020), B.1.351 (South Africa, late December 2020), COH.20 g/N501Y (the USA, late December 2022) and P.1 strain (501Y·V3, Brazil, January 2021), suggesting that this residue may play an important role for the virus evolution and transmission..",PMC8213438
P.1,"It is worth noting that N501Y mutation was detected in four SARS-CoV-2 mutants, which appeared almost simultaneously in different countries, including B.1.1.7 (UK, mid-December 2020), B.1.351 (South Africa, late December 2020), COH.20 g/N501Y (the USA, late December 2022) and P.1 strain (501Y·V3, Brazil, January 2021), suggesting that this residue may play an important role for the virus evolution and transmission..",PMC8213438
B.1.1.298,"Here, we demonstrate that two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R (in B.1.427/429 and B.1.617) and Y453F (in B.1.1.298), confer escape from HLA-A24-restricted cellular immunity.",PMC8205251
B.1.427,"Here, we demonstrate that two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R (in B.1.427/429 and B.1.617) and Y453F (in B.1.1.298), confer escape from HLA-A24-restricted cellular immunity.",PMC8205251
B.1.617,"Here, we demonstrate that two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R (in B.1.427/429 and B.1.617) and Y453F (in B.1.1.298), confer escape from HLA-A24-restricted cellular immunity.",PMC8205251
B.1.351,"Additionally, since fall of 2020, new SARS-CoV-2 variants such as B.1.1.7 (also known as a variant of concern 202012/01 or 20I/501Y.V1), B.1.351 (also known as 20H/501Y.V2), and P.1 (also known as 501Y.V3) lineages have emerged in the UK, South Africa, and Brazil, respectively, and have rapidly spread worldwide (CDC, 2020).",PMC8205251
P.1,"Additionally, since fall of 2020, new SARS-CoV-2 variants such as B.1.1.7 (also known as a variant of concern 202012/01 or 20I/501Y.V1), B.1.351 (also known as 20H/501Y.V2), and P.1 (also known as 501Y.V3) lineages have emerged in the UK, South Africa, and Brazil, respectively, and have rapidly spread worldwide (CDC, 2020).",PMC8205251
B.1.1.7,"Additionally, since fall of 2020, new SARS-CoV-2 variants such as B.1.1.7 (also known as a variant of concern 202012/01 or 20I/501Y.V1), B.1.351 (also known as 20H/501Y.V2), and P.1 (also known as 501Y.V3) lineages have emerged in the UK, South Africa, and Brazil, respectively, and have rapidly spread worldwide (CDC, 2020).",PMC8205251
B.1.429,"The HIV-1-based reporter virus pseudotyped with the parental SARS-CoV-2 S or its derivatives (E, L452R, Y453F, and N501Y; F, D614G, B.1.429 [S13I/W152C/L452R/D614G], and B.1.1.298 [HV69-70del/Y453F/D614G]) was inoculated into HEK293 cells transiently expressing human ACE2 and TMPRSS2 at four different doses (1, 3, 5, and 10 ng p24 antigens).",PMC8205251
B.1.39,"Although the L452R mutant was first detected in the B.1.39 lineage in Denmark on March 17, 2020 (GISAID ID: EPI_ISL_429311) (Table 1), this variant did not spread.",PMC8205251
B.1,"A.1 lineage was the Primary outbreak in Washington State, USA and B.1 with B.2 lineage were comprised the large Italian outbreak (Rambaut et al., 2020)..",PMC8190378
Beta,"The Model 7 (M7, beta) is a null model contains the sites-classes which are lower or equal to the neutrality and Model 8 (M8, beta + ω > 1) as an alternative model was used to observe differences over sites through a beta distribution, whereas M8 only contains the sites-classes that above neutrality.",PMC8190378
Alpha,"The Val 1229 is located in in the βSM alpha helix structure of NSP3 I-TASSER model, in spite of the Val weakly destabilizing the alpha helix structure it was found to be more favored than Gly and Thr in HCoV-OC43 and SARS, respectively, but less favored than Glu in HCoV-HKU1 (Supplementary Fig.",PMC8190378
B.1.177,"The phylogenetic analyses revealed a total of 34 different lineages in Cyprus, with B.1.258, B.1.1.29, B.1.177, B.1.2, B.1 and B.1.1.7 (designated a Variant of Concern 202012/01, VOC) being the most prevalent lineages on the island during the study period.",PMC8227210
B.1.1.29,"The phylogenetic analyses revealed a total of 34 different lineages in Cyprus, with B.1.258, B.1.1.29, B.1.177, B.1.2, B.1 and B.1.1.7 (designated a Variant of Concern 202012/01, VOC) being the most prevalent lineages on the island during the study period.",PMC8227210
B.1.2,"The phylogenetic analyses revealed a total of 34 different lineages in Cyprus, with B.1.258, B.1.1.29, B.1.177, B.1.2, B.1 and B.1.1.7 (designated a Variant of Concern 202012/01, VOC) being the most prevalent lineages on the island during the study period.",PMC8227210
B.1.1.7,"The phylogenetic analyses revealed a total of 34 different lineages in Cyprus, with B.1.258, B.1.1.29, B.1.177, B.1.2, B.1 and B.1.1.7 (designated a Variant of Concern 202012/01, VOC) being the most prevalent lineages on the island during the study period.",PMC8227210
B.1.258,"The phylogenetic analyses revealed a total of 34 different lineages in Cyprus, with B.1.258, B.1.1.29, B.1.177, B.1.2, B.1 and B.1.1.7 (designated a Variant of Concern 202012/01, VOC) being the most prevalent lineages on the island during the study period.",PMC8227210
B.1,"The phylogenetic analyses revealed a total of 34 different lineages in Cyprus, with B.1.258, B.1.1.29, B.1.177, B.1.2, B.1 and B.1.1.7 (designated a Variant of Concern 202012/01, VOC) being the most prevalent lineages on the island during the study period.",PMC8227210
B.1.351,"Other lineages that have emerged around the world are B.1.351 and P.1, detected in October 2020 in South Africa and January 2021 in Japan/Brazil, respectively.",PMC8227210
P.1,"Other lineages that have emerged around the world are B.1.351 and P.1, detected in October 2020 in South Africa and January 2021 in Japan/Brazil, respectively.",PMC8227210
B.1.1.41,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.317,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.141,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.251,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.153,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.67,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.277,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.288,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.130,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.1,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.161,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.307,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.159,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.6,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.192,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.218,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.1.315,"Within clade B.1.1.x, excluding B.1.1.29, the following lineages were identified: A (n = 1), B (n = 5), B.1 (n = 13), B.1.1.1 (n = 7), B.1.1.130 (n = 1), B.1.1.131 (n = 2), B.1.1.141 (n = 2), B.1.1.153 (n = 3), B.1.1.159 (n = 2), B.1.1.161 (n = 5), B.1.1.192 (n = 2), B.1.1.218 (n = 2), B.1.1.230 (n = 1), B.1.1.251 (n = 4), B.1.1.277 (n = 4), B.1.1.288 (n = 2), B.1.1.307 (n = 1), B.1.1.315 (n = 1), B.1.1.317 (n = 2), B.1.1.41 (n = 4), 1 B.1.1.67 (n = 1), B.6 (n = 1).",PMC8227210
B.1.160,"The composition of the B.basal clade consists of the following lineages: B.1 (n = 5), B.1.160 (n = 2), B.1.236 (n = 6), B.1.313 (n = 2), and B.1.36 (n = 2)..

Phylodynamic and phylogeographic analyses were performed to estimate the timed migration histories of the sequences in this study.",PMC8227210
B.1.313,"The composition of the B.basal clade consists of the following lineages: B.1 (n = 5), B.1.160 (n = 2), B.1.236 (n = 6), B.1.313 (n = 2), and B.1.36 (n = 2)..

Phylodynamic and phylogeographic analyses were performed to estimate the timed migration histories of the sequences in this study.",PMC8227210
B.1.236,"The composition of the B.basal clade consists of the following lineages: B.1 (n = 5), B.1.160 (n = 2), B.1.236 (n = 6), B.1.313 (n = 2), and B.1.36 (n = 2)..

Phylodynamic and phylogeographic analyses were performed to estimate the timed migration histories of the sequences in this study.",PMC8227210
B.1.36,"The composition of the B.basal clade consists of the following lineages: B.1 (n = 5), B.1.160 (n = 2), B.1.236 (n = 6), B.1.313 (n = 2), and B.1.36 (n = 2)..

Phylodynamic and phylogeographic analyses were performed to estimate the timed migration histories of the sequences in this study.",PMC8227210
B.1.1,"It is important to note that although not as prevalent as the B.1.1.29 and B.1.258 lineages, the B.1.1, B.1.2 and B.1.177 lineages were prevalent (Table 1).",PMC8227210
B.1.351,"Emerging SARS-CoV-2 strains, B.1.1.7 and B.1.351, from the UK and South Africa, respectively, show decreased neutralization by monoclonal antibodies and convalescent or vaccinee sera raised against the original wild-type virus, and are thus of clinical concern.",PMC8188728
B.1.1.7,"Emerging SARS-CoV-2 strains, B.1.1.7 and B.1.351, from the UK and South Africa, respectively, show decreased neutralization by monoclonal antibodies and convalescent or vaccinee sera raised against the original wild-type virus, and are thus of clinical concern.",PMC8188728
P.2,"The E484K mutation—detected in B.1.351 and recently emerging strains P.1 and P.2 (Faria et al., 2021)—impairs recognition of numerous antibodies (Wang et al., 2021a) and also weakly improves ACE2 binding affinity.",PMC8188728
P.1,"The E484K mutation—detected in B.1.351 and recently emerging strains P.1 and P.2 (Faria et al., 2021)—impairs recognition of numerous antibodies (Wang et al., 2021a) and also weakly improves ACE2 binding affinity.",PMC8188728
B.1.1.28,"Both antibody classes recognize predominantly the RBM, which is mutated convergently in many emerging viral lineages (e.g., K417T, E484K, and N501Y in both B.1.351 and B.1.1.28 [Brazil]).",PMC8188728
B.1.526,"This may explain the rapid spread of convergent RBD mutations in different emerging SARS-CoV-2 lineages (e.g., E484K mutation in Brazilian P.1, SA B.1.351, and US B.1.526 lineages) (Sabino et al., 2021; West et al., 2021).",PMC8188728
Alpha,"In addition, replacement of the H69 and V70 residues in the Alpha variant B.1.1.7 spike (where ΔH69/V70 occurs naturally) impairs spike incorporation and entry efficiency of the B.1.1.7 spike pseudotyped virus.",PMC8185188
B.1.1.7,"In addition, replacement of the H69 and V70 residues in the Alpha variant B.1.1.7 spike (where ΔH69/V70 occurs naturally) impairs spike incorporation and entry efficiency of the B.1.1.7 spike pseudotyped virus.",PMC8185188
B.1.258,"A second lineage with N439K, B.1.258, emerged later and subsequently acquired ΔH69/V70, leading to the initial rapid increase in the frequency of viruses possessing this deletion, spreading into Europe (Figure 1A; Brejová et al., 2021).Figure 5ΔH69/V70 appears after spike N439K and Y453F and compensates for their reduced infectivity(A and B) Maximum-likelihood phylogeny of global sequences carrying Spike mutant (A) N439K and (B) Y453F.",PMC8185188
Gamma,"This recurring deletion, spanning 6 nt, is due to an out-of-frame deletion of 6 nt and occurs in the terminal loop of a helix loop motif within the predicted RNA structure, as do other NTD deletions observed in new variants, such as B.1.1.7 (Alpha), B.1.617 (Delta), B.1.351 (Beta), and P.1 (Gamma) (Figure S5).",PMC8185188
B.1.617,"This recurring deletion, spanning 6 nt, is due to an out-of-frame deletion of 6 nt and occurs in the terminal loop of a helix loop motif within the predicted RNA structure, as do other NTD deletions observed in new variants, such as B.1.1.7 (Alpha), B.1.617 (Delta), B.1.351 (Beta), and P.1 (Gamma) (Figure S5).",PMC8185188
B.1.351,"This recurring deletion, spanning 6 nt, is due to an out-of-frame deletion of 6 nt and occurs in the terminal loop of a helix loop motif within the predicted RNA structure, as do other NTD deletions observed in new variants, such as B.1.1.7 (Alpha), B.1.617 (Delta), B.1.351 (Beta), and P.1 (Gamma) (Figure S5).",PMC8185188
P.1,"This recurring deletion, spanning 6 nt, is due to an out-of-frame deletion of 6 nt and occurs in the terminal loop of a helix loop motif within the predicted RNA structure, as do other NTD deletions observed in new variants, such as B.1.1.7 (Alpha), B.1.617 (Delta), B.1.351 (Beta), and P.1 (Gamma) (Figure S5).",PMC8185188
Beta,"This recurring deletion, spanning 6 nt, is due to an out-of-frame deletion of 6 nt and occurs in the terminal loop of a helix loop motif within the predicted RNA structure, as do other NTD deletions observed in new variants, such as B.1.1.7 (Alpha), B.1.617 (Delta), B.1.351 (Beta), and P.1 (Gamma) (Figure S5).",PMC8185188
B.1.525,"These analyses provide a rationale for preferential emergence of ΔH69/V70 and other deletions, such as the well-described NTD antibody escape deletion ΔY144 (Chi et al., 2020; McCarthy et al., 2020, 2021) (in B.1.1.7 and the recently reported B.1.525) at the terminal loops of helical loop motifs.",PMC8185188
B.1.351,"We assessed both neutralizing antibody and T cell responses in 44 South African COVID-19 patients infected either with B.1.351, now dominant in South Africa, or infected prior to its emergence (‘first wave’), to provide an overall measure of immune evasion.",PPR353360
P.1,"Four such variants of concern now circulate widely, namely B.1.1.7 in the US and Europe, B.1.351 in southern Africa, P.1 in Brazil and South America, and B.1.617 in India (2–6).",PPR353360
B.1.617,"Four such variants of concern now circulate widely, namely B.1.1.7 in the US and Europe, B.1.351 in southern Africa, P.1 in Brazil and South America, and B.1.617 in India (2–6).",PPR353360
B.1.1.7,"Four such variants of concern now circulate widely, namely B.1.1.7 in the US and Europe, B.1.351 in southern Africa, P.1 in Brazil and South America, and B.1.617 in India (2–6).",PPR353360
B.1.1,The complete genome sequences classified into the B.1 and B.1.1 SARS-CoV-2 lineages.,PMC8179693
B.1,The complete genome sequences classified into the B.1 and B.1.1 SARS-CoV-2 lineages.,PMC8179693
B.1.1.7,"The variant B.1.1.7, recently identified in United Kingdom (UK), is rapidly becoming the most prevalent variant in many European countries [9].",PMC8179693
B.1.351,"In South Africa, the B.1.351 emerged independently from B.1.1.7 [12], while the P.1 variant has been isolated in Brazil [13]..",PMC8179693
P.1,"In South Africa, the B.1.351 emerged independently from B.1.1.7 [12], while the P.1 variant has been isolated in Brazil [13]..",PMC8179693
B.1.1.7,The ΔH69/ΔV70 deletion in the N-terminus of the spike protein which arose in our patient is also present in the B.1.1.7 variant of concern and has been associated with viral escape mutagenesis after treatment of another immunocompromised patient with convalescent plasma.,PPR352548
B.52,"The viral lineage for all samples was identified as B.52 based on PANGO classification (pangolin.cog-uk.io (18)), except for the day 271 and 290 samples (albeit with poorer sequence coverage) defined as lineage B and B.1.1.7 respectively.",PPR352548
B.1.351,"The change N501Y is present in the three SARS-CoV-2 VOCs B.1.1.7, B.1.351(501Y.V2) and P1 (25, 26, 28).",PPR352548
B.1.1.7,"Given that the spread of the variant will depend on the number of B.1.1.7 variant infections, we first explore outcomes of our model given different initial conditions of I˜s and I˜m..",PMC8227606
B.1.351,"In particular, since December 2020, some VOCs have been reported by national public health authorities to the World Health Organization (WHO), including VOC-202012/01 (also known as lineage B.1.1.7, commonly referred to as the “B.1.1.7 variant” or the “British variant”), 20I/501Y.V2 (known as lineage B.1.351, commonly termed as the “South African variant”), and lineage B.1.1.28 (known as the “Brazilian variant”).",PMC8227606
B.1.1.28,"In particular, since December 2020, some VOCs have been reported by national public health authorities to the World Health Organization (WHO), including VOC-202012/01 (also known as lineage B.1.1.7, commonly referred to as the “B.1.1.7 variant” or the “British variant”), 20I/501Y.V2 (known as lineage B.1.351, commonly termed as the “South African variant”), and lineage B.1.1.28 (known as the “Brazilian variant”).",PMC8227606
P.1,"Other variants are under investigation and strict follow-up from international public health bodies, including the “Japanese variant” (variant P.1, lineage B.1.1.28) and the “USA variant” (L452R).",PMC8227606
Gamma,"Infine, la maggior parte dei casi gravi, con insufficienza respiratoria e necessità di ventilazione meccanica, era associata, in ordine decrescente, alle malattie neuromuscolari, alle disfunzioni renali croniche, alle malattie respiratorie croniche diverse dall’asma e alle malattie cardiache [23]..

Nella popolazione pediatrica si annovera un’ampia gamma di complicanze legate all’influenza, tra cui l’otite media acuta, la polmonite, la bronchiolite, il croup, la bronchite asmatica e le convulsioni febbrili, sino a condizioni più rare di tipo neurologico e metabolico.",PMC8639053
B.1.1.7,"For example, whereas the parental SARS-CoV-2 strains induce robust immunity against the B.1.1.7 variant that emerged in the United Kingdom, natural immunity induced by infection with the B.1.1.7 variant is much weaker against the parental strains [109,110].",PMC8542444
B.1.351,"Neither variant induces strong immunity against the B.1.351 variant that emerged in South Africa, but infection with B.1.351 variant induces robust immunity against its parental strain, as well as the B.1.1.28 variant first emerged in Brazil [111,112].",PMC8542444
B.1.1.28,"Neither variant induces strong immunity against the B.1.351 variant that emerged in South Africa, but infection with B.1.351 variant induces robust immunity against its parental strain, as well as the B.1.1.28 variant first emerged in Brazil [111,112].",PMC8542444
P.1,"Mutations R203K/G204R on N, carried by high transmissibility SARS-CoV-2 lineages including B.1.1.7 and P.1, has a rapid spread in the pandemic during the past year.",PPR345428
B.1.1.7,"Mutations R203K/G204R on N, carried by high transmissibility SARS-CoV-2 lineages including B.1.1.7 and P.1, has a rapid spread in the pandemic during the past year.",PPR345428
B.1.351,"Following B.1.1.7, another lineage B.1.351 
18
 was identified and considered the second version of N501Y variants (N501Y.v2).",PPR345428
B.1.315,"P.1 and B.1.315 are lineages resistant to antibodies 
21
.",PPR345428
B.1.525,"B.1.429+B.1.427 and B.1.525 are two newly identified lineages also associated with immune evasion 
22
.",PPR345428
B.1.617,"A recently evolved Indian lineage B.1.617 also carried a point mutation in 28881, but the mutation is G28881T not G28881A 
40
.",PPR345428
B.1.351,"Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD).",PMC8139174
B.1.1.7,"Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD).",PMC8139174
B.1.1.74,"In December 2020, new variants of concern have been identified in the UK (B.1.1.74), South Africa (B.1.3515) and Brazil (P.1 and P.2, both descendants from B.1.1.28[6], [7]).",PMC8139174
P.2,"In December 2020, new variants of concern have been identified in the UK (B.1.1.74), South Africa (B.1.3515) and Brazil (P.1 and P.2, both descendants from B.1.1.28[6], [7]).",PMC8139174
P.1,"In December 2020, new variants of concern have been identified in the UK (B.1.1.74), South Africa (B.1.3515) and Brazil (P.1 and P.2, both descendants from B.1.1.28[6], [7]).",PMC8139174
B.1.1.7,"However, we detected an additional mutation in Spike’s N-terminal domain of a B.1.1.7 strain, present at low-frequency (~1%) in the unvaccinated population, potentially affecting protein’s stability and functionality.",PPR344207
B.1.427,"More recently, the B.1.427/B.1.429 lineages, two forms collectively dubbed the “California variant”, were added to the CDC’s list of VOCs, as they have spread widely since their initial detection in July of 2020 in Los Angeles County, California (4).",PPR344207
B.1.375,"The distribution of lineages for Floridian sequences outside of Alachua County largely resembled that of the non-Floridian reference sequences, as expected given the filtering approach for genetic similarity described above; the exception to this similarity was the presence of the B.1.375 lineage within the Florida dataset, which was not present among reference sequences (Figure 1A).",PPR344207
B.1.234,"Whereas both the Alachua County and remaining Floridian samples were dominated by the B.1.234 lineage in November 2020, both regions quickly expanded to include at least seven other lineages by mid-January 2021 (Figure 1A).",PPR344207
B.1.247,"Given the growth in the UK and California variants within the Florida population, it is not surprising that three of the vaccinated individuals reported in this study were determined to belong to these VOCs – 1 B.1.1.7 and 2 B.1.247/B.1.249.",PPR344207
B.1,"The remaining two vaccinated individuals, however, presented with the high-frequency (~16%) B.1 lineage and low-frequency (<1%) B.1.377 lineage, neither of which is considered a VOC..",PPR344207
B.1.377,"The remaining two vaccinated individuals, however, presented with the high-frequency (~16%) B.1 lineage and low-frequency (<1%) B.1.377 lineage, neither of which is considered a VOC..",PPR344207
B.1.429,"The two individuals harboring the B.1.429 California VOC belonged to a clade of 20 individuals comprised of additional B.1.429/B.1.427 variants, confirming lineage classification using Pangolin (Figure 1C).",PPR344207
Alpha,"A notable exception is ORF6 alpha of SARS-CoV-2, which shows a high proportion of helices compared to other proteins across the different viruses..

SARS-CoV-2 virus has infected individuals across the world, and no demographics and individual characteristics has shown immunity to the infection.",PPR341627
Beta,"The authors declare no competing financial interests..


a, RAxML cladogram (branch lengths not proportional to change) showing relationships between SARS-CoV-2, MERS, Bat-SL-CoV, and SARS-related and rooted using a Beta Coronavirus outgroup.",PPR341627
B.1.427,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
B.1.525,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
B.1.429,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
B.1.1.7,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
P.2,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
B.1.351,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
P.1,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
B.1.526,"The B.1.526, B.1.525, P.2 Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) lineages are classified as VUIs, whereas the B.1.1.7, B.1.351, B.1.427, B.1.429, P.1 PangoLIN lineages are classified as VOCs..",PMC8156686
Gamma,A neighbor-joining (NJ) phylogenetic tree was constructed from the coding region of the SARS-CoV-2 genome using the maximum composite likelihood model along with gamma distribution as the rate variation parameter.,PMC8156686
B.6,This is identified as the B.6 variant in the PangoLIN classification [15].,PMC8156686
B.4,"Interestingly, another conserved pattern was also observed in 61/406 sequences in the ORF1ab (R207C, V378I, and M2790I) and classified within the B.4 variant in the PangoLIN classification (Figure 3, green).",PMC8156686
B.1.617,"Recently, a new PangoLIN lineage (B.1.617) was identified in Indian SARS-CoV-2 sequences, with the E484Q and L452R mutation (commonly known as a double mutant) in the spike protein of SARS-CoV-2, which is considered to have higher transmission rates.",PMC8156686
Epsilon,"FigTree v1.4.4 was used to visualize the generated tree..

A haplotype network plot was generated from the 96 SARS-Cov-2 sequences belonging to the unclassified cluster, along with representative sequences of the other clades using the median-joining method in PopART v1.7 with epsilon as 0.",PMC8156686
B.1.351,"The British B.1.1.7 (Rambaut et al., 2020), South African B.1.351 (Tegally et al., 2020), and Brazilian P.1 (Faria et al., 2021) VOC lineages arose in late 2020 and quickly became dominant within the countries in which they were first detected.",PPR340379
P.1,"The British B.1.1.7 (Rambaut et al., 2020), South African B.1.351 (Tegally et al., 2020), and Brazilian P.1 (Faria et al., 2021) VOC lineages arose in late 2020 and quickly became dominant within the countries in which they were first detected.",PPR340379
B.1.1.7,"The British B.1.1.7 (Rambaut et al., 2020), South African B.1.351 (Tegally et al., 2020), and Brazilian P.1 (Faria et al., 2021) VOC lineages arose in late 2020 and quickly became dominant within the countries in which they were first detected.",PPR340379
B.1.617.2,"The Indian B.1.617.2 variant has also recently been designated as a VOC (Public Health England, 2021).",PPR340379
B.1.617,"In particular, our analysis was performed prior to the observation of the various Indian B.1.617 variants.",PPR340379
Gamma,(1985) with empirical state frequency and gamma distribution of among-site rate variation (HKY+F+G).,PPR340379
B.1.1.7,"In the United Kingdom, a novel variant of SARS-CoV-2 (0B/501Y.V1, VOC 202012/01, or B.1.1.7 lineage) emerged, with an unusually large number of mutations.",PMC8142517
B.1.351,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern (VOCs), including the B.1.1.7, B.1.351 and P.1 lineages.",PPR339189
P.1,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern (VOCs), including the B.1.1.7, B.1.351 and P.1 lineages.",PPR339189
B.1.1.7,"Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern (VOCs), including the B.1.1.7, B.1.351 and P.1 lineages.",PPR339189
B.1.351,"The emergence of SARS-CoV-2 variants, as observed with the D614G spike protein mutant and, more recently, with B.1.1.7 (501Y.V1), B.1.351 (501Y.V2) and B.1.1.28.1 (P.1) lineages, represent a continuous threat and might lead to strains of higher infectivity and/or virulence.",PMC8151058
P.1,"The emergence of SARS-CoV-2 variants, as observed with the D614G spike protein mutant and, more recently, with B.1.1.7 (501Y.V1), B.1.351 (501Y.V2) and B.1.1.28.1 (P.1) lineages, represent a continuous threat and might lead to strains of higher infectivity and/or virulence.",PMC8151058
B.1.1.7,"The emergence of SARS-CoV-2 variants, as observed with the D614G spike protein mutant and, more recently, with B.1.1.7 (501Y.V1), B.1.351 (501Y.V2) and B.1.1.28.1 (P.1) lineages, represent a continuous threat and might lead to strains of higher infectivity and/or virulence.",PMC8151058
Alpha,This analysis revealed that the genetic variety of the hydrophobic cluster results in different positioning of the alpha helix connecting GLD to NTD (Figure 5b).,PMC8151058
B.1.617,"The B1.525 variant harbors a Q677H mutation [60], the variant B1.1.7 reported in the United Kingdom carries A570D and P681H mutations [61], the P1 variant from Brazil shows the H655Y mutation [62], and the recently reported B.1.617 strain in India shows a P681R change [63].",PMC8151058
B.1.1.7,"For example, the B.1.1.7 variant that was initially detected in the UK has become a dominant strain in many countries
13
.",PPR338764
B.1.351,"Two of these critical residues are mutated in COVID-19 variants, which are K417N in South Africa variant (lineage B.1.351), K417T in Brazil variant (lineage P.1), and N501Y in UK/South Africa/Brazil variants.",PPR338764
P.1,"Two of these critical residues are mutated in COVID-19 variants, which are K417N in South Africa variant (lineage B.1.351), K417T in Brazil variant (lineage P.1), and N501Y in UK/South Africa/Brazil variants.",PPR338764
B.1.617,"Two critical residues involved in COVID-19 variants, L452R and E484K, occur simultaneously as a double mutation in India variant (lineage B.1.617).",PPR338764
B.1.427,"E484K also appears in South Africa and Brazil variants as well as some sequences but not all in UK variant, and L452R appears in California variant (lineages B.1.427/B.1.429).",PPR338764
A.1,"Next, the derived A.1 lineage was introduced.",PPR337605
B.1,"For example, B.1 was introduced into LA County during its outbreak in Italy and New York, while B.1.2 was introduced into LA County during its outbreak in Louisiana.",PPR337605
B.1.2,"For example, B.1 was introduced into LA County during its outbreak in Italy and New York, while B.1.2 was introduced into LA County during its outbreak in Louisiana.",PPR337605
Zeta,"EVs were then characterized in bulk by Western blot, zeta potential measurement, and particle tracking.",PMC8123387
Beta,Introduction: Evidences accumulates for an active role of the insulin‐producing pancreatic beta cell in diabetes development.,PMC8123387
Alpha,"TRT consists of the administration of radiopharmaceuticals made of monoclonal antibodies or peptides coupled to a radionuclide emitting alpha, beta and Auger particles.",PMC8123387
Gamma,The cells were stimulated once or two times before EV isolation with 100 or 200ng/ml interferone gamma (IFNγ) over 48h.,PMC8123387
B.1.1.7,"Beyond the implications for individual patients, the emergence of B.1.1.7 SARS-CoV-2 and other lineages with potential for immune evasion has led to greater focus on the importance of genomic surveillance [9,10].",PMC8072072
B.1.291,"We analyzed the genomic variability during the SARS-CoV-2 pandemic in Costa Rica using 185 sequences, 52 from the first months of the pandemic, and 133 from the current wave..

Three GISAID clades (G, GH, and GR) and three PANGOLIN lineages (B.1, B.1.1, and B.1.291) were predominant, suggesting multiple re-introductions from other regions.",PMC8065237
B.1.1,"We analyzed the genomic variability during the SARS-CoV-2 pandemic in Costa Rica using 185 sequences, 52 from the first months of the pandemic, and 133 from the current wave..

Three GISAID clades (G, GH, and GR) and three PANGOLIN lineages (B.1, B.1.1, and B.1.291) were predominant, suggesting multiple re-introductions from other regions.",PMC8065237
B.1,"We analyzed the genomic variability during the SARS-CoV-2 pandemic in Costa Rica using 185 sequences, 52 from the first months of the pandemic, and 133 from the current wave..

Three GISAID clades (G, GH, and GR) and three PANGOLIN lineages (B.1, B.1.1, and B.1.291) were predominant, suggesting multiple re-introductions from other regions.",PMC8065237
B.1.177,"The 86.40% of Italian sequences assigned to this clade, characterized by the A222V amino acid substitution in the Spike protein, belong to the Pangolin B.1.177 lineage, that has been spreading globally in the last months [29]. .

Interestingly, two new emerging clades, 20A.EU1 and 20A.EU2, are gaining relevant prevalence rates in our regions..",PMC8147059
B.1.160,"All 20 genomes from Apulia and Basilicata associated with clade 20A.EU2 belong to lineage B.1.160, which was detected for the first time in Italy and submitted to GISAID.",PMC8147059
B.1.1.7,"This new rapidly spreading variant, firstly reported in the UK [31,32], originates from the SARS-CoV-2 20B/GR clade (lineage B.1.1.7) and contains multiple mutations, including a combination of the S:N501Y (i.e., an asparagine to tyrosine amino acid substitution at position 501 in the viral S gene) and the S:69–70del (i.e., a deletion of six bases coding for histidine and valine at positions 69 and 70, respectively, in the viral S gene) mutations.",PMC8147059
B.1.258.14,"Among the genome sequenced, we detected several lineages with a low frequency rate based on data available in the GISAID repository..

Three genomes belonging to 20A clade, collected from Brindisi in late October and early November 2020, were assigned to lineage B.1.258.14, of which only 26 other cases were reported worldwide..",PMC8147059
B.1.1.115,"We identified and reported for the first time in Italy new emerging lineages, such as B.1.1.115, B.1.1.204, B.1.1.229, B.1.1.277, B.1.1.293, B.1.1.33, and B.1.1.39.",PMC8147059
B.1.1.277,"We identified and reported for the first time in Italy new emerging lineages, such as B.1.1.115, B.1.1.204, B.1.1.229, B.1.1.277, B.1.1.293, B.1.1.33, and B.1.1.39.",PMC8147059
B.1.1.204,"We identified and reported for the first time in Italy new emerging lineages, such as B.1.1.115, B.1.1.204, B.1.1.229, B.1.1.277, B.1.1.293, B.1.1.33, and B.1.1.39.",PMC8147059
B.1.1.33,"We identified and reported for the first time in Italy new emerging lineages, such as B.1.1.115, B.1.1.204, B.1.1.229, B.1.1.277, B.1.1.293, B.1.1.33, and B.1.1.39.",PMC8147059
B.1.427,"Named B.1.427/B.1.429 to denote its two lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced cases from September 2020 to January 2021, showing 18.6%–24% increased transmissibility relative to wild-type circulating strains.",PMC8057738
B.1.351,"We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1.",PMC8057738
B.1.1.7,"We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1.",PMC8057738
P.1,"The other two VOCs, B.1.351 detected in South Africa (Tegally et al., 2020) and P.1 first detected in Brazil (Sabino et al., 2021), carry E484K and K417N/K417T in addition to N501Y mutations.",PMC8057738
B.1.429,"A variant, subsequently named 20C/L452R according to the Nextstrain nomenclature system (Bedford et al., 2021) or B.1.427/B.1.429 according to the Pango system (Rambaut et al., 2020a) (henceforth referred to using the Pango designation to distinguish between the B.1.427 and B.1.429 lineages), was identified in 21.5% (466 of 2,172) of the genomes (Table S1).",PMC8057738
B.1.426,"The resulting tree consisting of 1,153 subsampled genomes was visualized in the Nextstrain web application Auspice (root-to-tip divergence plot in Figure 2B) and in Geneious v11.1.5 (circular phylogenetic tree in Figure 2C) (Kearse et al., 2012)..

Molecular dating analysis of SARS-CoV-2 for estimating the TMRCA (time to most recent common ancestor) and divergence dates for the B.1.426/B.1.427 variant was performed using the Markov chain Monte Carlo (MCMC) method implemented by Bayesian Evolutionary Analysis on Sampling Trees (BEAST) software v.2.63 (Bouckaert et al., 2019; Drummond et al., 2012).",PMC8057738
B.1.1.7,"Recently, genomes representing the novel SARS-CoV-2 lineage B.1.1.7 have been observed around the world.",PMC8054698
B.1.1.7,"Real-time monitoring of SARS-CoV-2 VOCs could impact epidemiological tracking and guide clinical management prior to administering monoclonal antibody therapy..

For proof of concept, we targeted three deletion mutations initially described in the UK B.1.1.7 VOC.",PPR313306
B.1.351,"14
 An ORF1A deletion (SDF3675_3677del) is present in B.1.1.7 (UK variant),4 B.1.351 (South African, originally N150Y.2),
15
 P.1 (Brazil),
16
 and B.1.526 (New York) variants.",PPR313306
P.1,"14
 An ORF1A deletion (SDF3675_3677del) is present in B.1.1.7 (UK variant),4 B.1.351 (South African, originally N150Y.2),
15
 P.1 (Brazil),
16
 and B.1.526 (New York) variants.",PPR313306
B.1.526,"14
 An ORF1A deletion (SDF3675_3677del) is present in B.1.1.7 (UK variant),4 B.1.351 (South African, originally N150Y.2),
15
 P.1 (Brazil),
16
 and B.1.526 (New York) variants.",PPR313306
B.1.429,"During validation studies, we realized the reverse primer for S144 overlapped with the W152C mutation present in the emerging B.1.429/ B.1.427 variants (California, CAL.20C).",PPR313306
B.1.427,"During validation studies, we realized the reverse primer for S144 overlapped with the W152C mutation present in the emerging B.1.429/ B.1.427 variants (California, CAL.20C).",PPR313306
B.1.241,"Rather, three strains were classified as B.1.526 (N501Y absent and E484K present, Fig.2 J,K) and the other two cases as B.1.241 (N501Y and E484K absent).",PPR313306
B.1.529,"This assay can detect characteristic viral genomic changes found in B.1.1.7 (UK), P.1 (Brazil), B.1.351 (South African), B.1.529 (New York), and B.1.427/ B.1.429 (California) lineages.",PPR313306
B.1.1,"Many of the PANGOLIN lineages, notably the B.1.1 lineage, were brought into Russia repeatedly (Fig.",PPR309558
B.1.1.7,"* includes B.1.1.7 but not B.1.1 or B.1.1.31..

Sequences are ordered by sampling date, split into 14 day bins.",PPR309558
B.1.351,The emergence of novel SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern with increased transmission dynamics has raised questions regarding stability and disinfection of these viruses.,PPR308695
B.1.1.7,The emergence of novel SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern with increased transmission dynamics has raised questions regarding stability and disinfection of these viruses.,PPR308695
P.1,"In-dependent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1 [2].",PPR308695
B.1.1.70,"Residual titer (TCID50/mL) of B.1.1.70 (white bars) B.1.1.7 (blue bars) and B.1.351 (green bars) variants after inactivation via heat (56 °C, left panel) for 1, 5, 10 and 30 min (left to right), soap (middle panel) for 30 s, 1, 5 and 10 min (left to right) and ethanol (right panel, 20%, 30%, 40%, 60% and 80%, left to right).",PPR308695
B.1.351,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
P.1,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
B.1.427,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
B.1.1.7,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD.",PPR308676
B.1.429,"SARS-CoV-2 genetic drift has resulted in new emerging variants of concern (VOC) characterized by higher transmissibility, immune evasion and/or disease severity such as B.1.1.7, B.1.351, B.1.429, and P.1 originally identified in the UK, South Africa, California, and Brazil, respectively
3–6
.",PPR308676
B.1.1,"Many of the PANGOLIN lineages, notably the B.1.1 lineage, were brought into Russia repeatedly (Fig.",PPR307522
B.1.1.7,"* includes B.1.1.7 but not B.1.1 or B.1.1.31..

Sequences are ordered by sampling date, split into 14 day bins.",PPR307522
B.1.177,"Qingtian Guan and coworkers also proposed that the lineages be distributed into five clades, but with different names: G614, S84, V251, I378 and D392 (Guan et al., 2020), which are somewhat related to the A, B, B.1, B.1.1 and B.1.177 clades proposed by Andrew Rambaut and coworkers, based on the epidemic in the UK (https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)..

Overlapping these classifications is yet another series of six clades and their underlying signature SNPs, which was validated by early availability of variant sequences.",PMC8251359
B.1.1,"Qingtian Guan and coworkers also proposed that the lineages be distributed into five clades, but with different names: G614, S84, V251, I378 and D392 (Guan et al., 2020), which are somewhat related to the A, B, B.1, B.1.1 and B.1.177 clades proposed by Andrew Rambaut and coworkers, based on the epidemic in the UK (https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)..

Overlapping these classifications is yet another series of six clades and their underlying signature SNPs, which was validated by early availability of variant sequences.",PMC8251359
B.1,"Qingtian Guan and coworkers also proposed that the lineages be distributed into five clades, but with different names: G614, S84, V251, I378 and D392 (Guan et al., 2020), which are somewhat related to the A, B, B.1, B.1.1 and B.1.177 clades proposed by Andrew Rambaut and coworkers, based on the epidemic in the UK (https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)..

Overlapping these classifications is yet another series of six clades and their underlying signature SNPs, which was validated by early availability of variant sequences.",PMC8251359
B.1.351,"At the time of writing, several variants with a number of mutations are circulating widely (https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html), and UK variant, B.1.1.7, South African variant, B.1.351, and Brazilian variant, B.1.248 (Firestone et al., 2021) are spreading worldwide.",PMC8251359
B.1.1.7,"At the time of writing, several variants with a number of mutations are circulating widely (https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html), and UK variant, B.1.1.7, South African variant, B.1.351, and Brazilian variant, B.1.248 (Firestone et al., 2021) are spreading worldwide.",PMC8251359
B.1.248,"At the time of writing, several variants with a number of mutations are circulating widely (https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html), and UK variant, B.1.1.7, South African variant, B.1.351, and Brazilian variant, B.1.248 (Firestone et al., 2021) are spreading worldwide.",PMC8251359
B.1.525,"Covariation is illustrated in lineage B.1.525, an interesting new variant identified in 13 countries with spike protein mutations E484K, Q677H, F888L and a suite of deletions identical to those found in B.1.1.7 (https://cov-lineages.org/global_report_B.1.525.html).",PMC8251359
B.1.1.7,"The influence of temperature, relative humidity, and simulated sunlight on the decay of four SARS-CoV-2 isolates in aerosols, including one belonging to the recently emerged B.1.1.7 lineage, were compared in a rotating drum chamber.",PMC8083468
B.1,"There are several nomenclature systems commonly used to classify SARS-CoV-2.7,8,9,10 Six distinct SARS-CoV-2 clades, in addition to the progenitor clade (Wuhan), are classified by the Global Initiative on Sharing All Influenza Data (GISAID): S, L, V, G, GH, and GR.11 These roughly correspond to the virus lineages A, B, B.2, B.1, B.1.",PMC8076962
B.1.1.1,"*, and B.1.1.1, respectively.8 Three clades (G, GH, and GR) contain the 23403A>G (D614G) variant within the gene that encodes the spike glycoprotein.",PMC8076962
B.1.351,"SARS-CoV-2 naïve individuals required both vaccine doses for optimal increases in antibodies, particularly for neutralizing titers against the B.1.351 variant.",PMC8158969
Gamma,"(1) A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations
.",PMC8021487
Alpha,"Tumor Necrosis Factor Alpha, Induced Protein 3 (TNFAIP3) is a protein coding gene associated with A20 haploinsufficiency..

A 3-year-old female presented at 4-months old to the intensive care unit in shock with a vesiculopustular skin rash & indurated plaques on her extremities.",PMC8021487
Mu,Results: Enzyme activity level for NE ranged between 1.7 and 10.0 mU (mean 4.5 ± 1.9; N=89) and for MPO ranged between 0.22 and 2.53 mU (mean 0.91 ± 0.46; N=93).,PMC8021487
Beta,"First, cross-reactivity between antibodies to SARS-CoV-2 and alpha (NL63 and 229E) and beta (OC43 and HKU1) coronaviruses has been reported in the literature.",PMC8021487
Alpha,"Our results suggest that in these cells the variant of concern B.1.1.7, (aka Alpha variant), became the predominant circulating variant in several countries by a clear transmission advantage.",PPR305628
B.1.1.7,"Our results suggest that in these cells the variant of concern B.1.1.7, (aka Alpha variant), became the predominant circulating variant in several countries by a clear transmission advantage.",PPR305628
B.1.177,"In fact, in these cells B.1.1.7 outcompetes its ancestor B.1.177 in terms of a much faster kinetics of entry.",PPR305628
B.1.1.177,"On bottom, genome (GenBank accession number NC_045512 used as reference genome) and primary sequence map of the S1/S2 boundary for virus isolates belonging to B.1.1.177 and B.1.1.7 lineages.",PPR305628
B.1.1.7,"A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020.",PMC8009612
B.1.351,"A novel SARS-CoV-2 variant, designated variant of concern 202012/01 (also known as lineage B.1.1.7),9 was identified in Kent, UK, in late 2020, and accounted for an expanding proportion of cases at that time, particularly in the southeast and east of England.9 Whereas most SARS-CoV-2 lineages show few mutations, B.1.1.7 has accrued 23 mutations across the genome, including a non-synonymous mutation affecting the spike protein, N501Y (Asn501Tyr), which might increase ACE2 receptor binding affinity,10 the spike deletion 69–70del associated with viral escape in immunocompromised individuals,9 and the non-synonymous mutation P681H (Pro681His) affecting the furin cleavage site between the S1 and S2 subunits of spike protein, associated with in-vitro enhanced membrane fusion of infected cells.9, 11 N501Y is also seen in the B.1.351 and P.1 lineages, which are also variants of concern.7, 8.",PMC8009612
P.1,"A novel SARS-CoV-2 variant, designated variant of concern 202012/01 (also known as lineage B.1.1.7),9 was identified in Kent, UK, in late 2020, and accounted for an expanding proportion of cases at that time, particularly in the southeast and east of England.9 Whereas most SARS-CoV-2 lineages show few mutations, B.1.1.7 has accrued 23 mutations across the genome, including a non-synonymous mutation affecting the spike protein, N501Y (Asn501Tyr), which might increase ACE2 receptor binding affinity,10 the spike deletion 69–70del associated with viral escape in immunocompromised individuals,9 and the non-synonymous mutation P681H (Pro681His) affecting the furin cleavage site between the S1 and S2 subunits of spike protein, associated with in-vitro enhanced membrane fusion of infected cells.9, 11 N501Y is also seen in the B.1.351 and P.1 lineages, which are also variants of concern.7, 8.",PMC8009612
B.1.177,The majority of cases of non-B.1.1.7 lineage were caused by B.1.177 (figure 2).,PMC8009612
B.1.351,"The vaccine candidate demonstrates an 85% protection from moderate and severe infection, including from the B.1.351 variant.",PMC8006140
P.1,"Perhaps most prominent among these are B.1.1.7 (UK variant), B.1.351 (South African variant), and the P.1 (Brazil, B.1.1.28 branch) lineage [87].",PMC8006140
B.1.1.28,"Perhaps most prominent among these are B.1.1.7 (UK variant), B.1.351 (South African variant), and the P.1 (Brazil, B.1.1.28 branch) lineage [87].",PMC8006140
B.1.1.7,"Perhaps most prominent among these are B.1.1.7 (UK variant), B.1.351 (South African variant), and the P.1 (Brazil, B.1.1.28 branch) lineage [87].",PMC8006140
Beta,"In a preliminary clinical study, lopinavir/ritonavir combined with interferon beta, an immune modulator, and ribavirin, a nucleoside analog and inhibitor, improved symptoms and decreased infection time compared to lopinavir/ritonavir by itself and to standard care [188].",PMC8006140
B.1.351,"Such variants of concern (VOC) include isolates of lineage B.1.1.7, first identified in the UK, and B.1.351, first identified in South Africa.",PPR304445
B.1.1.7,"Such variants of concern (VOC) include isolates of lineage B.1.1.7, first identified in the UK, and B.1.351, first identified in South Africa.",PPR304445
P.1,"The third variant of concern, P.1 (formerly B.1.1.28.1) is characterized by K417T, in addition to E484K and N501Y, and accounted for 80% of all viruses sequenced in Brazil on 1 March 2021.",PPR304445
B.1.177,"In early 2021, E484K had been detected first in lineage B.1.1.7 in the United Kingdom (UK)
5
 and subsequently in lineages A23.1, B.1 and B.1.177, as well as in imported cases of B.1.51 and P.21F1F [2].",PPR304445
B.1,"In early 2021, E484K had been detected first in lineage B.1.1.7 in the United Kingdom (UK)
5
 and subsequently in lineages A23.1, B.1 and B.1.177, as well as in imported cases of B.1.51 and P.21F1F [2].",PPR304445
B.1.351,"Our protocol provides results that can be used to focus contact-tracing efforts and it is cheap enough for the tracking and surveillance of all positive samples for emerging variants such as B.1.1.7, B.1.351 and P.1 as of January 2021..",PPR304171
P.1,"Our protocol provides results that can be used to focus contact-tracing efforts and it is cheap enough for the tracking and surveillance of all positive samples for emerging variants such as B.1.1.7, B.1.351 and P.1 as of January 2021..",PPR304171
B.1.1.7,"Our protocol provides results that can be used to focus contact-tracing efforts and it is cheap enough for the tracking and surveillance of all positive samples for emerging variants such as B.1.1.7, B.1.351 and P.1 as of January 2021..",PPR304171
A.23.1,"In February 2021, there are currently two additional lineages of note, B.1.525 and A.23.1, that contain key defining mutations within the amplicon sequenced.",PPR304171
B.1.525,"In February 2021, there are currently two additional lineages of note, B.1.525 and A.23.1, that contain key defining mutations within the amplicon sequenced.",PPR304171
B.1.351,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
P.1,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
B.1.617,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
B.1.1.7,"We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency.",PPR303818
Alpha,"One such variant, B.1.1.7 (WHO classification: Alpha), emerged from southeast England in October 2020 and accounted for two-thirds of new infections in London in December 2020, with a higher transmission rate (43-90%) and risk of mortality (32-104%) than previously circulating strains (7, 8).",PPR303818
Beta,"Other variants, such as B.1.351 (Beta) and P.1 (Gamma), also became prevalent in three provinces in South Africa and Manaus, Brazil, respectively (6, 9, 10).",PPR303818
Gamma,"Other variants, such as B.1.351 (Beta) and P.1 (Gamma), also became prevalent in three provinces in South Africa and Manaus, Brazil, respectively (6, 9, 10).",PPR303818
B.1.617.2,"The B.1.617.2 (Delta) variant, which was initially identified in India, is becoming a dominant strain in many countries (11, 12) and responsible for the majority of new COVID-19 cases.",PPR303818
B.1,"The D614G mutation is associated with the B.1 lineage of SARS‐CoV‐2, which now dominates the global pandemic..

British scientists extended their genomic analysis though the second infection wave in the UK until end of December, 2020 (Volz et al., 2021).",PMC8085963
B.1.1.7,They noted that a variant called B.1.1.7 or virus of concern (VOC) is rapidly expanding its geographic range and frequency in England with a focus on London and the South East.,PMC8085963
B.1.1.56,"When analysing 2500 SARS‐CoV‐2 whole genomes, a new monophyletic cluster emerged in September and rapidly became the dominant lineage, superseding the three previously main South African lineages (B.1.1.54, B.1.1.56 and C.1) that were circulating during the prior wave (Tegally et al.,
2021).",PMC8085963
B.1.1.54,"When analysing 2500 SARS‐CoV‐2 whole genomes, a new monophyletic cluster emerged in September and rapidly became the dominant lineage, superseding the three previously main South African lineages (B.1.1.54, B.1.1.56 and C.1) that were circulating during the prior wave (Tegally et al.,
2021).",PMC8085963
C.1,"When analysing 2500 SARS‐CoV‐2 whole genomes, a new monophyletic cluster emerged in September and rapidly became the dominant lineage, superseding the three previously main South African lineages (B.1.1.54, B.1.1.56 and C.1) that were circulating during the prior wave (Tegally et al.,
2021).",PMC8085963
B.1.1.28,"In Manaus, a 2‐million inhabitant city in the Amazonian region and a hotspot of the Brazilian COVID‐19 epidemic during late spring 2020, Brazilian virologists sequenced 31 viral genomes isolated in December 2020; 65% of the sequences belonged to the B.1.1.28 lineage.",PMC8085963
P.1,"Notably, 13 out of 31 of the mid/late‐December genomes defined a new P.1 lineage which was related to, but distinct from, the B.1.1.28 lineage.",PMC8085963
B.1.351,"It is significant that the variants of global concern are RDR mutants and include a Mink variant with Δ69‐70, the UK variant B.1.1.7 with Δ69‐70 and Δ144/145 and the South African variant B.1.351 with Δ242‐244 (McCarthy et al.,
2021)..

Due to its practical importance, coronavirus genome sequencing is being conducted at an unprecedented quantitative scale.",PMC8085963
B.4,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1.2,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1.1,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
A.2,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
A.1,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.6,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
A.3,"The overall 17 different lineages were observed (A, A.1, A.2, A.3, B, B.1, B.1.1, B.1.18, B.1.2, B.1.5, B.136, B.2, B.2.1, B.2.2, B.4 and B.6) of the virus circulating in India.",PMC7972664
B.1.36,"The dominant lineages observed was B.1.36 (n = 184), B.1 (n = 143), A (n = 14), B.6 (n = 12), B.1.1 (n = 5), B (n = 3).",PMC7972664
P.1,"Also, one case of Brazil variant known as 20J/501Y.V3 or P.1 lineage was also reported recently.",PMC7972664
Mu,"First it is not invasive, second it allows the study of the MU in vivo even during contractions of moderate/high intensity (50-80% of the maximum voluntary contraction).",PMC8056169
B.1.351,"Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design..

McCallum et al.",PMC7962585
P.1,"Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design..

McCallum et al.",PMC7962585
B.1.1.7,"Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design..

McCallum et al.",PMC7962585
B.1.1.7,"This B.1.1.7 variant increased rapidly in prevalence among sequenced strains, attributed to an increase in infection and/or transmission efficiency.",PPR295840
Alpha,"In all statistical tests, two-sided alpha = .05.",PPR295840
B.1.1.7,"The recent VOCs all contain a N501Y substitution in the receptor-binding domain (RBD) of the spike glycoprotein (S), which increases the binding affinity of S for the ACE2 receptor on cells 
1
 The B.1.1.7 lineage was identified during September 2020 in the UK 
2
.",PPR294740
B.1.351,"Lineage B.1.351 
3
 was identified in South Africa during November 2020 and has two additional aa.",PPR294740
B.1.1.7,"This B.1.1.7 variant increased rapidly in prevalence among sequenced strains, attributed to an increase in infection and/or transmission efficiency.",PPR294806
B.1.427,"Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged around May 2020 and increased from 0% to >50% of sequenced cases from September 1, 2020 to January 29, 2021, exhibiting an 18.6-24% increase in transmissibility relative to wild-type circulating strains.",PPR294221
B.1.351,"Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants.",PPR294221
P.1,"Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants.",PPR294221
B.1.1.7,"Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants.",PPR294221
B.1.429,"A novel variant, subsequently named 20C/L452R according to the NextStrain nomenclature system (Bedford et al., 2021) or B.1.427/B.1.429 according to the Pango system (Rambaut et al., 2020a) (henceforth referred to using the Pango designation to distinguish between the B.1.427 and B.1.429 lineages), was identified in 21.1% (459 of 2,172) of the genomes (Supplementary Table 1).",PPR294221
B.1.426,"Molecular clock analysis of SARS-CoV-2 for estimating the TMRCA (time to most recent common ancestor) and divergence dates for the B.1.426/B.1.427 variant was performed using the Markov chain Monte Carlo (MCMC) method implemented by Bayesian Evolutionary Analysis on Sampling Trees (BEAST) software v.2.63 (Drummond et al., 2012).",PPR294221
B.1.351,"Ongoing genomic-based COVID-19 surveillance has recently been highlighted as a critical public health tool to detect novel SARS-CoV-2 variants, such as the B.1.1.7, B.1.351, and P.1 variants (29, 30).",PPR293578
P.1,"Ongoing genomic-based COVID-19 surveillance has recently been highlighted as a critical public health tool to detect novel SARS-CoV-2 variants, such as the B.1.1.7, B.1.351, and P.1 variants (29, 30).",PPR293578
B.1.1.7,"Ongoing genomic-based COVID-19 surveillance has recently been highlighted as a critical public health tool to detect novel SARS-CoV-2 variants, such as the B.1.1.7, B.1.351, and P.1 variants (29, 30).",PPR293578
B.1.1.7,"Recently, a variant named lineage B.1.1.7 was detected and shown to be rapidly spreading across the UK since November 2020.",PPR293365
B.1.351,"We show that ES can provide an early warning of VOCs becoming prevalent in the population and that, as well as B.1.1.7, our method can potentially detect VOCs B.1.351 and P.1, first identified in South Africa and Brazil, respectively, and other viruses also carrying critical spike mutation E484K, known to have an effect on virus antigenicity..

A novel SARS-CoV-2 lineage B.1.1.7 was recently identified and shown to be rapidly expanding across the UK, particularly in London, the South East, and the East of England [1, 2].",PPR293365
P.1,"We show that ES can provide an early warning of VOCs becoming prevalent in the population and that, as well as B.1.1.7, our method can potentially detect VOCs B.1.351 and P.1, first identified in South Africa and Brazil, respectively, and other viruses also carrying critical spike mutation E484K, known to have an effect on virus antigenicity..

A novel SARS-CoV-2 lineage B.1.1.7 was recently identified and shown to be rapidly expanding across the UK, particularly in London, the South East, and the East of England [1, 2].",PPR293365
B.1.429,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
B.1.351,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
P.1,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
B.1.1.7,"examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California).",PMC7919536
B.1.298,"For example, a substitution in nonstructural protein 12 or NSP12 (P323L), a component of the viral RdRp, is observed in all four human variants as well as the Danish mink strain, B.1.298, that has been linked to various human infections.",PMC7919536
B.1.1.298,"Lineages B.1.351, B.1.1.7, and B.1.1.298 reflect sequences deposited on or before 06 January 2021.",PMC7919536
Alpha,"Other substitutions are located in more internal alpha helices in the spike protein (T1027I, D1118H).",PMC7919536
B.1.35,"∗Samples from this study..

For the pangolin lineage assignment, the samples were assigned to lineage B.1 (N = 26), B.1.1.64 (N = 1), B.1.114 (N = 1), B.1.35 (N = 1), B.1.5 (N = 1), B.1.5.6 (N = 1), and B.2 (N = 2) (Table I)..",PMC7908852
B.1,"∗Samples from this study..

For the pangolin lineage assignment, the samples were assigned to lineage B.1 (N = 26), B.1.1.64 (N = 1), B.1.114 (N = 1), B.1.35 (N = 1), B.1.5 (N = 1), B.1.5.6 (N = 1), and B.2 (N = 2) (Table I)..",PMC7908852
B.1.351,"Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD).",PPR287242
B.1.1.7,"Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD).",PPR287242
P.2,"In December 2020, new variants of concern have been identified in the UK (B.1.1.7; [4]), South Africa (B.1.351; [5]) and Brazil (P.1 and P.2, both descendants from B.1.1.28; [6, 7]).",PPR287242
P.1,"In December 2020, new variants of concern have been identified in the UK (B.1.1.7; [4]), South Africa (B.1.351; [5]) and Brazil (P.1 and P.2, both descendants from B.1.1.28; [6, 7]).",PPR287242
B.1,"Of note, the two sequences from the first and second symptomatic episodes of the same patient (samples E1 and E2) were also from different clades (lineages B.1 and B.1.80) arguing for reinfection (Fig.",PMC7880834
B.1.351,SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries.,PPR282216
B.1.1.7,SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries.,PPR282216
P.2,"The B.1.1.7 variant emerged in the UK, the B.1.351 variant (also termed 501Y.V2) in South Africa and the P.1 and P.2 lineages in Brazil
2,3,5,9-12
.",PPR282216
P.1,"The B.1.1.7 variant emerged in the UK, the B.1.351 variant (also termed 501Y.V2) in South Africa and the P.1 and P.2 lineages in Brazil
2,3,5,9-12
.",PPR282216
B.1.117,Their nasal swabs similarly neutralized the D614G and B.1.117 strains and were inactive against B.1.351.,PPR282216
B.1.1.351,The B.1.1.351 strain (CNR 202100078) originated from a patient in Creteil (France).,PPR282216
B.1.1,"Some of the early lineages have been assigned to geographical locations including A.1 in Washington State, USA outbreak, B.1 in the Italian outbreak, then other parts of Europe and the world, and B.1.1 being the major European lineage which was spread throughout the world13.",PMC7881023
B.1,"Some of the early lineages have been assigned to geographical locations including A.1 in Washington State, USA outbreak, B.1 in the Italian outbreak, then other parts of Europe and the world, and B.1.1 being the major European lineage which was spread throughout the world13.",PMC7881023
A.1,"Some of the early lineages have been assigned to geographical locations including A.1 in Washington State, USA outbreak, B.1 in the Italian outbreak, then other parts of Europe and the world, and B.1.1 being the major European lineage which was spread throughout the world13.",PMC7881023
B.1.13,"A cluster of samples in the B.1.13 lineage suggests a shared source of infection or community transfer related to reference sequence 6, which is represented by dozens of samples primarily in the USA but also in Europe, Australia, Asia and the Middle East (Supplementary Table 3).",PMC7881023
B.1.111,"Samples in the B.1.2 lineage (S41), B.1.3 lineage (S36), B.1.111 lineage (S18) and B.1.114 lineage (S11) are likewise prevalent in the USA, suggesting that many of the samples on lineage B.1 may have been introduced from the USA.",PMC7881023
B.1.3,"Samples in the B.1.2 lineage (S41), B.1.3 lineage (S36), B.1.111 lineage (S18) and B.1.114 lineage (S11) are likewise prevalent in the USA, suggesting that many of the samples on lineage B.1 may have been introduced from the USA.",PMC7881023
B.1.2,"Samples in the B.1.2 lineage (S41), B.1.3 lineage (S36), B.1.111 lineage (S18) and B.1.114 lineage (S11) are likewise prevalent in the USA, suggesting that many of the samples on lineage B.1 may have been introduced from the USA.",PMC7881023
B.1.1.7,"Some mutations in the virus appear to provide fitness advantages and facilitate quicker spread of particular lineages, such as the globally dispersed variant with a Asp614Gly spike substitution,1 and the recently described variant of concern 202012/01 (B.1.1.7) lineage in the UK.2 A number of studies have yielded insight into the relationship between SARS-CoV-2 genomic variability and the host immune response; in this Comment, we discuss whether such variability has the potential to affect the efficacy of recently developed vaccines..

Firstly, what can we learn from other viral vaccines?",PMC8009632
B.1.351,"The RBD amino acid substitution selected for in this experiment, Glu484Lys, is at the same position as mutations reported in a preprint paper describing monoclonal antibody selection experiments (with the mutant variants also escaping neutralisation by convalescent human sera),10 and as that found in501Y.V2 (B.1.351), a SARS-CoV-2 variant spreading rapidly in South Africa.11 An orthogonal approach is to take different SARS-CoV-2 variants and examine whether patient sera shows variable effectiveness in neutralising the variants.",PMC8009632
B.1,"Bat CoV RaTG13, Bat CoVs ZC45, BtKY72 and BGR2008 have also been tested and did not bind hACE2..

N439K is a prevalent RBM mutation (the second most common mutation in the RBD through the end of 2020) which was first sampled in March 2020 in Scotland from lineage B.1 (Rambaut et al., 2020) on the background of D614G.",PMC7843029
B.1.258,"N439K lineages i and ii have recently received the lineage designations B.1.141 and B.1.258, respectively (Rambaut et al., 2020).",PMC7843029
B.1,"WGS revealed that SARS-CoV-2 in A2, A3, and A4 belong to clades V/B.2, S/A, and G/B.1, respectively, whereas that of A5–A7 and S1-S5 are of the V/B.2.1 clade and closely clustered.",PMC7834897
B.1.1.33,Whole-genome sequencing using Illumina MiSeq System confirmed the lineage of three genomes as B.1.1.33 (clade G) containing the nucleotide substitutions observed in strains that circulate in the Rio de Janeiro during the period of this study.,PMC7832254
Gamma,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.617.2,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.1.7,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.1.529,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
Alpha,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
B.1.351,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
P.1,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
Beta,"Current VOC as defined by the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021.",PMC8829001
A.3,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figures 1A,C.",PMC8829001
A.1,"The first samples sequenced in March and April 2020 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figures 1A,C.",PMC8829001
B.1,The large European lineage B.1 was detected in six samples in April 2020.,PMC8829001
Iota,"The former VOC, B.1.526 (Iota), which is a lineage predominantly circulating in New York, was detected from March to June 2021 in 29 samples.",PMC8829001
B.1.526,"The former VOC, B.1.526 (Iota), which is a lineage predominantly circulating in New York, was detected from March to June 2021 in 29 samples.",PMC8829001
B.1.1.8,"Pangolin lineages B.1.1.8 and B.1.113 identified within GR and GH clades, respectively, were noted to be indigenous evolutions.",PMC8184080
B.1.113,"Pangolin lineages B.1.1.8 and B.1.113 identified within GR and GH clades, respectively, were noted to be indigenous evolutions.",PMC8184080
B.1.1,"As per the Pangolin nomenclature, majority of the Indian sequences belonged to sub-lineages B.1.1.32, B.6, B.1, B.1.1, B.1.113 and B.1.1.8 (Fig.",PMC8184080
B.6,"As per the Pangolin nomenclature, majority of the Indian sequences belonged to sub-lineages B.1.1.32, B.6, B.1, B.1.1, B.1.113 and B.1.1.8 (Fig.",PMC8184080
B.1,"As per the Pangolin nomenclature, majority of the Indian sequences belonged to sub-lineages B.1.1.32, B.6, B.1, B.1.1, B.1.113 and B.1.1.8 (Fig.",PMC8184080
A.7,"As per the Pangolin lineage summaries (https://cov-lineages.org/lineages.html), some of the lineages most likely to have evolved in India are B.1.113 (n=372), B.1.1.8 (n=193), A.7 (n=23) and A.9 (n=6).",PMC8184080
A.9,"As per the Pangolin lineage summaries (https://cov-lineages.org/lineages.html), some of the lineages most likely to have evolved in India are B.1.113 (n=372), B.1.1.8 (n=193), A.7 (n=23) and A.9 (n=6).",PMC8184080
B.1.36,"2 (available from https://www.ijmr.org.in/articles/2021/153/1/images/IndianJMedRes_2021_153_1_166_311942_sm14.pdf)) of the most likely transmission events (https://nextstrain.org/ncov/asia?c=clade_membership&f_country=India&f_region=Asia) revealed that the dominant clade B.6 (GISAID O) that emerged from 19A was introduced into India from China, Europe, South-East Asia and Middle-East while B.1 (G) and B.1.36 (GH) that emerged from 20A had their origins from Europe, Middle-East and Africa.",PMC8184080
B.4,"The other sub-group (B.4) involved mainly Karnataka, Maharashtra, Ladakh, Telangana and Gujarat.",PMC8184080
B.1.291,"We analyzed the genomic variability during the SARS-CoV-2 pandemic in Costa Rica using 185 sequences, 52 from the first months of the pandemic, and 133 from the current wave..

Three GISAID clades (G, GH, and GR) and three PANGOLIN lineages (B.1, B.1.1, and B.1.291) are predominant, with phylogenetic relationships that are in line with the results of other Latin American countries, suggesting introduction and multiple re-introductions from other regions of the world.",PPR257231
B.1.1,"We analyzed the genomic variability during the SARS-CoV-2 pandemic in Costa Rica using 185 sequences, 52 from the first months of the pandemic, and 133 from the current wave..

Three GISAID clades (G, GH, and GR) and three PANGOLIN lineages (B.1, B.1.1, and B.1.291) are predominant, with phylogenetic relationships that are in line with the results of other Latin American countries, suggesting introduction and multiple re-introductions from other regions of the world.",PPR257231
B.1,"We analyzed the genomic variability during the SARS-CoV-2 pandemic in Costa Rica using 185 sequences, 52 from the first months of the pandemic, and 133 from the current wave..

Three GISAID clades (G, GH, and GR) and three PANGOLIN lineages (B.1, B.1.1, and B.1.291) are predominant, with phylogenetic relationships that are in line with the results of other Latin American countries, suggesting introduction and multiple re-introductions from other regions of the world.",PPR257231
B.1.1,"The 43 samples can also be clustered into two major legacy clades, the A2a and B4 whereby the B4 clade comprises of the pangolin clade A, while the A2a clade comprises samples in the B.1 and B.1.1 pangolin clades.",PMC7746953
B.1,"The 43 samples can also be clustered into two major legacy clades, the A2a and B4 whereby the B4 clade comprises of the pangolin clade A, while the A2a clade comprises samples in the B.1 and B.1.1 pangolin clades.",PMC7746953
Alpha,"Using data obtained by array CGH, a long read with hard clipping showed a breakpoint in repeated sequence with about 90% homology with D18Z1 alpha satellite.",PMC7705438
V.2,Variants with minor allele frequency less than 0.005 as per GnomAD v.2 were filtered and those located in genes known to be associated with cataract development as per Cat-Map database were given a priority for further evaluation.,PMC7705438
C.14,"We identified one previously reported (c.2729 C>T), five novel missense (c.3029 A>G, c.1738-1739 del ins TT, c.1163 G>A, c.3058 C>T, c.329 G>A) and two novel nonsense (c.1213 delT fs*, c.14 C>A fs*) mutations.",PMC7705438
V.1,"All variants were reclassified according to ACMG/AMP guidelines (both applying the TP53 rule specifications (v.1) provided by the ClinGen TP53 Expert Panel, and automatically using PathoMan)..",PMC7705438
C.38,"Results: We found 8 mutations in this patient in 2018 when he found the cancer and the mutation sites were APC c.3189 delT (50.81%), TP53 c.339 delC (55.46%), KRAS c.38 G>A (39.38%), EYS c.157 T>G (0.38%), KIT c.147 C>T (0.31%), PHACTR1 c.760 C>G (0.20%), CSMD3 c.837 T>G (0.08%) and SLITRK4 c.329 A>C (0.05%).",PMC7705438
Beta,"A simple next generation sequencing method to detect sequence variants causing alpha and beta thalassemia
.",PMC7705438
Lambda,Introduction: Single nucleotide polymorphisms (SNPs) in interferon lambda 3 and 4 (IFNL3/4) are well-established prognostic markers for Pegylated-Interferon-alpha/ribavirin (Peg-IFN-α/RBV) treatment in Chronic Hepatitis C (CHC).,PMC7705438
B.1.1,"All SARS-CoV-2 genomes were similar (92–100% sequence homology) to the reference sequence Wuhan_1 (NC_045512), and 32 strains belonged to the B.1.1 lineage.",PMC7671498
B.3,"When compared to all GISAID sequences, our sequences fell into six lineages including B.1, B.1.1, B.1.1.1, B.2, B.2.1 and B.3, with the dominant lineage being B.1.1 (32/44) (Fig 1).",PMC7671498
B.1.1.1,"When compared to all GISAID sequences, our sequences fell into six lineages including B.1, B.1.1, B.1.1.1, B.2, B.2.1 and B.3, with the dominant lineage being B.1.1 (32/44) (Fig 1).",PMC7671498
B.1,"When compared to all GISAID sequences, our sequences fell into six lineages including B.1, B.1.1, B.1.1.1, B.2, B.2.1 and B.3, with the dominant lineage being B.1.1 (32/44) (Fig 1).",PMC7671498
A.1,"The SARS-CoV-2 lineage was determined using Pangolin software (https://pangolin.cog-uk.io/), which placed the individual’s viral genomes in lineage A.1, which consists of genomes originating from the primary outbreak in Washington state (Rambaut et al., 2020).",PMC7640888
V.1,"The virus neutralization titer is displayed as the reciprocal value of the highest dilution of serum/plasma that still inhibited virus replication at which no cytopathic effect was observed..

Clinical Samples - Viral RNA was extracted from patient nasopharyngeal swabs using Trizol (Invitrogen) for use with the ARTIC nCoV-2019 sequencing protocol V.1 (Protocols.io; https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w).",PMC7640888
V.2,"The genomic sequences were aligned with primers used in the diagnosis of COVID‐19 by the RT‐PCR using the Sequence Manipulation Site: PCR Products tool v.2 (https://www.bioinformatics.org/sms2/pcr_products.html) and Primer3Plus v.2.4.2 (https://primer3plus.com/cgi-bin/dev/primer3plus.cgi), including the sequence NC_045512.2 as reference..",PMC7675408
B.1,"Strains sequenced in this study can be assigned to the two major clades that occurred so far during this pandemic, namely A and B.1 according to the Pangolin lineage.",PPR218521
B.1.1,"In contrast, the B.1 lineage comprises sequences associated with the large Italian outbreak in February 2020 and represents to date (date 21.07.2020), together with its sublineage B.1.1, the worldwide prevalent virus clade [19].",PPR218521
B.1.350,"Overall, our mutational fingerprinting and nomenclature provides a simple way to glean the ancestry of new variants in contrast to phylogenetic designations (e.g., B.1.350 and B.1.1.7
33
)..",PPR218620
A.1,"This includes all small and medium-sized phylogenetic groups (up to 488 genomes) and two large groups (A.1 with 1,377 genomes and B.1.2 with 749 genomes).",PPR218620
B.1.2,"This includes all small and medium-sized phylogenetic groups (up to 488 genomes) and two large groups (A.1 with 1,377 genomes and B.1.2 with 749 genomes).",PPR218620
B.1.1,"One large group, B.1.1, predominately connects with ε3 node (79%, 4,832 genomes), but some of its members belong to ε3 offshoots because they contain respective diagnostic mutations.",PPR218620
B.1.1.1,"For group B.1.1.1, two other ε3 offshoots are mixed up almost equally.",PPR218620
Beta,"Correspondence and requests for materials should be addressed to s.kumar@temple.edu..

Live evolutionary history and spatiotemporal distributions of common variants can be accessed via http://igem.temple.edu/COVID-19 (beta version).",PPR218620
B.1.1.1,"Lineage B is associated with variants G, V, and O, meanwhile lineage A is related to the variant S. The predominant variant G houses the sublineages B.1, B.1.1, B.1.1.1, B.1.1.10, B.1.5, and B.1.5.4, variant V houses the lineages B, B.2, B.2.1, and B.2.5, and variant O is also associated with the lineage B.",PMC7536338
B.1.1,"Lineage B is associated with variants G, V, and O, meanwhile lineage A is related to the variant S. The predominant variant G houses the sublineages B.1, B.1.1, B.1.1.1, B.1.1.10, B.1.5, and B.1.5.4, variant V houses the lineages B, B.2, B.2.1, and B.2.5, and variant O is also associated with the lineage B.",PMC7536338
B.1,"Lineage B is associated with variants G, V, and O, meanwhile lineage A is related to the variant S. The predominant variant G houses the sublineages B.1, B.1.1, B.1.1.1, B.1.1.10, B.1.5, and B.1.5.4, variant V houses the lineages B, B.2, B.2.1, and B.2.5, and variant O is also associated with the lineage B.",PMC7536338
B.1.1.10,"Lineage B is associated with variants G, V, and O, meanwhile lineage A is related to the variant S. The predominant variant G houses the sublineages B.1, B.1.1, B.1.1.1, B.1.1.10, B.1.5, and B.1.5.4, variant V houses the lineages B, B.2, B.2.1, and B.2.5, and variant O is also associated with the lineage B.",PMC7536338
A.2,"On the other hand, variant S is associated with sublineages A.1, A.2, and A.5 (Table 1, Supplementary Figure 1).",PMC7536338
A.5,"On the other hand, variant S is associated with sublineages A.1, A.2, and A.5 (Table 1, Supplementary Figure 1).",PMC7536338
A.1,"On the other hand, variant S is associated with sublineages A.1, A.2, and A.5 (Table 1, Supplementary Figure 1).",PMC7536338
A.1,"Next, the derived A.1 lineage was introduced.",PPR215639
B.1,"For example, B.1 was introduced into LA County during its outbreak in Italy and New York, while B.1.2 was introduced into LA County during its outbreak in Louisiana.",PPR215639
B.1.2,"For example, B.1 was introduced into LA County during its outbreak in Italy and New York, while B.1.2 was introduced into LA County during its outbreak in Louisiana.",PPR215639
B.1.1,"Mutational profiles 3 (B.1.1) and 6 (B.1), which contain the D936Y mutation, became the predominant profiles over time, spreading from Stockholm to other Swedish regions during April and the beginning of May.",PMC7551444
B.1,"Mutational profiles 3 (B.1.1) and 6 (B.1), which contain the D936Y mutation, became the predominant profiles over time, spreading from Stockholm to other Swedish regions during April and the beginning of May.",PMC7551444
B.1.351,"Our analyses further indicate that the human endemic strains hCoV-HKU1 and hCoV-OC43 have evolved more stable N-terminal helix interactions through enhancement of an interfacing loop region on the viral RBD, whereas the highly transmissible SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1) have evolved more stable viral binding via more focused interactions between the viral N501 and ACE2 K353 alone..",PPR213424
P.1,"Our analyses further indicate that the human endemic strains hCoV-HKU1 and hCoV-OC43 have evolved more stable N-terminal helix interactions through enhancement of an interfacing loop region on the viral RBD, whereas the highly transmissible SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1) have evolved more stable viral binding via more focused interactions between the viral N501 and ACE2 K353 alone..",PPR213424
B.1.1.7,"Our analyses further indicate that the human endemic strains hCoV-HKU1 and hCoV-OC43 have evolved more stable N-terminal helix interactions through enhancement of an interfacing loop region on the viral RBD, whereas the highly transmissible SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1) have evolved more stable viral binding via more focused interactions between the viral N501 and ACE2 K353 alone..",PPR213424
Beta,A hybrid model of the bat HKU4 beta coronavirus interaction with ACE2 was similarly constructed using PDB: 4qzv (Wang et al.,PPR213424
Alpha,7 for each ortholog in red and blue; Fig 3C) using a sliding window of 30 sites and an alpha level of significance of 0.01.,PPR213424
Beta,"Following this brief inflammatory phase, the alveolar macrophages clear all debris arising from apoptotic virus-infected cells, limit the buildup of surfactant, and resolve inflammation within the lung microenvironment by secreting cytokines like IL-10, transforming growth factor beta (TGF-β) and increased expression of checkpoint inhibitors such as CD200 that strive to return this niche to its conventional anti-inflammatory state [105].",PMC7431311
B.1,"All but one of the newly-characterized genomes belonged to the lineage B.1, the most frequently identified in European countries, including Italy.",PMC7472216
Alpha,"Sampling probability (ρ) was estimated assuming a prior Beta (alpha = 1.0 and beta = 999), corresponding to a minority of the sampled cases (between 10−5 to 10−3).",PMC7472216
Beta,"Sampling probability (ρ) was estimated assuming a prior Beta (alpha = 1.0 and beta = 999), corresponding to a minority of the sampled cases (between 10−5 to 10−3).",PMC7472216
B.1.1,"About 1 out of 4 isolates were classified in different descendant lineages, always included in the main B.1 lineage (such as B.1.1 and B.1.5), most on a temporal basis, being these lineages more represented among the genomes sampled in the second half of March and April (9/14, 64%), while B.1 lineage was more represented in the genomes obtained in February and first half of March (33/47, 70.2%)..",PMC7472216
